Unnamed: 0,manuscript_title,team,doi_pre,doi_pub,original_research,OpenAlex_ID,ListofAlexIds,ListofNames,ListofOrcids,Role,Team,FirstLastName
0.0,LRRK2 phosphorylation of Rab GTPases in Parkinson’s disease,Alessi,review,10.1002/1873-3468.14492,0.0,W4296162466,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
1.0,PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease,Alessi,review,10.1016/j.conb.2021.09.005,0.0,W3209929601,A5051090753,Shalini Agarwal,0000-0002-5526-6872,Key Personnel,Team Alessi,Shalini Agarwal
2.0,PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease,Alessi,review,10.1016/j.conb.2021.09.005,0.0,W3209929601,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
3.0,Isotope tracing in health and disease,Alessi,review,10.1016/j.copbio.2022.102739,0.0,W4283208018,A5033915840,Wentao Dong,0000-0001-5490-4265,Key Personnel,Team Alessi,Wentao Dong
4.0,Isotope tracing in health and disease,Alessi,review,10.1016/j.copbio.2022.102739,0.0,W4283208018,A5015996784,Eshaan S. Rawat,0000-0002-2595-7605,Key Personnel,Team Alessi,Eshaan Rawat
5.0,Isotope tracing in health and disease,Alessi,review,10.1016/j.copbio.2022.102739,0.0,W4283208018,A5009763658,Gregory Stephanopoulos,,,,Gregory Stephanopoulos
6.0,Isotope tracing in health and disease,Alessi,review,10.1016/j.copbio.2022.102739,0.0,W4283208018,A5045437960,Monther Abu-Remaileh,0000-0003-3772-0477,Co-PI,Team Alessi,Monther Abu-Remaileh
7.0,Whole proteome copy number dataset in primary mouse cortical neurons,Alessi,none? review,10.1016/j.dib.2023.109336,0.0,W4381848193,A5039704196,Odetta Antico,0000-0002-7325-3303,Key Personnel,Team Alessi,Odetta Antico
8.0,Whole proteome copy number dataset in primary mouse cortical neurons,Alessi,none? review,10.1016/j.dib.2023.109336,0.0,W4381848193,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
9.0,Whole proteome copy number dataset in primary mouse cortical neurons,Alessi,none? review,10.1016/j.dib.2023.109336,0.0,W4381848193,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
10.0,Role of autophagy pathway in Parkinson’s disease and related Genetic Neurological disorders,Alessi,review,10.1016/j.jmb.2023.168144,0.0,W4376272271,A5083210549,Christos Themistokleous,0000-0002-1844-6639,Key Personnel,Team Alessi,Christos Themistokleous
11.0,Role of autophagy pathway in Parkinson’s disease and related Genetic Neurological disorders,Alessi,review,10.1016/j.jmb.2023.168144,0.0,W4376272271,A5009978283,Enrico Bagnoli,0000-0002-0664-9981,Project Manager,Team Alessi,Enrico Bagnoli
12.0,Role of autophagy pathway in Parkinson’s disease and related Genetic Neurological disorders,Alessi,review,10.1016/j.jmb.2023.168144,0.0,W4376272271,A5004462406,Ramaa Parulekar,0000-0002-1030-4265,,,Ramaa Parulekar
13.0,Role of autophagy pathway in Parkinson’s disease and related Genetic Neurological disorders,Alessi,review,10.1016/j.jmb.2023.168144,0.0,W4376272271,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
14.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5000257912,Alexia F. Kalogeropulou,0000-0001-5185-7694,,,Alexia Kalogeropulou
15.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5002947066,Elena Purlyte,0000-0001-7291-1549,,,Elena Purlyte
16.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
17.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5044370251,Sven M. Lange,0000-0002-6011-8647,,,Sven Lange
18.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5017025792,Melanie Wightman,,,,Melanie Wightman
19.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5027617773,Alan R. Prescott,0000-0002-0747-7317,,,Alan Prescott
20.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5015643840,Shalini Padmanabhan,,,,Shalini Padmanabhan
21.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5067865589,Esther Sammler,0000-0003-3218-7116,Key Personnel,Team Alessi,Esther Sammler
22.0,Impact of 100 LRRK2 variants linked to Parkinson's disease on kinase activity and microtubule binding,Alessi,10.1101/2022.04.01.486724,10.1042/BCJ20220161,1.0,W4290803974,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
23.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5026148952,Asad Malik,0000-0001-8550-9604,,,Asad Malik
24.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5082080959,Athanasios Karapetsas,,,,Athanasios Karapetsas
25.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
26.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5086343829,Deep Chatterjee,0000-0001-8190-9213,Key Personnel,Team Reck-Peterson,Deep Chatterjee
27.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5004300103,Toan K. Phung,0000-0002-2964-6070,Key Personnel,Team Alessi,Toan Phung
28.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5017025792,Melanie Wightman,,,,Melanie Wightman
29.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5078460066,Robert Gourlay,0000-0003-1592-1972,,,Robert Gourlay
30.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5028009861,Nick Morrice,,,,Nick Morrice
31.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5042127936,Sebastian Mathea,0000-0001-8500-4569,Key Personnel,Team Reck-Peterson,Sebastian Mathea
32.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5013336817,Stefan Knapp,0000-0001-5995-6494,Co-PI,Team Reck-Peterson,Stefan Knapp
33.0,"PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain",Alessi,10.1101/2022.06.09.495448,10.1042/BCJ20220308,1.0,W4293567400,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
34.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5056888177,Rotimi Fasimoye,0000-0001-8057-0879,Key Personnel,Team Alessi,Rotimi Fasimoye
35.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5033915840,Wentao Dong,0000-0001-5490-4265,Key Personnel,Team Alessi,Wentao Dong
36.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
37.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5015996784,Eshaan S. Rawat,0000-0002-2595-7605,Key Personnel,Team Alessi,Eshaan Rawat
38.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5031607426,Miharu Iguchi,0000-0002-3515-2114,,,Miharu Iguchi
39.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5042835632,Kwamina Nyame,0000-0001-8898-4689,Key Personnel,Team Alessi,Kwamina Nyame
40.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5004300103,Toan K. Phung,0000-0002-2964-6070,Key Personnel,Team Alessi,Toan Phung
41.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5009978283,Enrico Bagnoli,0000-0002-0664-9981,Project Manager,Team Alessi,Enrico Bagnoli
42.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5027617773,Alan R. Prescott,0000-0002-0747-7317,,,Alan Prescott
43.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
44.0,"Golgi-IP, a novel tool for multimodal analysis of Golgi molecular content",Alessi,10.1101/2022.11.22.517583,10.1073/pnas.2219953120,1.0,W4375956084,A5045437960,Monther Abu-Remaileh,0000-0003-3772-0477,Co-PI,Team Alessi,Monther Abu-Remaileh
45.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5004300103,Toan K. Phung,0000-0002-2964-6070,Key Personnel,Team Alessi,Toan Phung
46.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5047301907,Kerryn Berndsen,0000-0002-9353-7565,,,Kerryn Berndsen
47.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5050881627,R. Shastry,0000-0002-7910-734X,,,R. Shastry
48.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5113114021,Tran L. C. H. B. Phan,,,,Tran Phan
49.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
50.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
51.0,CURTAIN – A Unique Web-based tool for exploration and sharing of MS-based proteomics data | bioRxiv,Alessi,10.1101/2023.07.25.550405,10.1073/pnas.2312676121,1.0,W4391594220,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
52.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5071273941,Wondwossen M Yeshaw,0000-0002-3134-3458,,,Wondwossen Yeshaw
53.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5066757585,Ayan Adhikari,0000-0002-8525-3263,Key Personnel,Team Alessi,Ayan Adhikari
54.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5085896336,Claire Y Chiang,0000-0002-0999-9856,Key Personnel,Team Alessi,Claire Chiang
55.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5036096692,Herschel S. Dhekne,0000-0002-2240-1230,,,Herschel Dhekne
56.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5060993864,Paulina S. Wawro,0000-0002-9464-1321,,,Paulina Wawro
57.0,Localization of PPM1H phosphatase tunes Parkinson’s disease-linked LRRK2 kinase-mediated Rab GTPase phosphorylation and ciliogenesis,Alessi,10.1101/2023.06.15.545139,10.1073/pnas.2315171120,1.0,W4387970169,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
58.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5073333267,Shahzad S. Khan,0000-0003-3962-0226,,,Shahzad Khan
59.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
60.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5036045846,Yu‐En Lin,0000-0002-5848-5405,Key Personnel,Team Alessi,Yu‐En Lin
61.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5087824431,Jonas Nikoloff,0000-0002-7823-454X,,,Jonas Nikoloff
62.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
63.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
64.0,Loss of primary cilia and dopaminergic neuroprotection in pathogenic LRRK2-driven and idiopathic Parkinsons disease | bioRxiv,Alessi,10.1101/2024.01.15.575737,10.1073/pnas.2402206121,1.0,W4401213995,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
65.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5039704196,Odetta Antico,0000-0002-7325-3303,Key Personnel,Team Alessi,Odetta Antico
66.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5050948158,Alban Ordureau,0000-0002-4924-8520,,,Alban Ordureau
67.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5103155091,Michael Stevens,0000-0001-8105-6302,,,Michael Stevens
68.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5081374585,François Singh,0000-0002-1696-9815,,,François Singh
69.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
70.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5013433142,Marek Gierliński,0000-0001-9149-3514,,,Marek Gierliński
71.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5054977583,Erica Barini,0000-0002-3093-4053,,,Erica Barini
72.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5081090599,Mollie L. Rickwood,0000-0002-3715-8915,,,Mollie Rickwood
73.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5027617773,Alan R. Prescott,0000-0002-0747-7317,,,Alan Prescott
74.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5067524265,Rachel Toth,0000-0002-1337-0612,,,Rachel Toth
75.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5001971427,Ian G. Ganley,0000-0003-1481-9407,Co-PI,Team Hurley,Ian Ganley
76.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
77.0,Global ubiquitylation analysis of mitochondria in primary neurons identifies endogenous Parkin targets following activation of PINK1,Alessi,10.1101/2021.04.01.438131,10.1126/sciadv.abj0722,1.0,W3213349298,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
78.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5038587130,Prosenjit Pal,0000-0001-6848-4863,Key Personnel,Team Alessi,Prosenjit Pal
79.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5000399121,Matthew Taylor,0000-0002-4003-3128,,,Matthew Taylor
80.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5018861529,Yuko P. Y. Lam,0000-0001-5486-091X,Key Personnel,Team Alessi,Yuko Lam
81.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
82.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5062558774,Chloe A Hecht,0000-0001-9248-9576,,,Chloe Hecht
83.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5027580687,Paweł Lis,0000-0002-4978-7671,Key Personnel,Team Alessi,Paweł Lis
84.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
85.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5004300103,Toan K. Phung,0000-0002-2964-6070,Key Personnel,Team Alessi,Toan Phung
86.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5071273941,Wondwossen M Yeshaw,0000-0002-3134-3458,,,Wondwossen Yeshaw
87.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
88.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5056888177,Rotimi Fasimoye,0000-0001-8057-0879,Key Personnel,Team Alessi,Rotimi Fasimoye
89.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5005308525,Emily A. Dickie,0000-0002-4509-5045,Key Personnel,Team Alessi,Emily Dickie
90.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5017025792,Melanie Wightman,,,,Melanie Wightman
91.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5079890631,Thomas Macartney,0000-0002-6745-183X,,,Thomas Macartney
92.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
93.0,Parkinson's VPS35[D620N] mutation induces LRRK2 mediated lysosomal association of RILPL1 and TMEM55B,Alessi,10.1101/2023.06.07.544051,10.1126/sciadv.adj1205,1.0,W4389697128,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
94.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5005167488,Olawale G. Raimi,0000-0003-2782-7318,,,Olawale Raimi
95.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5074624296,Hina Ojha,0000-0002-1458-4620,,,Hina Ojha
96.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5093567998,Kenneth Ehses,0000-0002-8595-5994,Key Personnel,Team Harper,Kenneth Ehses
97.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5102848969,Verena Dederer,0009-0006-7557-5388,Key Personnel,Team Reck-Peterson,Verena Dederer
98.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5044370251,Sven M. Lange,0000-0002-6011-8647,,,Sven Lange
99.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5067683892,Cristian Polo Rivera,0000-0002-1433-4111,,,Cristian Rivera
100.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5079736311,Tom Deegan,0000-0001-9639-7636,,,Tom Deegan
101.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5067351122,Yin-Chen Chen,,,,Yin-Chen Chen
102.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5017025792,Melanie Wightman,,,,Melanie Wightman
103.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5067524265,Rachel Toth,0000-0002-1337-0612,,,Rachel Toth
104.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5073735040,Karim Labib,0000-0001-8861-379X,,,Karim Labib
105.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5042127936,Sebastian Mathea,0000-0001-8500-4569,Key Personnel,Team Reck-Peterson,Sebastian Mathea
106.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5025814244,Neil A. Ranson,0000-0002-3640-5275,,,Neil Ranson
107.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5061030857,Rubén Fernández‐Busnadiego,0000-0002-8366-7622,Co-PI,Team Harper,Rubén Fernández‐Busnadiego
108.0,Mechanism of human PINK1 activation at the TOM complex in a reconstituted system | bioRxiv,Alessi,10.1101/2023.12.23.573181,10.1126/sciadv.adn7191,1.0,W4399425564,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
109.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5102713614,Hanwen Zhu,0000-0002-6172-0189,,,Hanwen Zhu
110.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
111.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5081479060,Martin Turk,0000-0001-8680-2060,,,Martin Turk
112.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5027617773,Alan R. Prescott,0000-0002-0747-7317,,,Alan Prescott
113.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
114.0,Rab29-dependent asymmetrical activation of leucine-rich repeat kinase 2,Alessi,10.1101/2022.04.26.489605,10.1126/science.adi9926,1.0,W4390046099,A5038928062,Ji Sun,0000-0002-9302-3177,,,Ji Sun
115.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5041063476,Dieter Waschbüsch,0000-0002-8953-2585,,,Dieter Waschbüsch
116.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5047301907,Kerryn Berndsen,0000-0002-9353-7565,,,Kerryn Berndsen
117.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5027580687,Paweł Lis,0000-0002-4978-7671,Key Personnel,Team Alessi,Paweł Lis
118.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5024724887,Axel Knebel,0000-0002-9197-6054,,,Axel Knebel
119.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5018861529,Yuko P. Y. Lam,0000-0001-5486-091X,Key Personnel,Team Alessi,Yuko Lam
120.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
121.0,Structural basis for the specificity of PPM1H phosphatase for Rab GTPases,Alessi,10.1101/2021.02.17.431620,10.15252/embr.202152675,1.0,W3204672542,A5015057310,Amir R. Khan,0000-0003-1176-6952,,,Amir Khan
122.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5073333267,Shahzad S. Khan,0000-0003-3962-0226,,,Shahzad Khan
123.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5039317060,Yuriko Sobu,0000-0003-1178-005X,,,Yuriko Sobu
124.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5036096692,Herschel S. Dhekne,0000-0002-2240-1230,,,Herschel Dhekne
125.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
126.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5047301907,Kerryn Berndsen,0000-0002-9353-7565,,,Kerryn Berndsen
127.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
128.0,Pathogenic LRRK2 control of primary cilia and Hedgehog signaling in neurons and astrocytes of mouse brain,Alessi,10.1101/2021.03.02.433576,10.7554/eLife.67900,1.0,W3205174301,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
129.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5004693112,Edmundo G. Vides,0000-0002-3609-9001,,,Edmundo Vides
130.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5066757585,Ayan Adhikari,0000-0002-8525-3263,Key Personnel,Team Alessi,Ayan Adhikari
131.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5085896336,Claire Y Chiang,0000-0002-0999-9856,Key Personnel,Team Alessi,Claire Chiang
132.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5027580687,Paweł Lis,0000-0002-4978-7671,Key Personnel,Team Alessi,Paweł Lis
133.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5002947066,Elena Purlyte,0000-0001-7291-1549,,,Elena Purlyte
134.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5088076037,Charles Limouse,0000-0003-2589-4576,,,Charles Limouse
135.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5049895179,Justin L Shumate,0000-0002-3223-0922,,,Justin Shumate
136.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5035246573,Elena Spínola-Lasso,0000-0003-2207-5786,,,Elena Spínola-Lasso
137.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5036096692,Herschel S. Dhekne,0000-0002-2240-1230,,,Herschel Dhekne
138.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
139.0,A feed-forward pathway drives LRRK2 kinase membrane recruitment and activation,Alessi,10.1101/2022.04.25.489459,10.7554/eLife.79771,1.0,W4296793671,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
140.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5036096692,Herschel S. Dhekne,0000-0002-2240-1230,,,Herschel Dhekne
141.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
142.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5071273941,Wondwossen M Yeshaw,0000-0002-3134-3458,,,Wondwossen Yeshaw
143.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5085896336,Claire Y Chiang,0000-0002-0999-9856,Key Personnel,Team Alessi,Claire Chiang
144.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5088076037,Charles Limouse,0000-0003-2589-4576,,,Charles Limouse
145.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
146.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5002947066,Elena Purlyte,0000-0001-7291-1549,,,Elena Purlyte
147.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
148.0,Genome-wide screen reveals Rab12 GTPase as a critical activator of pathogenic LRRK2 kinase,Alessi,10.1101/2023.02.17.529028,10.7554/elife.87098,1.0,W4387892944,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
149.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5093929936,Daniel Saarela,0000-0001-8854-7438,Key Personnel,Team Alessi,Daniel Saarela
150.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5027580687,Paweł Lis,0000-0002-4978-7671,Key Personnel,Team Alessi,Paweł Lis
151.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5057925009,Sara Gomes,0000-0002-9086-2303,,,Sara Gomes
152.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
153.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5033915840,Wentao Dong,0000-0001-5490-4265,Key Personnel,Team Alessi,Wentao Dong
154.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5015996784,Eshaan S. Rawat,0000-0002-2595-7605,Key Personnel,Team Alessi,Eshaan Rawat
155.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5103000020,S. G. Glendinning,0009-0001-2969-198X,,,S. Glendinning
156.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5097355878,Karolina Zeneviciute,0000-0002-9628-3783,,,Karolina Zeneviciute
157.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5009978283,Enrico Bagnoli,0000-0002-0664-9981,Project Manager,Team Alessi,Enrico Bagnoli
158.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5056888177,Rotimi Fasimoye,0000-0001-8057-0879,Key Personnel,Team Alessi,Rotimi Fasimoye
159.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5062134775,Cindy Lin,0000-0003-4555-195X,Key Personnel,Team Alessi,Cindy Lin
160.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5042835632,Kwamina Nyame,0000-0001-8898-4689,Key Personnel,Team Alessi,Kwamina Nyame
161.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5003475573,Fanni Annamária Boros,0000-0003-2922-4537,,,Fanni Boros
162.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5061611026,Friederike Zunke,0000-0002-0408-6388,,,Friederike Zunke
163.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5075455832,Frédéric Lamoliatte,0000-0002-0549-6514,,,Frédéric Lamoliatte
164.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5087999104,Sadik Elshani,,Key Personnel,Team Alessi,Sadik Elshani
165.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5098937951,Matthew Jaconelli,,Key Personnel,Team Alessi,Matthew Jaconelli
166.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5076498092,Judith Jans,0000-0003-0960-6263,,,Judith Jans
167.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5103433409,Margriet Huisman,,,,Margriet Huisman
168.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5096198067,Christian Posern,,,,Christian Posern
169.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5022723738,Lena Marie Westermann,,,,Lena Westermann
170.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5101418446,Angela Schulz,0000-0001-9156-4861,,,Angela Schulz
171.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5072868409,Peter M. van Hasselt,0000-0001-9821-8398,,,Peter Hasselt
172.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
173.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5045437960,Monther Abu-Remaileh,0000-0003-3772-0477,Co-PI,Team Alessi,Monther Abu-Remaileh
174.0,Tagless LysoIP method for molecular profiling of lysosomal content in clinical samples,Alessi,10.1101/2024.05.17.594681,,1.0,W4397293294,A5067865589,Esther Sammler,0000-0003-3218-7116,Key Personnel,Team Alessi,Esther Sammler
175.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5009978283,Enrico Bagnoli,0000-0002-0664-9981,Project Manager,Team Alessi,Enrico Bagnoli
176.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5036045846,Yu‐En Lin,0000-0002-5848-5405,Key Personnel,Team Alessi,Yu‐En Lin
177.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5013302750,Sophie Burel,0000-0003-0557-3396,,,Sophie Burel
178.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
179.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5039704196,Odetta Antico,0000-0002-7325-3303,Key Personnel,Team Alessi,Odetta Antico
180.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5083210549,Christos Themistokleous,0000-0002-1844-6639,Key Personnel,Team Alessi,Christos Themistokleous
181.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5087824431,Jonas Nikoloff,0000-0002-7823-454X,,,Jonas Nikoloff
182.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5074491420,Ilaria Morella,0000-0001-5691-5400,,,Ilaria Morella
183.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5058101047,Jens O. Watzlawik,0000-0003-0610-0267,,,Jens Watzlawik
184.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5047826493,Fabienne C. Fiesel,0000-0002-1919-9676,,,Fabienne Fiesel
185.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5083674000,Wolfdieter Springer,0000-0002-1178-3149,,,Wolfdieter Springer
186.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
187.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5026981679,Simon P. Brooks,0000-0001-9853-6177,,,Simon Brooks
188.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5039606775,Stephen B. Dunnett,0000-0003-1826-1578,,,Stephen Dunnett
189.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5033463927,Riccardo Brambilla,0000-0003-3569-5706,,,Riccardo Brambilla
190.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
191.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
192.0,Endogenous LRRK2 and PINK1 function in a convergent neuroprotective ciliogenesis pathway in the brain,Alessi,10.1101/2024.06.11.598416,,1.0,W4399592645,A5084528692,Miratul M. K. Muqit,0000-0001-9733-2404,Co-PI,Team Alessi,Miratul Muqit
193.0,Pathogenic LRRK2 mutations cause loss of primary cilia and Neurturin in striatal Parvalbumin interneurons,Alessi,10.1101/2024.06.17.599289,,1.0,W4399726608,A5036045846,Yu‐En Lin,0000-0002-5848-5405,Key Personnel,Team Alessi,Yu‐En Lin
194.0,Pathogenic LRRK2 mutations cause loss of primary cilia and Neurturin in striatal Parvalbumin interneurons,Alessi,10.1101/2024.06.17.599289,,1.0,W4399726608,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
195.0,Pathogenic LRRK2 mutations cause loss of primary cilia and Neurturin in striatal Parvalbumin interneurons,Alessi,10.1101/2024.06.17.599289,,1.0,W4399726608,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
196.0,Pathogenic LRRK2 mutations cause loss of primary cilia and Neurturin in striatal Parvalbumin interneurons,Alessi,10.1101/2024.06.17.599289,,1.0,W4399726608,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
197.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5023471345,Ebsy Jaimon,0000-0001-6845-2095,Key Personnel,Team Alessi,Ebsy Jaimon
198.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5036045846,Yu‐En Lin,0000-0002-5848-5405,Key Personnel,Team Alessi,Yu‐En Lin
199.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
200.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5039704196,Odetta Antico,0000-0002-7325-3303,Key Personnel,Team Alessi,Odetta Antico
201.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
202.0,Restoration of striatal neuroprotective pathways by kinase inhibitor treatment of Parkinson’s linked-LRRK2 mutant mice,Alessi,10.1101/2024.07.31.606089,,1.0,W4401316242,A5033452410,Suzanne R. Pfeffer,0000-0002-6462-984X,Co-PI,Team Alessi,Suzanne Pfeffer
203.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5053931380,Gian Pietro Serra,0000-0001-8782-3162,,,Gian Serra
204.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5040340403,Adriane Guillaumin,0000-0002-6488-3207,,,Adriane Guillaumin
205.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5063816726,Bianca Vlcek,0000-0001-5442-2303,,,Bianca Vlcek
206.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5059983739,Lorena Delgado-Zabalza,0000-0002-3980-1900,,,Lorena Delgado-Zabalza
207.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5052775713,Alessia Ricci,0000-0002-9033-0104,,,Alessia Ricci
208.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5087924578,E. Rubino,0000-0002-5248-505X,Key Personnel,Team Cragg,E. Rubino
209.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5019091466,Sylvie Dumas,0000-0002-4415-9924,,,Sylvie Dumas
210.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5076099632,Jérôme Baufreton,0000-0002-2623-6375,,,Jérôme Baufreton
211.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5036547376,François Georges,0000-0002-2628-2638,,,François Georges
212.0,A role for the subthalamic nucleus in aversive learning,Awatramani,10.1101/2023.07.18.549513,10.1016/j.celrep.2023.113328,1.0,W4388335298,A5050070314,Åsa Wallén‐Mackenzie,0000-0002-8713-070X,Collaborating PI,Team Awatramani,Åsa Wallén‐Mackenzie
213.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5032566343,Michael Ryan,0000-0002-2650-0690,,,Michael Ryan
214.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5054880742,Allison E. Girasole,0000-0002-1055-9030,,,Allison Girasole
215.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5078293143,Andrew J. Flores,0000-0001-9472-2335,,,Andrew Flores
216.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5063333466,Emily L Twedell,0000-0003-0355-2399,Key Personnel,Team Edwards,Emily Twedell
217.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5078328854,Matthew McGregor,0000-0002-1547-5063,,,Matthew McGregor
218.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5012129766,Rea J Brakaj,,,,Rea Brakaj
219.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5008134841,Ronald F. Paletzki,,,,Ronald Paletzki
220.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5013611528,Thomas S. Hnasko,0000-0001-6176-8513,Co-PI,Team Awatramani,Thomas Hnasko
221.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5044283681,Charles R. Gerfen,0000-0001-9008-4882,,,Charles Gerfen
222.0,Excessive firing of dyskinesia-associated striatal direct pathway neurons is gated by dopamine and excitatory synaptic input,Awatramani,10.1101/2022.10.31.514594,10.1016/j.celrep.2024.114483,1.0,W4400735534,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
223.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5011349260,Joshua W. Callahan,,Key Personnel,Team Awatramani,Joshua Callahan
224.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5075809391,Juan Carlos Morales,0000-0003-2400-405X,,,Juan Morales
225.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5033809191,Jeremy F. Atherton,0000-0002-4144-0657,Key Personnel,Team Awatramani,Jeremy Atherton
226.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5077250713,Dorothy Wang,0000-0001-5850-7320,,,Dorothy Wang
227.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5114107229,Selena Kostic,,,,Selena Kostic
228.0,Movement-related increases in subthalamic activity optimize locomotion,Awatramani,10.1101/2023.12.07.570617,10.1016/j.celrep.2024.114495,1.0,W4401057336,A5069851964,Mark D. Bevan,0000-0001-9759-0163,Co-PI,Team Awatramani,Mark Bevan
229.0,Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology - PubMed (nih.gov),Awatramani,review,10.1016/j.nbd.2022.105925,0.0,W4309078860,A5049961130,Zachary Gaertner,0000-0002-1760-6549,Key Personnel,Team Awatramani,Zachary Gaertner
230.0,Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology - PubMed (nih.gov),Awatramani,review,10.1016/j.nbd.2022.105925,0.0,W4309078860,A5053163008,Maite Azcorra,0000-0002-2919-3825,,,Maite Azcorra
231.0,Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology - PubMed (nih.gov),Awatramani,review,10.1016/j.nbd.2022.105925,0.0,W4309078860,A5035273874,Daniel A. Dombeck,0000-0003-2576-5918,Co-PI,Team Awatramani,Daniel Dombeck
232.0,Molecular heterogeneity in the substantia nigra: A roadmap for understanding PD motor pathophysiology - PubMed (nih.gov),Awatramani,review,10.1016/j.nbd.2022.105925,0.0,W4309078860,A5082378596,Rajeshwar Awatramani,0000-0002-0713-2140,Lead-PI,Team Awatramani,Rajeshwar Awatramani
233.0,"Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents",Awatramani,NA_Review,10.1016/j.neuropharm.2024.110003,0.0,W4398194745,A5052775713,Alessia Ricci,0000-0002-9033-0104,,,Alessia Ricci
234.0,"Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents",Awatramani,NA_Review,10.1016/j.neuropharm.2024.110003,0.0,W4398194745,A5087924578,E. Rubino,0000-0002-5248-505X,Key Personnel,Team Cragg,E. Rubino
235.0,"Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents",Awatramani,NA_Review,10.1016/j.neuropharm.2024.110003,0.0,W4398194745,A5053931380,Gian Pietro Serra,0000-0001-8782-3162,,,Gian Serra
236.0,"Concerning neuromodulation as treatment of neurological and neuropsychiatric disorder: Insights gained from selective targeting of the subthalamic nucleus, para-subthalamic nucleus and zona incerta in rodents",Awatramani,NA_Review,10.1016/j.neuropharm.2024.110003,0.0,W4398194745,A5050070314,Åsa Wallén‐Mackenzie,0000-0002-8713-070X,Collaborating PI,Team Awatramani,Åsa Wallén‐Mackenzie
237.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5053163008,Maite Azcorra,0000-0002-2919-3825,,,Maite Azcorra
238.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5049961130,Zachary Gaertner,0000-0002-1760-6549,Key Personnel,Team Awatramani,Zachary Gaertner
239.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5061104031,Connor Davidson,,,,Connor Davidson
240.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5039421245,Qianzi He,0000-0002-4607-166X,Key Personnel,Team Awatramani,Qianzi He
241.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5102541724,Hailey Kim,,,,Hailey Kim
242.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5054493394,Shivathmihai Nagappan,0000-0001-5910-040X,Key Personnel,Team Awatramani,Shivathmihai Nagappan
243.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5053065922,Cooper K. Hayes,0000-0003-2419-0286,,,Cooper Hayes
244.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5036728423,Charu Ramakrishnan,0000-0002-3474-6332,,,Charu Ramakrishnan
245.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5015588106,Lief E. Fenno,0000-0002-5237-6179,,,Lief Fenno
246.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5077768705,Yoon Seok Kim,0000-0001-8940-6741,,,Yoon Kim
247.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5014360828,Karl Deisseroth,0000-0001-9440-3967,,,Karl Deisseroth
248.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5009157428,Richard Longnecker,0000-0001-7175-6217,,,Richard Longnecker
249.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5082378596,Rajeshwar Awatramani,0000-0002-0713-2140,Lead-PI,Team Awatramani,Rajeshwar Awatramani
250.0,Unique functional responses differentially map onto genetic subtypes of dopamine neurons,Awatramani,10.1101/2022.12.19.521076,10.1038/s41593-023-01401-9,1.0,W4385543838,A5035273874,Daniel A. Dombeck,0000-0003-2576-5918,Co-PI,Team Awatramani,Daniel Dombeck
251.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5006091776,Harry S. Xenias,0000-0002-9502-0973,,,Harry Xenias
252.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5065174544,Chuyu Chen,0000-0001-5666-5173,Key Personnel,Team Awatramani,Chuyu Chen
253.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5073371993,Shuo Kang,0000-0002-2691-6338,,,Shuo Kang
254.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5015371539,Suraj Cherian,0000-0003-1148-770X,,,Suraj Cherian
255.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5091387951,Xiaolei Situ,0009-0009-8500-357X,,,Xiaolei Situ
256.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5034702634,Bharanidharan Shanmugasundaram,,,,Bharanidharan Shanmugasundaram
257.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5101656255,Guoxiang Liu,0000-0002-4839-4307,,,Guoxiang Liu
258.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5069359376,Giuseppe Scesa,,,,Giuseppe Scesa
259.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5064586683,C. Savio Chan,0000-0002-3474-1718,,,C. Chan
260.0,"R1441C and G2019S LRRK2 knockin mice have distinct striatal molecular, physiological, and behavioral alterations",Awatramani,10.1101/2020.03.11.986455,10.1038/s42003-022-04136-8,1.0,W4309076165,A5066027781,Loukia Parisiadou,0000-0002-2569-4200,Co-PI,Team Awatramani,Loukia Parisiadou
261.0,LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights,Awatramani,NA Review,10.3390/cells11010169,0.0,W4205765336,A5034915643,Patrick D. Skelton,0000-0002-6691-9904,,,Patrick Skelton
262.0,LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights,Awatramani,NA Review,10.3390/cells11010169,0.0,W4205765336,A5007120603,Valerie Tokars,0000-0002-2619-3969,,,Valerie Tokars
263.0,LRRK2 at Striatal Synapses: Cell-Type Specificity and Mechanistic Insights,Awatramani,NA Review,10.3390/cells11010169,0.0,W4205765336,A5066027781,Loukia Parisiadou,0000-0002-2569-4200,Co-PI,Team Awatramani,Loukia Parisiadou
264.0,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta,Awatramani,10.1101/2024.02.28.582356,,1.0,W4392291506,A5086679528,William S. Conrad,0000-0001-7167-2822,,,William Conrad
265.0,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta,Awatramani,10.1101/2024.02.28.582356,,1.0,W4392291506,A5092463698,Lucie Oriol,,,,Lucie Oriol
266.0,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta,Awatramani,10.1101/2024.02.28.582356,,1.0,W4392291506,A5099060553,Grace J Kollman,,,,Grace Kollman
267.0,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta,Awatramani,10.1101/2024.02.28.582356,,1.0,W4392291506,A5083637883,Lauren Faget,0000-0002-8572-6542,,,Lauren Faget
268.0,Proportion and distribution of neurotransmitter-defined cell types in the ventral tegmental area and substantia nigra pars compacta,Awatramani,10.1101/2024.02.28.582356,,1.0,W4392291506,A5013611528,Thomas S. Hnasko,0000-0001-6176-8513,Co-PI,Team Awatramani,Thomas Hnasko
269.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5065174544,Chuyu Chen,0000-0001-5666-5173,Key Personnel,Team Awatramani,Chuyu Chen
270.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5053106007,Meghan Masotti,0000-0002-2696-3265,,,Meghan Masotti
271.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5099058302,Nathaniel Shepard,0000-0002-8629-3152,,,Nathaniel Shepard
272.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5017220802,Vanessa Promes,0000-0002-9078-6232,,,Vanessa Promes
273.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5037973577,Giulia Tombesi,0000-0003-0683-8050,Key Personnel,Team Awatramani,Giulia Tombesi
274.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5099058303,Daniel Arango,,,,Daniel Arango
275.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5005572028,Claudia Manzoni,0000-0001-5367-4023,Key Personnel,Team Hardy,Claudia Manzoni
276.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5056455938,Elisa Greggio,0000-0002-8172-3598,,,Elisa Greggio
277.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5063147284,Sabine Hilfiker,0000-0002-5167-7682,,,Sabine Hilfiker
278.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5058982351,Yevgenia Kozorovitskiy,0000-0002-3710-1484,,,Yevgenia Kozorovitskiy
279.0,LRRK2 mediates haloperidol-induced changes in indirect pathway striatal projection neurons,Awatramani,10.1101/2024.06.06.597594,,1.0,W4399456209,A5066027781,Loukia Parisiadou,0000-0002-2569-4200,Co-PI,Team Awatramani,Loukia Parisiadou
280.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5049961130,Zachary Gaertner,0000-0002-1760-6549,Key Personnel,Team Awatramani,Zachary Gaertner
281.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5047063128,Cameron Oram,,,,Cameron Oram
282.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5083262467,Amanda Schneeweis,0000-0003-4141-6064,Project Manager,Team Awatramani,Amanda Schneeweis
283.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5008907296,Elan Schonfeld,0000-0001-7368-1562,,,Elan Schonfeld
284.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5092500090,Cyril Bolduc,,,,Cyril Bolduc
285.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5065174544,Chuyu Chen,0000-0001-5666-5173,Key Personnel,Team Awatramani,Chuyu Chen
286.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5035273874,Daniel A. Dombeck,0000-0003-2576-5918,Co-PI,Team Awatramani,Daniel Dombeck
287.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5066027781,Loukia Parisiadou,0000-0002-2569-4200,Co-PI,Team Awatramani,Loukia Parisiadou
288.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5001017141,Jean‐François Poulin,0000-0002-1039-4985,,,Jean‐François Poulin
289.0,Molecular and spatial transcriptomic classification of midbrain dopamine neurons and their alterations in a LRRK2G2019S model of Parkinson’s disease,Awatramani,10.1101/2024.06.06.597807,,1.0,W4399457078,A5082378596,Rajeshwar Awatramani,0000-0002-0713-2140,Lead-PI,Team Awatramani,Rajeshwar Awatramani
290.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5046871229,Thomas Goralski,0000-0003-2625-9195,Key Personnel,Team Biederer,Thomas Goralski
291.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5036594161,Lindsay Meyerdirk,0000-0003-4640-9517,Key Personnel,Team Biederer,Lindsay Meyerdirk
292.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5108232890,Libby Breton,,Key Personnel,Team Biederer,Libby Breton
293.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5113152817,L. Brasseur,0009-0003-5331-138X,Key Personnel,Team Biederer,L. Brasseur
294.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5091973419,Kevin Kurgat,0000-0003-3237-7390,Key Personnel,Team Biederer,Kevin Kurgat
295.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5091973420,Daniella DeWeerd,0000-0002-2675-5132,Key Personnel,Team Biederer,Daniella DeWeerd
296.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5102714345,Lisa Turner,0000-0003-3586-8566,,,Lisa Turner
297.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5067142435,Katelyn Becker,0000-0003-4060-6181,,,Katelyn Becker
298.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5060598963,Marie Adams,0000-0001-7909-2339,,,Marie Adams
299.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5007181705,Daniel Newhouse,0000-0002-7694-0475,,,Daniel Newhouse
300.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Biederer,Michael Henderson
301.0,Spatial transcriptomics reveals molecular dysfunction associated with Lewy pathology,Biederer,10.1101/2023.05.17.541144,10.1038/s41467-024-47027-8,1.0,W4393196586,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Lee,Michael Henderson
302.0,Vibrational Stabilization of Cluster Synchronization in Oscillator Networks,Biederer,10.48550/arXiv.2308.07302,10.1109/ojcsys.2023.3331195,1.0,W4388505368,A5003846639,Yuzhen Qin,0000-0003-1851-1370,,,Yuzhen Qin
303.0,Vibrational Stabilization of Cluster Synchronization in Oscillator Networks,Biederer,10.48550/arXiv.2308.07302,10.1109/ojcsys.2023.3331195,1.0,W4388505368,A5050182773,Alberto Nobili,0000-0002-3073-8503,,,Alberto Nobili
304.0,Vibrational Stabilization of Cluster Synchronization in Oscillator Networks,Biederer,10.48550/arXiv.2308.07302,10.1109/ojcsys.2023.3331195,1.0,W4388505368,A5009266404,Danielle S. Bassett,0000-0002-6183-4493,Collaborating PI,Team Biederer,Danielle Bassett
305.0,Vibrational Stabilization of Cluster Synchronization in Oscillator Networks,Biederer,10.48550/arXiv.2308.07302,10.1109/ojcsys.2023.3331195,1.0,W4388505368,A5049920415,Fabio Pasqualetti,0000-0002-8457-8656,,,Fabio Pasqualetti
306.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5027680501,Noah Lubben,,Key Personnel,Team Biederer,Noah Lubben
307.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5091794967,Julia K. Brynildsen,0000-0002-1627-6576,Key Personnel,Team Biederer,Julia Brynildsen
308.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5066728154,Connor M. Webb,0000-0003-2304-2310,,,Connor Webb
309.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5054060736,Howard L. Li,,,,Howard Li
310.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5035944191,Cheryl E. G. Leyns,0000-0001-5513-7758,,,Cheryl Leyns
311.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5020602164,Lakshmi Changolkar,,,,Lakshmi Changolkar
312.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5100392884,Bin Zhang,0000-0002-9549-5653,,,Bin Zhang
313.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5018005188,Emily S. Meymand,0000-0002-7450-1380,,,Emily Meymand
314.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5027778522,Mia O’Reilly,0000-0002-0124-4766,,,Mia O’Reilly
315.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5091704907,Zach Madaj,,,,Zach Madaj
316.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5091973420,Daniella DeWeerd,0000-0002-2675-5132,Key Personnel,Team Biederer,Daniella DeWeerd
317.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5088117447,Matthew Fell,0000-0002-7776-2877,,,Matthew Fell
318.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5065852445,Virginia M.‐Y. Lee,0000-0003-3536-6902,,,Virginia Lee
319.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5110814853,Dani S. Bassett,,,,Dani Bassett
320.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Biederer,Michael Henderson
321.0,LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology spread,Biederer,10.1101/2023.10.06.561190,10.1186/s40035-024-00403-2,1.0,W4392375298,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Lee,Michael Henderson
322.0,Vibrational Stabilization of Complex Network Systems,Biederer,10.48550/arXiv.2308.05823,10.23919/acc55779.2023.10156032,1.0,W4382936236,A5050182773,Alberto Nobili,0000-0002-3073-8503,,,Alberto Nobili
323.0,Vibrational Stabilization of Complex Network Systems,Biederer,10.48550/arXiv.2308.05823,10.23919/acc55779.2023.10156032,1.0,W4382936236,A5003846639,Yuzhen Qin,0000-0003-1851-1370,,,Yuzhen Qin
324.0,Vibrational Stabilization of Complex Network Systems,Biederer,10.48550/arXiv.2308.05823,10.23919/acc55779.2023.10156032,1.0,W4382936236,A5086535808,Carlo Alberto Avizzano,0000-0001-5802-541X,,,Carlo Avizzano
325.0,Vibrational Stabilization of Complex Network Systems,Biederer,10.48550/arXiv.2308.05823,10.23919/acc55779.2023.10156032,1.0,W4382936236,A5009266404,Danielle S. Bassett,0000-0002-6183-4493,Collaborating PI,Team Biederer,Danielle Bassett
326.0,Vibrational Stabilization of Complex Network Systems,Biederer,10.48550/arXiv.2308.05823,10.23919/acc55779.2023.10156032,1.0,W4382936236,A5049920415,Fabio Pasqualetti,0000-0002-8457-8656,,,Fabio Pasqualetti
327.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5055115140,Nolwazi Z. Gcwensa,0000-0001-9708-6119,,,Nolwazi Gcwensa
328.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5078007115,Drèson L. Russell,,,,Drèson Russell
329.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5104344925,Khaliah Y. Long,,,,Khaliah Long
330.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5078608675,Charlotte F. Brzozowski,0000-0002-8871-2453,Key Personnel,Team Biederer,Charlotte Brzozowski
331.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5108128866,Xin-Ran Liu,,,,Xin-Ran Liu
332.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5067918792,Karen L. Gamble,0000-0003-3813-8577,,,Karen Gamble
333.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5069656529,Rita M. Cowell,0000-0001-5814-9412,,,Rita Cowell
334.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5049620072,Laura A. Volpicelli‐Daley,0000-0001-8934-4018,Co-PI,Team Biederer,Laura Volpicelli‐Daley
335.0,Cortico-amygdala synaptic structural abnormalities produced by templated aggregation of α-synuclein,Biederer,10.1101/2024.05.15.594419,,1.0,W4396965087,A5049620072,Laura A. Volpicelli‐Daley,0000-0001-8934-4018,Key Personnel,Team Kordower,Laura Volpicelli‐Daley
336.0,Vibrational Control of Complex Networks,Biederer,10.48550/arXiv.2408.08263,,1.0,W4406024079,A5003846639,Yuzhen Qin,0000-0003-1851-1370,,,Yuzhen Qin
337.0,Vibrational Control of Complex Networks,Biederer,10.48550/arXiv.2408.08263,,1.0,W4406024079,A5049920415,Fabio Pasqualetti,0000-0002-8457-8656,,,Fabio Pasqualetti
338.0,Vibrational Control of Complex Networks,Biederer,10.48550/arXiv.2408.08263,,1.0,W4406024079,A5009266404,Danielle S. Bassett,0000-0002-6183-4493,Collaborating PI,Team Biederer,Danielle Bassett
339.0,Vibrational Control of Complex Networks,Biederer,10.48550/arXiv.2408.08263,,1.0,W4406024079,A5074794877,Marcel van Gerven,0000-0002-2206-9098,,,Marcel Gerven
340.0,The integrated stress response in brain diseases: a double-edged sword for proteostasis and synapses,Calakos,NA_Review,10.1016/j.conb.2024.102886,0.0,W4399795832,A5054911451,Elana R. Lockshin,0000-0001-5808-7995,Key Personnel,Team Calakos,Elana Lockshin
341.0,The integrated stress response in brain diseases: a double-edged sword for proteostasis and synapses,Calakos,NA_Review,10.1016/j.conb.2024.102886,0.0,W4399795832,A5085465113,Nicole Calakos,0000-0002-9918-3294,Lead-PI,Team Calakos,Nicole Calakos
342.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5023506109,Justin T Savage,0000-0002-1530-4942,Key Personnel,Team Calakos,Justin Savage
343.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5085161076,J.J. Ramirez,0000-0001-5724-6384,,,J.J. Ramirez
344.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5028640309,W. Christopher Risher,0000-0002-2230-2865,,,W. Risher
345.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5083351215,Yizhi Wang,0000-0001-5279-5034,,,Yizhi Wang
346.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5037612007,Dolores Irala,0000-0001-5799-5342,,,Dolores Irala
347.0,SynBot: An open-source image analysis software for automated quantification of synapses,Calakos,10.1101/2023.06.26.546578,10.1016/j.crmeth.2024.100861,1.0,W4402357127,A5017962710,Çağla Eroğlu,0000-0002-7204-0218,Co-PI,Team Calakos,Çağla Eroğlu
348.0,An open-source head-fixation and implant-protection system for mice,Calakos,NA_hardware article,10.1016/j.ohx.2022.e00391,0.0,W4313219376,A5080279475,I. Weaver,0000-0002-9375-4447,,,I. Weaver
349.0,An open-source head-fixation and implant-protection system for mice,Calakos,NA_hardware article,10.1016/j.ohx.2022.e00391,0.0,W4313219376,A5025366779,S. Aryana Yousefzadeh,0000-0003-2842-7121,Key Personnel,Team Calakos,S. Yousefzadeh
350.0,An open-source head-fixation and implant-protection system for mice,Calakos,NA_hardware article,10.1016/j.ohx.2022.e00391,0.0,W4313219376,A5078373067,Michael R. Tadross,0000-0002-7752-6380,Co-PI,Team Calakos,Michael Tadross
351.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5073420685,Dhanesh Sivadasan Bindu,,,,Dhanesh Bindu
352.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5023506109,Justin T Savage,0000-0002-1530-4942,Key Personnel,Team Calakos,Justin Savage
353.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5064817514,Nicholas Brose,0000-0003-1559-0237,Key Personnel,Team Calakos,Nicholas Brose
354.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5107935517,Luke Bradley,,Key Personnel,Team Calakos,Luke Bradley
355.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5033925667,Kylie Dimond,,,,Kylie Dimond
356.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5002647104,Christabel Xin Tan,0000-0002-6483-5838,,,Christabel Tan
357.0,GEARBOCS: An Adeno Associated Virus Tool for In Vivo Gene Editing in Astrocytes,Calakos,10.1101/2023.01.17.524433,,1.0,W4317490316,A5017962710,Çağla Eroğlu,0000-0002-7204-0218,Co-PI,Team Calakos,Çağla Eroğlu
358.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5064202687,Shiyi Wang,0000-0003-3433-3025,Key Personnel,Team Calakos,Shiyi Wang
359.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5090150783,Ryan Baumert,0000-0003-0487-4912,Key Personnel,Team Calakos,Ryan Baumert
360.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5021652883,Gabrielle Séjourné,0000-0002-4633-2700,Key Personnel,Team Calakos,Gabrielle Séjourné
361.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5073420685,Dhanesh Sivadasan Bindu,,,,Dhanesh Bindu
362.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5033925667,Kylie Dimond,,,,Kylie Dimond
363.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5057799597,Kristina Sakers,0000-0001-8853-053X,,,Kristina Sakers
364.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5075979524,L. Hermer Vazquez,0000-0002-5609-980X,Key Personnel,Team Calakos,L. Vazquez
365.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5020826892,Jessica L. Moore,0000-0002-7577-7127,,,Jessica Moore
366.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5002647104,Christabel Xin Tan,0000-0002-6483-5838,,,Christabel Tan
367.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5021256917,Tetsuya Takano,0000-0002-2599-3155,,,Tetsuya Takano
368.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5072073867,M. Rodríguez,0000-0003-0949-3326,,,M. Rodríguez
369.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5080635428,Scott H. Soderling,0000-0001-7808-197X,Co-PI,Team Calakos,Scott Soderling
370.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5064140449,Albert R. La Spada,0000-0001-6151-2964,,,Albert Spada
371.0,Astrocytic LRRK2 Controls Synaptic Connectivity through ERM Phosphorylation,Calakos,10.1101/2023.04.09.536178,,1.0,W4363676015,A5017962710,Çağla Eroğlu,0000-0002-7204-0218,Co-PI,Team Calakos,Çağla Eroğlu
372.0,Reward perseveration is shaped by GABAA-mediated dopamine pauses,Calakos,10.1101/2024.05.09.593320,,1.0,W4396811761,A5066705025,Sasha Burwell,0000-0003-3553-1365,,,Sasha Burwell
373.0,Reward perseveration is shaped by GABAA-mediated dopamine pauses,Calakos,10.1101/2024.05.09.593320,,1.0,W4396811761,A5072138284,Hai Yan,0000-0003-0916-8865,Key Personnel,Team Calakos,Hai Yan
374.0,Reward perseveration is shaped by GABAA-mediated dopamine pauses,Calakos,10.1101/2024.05.09.593320,,1.0,W4396811761,A5036850510,Shaun S.X. Lim,0000-0001-9312-6275,Key Personnel,Team Calakos,Shaun Lim
375.0,Reward perseveration is shaped by GABAA-mediated dopamine pauses,Calakos,10.1101/2024.05.09.593320,,1.0,W4396811761,A5060965341,Brenda C. Shields,0000-0001-9036-2686,Key Personnel,Team Calakos,Brenda Shields
376.0,Reward perseveration is shaped by GABAA-mediated dopamine pauses,Calakos,10.1101/2024.05.09.593320,,1.0,W4396811761,A5078373067,Michael R. Tadross,0000-0002-7752-6380,Co-PI,Team Calakos,Michael Tadross
377.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5020152429,Pranay Srivastava,0000-0002-9289-2696,,,Pranay Srivastava
378.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5036502710,Shuhei Nishiyama,0000-0002-0248-1595,,,Shuhei Nishiyama
379.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5021640967,Fang Zhou,0000-0002-8211-9181,Key Personnel,Team Chen,Fang Zhou
380.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5102594393,Sonia Lin,,,,Sonia Lin
381.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5114142243,Akriti Srivastava,,Key Personnel,Team Chen,Akriti Srivastava
382.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5083908936,Chien‐Wen Su,0000-0002-5457-9295,,,Chien‐Wen Su
383.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5102444871,Yuehang Xu,,,,Yuehang Xu
384.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5071360122,Weiyi Peng,0000-0002-7785-6240,Co-PI,Team Chen,Weiyi Peng
385.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5088331314,Michaël Levy,0000-0003-2766-5777,,,Michaël Levy
386.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5041777746,Michael A. Schwarzschild,0000-0001-6019-8280,Co-PI,Team Chen,Michael Schwarzschild
387.0,Peripheral MC1R activation modulates immune responses and is neuroprotective in a mouse model of Parkinson's disease,Chen,10.21203/rs.3.rs-3042571/v1,10.1007/s11481-023-10094-7,1.0,W4389947944,A5012470875,Xiqun Chen,0000-0001-8582-8891,Lead-PI,Team Chen,Xiqun Chen
388.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5103031810,Waijiao Cai,0000-0003-4730-1145,,,Waijiao Cai
389.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5010983774,Kazumasa Wakamatsu,0000-0003-1748-9001,,,Kazumasa Wakamatsu
390.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5040986998,Fabio A. Zucca,0000-0003-1230-1129,,,Fabio Zucca
391.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5100434915,Qing Wang,0009-0003-7328-8762,Key Personnel,Team Chen,Qing Wang
392.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5100420873,Kai Yang,0000-0002-5983-198X,,,Kai Yang
393.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5028737762,Niyaz Mohamadzadehonarvar,,,,Niyaz Mohamadzadehonarvar
394.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5020152429,Pranay Srivastava,0000-0002-9289-2696,,,Pranay Srivastava
395.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5012085690,Hitomi Tanaka,0000-0002-5646-9620,,,Hitomi Tanaka
396.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5051483013,Gabriel Holly,,,,Gabriel Holly
397.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5026694008,Luigi Casella,0000-0002-7671-0506,,,Luigi Casella
398.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5065973944,Shosuke Ito,0000-0001-9182-5144,,,Shosuke Ito
399.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5030347715,Luigi Zecca,0000-0002-7409-6653,,,Luigi Zecca
400.0,DOPA pheomelanin is increased in nigral neuromelanin of Parkinson’s disease,Chen,10.1101/2022.06.30.22277063,10.1016/j.pneurobio.2023.102414,1.0,W4319071820,A5031896665,Xiqun Chen,0000-0001-8285-084X,Lead-PI,Team Chen,Xiqun Chen
401.0,Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants,Chen,missing,10.1136/bmjopen-2020-046329,1.0,W3177121370,A5100400229,Xinyuan Zhang,0000-0002-2974-8392,,,Xinyuan Zhang
402.0,Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants,Chen,missing,10.1136/bmjopen-2020-046329,1.0,W3177121370,A5102906733,David Guarin,0000-0003-3011-3252,,,David Guarin
403.0,Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants,Chen,missing,10.1136/bmjopen-2020-046329,1.0,W3177121370,A5028201977,Niyaz Mohammadzadehhonarvar,,,,Niyaz Mohammadzadehhonarvar
404.0,Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants,Chen,missing,10.1136/bmjopen-2020-046329,1.0,W3177121370,A5031896665,Xiqun Chen,0000-0001-8285-084X,Lead-PI,Team Chen,Xiqun Chen
405.0,Parkinson’s disease and cancer: a systematic review and meta-analysis of over 17 million participants,Chen,missing,10.1136/bmjopen-2020-046329,1.0,W3177121370,A5100658122,Xiang Gao,0000-0003-2617-6509,,,Xiang Gao
406.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5103031810,Waijiao Cai,0000-0003-4730-1145,,,Waijiao Cai
407.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5020152429,Pranay Srivastava,0000-0002-9289-2696,,,Pranay Srivastava
408.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5006612113,Danielle Feng,,,,Danielle Feng
409.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5109499373,Yue Lin,,,,Yue Lin
410.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5040726643,Charles Vanderburg,0000-0001-8979-5054,,,Charles Vanderburg
411.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5102444871,Yuehang Xu,,,,Yuehang Xu
412.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5000693728,Pamela J. McLean,0000-0003-4870-5715,,,Pamela McLean
413.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5005004760,Matthew P. Frosch,0000-0002-3940-9861,,,Matthew Frosch
414.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5078874539,David E. Fisher,0000-0002-5506-0575,,,David Fisher
415.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5041777746,Michael A. Schwarzschild,0000-0001-6019-8280,Co-PI,Team Chen,Michael Schwarzschild
416.0,Melanocortin 1 receptor activation protects against alpha-synuclein pathologies in models of Parkinson’s disease,Chen,10.21203/rs.3.rs-286792/v1,10.1186/s13024-022-00520-4,1.0,W4214701465,A5012470875,Xiqun Chen,0000-0001-8582-8891,Lead-PI,Team Chen,Xiqun Chen
417.0,Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase,Chen,10.21203/rs.3.rs-220057/v2,10.4103/1673-5374.361516,1.0,W4312195675,A5012470875,Xiqun Chen,0000-0001-8582-8891,Lead-PI,Team Chen,Xiqun Chen
418.0,Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase,Chen,10.21203/rs.3.rs-220057/v2,10.4103/1673-5374.361516,1.0,W4312195675,A5100347568,Qing Ye,,,,Qing Ye
419.0,Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase,Chen,10.21203/rs.3.rs-220057/v2,10.4103/1673-5374.361516,1.0,W4312195675,A5020152429,Pranay Srivastava,0000-0002-9289-2696,,,Pranay Srivastava
420.0,Oncogenic BRAFV600E induces microglial proliferation through extracellular signal-regulated kinase and neuronal death through c-Jun N-terminal kinase,Chen,10.21203/rs.3.rs-220057/v2,10.4103/1673-5374.361516,1.0,W4312195675,A5007648760,Nasser Al-Kuwari,,,,Nasser Al-Kuwari
421.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5045943833,Ningbo Zheng,0000-0002-3684-5596,Key Personnel,Team Chen,Ningbo Zheng
422.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5088133308,Roshni Jaffery,0000-0003-4128-345X,Key Personnel,Team Chen,Roshni Jaffery
423.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5052116447,Ashley Guerrero,0009-0008-6393-9433,Key Personnel,Team Chen,Ashley Guerrero
424.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5012952780,Jiakai Hou,0000-0003-2875-8756,Key Personnel,Team Chen,Jiakai Hou
425.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5031753981,Yuchen Pan,0000-0001-9260-4562,,,Yuchen Pan
426.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5101866284,Fang Zhou,0000-0002-8913-1300,Key Personnel,Team Chen,Fang Zhou
427.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5047006608,Si Chen,0009-0007-7508-9619,,,Si Chen
428.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5070436622,C Xu,,,,C Xu
429.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5103047426,Nicholas A. Egan,0009-0003-7662-9817,,,Nicholas Egan
430.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5087536188,Ritu Bohat,0000-0001-6660-4235,,,Ritu Bohat
431.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5100420347,Ken Chen,0000-0003-4013-5279,,,Ken Chen
432.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5041777746,Michael A. Schwarzschild,0000-0001-6019-8280,Co-PI,Team Chen,Michael Schwarzschild
433.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5012470875,Xiqun Chen,0000-0001-8582-8891,Lead-PI,Team Chen,Xiqun Chen
434.0,LRRK2 G2019S mutation suppresses differentiation of Th9 and Treg cells via JAK/STAT3,Chen,10.1101/2024.02.28.582561,,1.0,W4392571096,A5071360122,Weiyi Peng,0000-0002-7785-6240,Co-PI,Team Chen,Weiyi Peng
435.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5043060138,Peter Kilfeather,0000-0002-9882-8417,,,Peter Kilfeather
436.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5004436692,Jia Hui Khoo,0000-0001-8385-5669,,,Jia Khoo
437.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5061600344,Katherina Wagner,,,,Katherina Wagner
438.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5053104107,Han Liang,0000-0001-7633-286X,,,Han Liang
439.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5044697919,Maria Claudia Caiazza,0000-0002-0568-964X,Key Personnel,Team Cragg,Maria Caiazza
440.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5076956721,Yanru An,,,,Yanru An
441.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5102925863,Xingju Zhang,0000-0003-0717-2510,,,Xingju Zhang
442.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5009721225,Xiaoyan Chen,0000-0003-3719-6601,,,Xiaoyan Chen
443.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5024445452,Natalie Connor‐Robson,0000-0001-8350-6928,,,Natalie Connor‐Robson
444.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5048636257,Zhouchun Shang,0000-0002-1740-7961,,,Zhouchun Shang
445.0,"Single cell spatial transcriptomic and translatomic profiling of dopaminergic neurons in health, ageing and disease",Cragg,10.1101/2023.04.20.537553,10.1016/j.celrep.2024.113784,1.0,W4392010121,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
446.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5054612290,Mai-Anh Vu,0000-0003-4766-1159,Key Personnel,Team Cragg,Mai-Anh Vu
447.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5113489962,E. Brown,,,,E. Brown
448.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5010083359,Michelle J. Wen,,,,Michelle Wen
449.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5093284830,Christian A. Noggle,0009-0003-0225-3677,,,Christian Noggle
450.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5101797192,Zicheng Zhang,0000-0002-7247-7938,,,Zicheng Zhang
451.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5004348674,Kevin J. Monk,0000-0003-2055-2614,,,Kevin Monk
452.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5085666638,Safa Bouabid,0000-0003-4184-3795,Key Personnel,Team Cragg,Safa Bouabid
453.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5040981342,Lydia Mroz,,,,Lydia Mroz
454.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5111258341,Benjamin Graham,0009-0004-6303-1784,,,Benjamin Graham
455.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5100773066,Yizhou Zhuo,0000-0001-5359-8489,,,Yizhou Zhuo
456.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5100428710,Yulong Li,0000-0002-9166-9919,Collaborating PI,Team Cragg,Yulong Li
457.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5017395120,Timothy M. Otchy,0000-0001-8259-3628,,,Timothy Otchy
458.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5080490976,Lin Tian,0000-0001-7012-6926,Collaborating PI,Team Gradinaru,Lin Tian
459.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5020594160,Ian G. Davison,0000-0003-0998-7676,,,Ian Davison
460.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5035399148,David A. Boas,0000-0002-6709-7711,,,David Boas
461.0,"Targeted micro-fiber arrays for measuring and manipulating localized multi-scale neural dynamics over large, deep brain volumes during behavior",Cragg,10.1101/2023.11.17.567425,10.1016/j.neuron.2023.12.011,1.0,W4391056187,A5003078833,Mark W. Howe,0000-0002-6865-5084,Co-PI,Team Cragg,Mark Howe
462.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5029629836,Quyen Do,0000-0003-4223-0886,,,Quyen Do
463.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5101661470,Humaira Noor,0000-0002-7141-2681,Key Personnel,Team Cragg,Humaira Noor
464.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5082797221,Ricardo Márquez-Gómez,0000-0002-5810-2670,Key Personnel,Team Cragg,Ricardo Márquez-Gómez
465.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5003734230,Kaitlyn M. L. Cramb,0000-0003-2822-7752,Key Personnel,Team Cragg,Kaitlyn Cramb
466.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5006234336,Bryan Ng,0000-0002-6819-0176,,,Bryan Ng
467.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5111172243,Ajantha Abbey,,,,Ajantha Abbey
468.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5000609169,Naroa Ibarra-Aizpurua,,,,Naroa Ibarra-Aizpurua
469.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5044697919,Maria Claudia Caiazza,0000-0002-0568-964X,Key Personnel,Team Cragg,Maria Caiazza
470.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5017470353,Parnaz Sharifi,0000-0002-8735-0913,Key Personnel,Team Cragg,Parnaz Sharifi
471.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5006503117,Charmaine Lang,0000-0001-8190-4850,,,Charmaine Lang
472.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5037902391,Dayne Beccano-Kelly,0000-0003-3592-8354,,,Dayne Beccano-Kelly
473.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5091089229,Jimena Baleriola,0000-0001-9628-4631,,,Jimena Baleriola
474.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5011590646,Nora Bengoa‐Vergniory,0000-0002-3700-0464,Key Personnel,Team Cragg,Nora Bengoa‐Vergniory
475.0,Early deficits in an in vitro striatal microcircuit model carrying the Parkinson’s GBA-N370S mutation | npj Parkinson's Disease (springer.com),Cragg,10.1101/2023.03.01.530566,10.1038/s41531-024-00694-2,1.0,W4394753925,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
476.0,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy | bioRxiv,Cragg,10.1101/2023.10.14.562004,10.1039/d4lc00107a,1.0,W4399401317,A5021317540,Federico Nebuloni,0000-0002-8032-3189,,,Federico Nebuloni
477.0,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy | bioRxiv,Cragg,10.1101/2023.10.14.562004,10.1039/d4lc00107a,1.0,W4399401317,A5029629836,Quyen Do,0000-0003-4223-0886,,,Quyen Do
478.0,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy | bioRxiv,Cragg,10.1101/2023.10.14.562004,10.1039/d4lc00107a,1.0,W4399401317,A5061481204,Peter R. Cook,0000-0002-6639-188X,,,Peter Cook
479.0,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy | bioRxiv,Cragg,10.1101/2023.10.14.562004,10.1039/d4lc00107a,1.0,W4399401317,A5062889892,Edmond J. Walsh,0000-0001-5264-1561,,,Edmond Walsh
480.0,A fluid-walled microfluidic platform for human neuron microcircuits and directed axotomy | bioRxiv,Cragg,10.1101/2023.10.14.562004,10.1039/d4lc00107a,1.0,W4399401317,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
481.0,Impaired dopamine release in Parkinson’s disease,Cragg,review,10.1093/brain/awad064,0.0,W4323036321,A5003734230,Kaitlyn M. L. Cramb,0000-0003-2822-7752,Key Personnel,Team Cragg,Kaitlyn Cramb
482.0,Impaired dopamine release in Parkinson’s disease,Cragg,review,10.1093/brain/awad064,0.0,W4323036321,A5037902391,Dayne Beccano-Kelly,0000-0003-3592-8354,,,Dayne Beccano-Kelly
483.0,Impaired dopamine release in Parkinson’s disease,Cragg,review,10.1093/brain/awad064,0.0,W4323036321,A5087084011,Stephanie J. Cragg,0000-0001-9677-2256,Lead-PI,Team Cragg,Stephanie Cragg
484.0,Impaired dopamine release in Parkinson’s disease,Cragg,review,10.1093/brain/awad064,0.0,W4323036321,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
485.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5061258414,Katherine R. Brimblecombe,0000-0003-0809-7292,Key Personnel,Team Cragg,Katherine Brimblecombe
486.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5024445452,Natalie Connor‐Robson,0000-0001-8350-6928,,,Natalie Connor‐Robson
487.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5082978839,Carole J. R. Bataille,0000-0002-3963-0021,,,Carole Bataille
488.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5021012577,Bradley M. Roberts,0000-0002-5192-2545,,,Bradley Roberts
489.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5022812451,Caitlin Gracie,,,,Caitlin Gracie
490.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5024223034,Bethan O’Connor,0000-0002-0093-5688,Key Personnel,Team Cragg,Bethan O’Connor
491.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5048225178,Rebecca te Water Naudé,,,,Rebecca Naudé
492.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5042953203,Gayathri Karthik,0000-0003-1876-0975,,,Gayathri Karthik
493.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5005924822,Angela J. Russell,0000-0003-3610-9369,,,Angela Russell
494.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
495.0,Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson’s,Cragg,10.1101/2020.07.03.186411,10.1111/ejn.16180,1.0,W4388535022,A5087084011,Stephanie J. Cragg,0000-0001-9677-2256,Lead-PI,Team Cragg,Stephanie Cragg
496.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5101575954,Shenjie Wu,0000-0001-7547-0048,,,Shenjie Wu
497.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5073352328,Nancy C. Hernandez Villegas,0000-0002-3982-7553,,,Nancy Villegas
498.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5069263056,Daniel W. Sirkis,0000-0003-3440-8859,,,Daniel Sirkis
499.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5035010942,Iona Thomas-Wright,,,,Iona Thomas-Wright
500.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5028723665,Richard Wade‐Martins,0000-0001-6691-580X,Co-PI,Team Cragg,Richard Wade‐Martins
501.0,Unconventional secretion of α-synuclein mediated by palmitoylated DNAJC5 oligomers,Cragg,10.1101/2022.01.27.477991,10.7554/eLife.85837,1.0,W4313988037,A5016859611,Randy Schekman,0000-0001-8615-6409,,,Randy Schekman
502.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5024312076,Moritz Weglage,0000-0002-9173-7459,,,Moritz Weglage
503.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5045052617,Sofie Ährlund‐Richter,0000-0002-7845-7831,,,Sofie Ährlund‐Richter
504.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5056549934,János Fuzik,0000-0002-5408-4882,,,János Fuzik
505.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5022184745,Vasiliki Skara,0000-0002-0017-6116,Key Personnel,Team Cragg,Vasiliki Skara
506.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5022862122,Iakovos Lazaridis,0000-0002-4578-2347,,,Iakovos Lazaridis
507.0,Sst+ GPi output neurons provide direct feedback to key nodes of the basal ganglia and drive behavioral flexibility,Cragg,10.1101/2022.03.16.484460,,1.0,W4220818899,A5004457607,Konstantinos Meletis,0000-0001-5665-4781,Co-PI,Team Cragg,Konstantinos Meletis
508.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5100367490,Yan-Feng Zhang,0000-0001-7815-6492,,,Yan-Feng Zhang
509.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5065353322,Pengwei Luan,0000-0002-4664-4093,,,Pengwei Luan
510.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5080845578,Qinbo Qiao,0000-0002-5071-5579,Key Personnel,Team Cragg,Qinbo Qiao
511.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5102025160,Yiran He,0000-0002-9572-6554,,,Yiran He
512.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5027191630,Peter Zatka-Haas,0000-0001-9054-2599,,,Peter Zatka-Haas
513.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5100693459,Guofeng Zhang,0000-0003-1180-4170,,,Guofeng Zhang
514.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5061736694,Michael Z. Lin,0000-0002-0492-1961,Collaborating PI,Team Cragg,Michael Lin
515.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5032963618,Armin Lak,0000-0003-1926-5458,,,Armin Lak
516.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5060865058,Jing Miao,0000-0002-4963-5993,,,Jing Miao
517.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5064709301,Edward O. Mann,0000-0002-2468-7148,,,Edward Mann
518.0,An axonal brake on striatal dopamine output by cholinergic interneurons,Cragg,10.1101/2024.02.17.580796,,1.0,W4392201373,A5087084011,Stephanie J. Cragg,0000-0001-9677-2256,Lead-PI,Team Cragg,Stephanie Cragg
519.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5021013042,Jeffrey Stedehouder,0000-0001-6017-7279,,,Jeffrey Stedehouder
520.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5021012577,Bradley M. Roberts,0000-0002-5192-2545,,,Bradley Roberts
521.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5098667594,Shinil Raina,0000-0002-1837-9616,Key Personnel,Team Cragg,Shinil Raina
522.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5064590132,Simon Bossi,0000-0001-6411-5075,Key Personnel,Team Cragg,Simon Bossi
523.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5073955030,Alan King Lun Liu,0000-0001-6109-1338,,,Alan Liu
524.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5062765301,Natalie M. Doig,0000-0001-6821-0264,Key Personnel,Team Cragg,Natalie Doig
525.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5052033332,Kevin McGerty,0000-0002-1553-3438,,,Kevin McGerty
526.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5015406158,Peter J. Magill,0000-0001-7141-7071,Co-PI,Team Cragg,Peter Magill
527.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5061880163,Laura Parkkinen,0000-0002-3392-8564,,,Laura Parkkinen
528.0,Rapid modulation of striatal cholinergic interneurons and dopamine release by satellite astrocytes,Cragg,10.1101/2024.05.15.594341,,1.0,W4396975587,A5087084011,Stephanie J. Cragg,0000-0001-9677-2256,Lead-PI,Team Cragg,Stephanie Cragg
529.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5085666638,Safa Bouabid,0000-0003-4184-3795,Key Personnel,Team Cragg,Safa Bouabid
530.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5010334050,Liangzhu Zhang,0000-0002-7968-6847,,,Liangzhu Zhang
531.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5054612290,Mai-Anh Vu,0000-0003-4766-1159,Key Personnel,Team Cragg,Mai-Anh Vu
532.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5113290446,Kylie Tang,,,,Kylie Tang
533.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5111258341,Benjamin Graham,0009-0004-6303-1784,,,Benjamin Graham
534.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5093284830,Christian A. Noggle,0009-0003-0225-3677,,,Christian Noggle
535.0,Spatially organized striatum-wide acetylcholine dynamics for the learning and extinction of Pavlovian cues and actions,Cragg,10.1101/2024.07.10.602947,,1.0,W4400672529,A5003078833,Mark W. Howe,0000-0002-6865-5084,Co-PI,Team Cragg,Mark Howe
536.0,Insights into VPS13 properties and function reveal a new mechanism of eukaryotic lipid transport,De Camilli,NA Review,10.1016/j.bbalip.2021.159003,0.0,W3181271241,A5074555049,Marianna Leonzino,0000-0002-3277-1112,,,Marianna Leonzino
537.0,Insights into VPS13 properties and function reveal a new mechanism of eukaryotic lipid transport,De Camilli,NA Review,10.1016/j.bbalip.2021.159003,0.0,W3181271241,A5059224100,Karin M. Reinisch,0000-0001-9140-6150,Co-PI,Team De Camilli,Karin Reinisch
538.0,Insights into VPS13 properties and function reveal a new mechanism of eukaryotic lipid transport,De Camilli,NA Review,10.1016/j.bbalip.2021.159003,0.0,W3181271241,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
539.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5081760770,Sisi Yang,0000-0003-0352-833X,,,Sisi Yang
540.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5078559789,Daehun Park,0000-0002-2829-1319,,,Daehun Park
541.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5034648382,Laura Manning,,,,Laura Manning
542.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5012955176,Sarah E. Hill,0000-0002-8499-7455,,,Sarah Hill
543.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5015445193,Mian Cao,0000-0002-8519-6764,,,Mian Cao
544.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5033248009,Xuan Zhao,0000-0002-8254-2887,,,Xuan Zhao
545.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5073594330,Ian Gonzalez,0000-0002-2893-3713,,,Ian Gonzalez
546.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5069834290,Yongming Dong,0000-0002-6510-0913,,,Yongming Dong
547.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5088112721,Benjamin A. Clark,0000-0002-0306-3184,,,Benjamin Clark
548.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5026423769,Lin Shao,0000-0002-1905-4442,,,Lin Shao
549.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5041244660,Ifechukwu Okeke,,,,Ifechukwu Okeke
550.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5053596130,Agustin Almoril-Porras,0000-0002-6949-6783,,,Agustin Almoril-Porras
551.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5002374231,Jihong Bai,0000-0001-6773-2175,,,Jihong Bai
552.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
553.0,Presynaptic autophagy is coupled to the synaptic vesicle cycle via ATG-9,De Camilli,10.1101/2020.12.28.424508,10.1016/j.neuron.2021.12.031,1.0,W4220988819,A5066749886,Daniel A. Colón‐Ramos,0000-0003-0223-7717,,,Daniel Colón‐Ramos
554.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5024169366,Xin Yi Ng,0000-0002-6093-8434,,,Xin Ng
555.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5004727785,Yumei Wu,0000-0003-0878-7605,Key Personnel,Team De Camilli,Yumei Wu
556.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5086876841,Youneng Lin,0000-0003-3634-9135,,,Youneng Lin
557.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5089349964,Sidra Mohamed Yaqoob,,,,Sidra Yaqoob
558.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5004657382,Lois E. Greene,0000-0003-3786-8594,,,Lois Greene
559.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
560.0,Mutations in Parkinsonism-linked endocytic proteins synaptojanin1 and auxilin have synergistic effects on dopaminergic axonal pathology,De Camilli,10.1101/2022.02.28.482419,10.1038/s41531-023-00465-5,1.0,W4321002449,A5015445193,Mian Cao,0000-0002-8519-6764,,,Mian Cao
561.0,Lysosomal TBK1 Responds to Amino Acid Availability to Relieve Rab7-Dependent mTORC1 Inhibition | bioRxiv,De Camilli,10.1101/2023.12.16.571979,10.1038/s44318-024-00180-8,1.0,W4401332739,A5016695766,Gabriel Talaia,0000-0003-1870-4658,Key Personnel,Team De Camilli,Gabriel Talaia
562.0,Lysosomal TBK1 Responds to Amino Acid Availability to Relieve Rab7-Dependent mTORC1 Inhibition | bioRxiv,De Camilli,10.1101/2023.12.16.571979,10.1038/s44318-024-00180-8,1.0,W4401332739,A5019788743,Amanda Bentley‐DeSousa,0000-0002-3667-4029,Key Personnel,Team De Camilli,Amanda Bentley‐DeSousa
563.0,Lysosomal TBK1 Responds to Amino Acid Availability to Relieve Rab7-Dependent mTORC1 Inhibition | bioRxiv,De Camilli,10.1101/2023.12.16.571979,10.1038/s44318-024-00180-8,1.0,W4401332739,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718,Co-PI,Team De Camilli,Shawn Ferguson
564.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5040142346,Shujun Cai,0000-0002-8558-6279,,,Shujun Cai
565.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5004727785,Yumei Wu,0000-0003-0878-7605,Key Personnel,Team De Camilli,Yumei Wu
566.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5045643276,Andrés Guillén-Samander,0000-0002-6882-3850,,,Andrés Guillén-Samander
567.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5086649578,William Hancock‐Cerutti,0000-0002-8051-1112,,,William Hancock‐Cerutti
568.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5100362078,Jun Liu,0000-0003-3108-6735,,,Jun Liu
569.0,In situ architecture of the lipid transport protein VPS13C at ER–lysosome membrane contacts,De Camilli,10.1101/2022.03.08.482579,10.1073/pnas.2203769119,1.0,W4285088070,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
570.0,LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition | PNAS,De Camilli,10.1101/2022.12.17.520834,10.1073/pnas.2303789120,1.0,W4385191034,A5022806006,Narayana Yadavalli,0000-0001-9015-0464,,,Narayana Yadavalli
571.0,LRRK2 suppresses lysosome degradative activity in macrophages and microglia through MiT-TFE transcription factor inhibition | PNAS,De Camilli,10.1101/2022.12.17.520834,10.1073/pnas.2303789120,1.0,W4385191034,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718,Co-PI,Team De Camilli,Shawn Ferguson
572.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5100762075,Xinbo Wang,0000-0001-8524-9662,Key Personnel,Team De Camilli,Xinbo Wang
573.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5090536824,Javier Espadas,0000-0002-4559-5410,,,Javier Espadas
574.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5004727785,Yumei Wu,0000-0003-0878-7605,Key Personnel,Team De Camilli,Yumei Wu
575.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5040142346,Shujun Cai,0000-0002-8558-6279,,,Shujun Cai
576.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5060299931,Jinghua Ge,0000-0002-5820-1521,,,Jinghua Ge
577.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5026423769,Lin Shao,0000-0002-1905-4442,,,Lin Shao
578.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5017325892,Aurélien Roux,0000-0002-6088-0711,,,Aurélien Roux
579.0,Membrane remodeling properties of the Parkinson’s disease protein LRRK2 | PNAS,De Camilli,10.1101/2022.08.10.503505,10.1073/pnas.2309698120,1.0,W4387665107,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
580.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5056728588,Jonathan S. Marvin,0000-0003-2294-4515,,,Jonathan Marvin
581.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5075174957,Alexandros C. Kokotos,0000-0003-4024-9866,Key Personnel,Team De Camilli,Alexandros Kokotos
582.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5051850846,Mukesh Kumar,0000-0002-0277-2958,Key Personnel,Team De Camilli,Mukesh Kumar
583.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5056730601,Camila Pulido,0000-0002-5648-066X,Key Personnel,Team De Camilli,Camila Pulido
584.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5045181969,Ariana N. Tkachuk,0000-0001-8991-9643,,,Ariana Tkachuk
585.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5072896554,J. Yao,0000-0002-8007-8160,,,J. Yao
586.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5052320233,Timothy A. Brown,0000-0001-8941-7678,,,Timothy Brown
587.0,iATPSnFR2: a high dynamic range fluorescent sensor for monitoring intracellular ATP,De Camilli,10.1101/2023.08.24.554624,10.1073/pnas.2314604121,1.0,W4396919562,A5051928889,Timothy A. Ryan,0000-0003-2533-9548,Co-PI,Team De Camilli,Timothy Ryan
588.0,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,De Camilli,10.1101/2023.10.12.562142,10.1073/pnas.2318943121,1.0,W4394909958,A5083173121,Nisha Mohd Rafiq,0000-0002-4434-0504,,,Nisha Rafiq
589.0,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,De Camilli,10.1101/2023.10.12.562142,10.1073/pnas.2318943121,1.0,W4394909958,A5035503318,Kenshiro Fujise,0000-0001-9018-6504,Key Personnel,Team De Camilli,Kenshiro Fujise
590.0,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,De Camilli,10.1101/2023.10.12.562142,10.1073/pnas.2318943121,1.0,W4394909958,A5113022420,Martin Rosenfeld,,,,Martin Rosenfeld
591.0,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,De Camilli,10.1101/2023.10.12.562142,10.1073/pnas.2318943121,1.0,W4394909958,A5045181995,Peng Xu,0000-0001-5197-9560,Key Personnel,Team De Camilli,Peng Xu
592.0,Parkinsonism Sac domain mutation in Synaptojanin-1 affects ciliary properties in iPSC-derived dopaminergic neurons,De Camilli,10.1101/2023.10.12.562142,10.1073/pnas.2318943121,1.0,W4394909958,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
593.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5045643276,Andrés Guillén-Samander,0000-0002-6882-3850,,,Andrés Guillén-Samander
594.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5074555049,Marianna Leonzino,0000-0002-3277-1112,,,Marianna Leonzino
595.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5076782995,Michael G. Hanna,0000-0002-1975-0501,Key Personnel,Team De Camilli,Michael Hanna
596.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5043651129,Ni Tang,0000-0002-4649-9877,,,Ni Tang
597.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5005621524,Hongying Shen,0000-0002-2115-7037,,,Hongying Shen
598.0,VPS13D bridges the ER to mitochondria and peroxisomes via Miro,De Camilli,10.1101/2020.10.07.328906,10.1083/jcb.202010004,1.0,W3156441532,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
599.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5086649578,William Hancock‐Cerutti,0000-0002-8051-1112,,,William Hancock‐Cerutti
600.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5087435298,Zheng Wu,0000-0002-7355-0316,,,Zheng Wu
601.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5045181995,Peng Xu,0000-0001-5197-9560,Key Personnel,Team De Camilli,Peng Xu
602.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5022806006,Narayana Yadavalli,0000-0001-9015-0464,,,Narayana Yadavalli
603.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5074555049,Marianna Leonzino,0000-0002-3277-1112,,,Marianna Leonzino
604.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5031182104,Arun Kumar Tharkeshwar,0000-0002-5529-9754,,,Arun Tharkeshwar
605.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718,Co-PI,Team De Camilli,Shawn Ferguson
606.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5079476247,Gerald S. Shadel,0000-0003-2899-8717,,,Gerald Shadel
607.0,ER-lysosome lipid transfer protein VPS13C/PARK23 prevents aberrant mtDNA-dependent STING signaling,De Camilli,10.1101/2021.06.08.447593,10.1083/jcb.202106046,1.0,W4281946664,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
608.0,SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic,De Camilli,10.1101/2021.11.04.467353,10.1083/jcb.202111018,1.0,W4225282945,A5076782995,Michael G. Hanna,0000-0002-1975-0501,Key Personnel,Team De Camilli,Michael Hanna
609.0,SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic,De Camilli,10.1101/2021.11.04.467353,10.1083/jcb.202111018,1.0,W4225282945,A5034293964,Patreece Suen,,,,Patreece Suen
610.0,SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic,De Camilli,10.1101/2021.11.04.467353,10.1083/jcb.202111018,1.0,W4225282945,A5004727785,Yumei Wu,0000-0003-0878-7605,Key Personnel,Team De Camilli,Yumei Wu
611.0,SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic,De Camilli,10.1101/2021.11.04.467353,10.1083/jcb.202111018,1.0,W4225282945,A5059224100,Karin M. Reinisch,0000-0001-9140-6150,Co-PI,Team De Camilli,Karin Reinisch
612.0,SHIP164 is a chorein motif lipid transfer protein that controls endosome–Golgi membrane traffic,De Camilli,10.1101/2021.11.04.467353,10.1083/jcb.202111018,1.0,W4225282945,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
613.0,Structural and biochemical insights into lipid transport by VPS13 proteins,De Camilli,10.1101/2022.03.11.484024,10.1083/jcb.202202030,1.0,W4221090868,A5077480278,Jyoti Adlakha,0000-0002-3369-1392,,,Jyoti Adlakha
614.0,Structural and biochemical insights into lipid transport by VPS13 proteins,De Camilli,10.1101/2022.03.11.484024,10.1083/jcb.202202030,1.0,W4221090868,A5072197894,Zhouping Hong,0000-0002-8513-3288,,,Zhouping Hong
615.0,Structural and biochemical insights into lipid transport by VPS13 proteins,De Camilli,10.1101/2022.03.11.484024,10.1083/jcb.202202030,1.0,W4221090868,A5011728143,Peiqi Li,0000-0002-6958-1646,,,Peiqi Li
616.0,Structural and biochemical insights into lipid transport by VPS13 proteins,De Camilli,10.1101/2022.03.11.484024,10.1083/jcb.202202030,1.0,W4221090868,A5059224100,Karin M. Reinisch,0000-0001-9140-6150,Co-PI,Team De Camilli,Karin Reinisch
617.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5072197894,Zhouping Hong,0000-0002-8513-3288,,,Zhouping Hong
618.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5077480278,Jyoti Adlakha,0000-0002-3369-1392,,,Jyoti Adlakha
619.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5026456602,Neng Wan,0000-0001-6094-2305,,,Neng Wan
620.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5037309162,Emily Guinn,0000-0003-3957-6683,,,Emily Guinn
621.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5069459526,Fabian Giska,,,,Fabian Giska
622.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5038262390,Kallol Gupta,0000-0002-3557-3242,Co-PI,Team De Camilli,Kallol Gupta
623.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5019657763,Thomas J. Melia,0000-0002-5798-4624,Collaborating PI,Team De Camilli,Thomas Melia
624.0,Mitoguardin-2–mediated lipid transfer preserves mitochondrial morphology and lipid droplet formation,De Camilli,10.1101/2022.07.08.499339,10.1083/jcb.202207022,1.0,W4307585140,A5059224100,Karin M. Reinisch,0000-0001-9140-6150,Co-PI,Team De Camilli,Karin Reinisch
625.0,"Endoplasmic Reticulum Membrane Contact Sites, Lipid Transport, and Neurodegeneration",De Camilli,NA review,10.1101/cshperspect.a041257,0.0,W4296290327,A5045643276,Andrés Guillén-Samander,0000-0002-6882-3850,,,Andrés Guillén-Samander
626.0,"Endoplasmic Reticulum Membrane Contact Sites, Lipid Transport, and Neurodegeneration",De Camilli,NA review,10.1101/cshperspect.a041257,0.0,W4296290327,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
627.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5075174957,Alexandros C. Kokotos,0000-0003-4024-9866,Key Personnel,Team De Camilli,Alexandros Kokotos
628.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5007475523,Aldana M. Antoniazzi,0000-0002-0728-3352,Key Personnel,Team Kaplitt,Aldana Antoniazzi
629.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5003692234,Santiago R. Unda,0000-0001-7319-6794,Key Personnel,Team Kaplitt,Santiago Unda
630.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5059478351,Myung S. Ko,0000-0001-9176-5399,,,Myung Ko
631.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5078559789,Daehun Park,0000-0002-2829-1319,,,Daehun Park
632.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5023661358,David Eliezer,0000-0002-1311-7537,,,David Eliezer
633.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5027250646,Michael G. Kaplitt,0000-0002-8979-2459,Lead-PI,Team Kaplitt,Michael Kaplitt
634.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
635.0,Phosphoglycerate kinase is a central leverage point in Parkinson’s Disease driven neuronal metabolic deficits | bioRxiv,De Camilli,10.1101/2023.10.10.561760,10.1126/sciadv.adn6016,1.0,W4401724314,A5051928889,Timothy A. Ryan,0000-0003-2533-9548,Co-PI,Team De Camilli,Timothy Ryan
636.0,"RBG Motif Bridge-Like Lipid Transport Proteins: Structure, Functions, and Open Questions",De Camilli,review,10.1146/annurev-cellbio-120420-014634,0.0,W4383198320,A5076782995,Michael G. Hanna,0000-0002-1975-0501,Key Personnel,Team De Camilli,Michael Hanna
637.0,"RBG Motif Bridge-Like Lipid Transport Proteins: Structure, Functions, and Open Questions",De Camilli,review,10.1146/annurev-cellbio-120420-014634,0.0,W4383198320,A5045643276,Andrés Guillén-Samander,0000-0002-6882-3850,,,Andrés Guillén-Samander
638.0,"RBG Motif Bridge-Like Lipid Transport Proteins: Structure, Functions, and Open Questions",De Camilli,review,10.1146/annurev-cellbio-120420-014634,0.0,W4383198320,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
639.0,"Erythroid Differentiation Dependent Interaction of VPS13A with XK at the Plasma Membrane of K562 Cells - Chase Amos, Peng Xu, Pietro De Camilli, 2023 (sagepub.com)",De Camilli,10.1101/2023.08.09.552634,10.1177/25152564231215133,1.0,W4390118003,A5011341629,Chase Amos,0000-0002-3176-9387,Key Personnel,Team De Camilli,Chase Amos
640.0,"Erythroid Differentiation Dependent Interaction of VPS13A with XK at the Plasma Membrane of K562 Cells - Chase Amos, Peng Xu, Pietro De Camilli, 2023 (sagepub.com)",De Camilli,10.1101/2023.08.09.552634,10.1177/25152564231215133,1.0,W4390118003,A5045181995,Peng Xu,0000-0001-5197-9560,Key Personnel,Team De Camilli,Peng Xu
641.0,"Erythroid Differentiation Dependent Interaction of VPS13A with XK at the Plasma Membrane of K562 Cells - Chase Amos, Peng Xu, Pietro De Camilli, 2023 (sagepub.com)",De Camilli,10.1101/2023.08.09.552634,10.1177/25152564231215133,1.0,W4390118003,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
642.0,"A possible role for VPS13-family proteins in bulk lipid transfer, membrane expansion and organelle biogenesis",De Camilli,review,10.1242/jcs.259357,0.0,W4221056627,A5019657763,Thomas J. Melia,0000-0002-5798-4624,Collaborating PI,Team De Camilli,Thomas Melia
643.0,"A possible role for VPS13-family proteins in bulk lipid transfer, membrane expansion and organelle biogenesis",De Camilli,review,10.1242/jcs.259357,0.0,W4221056627,A5059224100,Karin M. Reinisch,0000-0001-9140-6150,Co-PI,Team De Camilli,Karin Reinisch
644.0,A STING-CASM-GABARAP Pathway Activates LRRK2 at Lysosomes | bioRxiv,De Camilli,10.1101/2023.10.31.564602,,1.0,W4388141595,A5019788743,Amanda Bentley‐DeSousa,0000-0002-3667-4029,Key Personnel,Team De Camilli,Amanda Bentley‐DeSousa
645.0,A STING-CASM-GABARAP Pathway Activates LRRK2 at Lysosomes | bioRxiv,De Camilli,10.1101/2023.10.31.564602,,1.0,W4388141595,A5068282890,Agnes Roczniak-Ferguson,0000-0003-0838-2157,Key Personnel,Team De Camilli,Agnes Roczniak-Ferguson
646.0,A STING-CASM-GABARAP Pathway Activates LRRK2 at Lysosomes | bioRxiv,De Camilli,10.1101/2023.10.31.564602,,1.0,W4388141595,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718,Co-PI,Team De Camilli,Shawn Ferguson
647.0,Isolation and Lipidomic Profiling of Neuronal Lipid Droplets: Unveiling the Lipid Landscape for insights into Neurodegenerative Disorders,De Camilli,10.1101/2023.12.13.571527,,1.0,W4389722926,A5051850846,Mukesh Kumar,0000-0002-0277-2958,Key Personnel,Team De Camilli,Mukesh Kumar
648.0,Isolation and Lipidomic Profiling of Neuronal Lipid Droplets: Unveiling the Lipid Landscape for insights into Neurodegenerative Disorders,De Camilli,10.1101/2023.12.13.571527,,1.0,W4389722926,A5114108738,Justin A Knapp,,Key Personnel,Team De Camilli,Justin Knapp
649.0,Isolation and Lipidomic Profiling of Neuronal Lipid Droplets: Unveiling the Lipid Landscape for insights into Neurodegenerative Disorders,De Camilli,10.1101/2023.12.13.571527,,1.0,W4389722926,A5038262390,Kallol Gupta,0000-0002-3557-3242,Co-PI,Team De Camilli,Kallol Gupta
650.0,Isolation and Lipidomic Profiling of Neuronal Lipid Droplets: Unveiling the Lipid Landscape for insights into Neurodegenerative Disorders,De Camilli,10.1101/2023.12.13.571527,,1.0,W4389722926,A5051928889,Timothy A. Ryan,0000-0003-2533-9548,Co-PI,Team De Camilli,Timothy Ryan
651.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5040327186,Berrak Uğur,0000-0003-4806-8891,Key Personnel,Team De Camilli,Berrak Uğur
652.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5028729865,Florian Schueder,0000-0003-3412-5066,,,Florian Schueder
653.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5063101749,Jimann Shin,0000-0003-1027-0517,,,Jimann Shin
654.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5076782995,Michael G. Hanna,0000-0002-1975-0501,Key Personnel,Team De Camilli,Michael Hanna
655.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5004727785,Yumei Wu,0000-0003-0878-7605,Key Personnel,Team De Camilli,Yumei Wu
656.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5074555049,Marianna Leonzino,0000-0002-3277-1112,,,Marianna Leonzino
657.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5055594834,Maohan Su,0000-0001-5523-9607,,,Maohan Su
658.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5045788953,Anthony R. McAdow,0000-0003-3440-935X,,,Anthony McAdow
659.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5101654927,Catherine Wilson,0000-0001-5468-0433,,,Catherine Wilson
660.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5084768099,John H. Postlethwait,0000-0002-5476-2137,,,John Postlethwait
661.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5033104500,Lilianna Solnica‐Krezel,0000-0003-0983-221X,,,Lilianna Solnica‐Krezel
662.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5037258583,Joerg Bewersdorf,0000-0002-4085-7020,,,Joerg Bewersdorf
663.0,VPS13B is localized at the cis-trans Golgi complex interface and is a functional partner of FAM177A1 | bioRxiv,De Camilli,10.1101/2023.12.18.572081,,1.0,W4389903301,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
664.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5103792213,Caroline Brown,0009-0002-9988-8144,Key Personnel,Team De Camilli,Caroline Brown
665.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5030583873,Snehasish Ghosh,0000-0003-0472-747X,Key Personnel,Team De Camilli,Snehasish Ghosh
666.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5053038504,Rachel McAllister,,Key Personnel,Team De Camilli,Rachel McAllister
667.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5058591739,Mukesh Kumar,0000-0001-6389-2040,Key Personnel,Team De Camilli,Mukesh Kumar
668.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5074983993,Gerard Walker,0000-0003-1200-7317,,,Gerard Walker
669.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5026277672,Eric I. Sun,,,,Eric Sun
670.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5093914253,Talat Aman,,,,Talat Aman
671.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5054319229,Aniruddha Panda,0000-0002-9447-9547,,,Aniruddha Panda
672.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5102888558,Shailesh Kumar,0000-0002-2321-4322,,,Shailesh Kumar
673.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5012285415,Wenxue Li,0000-0002-8902-0184,,,Wenxue Li
674.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5038337581,Jeff Coleman,0000-0003-0110-9289,,,Jeff Coleman
675.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5025063698,Yansheng Liu,0000-0002-2626-3912,,,Yansheng Liu
676.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5107942278,James E. Rothman,,,,James Rothman
677.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5080298741,Moitrayee Bhattacharyya,0000-0002-2168-1541,,,Moitrayee Bhattacharyya
678.0,A proteome-wide quantitative platform for nanoscale spatially resolved extraction of membrane proteins into native nanodiscs,De Camilli,10.1101/2024.02.10.579775,,1.0,W4391757018,A5038262390,Kallol Gupta,0000-0002-3557-3242,Co-PI,Team De Camilli,Kallol Gupta
679.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5100762075,Xinbo Wang,0000-0001-8524-9662,Key Personnel,Team De Camilli,Xinbo Wang
680.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5045181995,Peng Xu,0000-0001-5197-9560,Key Personnel,Team De Camilli,Peng Xu
681.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5019788743,Amanda Bentley‐DeSousa,0000-0002-3667-4029,Key Personnel,Team De Camilli,Amanda Bentley‐DeSousa
682.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5086649578,William Hancock‐Cerutti,0000-0002-8051-1112,,,William Hancock‐Cerutti
683.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5040142346,Shujun Cai,0000-0002-8558-6279,,,Shujun Cai
684.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5009793962,Benjamin T. Johnson,0000-0003-3444-9669,Project Manager,Team De Camilli,Benjamin Johnson
685.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
686.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5026423769,Lin Shao,0000-0002-1905-4442,,,Lin Shao
687.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5016695766,Gabriel Talaia,0000-0003-1870-4658,Key Personnel,Team De Camilli,Gabriel Talaia
688.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
689.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5091271525,Shawn M. Ferguson,0000-0002-3092-7718,Co-PI,Team De Camilli,Shawn Ferguson
690.0,Lysosome damage triggers acute formation of ER to lysosomes membrane tethers mediated by the bridge-like lipid transport protein VPS13C,De Camilli,10.1101/2024.06.08.598070,,1.0,W4399456222,A5037459294,Pietro De Camilli,0000-0001-9045-0723,Lead PI,Team De Camilli,Pietro Camilli
691.0,Microbes and Parkinson’s disease: from associations to mechanisms: Trends in Microbiology (cell.com),Desjardins,review,10.1016/j.tim.2022.01.004,0.0,W4210482530,A5082232568,Tyler Cannon,0000-0001-6809-5470,,,Tyler Cannon
692.0,Microbes and Parkinson’s disease: from associations to mechanisms: Trends in Microbiology (cell.com),Desjardins,review,10.1016/j.tim.2022.01.004,0.0,W4210482530,A5007887366,Samantha Gruenheid,0000-0002-0908-6715,Co-PI,Team Desjardins,Samantha Gruenheid
693.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5056445708,Benoît Delignat‐Lavaud,0000-0003-4680-9115,,,Benoît Delignat‐Lavaud
694.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5079118562,Jana Kano,,,,Jana Kano
695.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5016228657,Charles Ducrot,0000-0002-5451-1610,,,Charles Ducrot
696.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5040736337,Ian Massé,0000-0003-3903-0912,,,Ian Massé
697.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5066311857,Sriparna Mukherjee,0000-0002-1299-4343,Key Personnel,Team Desjardins,Sriparna Mukherjee
698.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5047357837,Nicolas Giguère,0000-0001-8130-5321,Key Personnel,Team Desjardins,Nicolas Giguère
699.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5005305362,Luc Moquin,,,,Luc Moquin
700.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5019975997,Catherine Lévesque,,,,Catherine Lévesque
701.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5075276795,Samuel Burke Nanni,0000-0002-7363-5133,,,Samuel Nanni
702.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5036747744,Raphaëlle Denis,0000-0003-0524-9385,,,Raphaëlle Denis
703.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5109166530,Marie‐Josée Bourque,,,,Marie‐Josée Bourque
704.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5092444285,Alex Tchung,0000-0001-7000-7046,,,Alex Tchung
705.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5091097481,Pedro Rosa‐Neto,0000-0001-9116-1376,,,Pedro Rosa‐Neto
706.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5065146020,Daniel Lévesque,0000-0002-3019-3048,,,Daniel Lévesque
707.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5004657450,Louis De Beaumont,,,,Louis Beaumont
708.0,Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice,Desjardins,10.1101/2021.09.15.460511,10.1038/s41467-023-39805-7,1.0,W4383888069,A5024580674,Louis‐Éric Trudeau,0000-0003-4684-1377,Co-PI,Team Desjardins,Louis‐Éric Trudeau
709.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5092582348,Lovatiana Andriamboavonjy,0009-0006-3527-9066,,,Lovatiana Andriamboavonjy
710.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5083549654,Adam MacDonald,0000-0002-6470-1186,Key Personnel,Team Desjardins,Adam MacDonald
711.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5103213855,Laura K. Hamilton,0000-0001-7520-8306,,,Laura Hamilton
712.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5020815792,Marjorie Labrecque,0000-0002-6150-4144,,,Marjorie Labrecque
713.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5053729428,Marie‐Noëlle Boivin,0009-0000-6073-9286,,,Marie‐Noëlle Boivin
714.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5002890512,Jason Karamchandani,0000-0002-3906-5616,,,Jason Karamchandani
715.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5074478086,Jo Anne Stratton,0000-0002-1205-1353,Collaborating PI,Team Desjardins,Jo Stratton
716.0,Comparative analysis of methods to reduce activation signature gene expression in PBMCs,Desjardins,10.1101/2023.07.31.549036,10.1038/s41598-023-49611-2,1.0,W4390338919,A5015673980,Martine Tétreault,0000-0001-7124-5919,,,Martine Tétreault
717.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5050542211,Sherilyn Junelle Recinto,0000-0001-9632-1201,Key Personnel,Team Desjardins,Sherilyn Recinto
718.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5091470177,Shobina Premachandran,0009-0002-0672-1362,,,Shobina Premachandran
719.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5066311857,Sriparna Mukherjee,0000-0002-1299-4343,Key Personnel,Team Desjardins,Sriparna Mukherjee
720.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5022184805,Alexis Allot,0000-0002-2706-9054,,,Alexis Allot
721.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5083549654,Adam MacDonald,0000-0002-6470-1186,Key Personnel,Team Desjardins,Adam MacDonald
722.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5090736279,Moein Yaqubi,0000-0001-7299-5930,Key Personnel,Team Desjardins,Moein Yaqubi
723.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5007887366,Samantha Gruenheid,0000-0002-0908-6715,Co-PI,Team Desjardins,Samantha Gruenheid
724.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5024580674,Louis‐Éric Trudeau,0000-0003-4684-1377,Co-PI,Team Desjardins,Louis‐Éric Trudeau
725.0,Characterizing enteric neurons in dopamine transporter (DAT)-Cre reporter mice reveals dopaminergic subtypes with dual-transmitter content,Desjardins,10.1101/2023.06.16.545271,10.1111/ejn.16307,1.0,W4392852013,A5074478086,Jo Anne Stratton,0000-0002-1205-1353,Collaborating PI,Team Desjardins,Jo Stratton
726.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5021119831,Ahmed M. Fahmy,0000-0003-0444-383X,Key Personnel,Team Desjardins,Ahmed Fahmy
727.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5082232568,Tyler Cannon,0000-0001-6809-5470,,,Tyler Cannon
728.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5114058031,Camberly Herdandez Paredes,,,,Camberly Paredes
729.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5080705295,Ali Ahmadi,0000-0003-0498-2235,Key Personnel,Team Desjardins,Ali Ahmadi
730.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5080920671,Yong Zhong Xu,0000-0002-9201-0446,Key Personnel,Team Desjardins,Yong Xu
731.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5092169727,Benoit Barette,,,,Benoit Barette
732.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5113930761,Maha Ibrahim,,Key Personnel,Team Desjardins,Maha Ibrahim
733.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5019594246,Joël Lanoix,0000-0001-7073-9298,Key Personnel,Team Desjardins,Joël Lanoix
734.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5018728557,Guillermo Arango Duque,0000-0002-1216-2571,,,Guillermo Duque
735.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5037740355,Erwin Schurr,0000-0002-2640-536X,Collaborating PI,Team Desjardins,Erwin Schurr
736.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5061057486,Éric Chevet,0000-0001-5855-4522,,,Éric Chevet
737.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5009187210,Pierre Thibault,0000-0001-5993-0331,Collaborating PI,Team Desjardins,Pierre Thibault
738.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5007887366,Samantha Gruenheid,0000-0002-0908-6715,Co-PI,Team Desjardins,Samantha Gruenheid
739.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5074688125,Heidi M. McBride,0000-0003-4666-2280,Co-PI,Team Desjardins,Heidi McBride
740.0,LRRK2 regulates the activation of the unfolded protein response and antigen presentation in macrophages during inflammation,Desjardins,10.1101/2023.06.14.545012,,1.0,W4380675113,A5086104642,Michel Desjardins,0000-0002-5684-5980,Lead-PI,Team Desjardins,Michel Desjardins
741.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5101450213,Mai Nguyen,0000-0002-9723-6321,Key Personnel,Team Desjardins,Mai Nguyen
742.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5045140565,Jack J. Collier,0000-0001-6282-0301,,,Jack Collier
743.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5057565207,Olesia Ignatenko,0000-0002-1510-6153,,,Olesia Ignatenko
744.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5062634523,Geneviève Morin,0009-0009-6398-9593,,,Geneviève Morin
745.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5049260562,Sidong Huang,0000-0002-2838-4726,,,Sidong Huang
746.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5086104642,Michel Desjardins,0000-0002-5684-5980,Lead-PI,Team Desjardins,Michel Desjardins
747.0,Parkinson’s genes orchestrate pyroptosis through selective trafficking of mtDNA to leaky lysosomes | bioRxiv,Desjardins,10.1101/2023.09.11.557213,,1.0,W4386638944,A5074688125,Heidi M. McBride,0000-0003-4666-2280,Co-PI,Team Desjardins,Heidi McBride
748.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5016558909,Alexandra Kazanova,0000-0003-4850-9845,Key Personnel,Team Desjardins,Alexandra Kazanova
749.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5001938986,Jacqueline Sung,0000-0002-6078-5140,,,Jacqueline Sung
750.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5017277356,Nathalia Oliveira,,Key Personnel,Team Desjardins,Nathalia Oliveira
751.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5006744374,Christina Gavino,0000-0002-3487-334X,,,Christina Gavino
752.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5050542211,Sherilyn Junelle Recinto,0000-0001-9632-1201,Key Personnel,Team Desjardins,Sherilyn Recinto
753.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5000784399,Hicham Bessaiah,0000-0001-7333-2581,,,Hicham Bessaiah
754.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5020370773,Jessica Pei,0000-0001-7115-5606,Key Personnel,Team Desjardins,Jessica Pei
755.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5101635082,L. H. Burns,0000-0003-4514-254X,,,L. Burns
756.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5104249765,Willemein Miller,,,,Willemein Miller
757.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5034391870,Morgane Brouillard-Galipeau,0000-0002-9649-3852,Key Personnel,Team Desjardins,Morgane Brouillard-Galipeau
758.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5100394072,Lei Zhu,0000-0002-5348-7532,,,Lei Zhu
759.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5058400312,Lucía Guerra-Menéndez,0000-0001-8724-6385,,,Lucía Guerra-Menéndez
760.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5082845439,Moustafa Nouh Elemeery,0000-0001-6507-7920,Key Personnel,Team Desjardins,Moustafa Elemeery
761.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5083549654,Adam MacDonald,0000-0002-6470-1186,Key Personnel,Team Desjardins,Adam MacDonald
762.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5019594246,Joël Lanoix,0000-0001-7073-9298,Key Personnel,Team Desjardins,Joël Lanoix
763.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5009187210,Pierre Thibault,0000-0001-5993-0331,Collaborating PI,Team Desjardins,Pierre Thibault
764.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5074688125,Heidi M. McBride,0000-0003-4666-2280,Co-PI,Team Desjardins,Heidi McBride
765.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5086104642,Michel Desjardins,0000-0002-5684-5980,Lead-PI,Team Desjardins,Michel Desjardins
766.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5074478086,Jo Anne Stratton,0000-0002-1205-1353,Collaborating PI,Team Desjardins,Jo Stratton
767.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5052493476,Nathalie Labrecque,0000-0001-7563-1542,Collaborating PI,Team Desjardins,Nathalie Labrecque
768.0,Modeling gene-environment interactions in Parkinson’s Disease: Helicobacter pylori infection of Pink1−/− mice induces CD8 T cell-dependent motor and cognitive dysfunction,Desjardins,10.1101/2024.02.25.580545,,1.0,W4392200935,A5007887366,Samantha Gruenheid,0000-0002-0908-6715,Co-PI,Team Desjardins,Samantha Gruenheid
769.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5082845439,Moustafa Nouh Elemeery,0000-0001-6507-7920,Key Personnel,Team Desjardins,Moustafa Elemeery
770.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5092444285,Alex Tchung,0000-0001-7000-7046,,,Alex Tchung
771.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5082347136,Salix Boulet,0000-0002-8446-8908,,,Salix Boulet
772.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5066311857,Sriparna Mukherjee,0000-0002-1299-4343,Key Personnel,Team Desjardins,Sriparna Mukherjee
773.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5088355635,Nicolas Giguère,0000-0001-8982-2411,Key Personnel,Team Desjardins,Nicolas Giguère
774.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5097398703,J-F Daudelin,0000-0002-0517-8794,,,J-F Daudelin
775.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5030531305,Anne-Yvonne Even,,,,Anne-Yvonne Even
776.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5042647853,Roxann Hétu-Arbour,,,,Roxann Hétu-Arbour
777.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5052424005,Diana Matheoud,0000-0001-5574-315X,,,Diana Matheoud
778.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5074478086,Jo Anne Stratton,0000-0002-1205-1353,Collaborating PI,Team Desjardins,Jo Stratton
779.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5052493476,Nathalie Labrecque,0000-0001-7563-1542,Collaborating PI,Team Desjardins,Nathalie Labrecque
780.0,Adoptive transfer of mitochondrial antigen-specific CD8+ T-cells in mice causes parkinsonism and compromises the dopamine system,Desjardins,10.1101/2024.02.26.582098,,1.0,W4392243978,A5024580674,Louis‐Éric Trudeau,0000-0003-4684-1377,Co-PI,Team Desjardins,Louis‐Éric Trudeau
781.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5050542211,Sherilyn Junelle Recinto,0000-0001-9632-1201,Key Personnel,Team Desjardins,Sherilyn Recinto
782.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5016558909,Alexandra Kazanova,0000-0003-4850-9845,Key Personnel,Team Desjardins,Alexandra Kazanova
783.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5000784399,Hicham Bessaiah,0000-0001-7333-2581,,,Hicham Bessaiah
784.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5051002187,Brendan Cordeiro,0000-0001-5677-0686,,,Brendan Cordeiro
785.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5027800404,Shinjini Mukherjee,0000-0001-9206-8739,Key Personnel,Team Voet,Shinjini Mukherjee
786.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5091470177,Shobina Premachandran,0009-0002-0672-1362,,,Shobina Premachandran
787.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5083549654,Adam MacDonald,0000-0002-6470-1186,Key Personnel,Team Desjardins,Adam MacDonald
788.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5020370773,Jessica Pei,0000-0001-7115-5606,Key Personnel,Team Desjardins,Jessica Pei
789.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5022184805,Alexis Allot,0000-0002-2706-9054,,,Alexis Allot
790.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5001085611,Elia Afanasiev,0000-0002-6527-4550,,,Elia Afanasiev
791.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5090736279,Moein Yaqubi,0000-0001-7299-5930,Key Personnel,Team Desjardins,Moein Yaqubi
792.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5074688125,Heidi M. McBride,0000-0003-4666-2280,Co-PI,Team Desjardins,Heidi McBride
793.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5024580674,Louis‐Éric Trudeau,0000-0003-4684-1377,Co-PI,Team Desjardins,Louis‐Éric Trudeau
794.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5007887366,Samantha Gruenheid,0000-0002-0908-6715,Co-PI,Team Desjardins,Samantha Gruenheid
795.0,A rewiring of the earliest immune events leading to T-cell mediated disease following intestinal microbial infection in a PINK1KO mouse model of Parkinson’s disease,Desjardins,10.1101/2024.06.18.598931,,1.0,W4399929413,A5074478086,Jo Anne Stratton,0000-0002-1205-1353,Collaborating PI,Team Desjardins,Jo Stratton
796.0,Alterations in neurotransmitter co-release in Parkinson's disease,Edwards,NA_review,10.1016/j.expneurol.2023.114562,0.0,W4387373549,A5084527843,Kelsey Barcomb,0000-0002-4050-0566,,,Kelsey Barcomb
797.0,Alterations in neurotransmitter co-release in Parkinson's disease,Edwards,NA_review,10.1016/j.expneurol.2023.114562,0.0,W4387373549,A5029464086,Christopher Ford,0000-0002-4175-2933,Collaborating PI,Team Edwards,Christopher Ford
798.0,Role of dopamine neuron activity in Parkinson's disease pathophysiology,Edwards,NA_review,10.1016/j.expneurol.2023.114645,0.0,W4389537908,A5073598563,Katerina Rademacher,0000-0001-9676-6673,Key Personnel,Team Edwards,Katerina Rademacher
799.0,Role of dopamine neuron activity in Parkinson's disease pathophysiology,Edwards,NA_review,10.1016/j.expneurol.2023.114645,0.0,W4389537908,A5081058318,Ken Nakamura,0000-0002-9192-182X,Co-PI,Team Edwards,Ken Nakamura
800.0,The role of α-synuclein in exocytosis,Edwards,NA_review,10.1016/j.expneurol.2023.114668,0.0,W4390168938,A5023349119,Gautam Runwal,0000-0002-1591-5786,Key Personnel,Team Edwards,Gautam Runwal
801.0,The role of α-synuclein in exocytosis,Edwards,NA_review,10.1016/j.expneurol.2023.114668,0.0,W4390168938,A5027616900,Robert H. Edwards,0000-0002-8650-3260,Lead-PI,Team Edwards,Robert Edwards
802.0,Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression,Edwards,NA_review,10.1016/j.expneurol.2024.114693,0.0,W4391055627,A5091850235,Jillian L. Seiler,0000-0003-4430-4797,,,Jillian Seiler
803.0,Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression,Edwards,NA_review,10.1016/j.expneurol.2024.114693,0.0,W4391055627,A5045027000,Xiaowen Zhuang,0000-0002-9064-4023,Key Personnel,Team Edwards,Xiaowen Zhuang
804.0,Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression,Edwards,NA_review,10.1016/j.expneurol.2024.114693,0.0,W4391055627,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
805.0,Dopamine across timescales and cell types: Relevance for phenotypes in Parkinson's disease progression,Edwards,NA_review,10.1016/j.expneurol.2024.114693,0.0,W4391055627,A5042504580,Talia N. Lerner,0000-0002-3875-0654,Co-PI,Team Edwards,Talia Lerner
806.0,Systems-level analyses dissociate genetic regualtors of reactive oxygen species and energy production,Edwards,10.1101/2023.10.14.562276,10.1073/pnas.2307904121,1.0,W4390734167,A5060434743,Neal K. Bennett,0000-0003-3120-4164,,,Neal Bennett
807.0,Systems-level analyses dissociate genetic regualtors of reactive oxygen species and energy production,Edwards,10.1101/2023.10.14.562276,10.1073/pnas.2307904121,1.0,W4390734167,A5078138327,Megan Lee,0009-0003-5876-8784,,,Megan Lee
808.0,Systems-level analyses dissociate genetic regualtors of reactive oxygen species and energy production,Edwards,10.1101/2023.10.14.562276,10.1073/pnas.2307904121,1.0,W4390734167,A5051686347,Adam L. Orr,0000-0003-0338-7709,,,Adam Orr
809.0,Systems-level analyses dissociate genetic regualtors of reactive oxygen species and energy production,Edwards,10.1101/2023.10.14.562276,10.1073/pnas.2307904121,1.0,W4390734167,A5081058318,Ken Nakamura,0000-0002-9192-182X,Co-PI,Team Edwards,Ken Nakamura
810.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5101764122,Shweta Jain,0000-0001-9716-7453,Key Personnel,Team Edwards,Shweta Jain
811.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5069292888,Andrew G. Yee,0000-0002-0981-6634,Key Personnel,Team Edwards,Andrew Yee
812.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5056539065,James W. Maas,,Project Manager,Team Edwards,James Maas
813.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5092613999,Sarah Gierok,,,,Sarah Gierok
814.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5059474885,Hongfei Xu,0000-0003-1381-2123,,,Hongfei Xu
815.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5060347997,Jasmine A Stansil,,,,Jasmine Stansil
816.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5083079309,Jacob Eriksen,0000-0003-0726-9769,,,Jacob Eriksen
817.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
818.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5055645414,Kätlin Silm,0000-0003-3677-0165,,,Kätlin Silm
819.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5029464086,Christopher Ford,0000-0002-4175-2933,Collaborating PI,Team Edwards,Christopher Ford
820.0,Adaptor protein-3 produces synaptic vesicles that release phasic dopamine | PNAS,Edwards,10.1101/2023.08.07.552338,10.1073/pnas.2309843120,1.0,W4387448734,A5027616900,Robert H. Edwards,0000-0002-8650-3260,Lead-PI,Team Edwards,Robert Edwards
821.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5077208726,Jonathan S. Schor,0000-0002-2806-8782,,,Jonathan Schor
822.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5013946643,Isabelle Gonzalez Montalvo,,,,Isabelle Montalvo
823.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5011140763,Perry W.E. Spratt,,,,Perry Spratt
824.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5012129766,Rea J Brakaj,,,,Rea Brakaj
825.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5060347997,Jasmine A Stansil,,,,Jasmine Stansil
826.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5063333466,Emily L Twedell,0000-0003-0355-2399,Key Personnel,Team Edwards,Emily Twedell
827.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5055608165,Kevin J. Bender,0000-0001-7084-1532,,,Kevin Bender
828.0,Therapeutic deep brain stimulation disrupts movement-related subthalamic nucleus activity in parkinsonian mice,Edwards,10.1101/2021.11.12.468404,10.7554/eLife.75253,1.0,W4283795759,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
829.0,M4-mediated cholinergic transmission is reduced in parkinsonian mice and its restoration alleviates motor deficits and levodopa-induced dyskinesia,Edwards,10.1101/2023.08.23.554510,,1.0,W4386117919,A5038735537,Beatriz E Nielsen,0000-0001-9927-3639,Key Personnel,Team Edwards,Beatriz Nielsen
830.0,M4-mediated cholinergic transmission is reduced in parkinsonian mice and its restoration alleviates motor deficits and levodopa-induced dyskinesia,Edwards,10.1101/2023.08.23.554510,,1.0,W4386117919,A5029464086,Christopher Ford,0000-0002-4175-2933,Collaborating PI,Team Edwards,Christopher Ford
831.0,Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson’s Disease,Edwards,10.1101/2024.02.19.581062,,1.0,W4392200679,A5045027000,Xiaowen Zhuang,0000-0002-9064-4023,Key Personnel,Team Edwards,Xiaowen Zhuang
832.0,Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson’s Disease,Edwards,10.1101/2024.02.19.581062,,1.0,W4392200679,A5094013498,Julia Lemak,0000-0003-4224-7805,,,Julia Lemak
833.0,Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson’s Disease,Edwards,10.1101/2024.02.19.581062,,1.0,W4392200679,A5006649044,Sadhana Sridhar,0000-0003-0041-3414,Key Personnel,Team Edwards,Sadhana Sridhar
834.0,Inhibition of Indirect Pathway Activity Causes Abnormal Decision-Making In a Mouse Model of Impulse Control Disorder in Parkinson’s Disease,Edwards,10.1101/2024.02.19.581062,,1.0,W4392200679,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
835.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5073598563,Katerina Rademacher,0000-0001-9676-6673,Key Personnel,Team Edwards,Katerina Rademacher
836.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5071153942,Zak Doric,0000-0003-2608-4196,,,Zak Doric
837.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5026471063,Dominik Haddad,0009-0001-9354-7747,,,Dominik Haddad
838.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5070921789,Aphroditi A. Mamaligas,0000-0002-9733-6285,,,Aphroditi Mamaligas
839.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5076562111,Szu-Chi Liao,0000-0003-2744-363X,Key Personnel,Team Edwards,Szu-Chi Liao
840.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5084319427,Rose B. Creed,0000-0003-4893-2010,Key Personnel,Team Edwards,Rose Creed
841.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5084978420,Kohei Kano,0000-0002-0223-5781,Key Personnel,Team Edwards,Kohei Kano
842.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5045559041,Zac Chatterton,0000-0002-6683-1400,Key Personnel,Team Edwards,Zac Chatterton
843.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5045559041,Zac Chatterton,0000-0002-6683-1400,Key Personnel,Team Kirik,Zac Chatterton
844.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Edwards,YuHong Fu
845.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Kirik,YuHong Fu
846.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5014280534,YuHong Fu,0000-0003-4539-2039,Key personnel,Team Vila,YuHong Fu
847.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5003511302,Joseph H. Garcia,0000-0002-7127-9534,,,Joseph Garcia
848.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5093743150,Victoria Vance,0000-0003-4546-5445,,,Victoria Vance
849.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5083846976,Yoshitaka Sei,0000-0002-4725-8725,Key Personnel,Team Edwards,Yoshitaka Sei
850.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5068273191,Anatol C. Kreitzer,0000-0001-7423-2398,,,Anatol Kreitzer
851.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Collaborating PI,Team Edwards,Glenda Halliday
852.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Kirik,Glenda Halliday
853.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Vila,Glenda Halliday
854.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5015829168,Alexandra Nelson,0000-0002-9305-5662,Co-PI,Team Edwards,Alexandra Nelson
855.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5004102600,Elyssa B. Margolis,0000-0001-8777-302X,,,Elyssa Margolis
856.0,Chronic hyperactivation of midbrain dopamine neurons causes preferential dopamine neuron degeneration,Edwards,10.1101/2024.04.05.588321,,1.0,W4394692897,A5081058318,Ken Nakamura,0000-0002-9192-182X,Co-PI,Team Edwards,Ken Nakamura
857.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5081555791,Samuel G. Brill-Weil,0000-0002-9018-7109,,,Samuel Brill-Weil
858.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5072114069,P. Kramer,0000-0002-0095-3712,,,P. Kramer
859.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5104336575,Anthony Yanez,0009-0003-5200-8194,Key Personnel,Team Edwards,Anthony Yanez
860.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5099525454,Faye H. Clever,,,,Faye Clever
861.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5020448323,Renshu Zhang,,,,Renshu Zhang
862.0,Presynaptic GABAA receptors control integration of nicotinic input onto dopaminergic axons in the striatum,Edwards,10.1101/2024.06.25.600616,,1.0,W4400052608,A5050910385,Zayd M. Khaliq,0000-0002-1445-1457,Co-PI,Team Edwards,Zayd Khaliq
863.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5076562111,Szu-Chi Liao,0000-0003-2744-363X,Key Personnel,Team Edwards,Szu-Chi Liao
864.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5084978420,Kohei Kano,0000-0002-0223-5781,Key Personnel,Team Edwards,Kohei Kano
865.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5063358488,Sadhna Phanse,0000-0001-6306-0551,,,Sadhna Phanse
866.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5052804925,Mai K. Nguyen,0000-0003-3550-7728,,,Mai Nguyen
867.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5004102600,Elyssa B. Margolis,0000-0001-8777-302X,,,Elyssa Margolis
868.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Edwards,YuHong Fu
869.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Kirik,YuHong Fu
870.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5014280534,YuHong Fu,0000-0003-4539-2039,Key personnel,Team Vila,YuHong Fu
871.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5103143941,Jonathan Xianglong Meng,0000-0002-4315-3483,Key Personnel,Team Edwards,Jonathan Meng
872.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5011729755,Mohamed Taha Moutaoufik,0000-0002-2013-1601,,,Mohamed Moutaoufik
873.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5045559041,Zac Chatterton,0000-0002-6683-1400,Key Personnel,Team Edwards,Zac Chatterton
874.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5045559041,Zac Chatterton,0000-0002-6683-1400,Key Personnel,Team Kirik,Zac Chatterton
875.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5103247265,H Aoki,0009-0005-9143-086X,,,H Aoki
876.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5109235996,Jeffrey A. Simms,,,,Jeffrey Simms
877.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5066817826,Ivy Hsieh,,,,Ivy Hsieh
878.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5106908683,Felecia Suteja,,,,Felecia Suteja
879.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5083846976,Yoshitaka Sei,0000-0002-4725-8725,Key Personnel,Team Edwards,Yoshitaka Sei
880.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5036894949,Eric J. Huang,0000-0002-5381-3801,,,Eric Huang
881.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5078933323,Kevin McAvoy,0000-0002-0025-1921,,,Kevin McAvoy
882.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5068204379,Giovanni Manfredi,0000-0003-3893-1348,,,Giovanni Manfredi
883.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Collaborating PI,Team Edwards,Glenda Halliday
884.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Kirik,Glenda Halliday
885.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Vila,Glenda Halliday
886.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5073300511,Mohan Babu,0000-0003-4118-6406,,,Mohan Babu
887.0,CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism,Edwards,10.1101/2024.08.30.610586,,1.0,W4402100495,A5081058318,Ken Nakamura,0000-0002-9192-182X,Co-PI,Team Edwards,Ken Nakamura
888.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5055105219,Artur Francisco Schumacher Schuh,0000-0002-8722-0908,,,Artur Schuh
889.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5066737591,Andrei Bieger,0000-0002-6669-2834,,,Andrei Bieger
890.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5026543283,Olaitan Okunoye,0000-0003-0758-0987,,,Olaitan Okunoye
891.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5086167465,Kin Y. Mok,0000-0003-3145-880X,Key Personnel,Team Hardy,Kin Mok
892.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5051056306,Shen‐Yang Lim,0000-0002-6942-2522,,,Shen‐Yang Lim
893.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5054404642,Soraya Bardien,0000-0002-3508-3438,,,Soraya Bardien
894.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5090949113,Azlina Ahmad‐Annuar,0000-0001-6329-4366,,,Azlina Ahmad‐Annuar
895.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5025108687,Bruno Lopes Santos‐Lobato,0000-0001-9321-5710,,,Bruno Santos‐Lobato
896.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5026455236,Matheus Zschornack Strelow,0000-0003-1574-614X,,,Matheus Strelow
897.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5073841537,Mohamed Salama,0000-0003-1644-0273,,,Mohamed Salama
898.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5018717121,Shilpa C. Rao,0000-0002-2284-9203,,,Shilpa Rao
899.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5070972978,Yared Z. Zewde,0000-0002-6442-7148,,,Yared Zewde
900.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5052767467,Saiesha Dindayal,0000-0002-9140-9359,,,Saiesha Dindayal
901.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5079568126,Jihan Azar,0000-0002-1604-3529,,,Jihan Azar
902.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5013274485,Prashanth Lingappa Kukkle,0000-0002-4610-947X,,,Prashanth Kukkle
903.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5030873012,Roopa Rajan,0000-0003-4987-7252,,,Roopa Rajan
904.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
905.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
906.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
907.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5072972205,Suzanne Lesage,0000-0003-4158-2601,,,Suzanne Lesage
908.0,Underrepresented Populations in Parkinson's Genetics Research: Current Landscape and Future Directions,GP2,10.1101/2021.12.07.21266995,10.1002/mds.29126,0.0,W4286586502,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
909.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
910.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
911.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5050559299,Elizabeth Geena Woo,0000-0002-8462-718X,,,Elizabeth Woo
912.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5011772005,Grisel Lopez,0000-0001-7785-2197,Key Personnel,Team Vangheluwe,Grisel Lopez
913.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5075832877,Luca Fierro,0000-0003-4381-7953,,,Luca Fierro
914.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
915.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5052995870,Naomi Limbachiya,,,,Naomi Limbachiya
916.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5016812185,Derralynn Hughes,0000-0003-4531-9173,,,Derralynn Hughes
917.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5086598456,Vanessa Pitz,0000-0002-2964-5553,,,Vanessa Pitz
918.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5022784144,Dhairya Patel,,,,Dhairya Patel
919.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
920.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
921.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
922.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
923.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
924.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5113839983,Mike A. Nalls,,,,Mike Nalls
925.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
926.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
927.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5027941722,Manisha Balwani,0000-0001-8047-5011,,,Manisha Balwani
928.0,Polygenic Parkinson’s disease genetic risk score as risk modifier of parkinsonism in Gaucher disease,GP2,10.1101/2022.12.19.22280175,10.1002/mds.29342,1.0,W4323066990,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
929.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5054206729,Oluwadamilola O. Ojo,0000-0001-6461-2653,,,Oluwadamilola Ojo
930.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
931.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
932.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5026092171,Peter Wild Crea,0000-0001-8944-5716,,,Peter Crea
933.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
934.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
935.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
936.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
937.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
938.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5113839983,Mike A. Nalls,,,,Mike Nalls
939.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
940.0,GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians,GP2,10.1101/2023.11.07.23298092,10.1002/mds.29753,1.0,W4392110015,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
941.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
942.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5048485278,Ruqaya Murtadha,,,,Ruqaya Murtadha
943.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
944.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5052149290,Alina Jama,,,,Alina Jama
945.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5047889723,Amica Corda Müller-Nedebock,0000-0002-5547-9704,,,Amica Müller-Nedebock
946.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5014865233,Ana-Luisa Gil-Martínez,,,,Ana-Luisa Gil-Martínez
947.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5006156714,Anastasia Illarionova,0000-0002-1711-7155,,,Anastasia Illarionova
948.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5037326311,Anni Moore,0000-0003-1953-6449,,,Anni Moore
949.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5048485464,Bernabé I. Bustos,0000-0003-2679-9503,,,Bernabé Bustos
950.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5006781042,Bharati Jadhav,,,,Bharati Jadhav
951.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5056418246,Brook Huxford,0000-0002-5908-6983,,,Brook Huxford
952.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5076072665,Catherine S. Storm,0000-0003-4957-1712,Key Personnel,Team Wood,Catherine Storm
953.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5045015749,Clodagh Towns,0000-0001-8418-6241,,,Clodagh Towns
954.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
955.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5010670966,Devina Chetty,0000-0003-4541-3696,,,Devina Chetty
956.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5078750013,Eric Yu,0000-0003-3525-4564,,,Eric Yu
957.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5088359460,Francis P. Grenn,,,,Francis Grenn
958.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5078765314,Gabriela Salazar,,,,Gabriela Salazar
959.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5070974672,Geoffrey Rateau,,,,Geoffrey Rateau
960.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
961.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5087641052,Inas Elsayed,0000-0003-4646-8218,,,Inas Elsayed
962.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5089820533,Isabelle F. Foote,0000-0002-0253-4116,,,Isabelle Foote
963.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5069575622,Zuné Jansen van Rensburg,0000-0002-4219-5139,,,Zuné Rensburg
964.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5112634696,Jonggeol Jeff Kim,,,,Jonggeol Kim
965.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5100745184,Jie Yuan,0009-0000-5682-6133,,,Jie Yuan
966.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5005520962,Julie Lake,0000-0002-3441-2455,,,Julie Lake
967.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5007398166,Kajsa Brolin,0000-0003-4832-922X,,,Kajsa Brolin
968.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5002529713,Konstantin Senkevich,0000-0003-3407-5716,,,Konstantin Senkevich
969.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5015597636,Lesley Wu,0000-0001-5464-5603,Key Personnel,Team Hardy,Lesley Wu
970.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
971.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5003674628,María Teresa Periñán,,,,María Periñán
972.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
973.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5010787890,Michael Ta,0000-0001-6148-3841,,,Michael Ta
974.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5022119019,Nikita Simone Pillay,0000-0002-9058-0920,,,Nikita Pillay
975.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5085461645,Oswaldo Lorenzo‐Betancor,0000-0002-5607-8363,,,Oswaldo Lorenzo‐Betancor
976.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5043042462,Paula Reyes‐Pérez,0000-0001-8062-7441,,,Paula Reyes‐Pérez
977.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5027391800,Pilar Álvarez Jerez,0000-0002-5812-1898,,,Pilar Jerez
978.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5113875706,Prabhjyot Saini,,,,Prabhjyot Saini
979.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5075934899,Rami Al‐Ouran,,,,Rami Al‐Ouran
980.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5088317137,Ramiya Sivakumar,,,,Ramiya Sivakumar
981.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
982.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
983.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5062621506,Ruifneg Hu,,,,Ruifneg Hu
984.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5016718482,Shameemah Abrahams,0000-0002-1120-678X,,,Shameemah Abrahams
985.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5018717121,Shilpa C. Rao,0000-0002-2284-9203,,,Shilpa Rao
986.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5016557310,Tarek Antar,0000-0002-8334-5359,,,Tarek Antar
987.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5022577620,Thiago Peixoto Leal,0000-0002-5829-6452,,,Thiago Leal
988.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5043808890,Vassilena Iankova,,,,Vassilena Iankova
989.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5046580269,William J. Scotton,0000-0003-0607-3190,,,William Scotton
990.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5102102851,Yeajin Song,,,,Yeajin Song
991.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
992.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5113839983,Mike A. Nalls,,,,Mike Nalls
993.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5054376900,Sumit Dey,0000-0002-9087-4486,,,Sumit Dey
994.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
995.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
996.0,"The IPDGC/GP2 Hackathon - an open science event for training in data science, genomics, and collaboration using Parkinson’s disease data",GP2,10.1101/2022.05.04.490670,10.1038/s41531-023-00472-6,0.0,W4323050121,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
997.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5045015749,Clodagh Towns,0000-0001-8418-6241,,,Clodagh Towns
998.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5023158112,Madeleine Richer,0009-0005-4339-4788,,,Madeleine Richer
999.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5106943354,Simona Jasaityte,0009-0009-6030-2901,,,Simona Jasaityte
1000.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5062276033,Eleanor J. Stafford,0000-0003-2451-4308,Key Personnel,Team Hardy,Eleanor Stafford
1001.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5017476654,Julie Joubert,,,,Julie Joubert
1002.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5016557310,Tarek Antar,0000-0002-8334-5359,,,Tarek Antar
1003.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
1004.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1005.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5033410295,Bradford Casey,0000-0002-2623-5997,,,Bradford Casey
1006.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
1007.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
1008.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1009.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5085589147,Caroline B. Pantazis,0000-0002-2768-4903,,,Caroline Pantazis
1010.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5048281682,Laurel A. Screven,0009-0007-8630-6754,,,Laurel Screven
1011.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
1012.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037170054,Claire Wegel,,,,Claire Wegel
1013.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5012476394,Justin Solle,0000-0002-9941-4830,,,Justin Solle
1014.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5113839983,Mike A. Nalls,,,,Mike Nalls
1015.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1016.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1017.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
1018.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
1019.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1020.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5091300605,Emilia Gatto,0000-0002-1346-5443,,,Emilia Gatto
1021.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037720412,Marcelo Kauffman,0000-0003-1680-5092,,,Marcelo Kauffman
1022.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5059234994,Samson Khachatryan,0000-0002-3098-2135,,,Samson Khachatryan
1023.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5015405948,Zaruhi Tavadyan,0000-0003-2575-7088,,,Zaruhi Tavadyan
1024.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5008905184,Claire E. Shepherd,0000-0002-0399-3218,,,Claire Shepherd
1025.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5104168770,Julie Hunter,,,,Julie Hunter
1026.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5078141872,Kishore R. Kumar,0000-0003-3482-6962,,,Kishore Kumar
1027.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5077077632,Melina Ellis,0000-0002-8542-048X,,,Melina Ellis
1028.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5018398870,Miguel E. Rentería,0000-0003-4626-7248,,,Miguel Rentería
1029.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037656140,Sulev Kõks,,,,Sulev Kõks
1030.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5027607255,Alexander Zimprich,0000-0002-1668-5177,,,Alexander Zimprich
1031.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5055105219,Artur Francisco Schumacher Schuh,0000-0002-8722-0908,,,Artur Schuh
1032.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5063139586,Carlos Roberto de Mello Rieder,0000-0003-2950-7211,,,Carlos Rieder
1033.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5033552616,Paula Saffie Awad,0000-0002-8056-365X,,,Paula Awad
1034.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5002568782,Vítor Tumas,0000-0003-2402-2709,,,Vítor Tumas
1035.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5015655920,Sarah Camargos,0000-0001-9829-6783,,,Sarah Camargos
1036.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5032473070,Edward A. Fon,0000-0002-5520-6239,,Team Sulzer,Edward Fon
1037.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5034564754,Oury Monchi,0000-0003-2148-5409,,,Oury Monchi
1038.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678252,Ted Fon,,,,Ted Fon
1039.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678242,Benjamin Pizarro Galleguillos,,,,Benjamin Galleguillos
1040.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5104159553,Marcelo Miranda,0009-0001-0974-4757,,,Marcelo Miranda
1041.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5030398514,M. Leonor Bustamante,0000-0001-9071-2463,,,M. Bustamante
1042.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5047118190,Patricio Olguı́n,0000-0002-8847-4969,,,Patricio Olguı́n
1043.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5045153735,Pedro Chaná,,,,Pedro Chaná
1044.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5087272196,Beisha Tang,0000-0003-2120-1576,,,Beisha Tang
1045.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5086704861,Huifang Shang,0000-0003-0947-1151,,,Huifang Shang
1046.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5073827486,Jifeng Guo,0000-0002-3658-3928,,,Jifeng Guo
1047.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5101740855,Piu Chan,0000-0001-5197-4356,,,Piu Chan
1048.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5084780227,Wei Luo,0000-0001-6951-7698,,,Wei Luo
1049.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5001275163,Gonzálo Arboleda,0000-0003-1781-939X,,,Gonzálo Arboleda
1050.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5001415637,Jorge Orozco,0000-0001-6598-1880,,,Jorge Orozco
1051.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5033560020,Marlene Jiménez-Del-Río,0000-0003-3477-2386,,,Marlene Jiménez-Del-Río
1052.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5053503028,Álvaro Hernández-Flores,0000-0003-1900-9868,,,Álvaro Hernández-Flores
1053.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5073841537,Mohamed Salama,0000-0003-1644-0273,,,Mohamed Salama
1054.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5019938629,Walaa A. Kamel,0000-0002-3363-0370,,,Walaa Kamel
1055.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5070972978,Yared Z. Zewde,0000-0002-6442-7148,,,Yared Zewde
1056.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
1057.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5004608080,Jean‐Christophe Corvol,0000-0001-7325-0199,,,Jean‐Christophe Corvol
1058.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5023320301,Ana Westenberger,0000-0001-8062-6959,,,Ana Westenberger
1059.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5006156714,Anastasia Illarionova,0000-0002-1711-7155,,,Anastasia Illarionova
1060.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
1061.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1062.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5088659282,Eva‐Juliane Vollstedt,0000-0002-6898-9201,,,Eva‐Juliane Vollstedt
1063.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5019379908,Franziska Hopfner,0000-0001-6524-0281,,,Franziska Hopfner
1064.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068749612,Günter U. Höglinger,0000-0001-7587-6187,,,Günter Höglinger
1065.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5087549169,Harutyun Madoev,0000-0001-5360-5319,,,Harutyun Madoev
1066.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5008185656,Joanne Trinh,0000-0001-9863-2070,,,Joanne Trinh
1067.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5013367189,Johanna Junker,0000-0003-0756-9569,,,Johanna Junker
1068.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5006957027,Katja Lohmann,0000-0002-5121-1460,,,Katja Lohmann
1069.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5047745647,Lara M. Lange,0000-0002-7162-9821,,,Lara Lange
1070.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5046131652,Manu Sharma,0000-0002-1260-5416,,,Manu Sharma
1071.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5019253327,Sergiu Groppa,0000-0002-2551-5655,,,Sergiu Groppa
1072.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5067744605,Thomas Gasser,0000-0002-1069-1146,,,Thomas Gasser
1073.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5023103752,Zih‐Hua Fang,0000-0002-0225-8772,,,Zih‐Hua Fang
1074.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068714429,Albert Akpalu,0000-0002-4802-9852,,,Albert Akpalu
1075.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5015590373,Georgia Xiromerisiou,0000-0001-7162-3588,,,Georgia Xiromerisiou
1076.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678245,Georgios Hadjigorgiou,,,,Georgios Hadjigorgiou
1077.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5073719631,Ioannis E. Dagklis,0000-0002-9120-2112,,,Ioannis Dagklis
1078.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068784389,Ioannis Tarnanas,0000-0003-4069-6551,,,Ioannis Tarnanas
1079.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5089947731,Leonidas Stefanis,0000-0003-3569-8990,,,Leonidas Stefanis
1080.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5062015847,María Stamelou,0000-0003-1668-9925,,,María Stamelou
1081.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678244,Efthymios Dadiotis,,,,Efthymios Dadiotis
1082.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5032652091,Alex Medina,0000-0001-8640-3967,,,Alex Medina
1083.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5004722077,Germaine Hiu-Fai Chan,,,,Germaine Chan
1084.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5038007210,Nancy Y. Ip,0000-0002-2763-8907,,,Nancy Ip
1085.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5069398886,Nelson Yuk-Fai Cheung,,,,Nelson Cheung
1086.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5027993515,Phillip Chan,0000-0002-4071-4409,,,Phillip Chan
1087.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5021156794,Xiaopu Zhou,0000-0001-5307-5805,,,Xiaopu Zhou
1088.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5113899655,Asha Kishore,0000-0003-3292-1544,,,Asha Kishore
1089.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5108858700,Divya KP,,,,Divya KP
1090.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5077448329,Pramod Kumar Pal,0000-0002-4085-2377,,,Pramod Pal
1091.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5013274485,Prashanth Lingappa Kukkle,0000-0002-4610-947X,,,Prashanth Kukkle
1092.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5030873012,Roopa Rajan,0000-0003-4987-7252,,,Roopa Rajan
1093.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5112595122,Rupam Borgohain,0000-0001-6734-3305,,,Rupam Borgohain
1094.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5078016071,Mehri Salari,0000-0002-1675-681X,,,Mehri Salari
1095.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5004029818,Andrea Quattrone,0000-0003-2071-2083,,,Andrea Quattrone
1096.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068582387,Enza Maria Valente,0000-0002-0600-6820,Key Personnel,Team Schapira,Enza Valente
1097.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5019846852,Lucilla Parnetti,0000-0001-5722-3967,,,Lucilla Parnetti
1098.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
1099.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5056512439,Tommaso Schirinzi,0000-0002-2517-6278,,,Tommaso Schirinzi
1100.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5019216025,Manabu Funayama,0000-0002-7412-3631,,,Manabu Funayama
1101.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5014705038,Nobutaka Hattori,0000-0002-2034-2556,,,Nobutaka Hattori
1102.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068941942,Tomotaka Shiraishi,0000-0002-0916-5800,,,Tomotaka Shiraishi
1103.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5064918107,Altynay Karimova,0000-0002-6249-1998,,,Altynay Karimova
1104.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5020461899,Gulnaz Kaishibayeva,0000-0002-3431-7300,,,Gulnaz Kaishibayeva
1105.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5059930298,Cholpon Shambetova,0000-0002-2547-315X,,,Cholpon Shambetova
1106.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5113669519,Rejko Krüger,,,,Rejko Krüger
1107.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5068729147,Ai Huey Tan,0000-0002-2979-3839,,,Ai Tan
1108.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5090949113,Azlina Ahmad‐Annuar,0000-0001-6329-4366,,,Azlina Ahmad‐Annuar
1109.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5043698430,Norlinah Mohamed Ibrahim,0000-0002-6684-7488,,,Norlinah Ibrahim
1110.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5060707384,Nor Azian Abdul Murad,0000-0002-6124-5517,,,Nor Murad
1111.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5020099557,Shahrul Azmin,0000-0003-4102-7915,,,Shahrul Azmin
1112.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5051056306,Shen‐Yang Lim,0000-0002-6942-2522,,,Shen‐Yang Lim
1113.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5048703191,Wael Mohamed,0000-0003-1317-0829,,,Wael Mohamed
1114.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5063000337,Yi Wen Tay,0000-0002-9319-0768,,,Yi Tay
1115.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5061821367,Daniel Martínez-Ramírez,0000-0001-8003-0610,,,Daniel Martínez-Ramírez
1116.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5027260814,Mayela Rodríguez‐Violante,0000-0002-6041-9941,,,Mayela Rodríguez‐Violante
1117.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5043042462,Paula Reyes‐Pérez,0000-0001-8062-7441,,,Paula Reyes‐Pérez
1118.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5067071994,Bayasgalan Tserensodnom,,,,Bayasgalan Tserensodnom
1119.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5079992557,Rajeev Ojha,0000-0001-7680-7036,,,Rajeev Ojha
1120.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5041971539,Tim Anderson,0000-0002-1116-3839,,,Tim Anderson
1121.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5066032940,Toni L. Pitcher,0000-0003-4661-5038,,,Toni Pitcher
1122.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5104221275,Arinola Sanyaolu,,,,Arinola Sanyaolu
1123.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
1124.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5054206729,Oluwadamilola O. Ojo,0000-0001-6461-2653,,,Oluwadamilola Ojo
1125.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5042029327,Jan Aasly,0000-0002-0558-7686,,,Jan Aasly
1126.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5061589783,Lasse Pihlstrøm,0000-0002-7635-8645,,,Lasse Pihlstrøm
1127.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
1128.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678250,Shoaib Ur-Rehman,,,,Shoaib Ur-Rehman
1129.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5000059029,Mario Cornejo‐Olivas,0000-0001-6313-5680,,,Mario Cornejo‐Olivas
1130.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5111084327,Maria Leila Doquenia,,,,Maria Doquenia
1131.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5043206162,Raymond L. Rosales,0000-0001-6387-1389,,,Raymond Rosales
1132.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5046571824,Ángel Viñuela,,,,Ángel Viñuela
1133.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5088061724,Е. А. Яковенко,,,,Е. Яковенко
1134.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5069567555,Bashayer Al Mubarak,,,,Bashayer Mubarak
1135.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5100726594,Muhammad Umair,0000-0001-6729-9746,,,Muhammad Umair
1136.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5111039562,Eng-King Tan,,,,Eng-King Tan
1137.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037134358,Jia Nee Foo,0000-0001-9899-2308,,,Jia Foo
1138.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5052376131,Ferzana Amod,0000-0003-4545-8704,,,Ferzana Amod
1139.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5034022925,Jonathan Carr,0000-0002-7677-426X,,,Jonathan Carr
1140.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5054404642,Soraya Bardien,0000-0002-3508-3438,,,Soraya Bardien
1141.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5113083148,Beomseok Jeon,,,,Beomseok Jeon
1142.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5059670570,Yun Joong Kim,0000-0002-2956-1552,,,Yun Kim
1143.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5107832157,Esther Cubo,,,,Esther Cubo
1144.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5007717076,Ignacio Álvarez,0000-0002-8537-3935,,,Ignacio Álvarez
1145.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5020511593,Janet Hoenicka,0000-0002-6790-6988,,,Janet Hoenicka
1146.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5111038654,Katrin Beyer,,,,Katrin Beyer
1147.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5086146440,María Teresa Periñán,0000-0001-7412-7440,,,María Periñán
1148.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5027347263,Pau Pástor,0000-0002-7493-8777,,,Pau Pástor
1149.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5076290706,Sarah El-Sadig,0000-0002-0596-5050,,,Sarah El-Sadig
1150.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5013309787,Christiane Zweier,0000-0001-8002-2020,,,Christiane Zweier
1151.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5106355230,Paul Krack,,,,Paul Krack
1152.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5033369742,Chin‐Hsien Lin,0000-0001-8566-7573,,,Chin‐Hsien Lin
1153.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5101668478,Hsiu-Chuan Wu,0000-0001-8526-9161,,,Hsiu-Chuan Wu
1154.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5090875740,Pin-Jui Kung,0000-0001-8369-0227,,,Pin-Jui Kung
1155.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5026465853,Ruey‐Meei Wu,0000-0002-4947-5467,,,Ruey‐Meei Wu
1156.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5062034731,Yih‐Ru Wu,0000-0003-1191-2542,,,Yih‐Ru Wu
1157.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5069738625,Rim Amouri,0000-0001-5641-5748,,,Rim Amouri
1158.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5080861807,Samia Ben Sassi,0000-0002-1002-5979,,,Samia Sassi
1159.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5002736771,A. Nazlı Başak,0000-0001-6977-2517,,,A. Başak
1160.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5085995429,Gençer Genç,0000-0002-8094-3062,,,Gençer Genç
1161.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5087636881,Özgür Öztop Çakmak,0000-0003-3413-0332,,,Özgür Çakmak
1162.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5108829197,Sibel Ertan,,,,Sibel Ertan
1163.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
1164.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5071609742,Anette Schrag,0000-0002-9872-6680,,,Anette Schrag
1165.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
1166.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5050860301,Camille Carroll,0000-0001-7472-953X,,,Camille Carroll
1167.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5111068238,Claire Bale,,,,Claire Bale
1168.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5105646792,Donald Grosset,,,,Donald Grosset
1169.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1170.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1171.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5086167465,Kin Y. Mok,0000-0003-3145-880X,Key Personnel,Team Hardy,Kin Mok
1172.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
1173.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
1174.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5105524449,Nigel Williams,,,,Nigel Williams
1175.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5026543283,Olaitan Okunoye,0000-0003-0758-0987,,,Olaitan Okunoye
1176.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
1177.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5016656760,Rauan Kaiyrzhanov,0000-0003-1640-4010,,,Rauan Kaiyrzhanov
1178.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5077718412,Rimona S. Weil,0000-0002-5092-6325,,,Rimona Weil
1179.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5016566297,Seth Love,0000-0001-8683-3625,,,Seth Love
1180.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5074464568,Simon Stott,0000-0002-5741-4664,,,Simon Stott
1181.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678251,Simona Jasaitye,,,,Simona Jasaitye
1182.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5054376900,Sumit Dey,0000-0002-9087-4486,,,Sumit Dey
1183.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5087911457,Vida Obese,0000-0002-1037-0510,,,Vida Obese
1184.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5041831296,Alberto J. Espay,0000-0002-3389-136X,,,Alberto Espay
1185.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5112921681,Alyssa O’Grady,,,,Alyssa O’Grady
1186.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5047028994,Andrew K. Sobering,0000-0002-9251-2614,,,Andrew Sobering
1187.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5071219743,Bernadette Siddiqi,,,,Bernadette Siddiqi
1188.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5038299174,Brian Fiske,0000-0002-8797-2042,,,Brian Fiske
1189.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5004943708,Cabell Jonas,,,,Cabell Jonas
1190.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5040490170,Carlos Cruchaga,0000-0002-0276-2899,,,Carlos Cruchaga
1191.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678243,Charisse Comart,,,,Charisse Comart
1192.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037170054,Claire Wegel,,,,Claire Wegel
1193.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5101571010,Deborah A. Hall,0000-0003-2772-7851,,,Deborah Hall
1194.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
1195.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092863302,Ejaz Shiamim,,,,Ejaz Shiamim
1196.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5065260226,Ekemini Riley,0000-0001-7040-5191,,,Ekemini Riley
1197.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5057555985,Faraz Faghri,0000-0001-5744-8728,,,Faraz Faghri
1198.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5012719250,Geidy E. Serrano,,,,Geidy Serrano
1199.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5010092165,Honglei Chen,0000-0003-3446-7779,,,Honglei Chen
1200.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
1201.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5071389283,Ignacio Juan Keller Sarmiento,0000-0003-0979-6001,,,Ignacio Sarmiento
1202.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5059562198,Jared Williamson,0000-0002-3210-6606,,,Jared Williamson
1203.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5112634696,Jonggeol Jeff Kim,,,,Jonggeol Kim
1204.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5086588012,Joseph Jankovic,,,,Joseph Jankovic
1205.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
1206.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5012476394,Justin Solle,0000-0002-9941-4830,,,Justin Solle
1207.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5104159552,Kaileigh Murphy,,,,Kaileigh Murphy
1208.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5050094200,Karen Nuytemans,0000-0003-2670-4914,,,Karen Nuytemans
1209.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5030324367,Karl Kieburtz,0000-0002-1645-6921,,,Karl Kieburtz
1210.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5032177907,Katerina Markopoulou,0000-0003-3973-5437,,,Katerina Markopoulou
1211.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
1212.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
1213.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5108304252,Lana M. Chahine,,,,Lana Chahine
1214.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5075450801,Laura Ibáñez,0000-0003-2381-7059,,,Laura Ibáñez
1215.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5107942301,Laurel Screven,,,,Laurel Screven
1216.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5039123731,Lauren Ruffrage,,,,Lauren Ruffrage
1217.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5042808940,Lisa Shulman,0000-0001-9832-1897,,,Lisa Shulman
1218.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5053346690,Luca Marsili,0000-0002-6438-9911,,,Luca Marsili
1219.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5091461490,Maggie Kuhl,,,,Maggie Kuhl
1220.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5105586266,Marissa Dean,,,,Marissa Dean
1221.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
1222.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5009132358,Megan J. Puckelwartz,0000-0002-0455-2983,,,Megan Puckelwartz
1223.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5085390903,Miguel Inca‐Martinez,0000-0003-3770-0476,,,Miguel Inca‐Martinez
1224.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5092678248,Naomi Louie,0009-0001-1104-8742,,,Naomi Louie
1225.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5048171462,Niccolò E. Mencacci,0000-0003-3383-9665,,,Niccolò Mencacci
1226.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5002817065,Roger L. Albin,0000-0002-0629-608X,,,Roger Albin
1227.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
1228.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5108889743,Ruth Walker,,,,Ruth Walker
1229.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1230.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5080665846,Sohini Chowdhury,0009-0009-8321-0081,,,Sohini Chowdhury
1231.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5050386074,Sonya B. Dumanis,0000-0002-3345-9497,,,Sonya Dumanis
1232.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5014599513,Steven Lubbe,0000-0002-7103-6671,,,Steven Lubbe
1233.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5073371884,Tao Xie,0000-0001-9551-6613,,,Tao Xie
1234.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
1235.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5107886850,Thomas Beach,,,,Thomas Beach
1236.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
1237.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5102102851,Yeajin Song,,,,Yeajin Song
1238.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5112720841,Duan Nguyen,,,,Duan Nguyen
1239.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5113083149,Toan Nguyen,,,,Toan Nguyen
1240.0,Global Parkinson’s Genetics Program (GP2) Complex Network Protocol: Defining the causes of sporadic Parkinson’s disease,GP2,10.1101/2022.11.25.22282764,10.1038/s41531-023-00533-w,1.0,W4386640166,A5029605145,Masharip Atadzhanov,0000-0003-3708-8141,,,Masharip Atadzhanov
1241.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5031512056,Jonggeol Jeffrey Kim,0000-0003-0738-0512,,,Jonggeol Kim
1242.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
1243.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5093603169,Diego Véliz Otani,,,,Diego Otani
1244.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5067211090,Michelle Mulan Lian,0000-0001-6881-2660,,,Michelle Lian
1245.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5061729724,Karl Heilbron,0000-0003-4776-1723,,,Karl Heilbron
1246.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5108147611,Stella Aslibekyan,,,,Stella Aslibekyan
1247.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5047245152,Adam Auton,0000-0002-1630-1225,,,Adam Auton
1248.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5082095399,Elizabeth Babalola,,,,Elizabeth Babalola
1249.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5110483097,Robert K. Bell,,,,Robert Bell
1250.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5081238120,Jessica Bielenberg,,,,Jessica Bielenberg
1251.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113983880,Katarzyna Bryc,,,,Katarzyna Bryc
1252.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5078374312,Emily Bullis,,,,Emily Bullis
1253.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5030584640,Paul J. Cannon,0000-0001-8721-1481,,,Paul Cannon
1254.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5082634050,Daniella Coker,0000-0003-3780-067X,,,Daniella Coker
1255.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5066568424,Gabriel Cuéllar-Partida,0000-0001-7648-4097,,,Gabriel Cuéllar-Partida
1256.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5017579932,Devika Dhamija,,,,Devika Dhamija
1257.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5101486094,Sayantan Das,0000-0001-6346-1590,,,Sayantan Das
1258.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5049823196,Sarah L. Elson,0000-0002-3211-3750,,,Sarah Elson
1259.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112456106,Nicholas Eriksson,,,,Nicholas Eriksson
1260.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5078478024,Teresa Filshtein,0000-0003-4008-8943,,,Teresa Filshtein
1261.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5066645014,Alison Fitch,,,,Alison Fitch
1262.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5045190132,Kipper Fletez‐Brant,0000-0002-2817-1579,,,Kipper Fletez‐Brant
1263.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5066806444,Pierre Fontanillas,0000-0002-8944-4454,,,Pierre Fontanillas
1264.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5005809025,Will Freyman,,,,Will Freyman
1265.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5050596379,Julie M. Granka,0000-0001-7571-9050,,,Julie Granka
1266.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5071842714,Alejandro Hernandez,,,,Alejandro Hernandez
1267.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5051509588,Barry Hicks,,,,Barry Hicks
1268.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5056201449,David A. Hinds,0000-0002-4911-803X,,,David Hinds
1269.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5007757678,Ethan M. Jewett,0000-0002-4857-5431,,,Ethan Jewett
1270.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5044249548,Yunxuan Jiang,0000-0001-8690-4008,,,Yunxuan Jiang
1271.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5064143184,Katelyn Kukar,,,,Katelyn Kukar
1272.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5058576929,Alan Kwong,0000-0002-0779-7126,,,Alan Kwong
1273.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5075223409,Keng‐Han Lin,,,,Keng‐Han Lin
1274.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5111213957,Bianca A. Llamas,,,,Bianca Llamas
1275.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5088761211,Maya Lowe,,,,Maya Lowe
1276.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5001128636,Jey C. McCreight,,,,Jey McCreight
1277.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113637750,Matthew H. McIntyre,,,,Matthew McIntyre
1278.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5040780932,Steven J. Micheletti,0000-0002-3842-0946,,,Steven Micheletti
1279.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5029875200,Meghan E. Moreno,,,,Meghan Moreno
1280.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5103129449,Priyanka Nandakumar,0000-0002-2739-7269,,,Priyanka Nandakumar
1281.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5047229257,Dominique T. Nguyen,,,,Dominique Nguyen
1282.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5107904487,Elizabeth S. Noblin,,,,Elizabeth Noblin
1283.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5036527648,Jared O’Connell,,,,Jared O’Connell
1284.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5064980385,Aaron A. Petrakovitz,,,,Aaron Petrakovitz
1285.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5010440433,G. David Poznik,0000-0003-4427-3556,,,G. Poznik
1286.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5074239593,Alexandra Reynoso,0000-0002-9194-8344,,,Alexandra Reynoso
1287.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5111063336,Madeleine Schloetter,,,,Madeleine Schloetter
1288.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5032320015,Morgan Schumacher,,,,Morgan Schumacher
1289.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5009671765,Anjali J. Shastri,,,,Anjali Shastri
1290.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5110018643,Janie F. Shelton,,,,Janie Shelton
1291.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5040599790,Jingchunzi Shi,0000-0002-9671-2568,,,Jingchunzi Shi
1292.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5086263251,Suyash Shringarpure,0000-0001-6464-2668,,,Suyash Shringarpure
1293.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5084613603,Qiaojuan Jane Su,,,,Qiaojuan Su
1294.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112062930,Susana A. Tat,,,,Susana Tat
1295.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5051044657,Christophe Toukam Tchakouté,,,,Christophe Tchakouté
1296.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5055452502,Vinh Tran,0000-0002-8939-2527,,,Vinh Tran
1297.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5067189241,Joyce Y. Tung,0000-0001-9267-208X,,,Joyce Tung
1298.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5100328132,Xin Wang,0000-0003-4262-579X,,,Xin Wang
1299.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5100391883,Wei Wang,0000-0002-1430-1360,,,Wei Wang
1300.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5075421457,Catherine H. Weldon,,,,Catherine Weldon
1301.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5076357570,Peter Wilton,0000-0003-1591-588X,,,Peter Wilton
1302.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5083604490,Corinna D. Wong,,,,Corinna Wong
1303.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
1304.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5005520962,Julie Lake,0000-0002-3441-2455,,,Julie Lake
1305.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112635533,Caroline Warly Solsberg,,,,Caroline Solsberg
1306.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1307.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1308.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5048549659,Eng‐King Tan,0000-0003-2977-9743,,,Eng‐King Tan
1309.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1310.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1311.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
1312.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5091300605,Emilia Gatto,0000-0002-1346-5443,,,Emilia Gatto
1313.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5037720412,Marcelo Kauffman,0000-0003-1680-5092,,,Marcelo Kauffman
1314.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059234994,Samson Khachatryan,0000-0002-3098-2135,,,Samson Khachatryan
1315.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5015405948,Zaruhi Tavadyan,0000-0003-2575-7088,,,Zaruhi Tavadyan
1316.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5008905184,Claire E. Shepherd,0000-0002-0399-3218,,,Claire Shepherd
1317.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5104168770,Julie Hunter,,,,Julie Hunter
1318.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5078141872,Kishore R. Kumar,0000-0003-3482-6962,,,Kishore Kumar
1319.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5077077632,Melina Ellis,0000-0002-8542-048X,,,Melina Ellis
1320.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5018398870,Miguel E. Rentería,0000-0003-4626-7248,,,Miguel Rentería
1321.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5037656140,Sulev Kõks,,,,Sulev Kõks
1322.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5027607255,Alexander Zimprich,0000-0002-1668-5177,,,Alexander Zimprich
1323.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5055105219,Artur Francisco Schumacher Schuh,0000-0002-8722-0908,,,Artur Schuh
1324.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5063139586,Carlos Roberto de Mello Rieder,0000-0003-2950-7211,,,Carlos Rieder
1325.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5033552616,Paula Saffie Awad,0000-0002-8056-365X,,,Paula Awad
1326.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5002568782,Vítor Tumas,0000-0003-2402-2709,,,Vítor Tumas
1327.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5015655920,Sarah Camargos,0000-0001-9829-6783,,,Sarah Camargos
1328.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5032473070,Edward A. Fon,0000-0002-5520-6239,,Team Sulzer,Edward Fon
1329.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5034564754,Oury Monchi,0000-0003-2148-5409,,,Oury Monchi
1330.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678252,Ted Fon,,,,Ted Fon
1331.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678242,Benjamin Pizarro Galleguillos,,,,Benjamin Galleguillos
1332.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5104159553,Marcelo Miranda,0009-0001-0974-4757,,,Marcelo Miranda
1333.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5030398514,M. Leonor Bustamante,0000-0001-9071-2463,,,M. Bustamante
1334.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5047118190,Patricio Olguı́n,0000-0002-8847-4969,,,Patricio Olguı́n
1335.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5045153735,Pedro Chaná,,,,Pedro Chaná
1336.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5087272196,Beisha Tang,0000-0003-2120-1576,,,Beisha Tang
1337.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5086704861,Huifang Shang,0000-0003-0947-1151,,,Huifang Shang
1338.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5073827486,Jifeng Guo,0000-0002-3658-3928,,,Jifeng Guo
1339.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5050112775,Piu Chan,0000-0002-4620-1268,,,Piu Chan
1340.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5084780227,Wei Luo,0000-0001-6951-7698,,,Wei Luo
1341.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5001275163,Gonzálo Arboleda,0000-0003-1781-939X,,,Gonzálo Arboleda
1342.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5093603168,Jorge Orozc,,,,Jorge Orozc
1343.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5033560020,Marlene Jiménez-Del-Río,0000-0003-3477-2386,,,Marlene Jiménez-Del-Río
1344.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5053503028,Álvaro Hernández-Flores,0000-0003-1900-9868,,,Álvaro Hernández-Flores
1345.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5073841537,Mohamed Salama,0000-0003-1644-0273,,,Mohamed Salama
1346.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5019938629,Walaa A. Kamel,0000-0002-3363-0370,,,Walaa Kamel
1347.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5070972978,Yared Z. Zewde,0000-0002-6442-7148,,,Yared Zewde
1348.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
1349.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5004608080,Jean‐Christophe Corvol,0000-0001-7325-0199,,,Jean‐Christophe Corvol
1350.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5023320301,Ana Westenberger,0000-0001-8062-6959,,,Ana Westenberger
1351.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5006156714,Anastasia Illarionova,0000-0002-1711-7155,,,Anastasia Illarionova
1352.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
1353.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1354.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5088659282,Eva‐Juliane Vollstedt,0000-0002-6898-9201,,,Eva‐Juliane Vollstedt
1355.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5019379908,Franziska Hopfner,0000-0001-6524-0281,,,Franziska Hopfner
1356.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068749612,Günter U. Höglinger,0000-0001-7587-6187,,,Günter Höglinger
1357.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5087549169,Harutyun Madoev,0000-0001-5360-5319,,,Harutyun Madoev
1358.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5008185656,Joanne Trinh,0000-0001-9863-2070,,,Joanne Trinh
1359.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5013367189,Johanna Junker,0000-0003-0756-9569,,,Johanna Junker
1360.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5006957027,Katja Lohmann,0000-0002-5121-1460,,,Katja Lohmann
1361.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5047745647,Lara M. Lange,0000-0002-7162-9821,,,Lara Lange
1362.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5046131652,Manu Sharma,0000-0002-1260-5416,,,Manu Sharma
1363.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5019253327,Sergiu Groppa,0000-0002-2551-5655,,,Sergiu Groppa
1364.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5067744605,Thomas Gasser,0000-0002-1069-1146,,,Thomas Gasser
1365.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5023103752,Zih‐Hua Fang,0000-0002-0225-8772,,,Zih‐Hua Fang
1366.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068714429,Albert Akpalu,0000-0002-4802-9852,,,Albert Akpalu
1367.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5015590373,Georgia Xiromerisiou,0000-0001-7162-3588,,,Georgia Xiromerisiou
1368.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678245,Georgios Hadjigorgiou,,,,Georgios Hadjigorgiou
1369.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5073719631,Ioannis E. Dagklis,0000-0002-9120-2112,,,Ioannis Dagklis
1370.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068784389,Ioannis Tarnanas,0000-0003-4069-6551,,,Ioannis Tarnanas
1371.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5089947731,Leonidas Stefanis,0000-0003-3569-8990,,,Leonidas Stefanis
1372.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5062015847,María Stamelou,0000-0003-1668-9925,,,María Stamelou
1373.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678244,Efthymios Dadiotis,,,,Efthymios Dadiotis
1374.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5032652091,Alex Medina,0000-0001-8640-3967,,,Alex Medina
1375.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5004722077,Germaine Hiu-Fai Chan,,,,Germaine Chan
1376.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5038007210,Nancy Y. Ip,0000-0002-2763-8907,,,Nancy Ip
1377.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5069398886,Nelson Yuk-Fai Cheung,,,,Nelson Cheung
1378.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5027993515,Phillip Chan,0000-0002-4071-4409,,,Phillip Chan
1379.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5021156794,Xiaopu Zhou,0000-0001-5307-5805,,,Xiaopu Zhou
1380.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113899655,Asha Kishore,0000-0003-3292-1544,,,Asha Kishore
1381.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5066301996,K. P. Divya,,,,K. Divya
1382.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5077448329,Pramod Kumar Pal,0000-0002-4085-2377,,,Pramod Pal
1383.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5013274485,Prashanth Lingappa Kukkle,0000-0002-4610-947X,,,Prashanth Kukkle
1384.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5030873012,Roopa Rajan,0000-0003-4987-7252,,,Roopa Rajan
1385.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112595122,Rupam Borgohain,0000-0001-6734-3305,,,Rupam Borgohain
1386.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5078016071,Mehri Salari,0000-0002-1675-681X,,,Mehri Salari
1387.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5004029818,Andrea Quattrone,0000-0003-2071-2083,,,Andrea Quattrone
1388.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068582387,Enza Maria Valente,0000-0002-0600-6820,Key Personnel,Team Schapira,Enza Valente
1389.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5019846852,Lucilla Parnetti,0000-0001-5722-3967,,,Lucilla Parnetti
1390.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
1391.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5056512439,Tommaso Schirinzi,0000-0002-2517-6278,,,Tommaso Schirinzi
1392.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5019216025,Manabu Funayama,0000-0002-7412-3631,,,Manabu Funayama
1393.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5014705038,Nobutaka Hattori,0000-0002-2034-2556,,,Nobutaka Hattori
1394.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068941942,Tomotaka Shiraishi,0000-0002-0916-5800,,,Tomotaka Shiraishi
1395.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5064918107,Altynay Karimova,0000-0002-6249-1998,,,Altynay Karimova
1396.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5020461899,Gulnaz Kaishibayeva,0000-0002-3431-7300,,,Gulnaz Kaishibayeva
1397.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059930298,Cholpon Shambetova,0000-0002-2547-315X,,,Cholpon Shambetova
1398.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113669519,Rejko Krüger,,,,Rejko Krüger
1399.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068729147,Ai Huey Tan,0000-0002-2979-3839,,,Ai Tan
1400.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5090949113,Azlina Ahmad‐Annuar,0000-0001-6329-4366,,,Azlina Ahmad‐Annuar
1401.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5043698430,Norlinah Mohamed Ibrahim,0000-0002-6684-7488,,,Norlinah Ibrahim
1402.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5060707384,Nor Azian Abdul Murad,0000-0002-6124-5517,,,Nor Murad
1403.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5020099557,Shahrul Azmin,0000-0003-4102-7915,,,Shahrul Azmin
1404.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5051056306,Shen‐Yang Lim,0000-0002-6942-2522,,,Shen‐Yang Lim
1405.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5048703191,Wael Mohamed,0000-0003-1317-0829,,,Wael Mohamed
1406.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5063000337,Yi Wen Tay,0000-0002-9319-0768,,,Yi Tay
1407.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5061821367,Daniel Martínez-Ramírez,0000-0001-8003-0610,,,Daniel Martínez-Ramírez
1408.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5027260814,Mayela Rodríguez‐Violante,0000-0002-6041-9941,,,Mayela Rodríguez‐Violante
1409.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5043042462,Paula Reyes‐Pérez,0000-0001-8062-7441,,,Paula Reyes‐Pérez
1410.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5067071994,Bayasgalan Tserensodnom,,,,Bayasgalan Tserensodnom
1411.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5079992557,Rajeev Ojha,0000-0001-7680-7036,,,Rajeev Ojha
1412.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5041971539,Tim Anderson,0000-0002-1116-3839,,,Tim Anderson
1413.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5066032940,Toni L. Pitcher,0000-0003-4661-5038,,,Toni Pitcher
1414.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5104221275,Arinola Sanyaolu,,,,Arinola Sanyaolu
1415.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
1416.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5054206729,Oluwadamilola O. Ojo,0000-0001-6461-2653,,,Oluwadamilola Ojo
1417.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5042029327,Jan Aasly,0000-0002-0558-7686,,,Jan Aasly
1418.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5061589783,Lasse Pihlstrøm,0000-0002-7635-8645,,,Lasse Pihlstrøm
1419.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
1420.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678250,Shoaib Ur-Rehman,,,,Shoaib Ur-Rehman
1421.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5072566408,Diego Véliz-Otani,0000-0001-5507-6457,,,Diego Véliz-Otani
1422.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5000059029,Mario Cornejo‐Olivas,0000-0001-6313-5680,,,Mario Cornejo‐Olivas
1423.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5111084327,Maria Leila Doquenia,,,,Maria Doquenia
1424.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5043206162,Raymond L. Rosales,0000-0001-6387-1389,,,Raymond Rosales
1425.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5046571824,Ángel Viñuela,,,,Ángel Viñuela
1426.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5088061724,Е. А. Яковенко,,,,Е. Яковенко
1427.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5069567555,Bashayer Al Mubarak,,,,Bashayer Mubarak
1428.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5100726594,Muhammad Umair,0000-0001-6729-9746,,,Muhammad Umair
1429.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5052376131,Ferzana Amod,0000-0003-4545-8704,,,Ferzana Amod
1430.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5034022925,Jonathan Carr,0000-0002-7677-426X,,,Jonathan Carr
1431.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5054404642,Soraya Bardien,0000-0002-3508-3438,,,Soraya Bardien
1432.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113083148,Beomseok Jeon,,,,Beomseok Jeon
1433.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059670570,Yun Joong Kim,0000-0002-2956-1552,,,Yun Kim
1434.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5107832157,Esther Cubo,,,,Esther Cubo
1435.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5007717076,Ignacio Álvarez,0000-0002-8537-3935,,,Ignacio Álvarez
1436.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5020511593,Janet Hoenicka,0000-0002-6790-6988,,,Janet Hoenicka
1437.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5025154668,Katrin Beyer,0000-0001-8905-1514,,,Katrin Beyer
1438.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5086146440,María Teresa Periñán,0000-0001-7412-7440,,,María Periñán
1439.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5027347263,Pau Pástor,0000-0002-7493-8777,,,Pau Pástor
1440.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5076290706,Sarah El-Sadig,0000-0002-0596-5050,,,Sarah El-Sadig
1441.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5007398166,Kajsa Brolin,0000-0003-4832-922X,,,Kajsa Brolin
1442.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5013309787,Christiane Zweier,0000-0001-8002-2020,,,Christiane Zweier
1443.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5067475369,Gerd Tinkhauser,0000-0002-1954-1873,,,Gerd Tinkhauser
1444.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5106355230,Paul Krack,,,,Paul Krack
1445.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5033369742,Chin‐Hsien Lin,0000-0001-8566-7573,,,Chin‐Hsien Lin
1446.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5101668478,Hsiu-Chuan Wu,0000-0001-8526-9161,,,Hsiu-Chuan Wu
1447.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5090875740,Pin-Jui Kung,0000-0001-8369-0227,,,Pin-Jui Kung
1448.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5026465853,Ruey‐Meei Wu,0000-0002-4947-5467,,,Ruey‐Meei Wu
1449.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5062034731,Yih‐Ru Wu,0000-0003-1191-2542,,,Yih‐Ru Wu
1450.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5069738625,Rim Amouri,0000-0001-5641-5748,,,Rim Amouri
1451.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5080861807,Samia Ben Sassi,0000-0002-1002-5979,,,Samia Sassi
1452.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5111102157,A. Nazl Başak,,,,A. Başak
1453.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5085995429,Gençer Genç,0000-0002-8094-3062,,,Gençer Genç
1454.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5087636881,Özgür Öztop Çakmak,0000-0003-3413-0332,,,Özgür Çakmak
1455.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5108829197,Sibel Ertan,,,,Sibel Ertan
1456.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
1457.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5071609742,Anette Schrag,0000-0002-9872-6680,,,Anette Schrag
1458.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
1459.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5105843123,Camille Carroll,,,,Camille Carroll
1460.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5111068238,Claire Bale,,,,Claire Bale
1461.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
1462.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5062276033,Eleanor J. Stafford,0000-0003-2451-4308,Key Personnel,Team Hardy,Eleanor Stafford
1463.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1464.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1465.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1466.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5086167465,Kin Y. Mok,0000-0003-3145-880X,Key Personnel,Team Hardy,Kin Mok
1467.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
1468.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
1469.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5105524449,Nigel Williams,,,,Nigel Williams
1470.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5026543283,Olaitan Okunoye,0000-0003-0758-0987,,,Olaitan Okunoye
1471.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
1472.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5016656760,Rauan Kaiyrzhanov,0000-0003-1640-4010,,,Rauan Kaiyrzhanov
1473.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5077718412,Rimona S. Weil,0000-0002-5092-6325,,,Rimona Weil
1474.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5016566297,Seth Love,0000-0001-8683-3625,,,Seth Love
1475.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5074464568,Simon Stott,0000-0002-5741-4664,,,Simon Stott
1476.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5106943354,Simona Jasaityte,0009-0009-6030-2901,,,Simona Jasaityte
1477.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5054376900,Sumit Dey,0000-0002-9087-4486,,,Sumit Dey
1478.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5087911457,Vida Obese,0000-0002-1037-0510,,,Vida Obese
1479.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5041831296,Alberto J. Espay,0000-0002-3389-136X,,,Alberto Espay
1480.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112921681,Alyssa O’Grady,,,,Alyssa O’Grady
1481.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5047028994,Andrew K. Sobering,0000-0002-9251-2614,,,Andrew Sobering
1482.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5071219743,Bernadette Siddiqi,,,,Bernadette Siddiqi
1483.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5033410295,Bradford Casey,0000-0002-2623-5997,,,Bradford Casey
1484.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5038299174,Brian Fiske,0000-0002-8797-2042,,,Brian Fiske
1485.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5004943708,Cabell Jonas,,,,Cabell Jonas
1486.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5040490170,Carlos Cruchaga,0000-0002-0276-2899,,,Carlos Cruchaga
1487.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5085589147,Caroline B. Pantazis,0000-0002-2768-4903,,,Caroline Pantazis
1488.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678243,Charisse Comart,,,,Charisse Comart
1489.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5037170054,Claire Wegel,,,,Claire Wegel
1490.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5101571010,Deborah A. Hall,0000-0003-2772-7851,,,Deborah Hall
1491.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
1492.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092863302,Ejaz Shiamim,,,,Ejaz Shiamim
1493.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5065260226,Ekemini Riley,0000-0001-7040-5191,,,Ekemini Riley
1494.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5057555985,Faraz Faghri,0000-0001-5744-8728,,,Faraz Faghri
1495.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5050607848,Geidy E. Serrano,0000-0002-9527-2011,Key Personnel,Team Scherzer,Geidy Serrano
1496.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5010092165,Honglei Chen,0000-0003-3446-7779,,,Honglei Chen
1497.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
1498.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5071389283,Ignacio Juan Keller Sarmiento,0000-0003-0979-6001,,,Ignacio Sarmiento
1499.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5059562198,Jared Williamson,0000-0002-3210-6606,,,Jared Williamson
1500.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5068655451,Joseph Jankovic,0000-0003-4129-3674,,,Joseph Jankovic
1501.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
1502.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5012476394,Justin Solle,0000-0002-9941-4830,,,Justin Solle
1503.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5104159552,Kaileigh Murphy,,,,Kaileigh Murphy
1504.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5050094200,Karen Nuytemans,0000-0003-2670-4914,,,Karen Nuytemans
1505.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5109102258,Karl Kieburtz,,,,Karl Kieburtz
1506.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5032177907,Katerina Markopoulou,0000-0003-3973-5437,,,Katerina Markopoulou
1507.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
1508.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
1509.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5108304252,Lana M. Chahine,,,,Lana Chahine
1510.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5075450801,Laura Ibáñez,0000-0003-2381-7059,,,Laura Ibáñez
1511.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5048281682,Laurel A. Screven,0009-0007-8630-6754,,,Laurel Screven
1512.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5039123731,Lauren Ruffrage,,,,Lauren Ruffrage
1513.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5077034230,Lisa M. Shulman,0000-0002-1652-1201,,,Lisa Shulman
1514.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5053346690,Luca Marsili,0000-0002-6438-9911,,,Luca Marsili
1515.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5091461490,Maggie Kuhl,,,,Maggie Kuhl
1516.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5062505725,Marissa Dean,0000-0002-9318-769X,,,Marissa Dean
1517.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
1518.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5009132358,Megan J. Puckelwartz,0000-0002-0455-2983,,,Megan Puckelwartz
1519.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5085390903,Miguel Inca‐Martinez,0000-0003-3770-0476,,,Miguel Inca‐Martinez
1520.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5092678248,Naomi Louie,0009-0001-1104-8742,,,Naomi Louie
1521.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5048171462,Niccolò E. Mencacci,0000-0003-3383-9665,,,Niccolò Mencacci
1522.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5002817065,Roger L. Albin,0000-0002-0629-608X,,,Roger Albin
1523.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
1524.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5108889743,Ruth Walker,,,,Ruth Walker
1525.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5080665846,Sohini Chowdhury,0009-0009-8321-0081,,,Sohini Chowdhury
1526.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5050386074,Sonya B. Dumanis,0000-0002-3345-9497,,,Sonya Dumanis
1527.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5014599513,Steven Lubbe,0000-0002-7103-6671,,,Steven Lubbe
1528.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5073371884,Tao Xie,0000-0001-9551-6613,,,Tao Xie
1529.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5107885762,Tatiana M. Foroud,,,,Tatiana Foroud
1530.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5114113452,Thomas Beach,,,,Thomas Beach
1531.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
1532.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5102102851,Yeajin Song,,,,Yeajin Song
1533.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5112720841,Duan Nguyen,,,,Duan Nguyen
1534.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113083149,Toan Nguyen,,,,Toan Nguyen
1535.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5029605145,Masharip Atadzhanov,0000-0003-3708-8141,,,Masharip Atadzhanov
1536.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1537.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5113839983,Mike A. Nalls,,,,Mike Nalls
1538.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5037134358,Jia Nee Foo,0000-0001-9899-2308,,,Jia Foo
1539.0,Multi-ancestry genome-wide meta-analysis in Parkinson’s disease,GP2,10.1101/2022.08.04.22278432,10.1038/s41588-023-01584-8,1.0,W4390345401,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
1540.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
1541.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1542.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1543.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5054206729,Oluwadamilola O. Ojo,0000-0001-6461-2653,,,Oluwadamilola Ojo
1544.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5026092171,Peter Wild Crea,0000-0001-8944-5716,,,Peter Crea
1545.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5011097370,Oladunni Abiodun,0000-0001-7652-6752,,,Oladunni Abiodun
1546.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
1547.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5103257680,Sani Abubakar,,,,Sani Abubakar
1548.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5019544029,Charles Achoru,0000-0003-2904-2557,,,Charles Achoru
1549.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
1550.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5055032582,Olaleye Adeniji,0000-0002-3402-7768,,,Olaleye Adeniji
1551.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5065550409,Osigwe P. Agabi,0000-0002-3084-6918,,,Osigwe Agabi
1552.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
1553.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5078708836,Uchechi Agulanna,0000-0002-0145-7833,,,Uchechi Agulanna
1554.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5080183584,Deborah J. Hall,0000-0002-7121-7261,,,Deborah Hall
1555.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5022954543,Rufus Akinyemi,0000-0001-5286-428X,,,Rufus Akinyemi
1556.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5073371884,Tao Xie,0000-0001-9551-6613,,,Tao Xie
1557.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5100720171,Mohammed Ali,0000-0002-5596-9877,,,Mohammed Ali
1558.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5042573408,Ejaz A. Shamim,0000-0003-0992-056X,,,Ejaz Shamim
1559.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5013118907,Ifeyinwa Ani‐Osheku,0000-0002-1387-9806,,,Ifeyinwa Ani‐Osheku
1560.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5032755098,Mahesh Padmanaban,0000-0002-7499-3661,,,Mahesh Padmanaban
1561.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5060122663,Owotemu Arigbodi,,,,Owotemu Arigbodi
1562.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
1563.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5056328513,Abiodun Bello,0000-0002-2078-6739,,,Abiodun Bello
1564.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5062505725,Marissa Dean,0000-0002-9318-769X,,,Marissa Dean
1565.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5025299813,Cyril Erameh,0000-0001-7783-2495,,,Cyril Erameh
1566.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5087641052,Inas Elsayed,0000-0003-4646-8218,,,Inas Elsayed
1567.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5068005873,Temitope Farombi,0000-0002-9109-7164,,,Temitope Farombi
1568.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5026543283,Olaitan Okunoye,0000-0003-0758-0987,,,Olaitan Okunoye
1569.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5076162050,Bimbo Fawale,0000-0003-3205-7514,,,Bimbo Fawale
1570.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5004869403,Kimberley Billingsley,0000-0002-8003-4029,,,Kimberley Billingsley
1571.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5043753825,Frank Imarhiagbe,0000-0002-8518-2186,,,Frank Imarhiagbe
1572.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5027391800,Pilar Álvarez Jerez,0000-0002-5812-1898,,,Pilar Jerez
1573.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5039638163,Emmanuel Iwuozo,0000-0003-2378-3872,,,Emmanuel Iwuozo
1574.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5067667773,Breeana Baker,,,,Breeana Baker
1575.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5018087158,Morenikeji Komolafe,0000-0002-0592-5120,,,Morenikeji Komolafe
1576.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5053048712,Laksh Malik,0000-0002-2498-146X,,,Laksh Malik
1577.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5085646910,Paul Nwani,0000-0002-1665-2738,,,Paul Nwani
1578.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5058382948,Kensuke Daida,0000-0002-9177-9587,,,Kensuke Daida
1579.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5088302952,Ernest Nwazor,0000-0001-7950-2449,,,Ernest Nwazor
1580.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5057261604,Abigail Miano‐Burkhardt,0000-0002-0447-4698,,,Abigail Miano‐Burkhardt
1581.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5071408334,Yakub Nyandaiti,0000-0002-3922-6344,,,Yakub Nyandaiti
1582.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5023103752,Zih‐Hua Fang,0000-0002-0225-8772,,,Zih‐Hua Fang
1583.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5058052059,Yahaya Obiabo,0000-0003-4563-8908,,,Yahaya Obiabo
1584.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5054771037,Jillian H. Kluss,0000-0002-6262-6661,,,Jillian Kluss
1585.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5066853821,Olanike Odeniyi,0000-0002-8778-2230,,,Olanike Odeniyi
1586.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5071035262,Dena Hernandez,,,,Dena Hernandez
1587.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5078310169,Francis Odiase,0000-0001-9788-6482,,,Francis Odiase
1588.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
1589.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5088316746,FI Ojini,0000-0003-4108-4995,,,FI Ojini
1590.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5069445496,Ellen Sidranksy,,,,Ellen Sidranksy
1591.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5047543496,Gerald Onwuegbuzie,0000-0002-5203-1074,,,Gerald Onwuegbuzie
1592.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5087977066,Andrea D’Souza,0000-0003-2611-2548,,,Andrea D’Souza
1593.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5028704735,Godwin Osaigbovo,0000-0001-5572-0548,,,Godwin Osaigbovo
1594.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5021774873,Bahafta Berhe,,,,Bahafta Berhe
1595.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5065606733,Nosakhare Osemwegie,0000-0002-8725-2256,,,Nosakhare Osemwegie
1596.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5055082420,Xylena Reed,0000-0002-7563-9365,,,Xylena Reed
1597.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5031211682,Olajumoke Oshinaike,0000-0002-6290-6866,,,Olajumoke Oshinaike
1598.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1599.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5040533723,Folajimi Otubogun,0000-0001-9753-4532,,,Folajimi Otubogun
1600.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5023026773,Chelsea X. Alvarado,0000-0002-5973-7512,,,Chelsea Alvarado
1601.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5036175578,Shyngle Oyakhire,0000-0002-8442-9896,,,Shyngle Oyakhire
1602.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5073298937,Simon Ozomma,0009-0001-6921-3544,,,Simon Ozomma
1603.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5064464334,Sarah Samuel,0000-0001-6178-8282,,,Sarah Samuel
1604.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5024575113,Funmilola Taiwo,0000-0002-5797-0943,,,Funmilola Taiwo
1605.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5039960305,Kolawole Wahab,0000-0002-2914-1953,,,Kolawole Wahab
1606.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5044241205,Yusuf Zubair,0000-0002-3017-7961,,,Yusuf Zubair
1607.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
1608.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5031512056,Jonggeol Jeffrey Kim,0000-0003-0738-0512,,,Jonggeol Kim
1609.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1610.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1611.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5113839983,Mike A. Nalls,,,,Mike Nalls
1612.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5061729724,Karl Heilbron,0000-0003-4776-1723,,,Karl Heilbron
1613.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5067477244,Lucy Norcliffe‐Kaufmann,0000-0003-0702-1333,,,Lucy Norcliffe‐Kaufmann
1614.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1615.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1616.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1617.0,Genome-wide Association Identifies Novel Etiological Insights Associated with Parkinson’s Disease in African and African Admixed Populations,GP2,10.1101/2023.05.05.23289529,,1.0,W4372782409,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
1618.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1619.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5057555985,Faraz Faghri,0000-0001-5744-8728,,,Faraz Faghri
1620.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5071831090,Elisa Majounie,,,,Elisa Majounie
1621.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
1622.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5114098016,Jeffrey Kim,,,,Jeffrey Kim
1623.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
1624.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1625.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1626.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
1627.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5026092171,Peter Wild Crea,0000-0001-8944-5716,,,Peter Crea
1628.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
1629.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5112282710,Sampath Arepalli,,,,Sampath Arepalli
1630.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5004869403,Kimberley Billingsley,0000-0002-8003-4029,,,Kimberley Billingsley
1631.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5006957027,Katja Lohmann,0000-0002-5121-1460,,,Katja Lohmann
1632.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1633.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5014599513,Steven Lubbe,0000-0002-7103-6671,,,Steven Lubbe
1634.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5041010859,Edwin Jabbari,0000-0001-6844-882X,Key Personnel,Team Hardy,Edwin Jabbari
1635.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5033552616,Paula Saffie Awad,0000-0002-8056-365X,,,Paula Awad
1636.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5007297638,Derek P. Narendra,0000-0002-8696-9108,,,Derek Narendra
1637.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5014168931,Armando Reyes‐Palomares,0000-0002-0289-6889,,,Armando Reyes‐Palomares
1638.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5061510230,John P. Quinn,0000-0003-3551-7803,,,John Quinn
1639.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5071378398,Claudia Schulte,0000-0003-4006-1265,,,Claudia Schulte
1640.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1641.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5035072440,Bryan J. Traynor,0000-0003-0527-2446,,,Bryan Traynor
1642.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
1643.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1644.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1645.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5050386074,Sonya B. Dumanis,0000-0002-3345-9497,,,Sonya Dumanis
1646.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5065260226,Ekemini Riley,0000-0001-7040-5191,,,Ekemini Riley
1647.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1648.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1649.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5113839983,Mike A. Nalls,,,,Mike Nalls
1650.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5108685883,Janina M. Jeff,,,,Janina Jeff
1651.0,NeuroBooster Array: A Genome-Wide Genotyping Platform to Study Neurological Disorders Across Diverse Populations | medRxiv,GP2,10.1101/2023.11.06.23298176,,1.0,W4388487627,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
1652.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5033552616,Paula Saffie Awad,0000-0002-8056-365X,,,Paula Awad
1653.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1654.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5087641052,Inas Elsayed,0000-0003-4646-8218,,,Inas Elsayed
1655.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5103026308,Arinola O. Sanyaolu,0000-0002-6506-4158,,,Arinola Sanyaolu
1656.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5026092171,Peter Wild Crea,0000-0001-8944-5716,,,Peter Crea
1657.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5055105219,Artur Francisco Schumacher Schuh,0000-0002-8722-0908,,,Artur Schuh
1658.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5108143881,Kristin S Levine,,,,Kristin Levine
1659.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5086171207,Dan Vitale,0000-0002-0637-3671,,,Dan Vitale
1660.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5042831687,Mathew J. Koretsky,0000-0003-4341-3991,,,Mathew Koretsky
1661.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5114098016,Jeffrey Kim,,,,Jeffrey Kim
1662.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5022577620,Thiago Peixoto Leal,0000-0002-5829-6452,,,Thiago Leal
1663.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5086146440,María Teresa Periñán,0000-0001-7412-7440,,,María Periñán
1664.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5054376900,Sumit Dey,0000-0002-9087-4486,,,Sumit Dey
1665.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
1666.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5014168931,Armando Reyes‐Palomares,0000-0002-0289-6889,,,Armando Reyes‐Palomares
1667.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5074682775,Noela Rodríguez-Losada,0000-0003-3629-4883,,,Noela Rodríguez-Losada
1668.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5037134358,Jia Nee Foo,0000-0001-9899-2308,,,Jia Foo
1669.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5048703191,Wael Mohamed,0000-0003-1317-0829,,,Wael Mohamed
1670.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5061729724,Karl Heilbron,0000-0003-4776-1723,,,Karl Heilbron
1671.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5067477244,Lucy Norcliffe‐Kaufmann,0000-0003-0702-1333,,,Lucy Norcliffe‐Kaufmann
1672.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
1673.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
1674.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5113839983,Mike A. Nalls,,,,Mike Nalls
1675.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1676.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1677.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1678.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
1679.0,Insights into Ancestral Diversity in Parkinson’s Disease Risk: A Comparative Assessment of Polygenic Risk Scores,GP2,10.1101/2023.11.28.23299090,,1.0,W4389129977,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1680.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5045015749,Clodagh Towns,0000-0001-8418-6241,,,Clodagh Towns
1681.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5023103752,Zih‐Hua Fang,0000-0002-0225-8772,,,Zih‐Hua Fang
1682.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
1683.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5106943354,Simona Jasaityte,0009-0009-6030-2901,,,Simona Jasaityte
1684.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5106927412,Theresa M. Schmaderer,,,,Theresa Schmaderer
1685.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5062276033,Eleanor J. Stafford,0000-0003-2451-4308,Key Personnel,Team Hardy,Eleanor Stafford
1686.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5112830450,Miriam Pollard,,,,Miriam Pollard
1687.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5022921717,Russel Tilney,0000-0003-3498-6990,,,Russel Tilney
1688.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5017589058,Megan Hodgson,,,,Megan Hodgson
1689.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5015597636,Lesley Wu,0000-0001-5464-5603,Key Personnel,Team Hardy,Lesley Wu
1690.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5083167091,Robyn Labrum,,,,Robyn Labrum
1691.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5102959090,Jason Hehir,0000-0002-8185-9241,,,Jason Hehir
1692.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5107864200,James Polke,,,,James Polke
1693.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5047745647,Lara M. Lange,0000-0002-7162-9821,,,Lara Lange
1694.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
1695.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5103157576,Kailash P. Bhatia,0000-0001-8185-286X,,,Kailash Bhatia
1696.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1697.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1698.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1699.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1700.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
1701.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5112222276,Paul Jarman,,,,Paul Jarman
1702.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1703.0,Parkinson’s Families Project: a UK-wide study of early onset and familial Parkinson’s disease,GP2,10.1101/2023.12.05.23299397,,1.0,W4389428169,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
1704.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5027391800,Pilar Álvarez Jerez,0000-0002-5812-1898,,,Pilar Jerez
1705.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5026092171,Peter Wild Crea,0000-0001-8944-5716,,,Peter Crea
1706.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5090408123,Daniel M. Ramos,0000-0002-4041-5273,,,Daniel Ramos
1707.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
1708.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
1709.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5063829492,Mandy Radefeldt,,,,Mandy Radefeldt
1710.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1711.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5054206729,Oluwadamilola O. Ojo,0000-0001-6461-2653,,,Oluwadamilola Ojo
1712.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5109632531,Kimberley J. Billingsley,,,,Kimberley Billingsley
1713.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5053048712,Laksh Malik,0000-0002-2498-146X,,,Laksh Malik
1714.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5058382948,Kensuke Daida,0000-0002-9177-9587,,,Kensuke Daida
1715.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5115413021,Sarah Bromberek,,,,Sarah Bromberek
1716.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5043344738,Caixia Hu,0000-0002-7786-9586,,,Caixia Hu
1717.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5079880183,Zachary Schneider,0000-0002-1335-9392,,,Zachary Schneider
1718.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5036188439,Aditya Surapaneni,0000-0003-4978-5980,,,Aditya Surapaneni
1719.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5016376182,Julia T. Stadler,0000-0003-1156-631X,,,Julia Stadler
1720.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5073112819,Mie Rizig,0000-0003-2420-4449,,,Mie Rizig
1721.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1722.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5085589147,Caroline B. Pantazis,0000-0002-2768-4903,,,Caroline Pantazis
1723.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5033284534,Hampton L. Leonard,0000-0003-2390-8110,,,Hampton Leonard
1724.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5048281682,Laurel A. Screven,0009-0007-8630-6754,,,Laurel Screven
1725.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5039117237,Yue Qi,0000-0003-1914-8710,,,Yue Qi
1726.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5041676520,Mike A. Nalls,0000-0003-0319-4325,,,Mike Nalls
1727.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5042119624,Sara Bandrés‐Ciga,0000-0003-0056-1361,,,Sara Bandrés‐Ciga
1728.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1729.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1730.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5088861717,Celeste Eng,0000-0001-7968-1862,,,Celeste Eng
1731.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5103515987,Esteban González Burchard,,,,Esteban Burchard
1732.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5055941002,Linda Kachuri,0000-0002-3226-4727,,,Linda Kachuri
1733.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5107853259,Andrew B. Singleton,,,,Andrew Singleton
1734.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5101835599,Steffen Fischer,0000-0002-9821-2313,,,Steffen Fischer
1735.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5086201841,Peter Bauer,0000-0001-9414-4555,,,Peter Bauer
1736.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5055082420,Xylena Reed,0000-0002-7563-9365,,,Xylena Reed
1737.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
1738.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
1739.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5087304778,Christian Beetz,0000-0001-7061-2895,,,Christian Beetz
1740.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5027663167,Michael E. Ward,0000-0002-5296-8051,,,Michael Ward
1741.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5081815660,Njideka Okubadejo,0000-0003-2975-8803,,,Njideka Okubadejo
1742.0,African ancestry neurodegeneration risk variant disrupts an intronic branchpoint in GBA1,GP2,10.1101/2024.02.20.24302827,,1.0,W4405363576,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1743.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5013367189,Johanna Junker,0000-0003-0756-9569,,,Johanna Junker
1744.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5047745647,Lara M. Lange,0000-0002-7162-9821,,,Lara Lange
1745.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5088659282,Eva‐Juliane Vollstedt,0000-0002-6898-9201,,,Eva‐Juliane Vollstedt
1746.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5001541100,Karisha Roopnarain,0009-0009-6040-2531,,,Karisha Roopnarain
1747.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5086884928,Maria Leila M. Doquenia,0000-0003-3708-6680,,,Maria Doquenia
1748.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5020401886,Azlina Ahmad,0000-0002-9000-793X,,,Azlina Ahmad
1749.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
1750.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5054404642,Soraya Bardien,0000-0002-3508-3438,,,Soraya Bardien
1751.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5092431510,Natascha Bahr,0009-0008-1284-3343,,,Natascha Bahr
1752.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5077077632,Melina Ellis,0000-0002-8542-048X,,,Melina Ellis
1753.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5028299010,Caterina Galandra,0000-0002-7048-814X,Key Personnel,Team Schapira,Caterina Galandra
1754.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5067744605,Thomas Gasser,0000-0002-1069-1146,,,Thomas Gasser
1755.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5057989264,Peter Heutink,0000-0001-5218-1737,,,Peter Heutink
1756.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5006156714,Anastasia Illarionova,0000-0002-1711-7155,,,Anastasia Illarionova
1757.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5034217468,Yuliia Kanana,0000-0002-0838-9714,,,Yuliia Kanana
1758.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5071389283,Ignacio Juan Keller Sarmiento,0000-0003-0979-6001,,,Ignacio Sarmiento
1759.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5078141872,Kishore R. Kumar,0000-0003-3482-6962,,,Kishore Kumar
1760.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5051056306,Shen‐Yang Lim,0000-0002-6942-2522,,,Shen‐Yang Lim
1761.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5087549169,Harutyun Madoev,0000-0001-5360-5319,,,Harutyun Madoev
1762.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5041851834,Ignácio F. Mata,0000-0003-1198-0633,,,Ignácio Mata
1763.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5048171462,Niccolò E. Mencacci,0000-0003-3383-9665,,,Niccolò Mencacci
1764.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5113839983,Mike A. Nalls,,,,Mike Nalls
1765.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5015643840,Shalini Padmanabhan,,,,Shalini Padmanabhan
1766.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5059930298,Cholpon Shambetova,0000-0002-2547-315X,,,Cholpon Shambetova
1767.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5012476394,Justin Solle,0000-0002-9941-4830,,,Justin Solle
1768.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5068729147,Ai Huey Tan,0000-0002-2979-3839,,,Ai Tan
1769.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5008185656,Joanne Trinh,0000-0001-9863-2070,,,Joanne Trinh
1770.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5068582387,Enza Maria Valente,0000-0002-0600-6820,Key Personnel,Team Schapira,Enza Valente
1771.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
1772.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
1773.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5006957027,Katja Lohmann,0000-0002-5121-1460,,,Katja Lohmann
1774.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5023103752,Zih‐Hua Fang,0000-0002-0225-8772,,,Zih‐Hua Fang
1775.0,Understanding monogenic Parkinson’s disease at a global scale,GP2,10.1101/2024.03.12.24304154,,1.0,W4392864525,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1776.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5068729147,Ai Huey Tan,0000-0002-2979-3839,,,Ai Tan
1777.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5033552616,Paula Saffie Awad,0000-0002-8056-365X,,,Paula Awad
1778.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5055105219,Artur Francisco Schumacher Schuh,0000-0002-8722-0908,,,Artur Schuh
1779.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5051056306,Shen‐Yang Lim,0000-0002-6942-2522,,,Shen‐Yang Lim
1780.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5087549169,Harutyun Madoev,0000-0001-5360-5319,,,Harutyun Madoev
1781.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5020401886,Azlina Ahmad,0000-0002-9000-793X,,,Azlina Ahmad
1782.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5012476394,Justin Solle,0000-0002-9941-4830,,,Justin Solle
1783.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5037170054,Claire Wegel,,,,Claire Wegel
1784.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5086884928,Maria Leila M. Doquenia,0000-0003-3708-6680,,,Maria Doquenia
1785.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5054376900,Sumit Dey,0000-0002-9087-4486,,,Sumit Dey
1786.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5086146440,María Teresa Periñán,0000-0001-7412-7440,,,María Periñán
1787.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5046196836,Mary B. Makarious,0000-0002-7978-1051,,,Mary Makarious
1788.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5083047242,Brian P. Fiske,0000-0001-5891-4268,,,Brian Fiske
1789.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1790.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
1791.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
1792.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5078141872,Kishore R. Kumar,0000-0003-3482-6962,,,Kishore Kumar
1793.0,Global Perspectives on Returning Genetic Research Results in Parkinson’s Disease,GP2,10.1101/2024.07.06.24309029,,1.0,W4400399398,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
1794.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
1795.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
1796.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5086883137,Jordan Follett,0000-0003-4315-0482,,,Jordan Follett
1797.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5008185656,Joanne Trinh,0000-0001-9863-2070,,,Joanne Trinh
1798.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5052006978,Sandeep Kumar Barodia,0000-0003-3517-162X,,,Sandeep Barodia
1799.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
1800.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5100355362,Zhiyong Liu,0000-0002-2959-5189,,,Zhiyong Liu
1801.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
1802.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5020986973,Jesse D. Fox,0000-0002-2102-6192,,,Jesse Fox
1803.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5028885943,Silke Appel‐Cresswell,0000-0002-5986-1468,,,Silke Appel‐Cresswell
1804.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5066908279,A. Jon Stoessl,0000-0002-9778-7246,,,A. Stoessl
1805.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5113559758,Alex Rajput,,,,Alex Rajput
1806.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5112842558,Ali H. Rajput,,,,Ali Rajput
1807.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5112728266,Roland Auer,,,,Roland Auer
1808.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5022921717,Russel Tilney,0000-0003-3498-6990,,,Russel Tilney
1809.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5084242150,Marc Sturm,0000-0002-6552-8362,,,Marc Sturm
1810.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5011228927,Tobias B. Haack,0000-0001-6033-4836,,,Tobias Haack
1811.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5072972205,Suzanne Lesage,0000-0003-4158-2601,,,Suzanne Lesage
1812.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5050227980,Christelle Tesson,0000-0001-7589-3710,,,Christelle Tesson
1813.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
1814.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5090203564,Carles Vilariño‐Güell,0000-0002-5612-5940,,,Carles Vilariño‐Güell
1815.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
1816.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
1817.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5083214199,Matthew S. Goldberg,0000-0002-5172-9841,,,Matthew Goldberg
1818.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5071278272,Andrew B. West,0000-0002-3034-4061,Co-PI,Team Liddle,Andrew West
1819.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
1820.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1821.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5046131652,Manu Sharma,0000-0002-1260-5416,,,Manu Sharma
1822.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5089452258,Ziv Gan‐Or,0000-0003-0332-234X,,,Ziv Gan‐Or
1823.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5033043178,Bedia Samancı,0000-0003-0667-2329,,,Bedia Samancı
1824.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5027580687,Paweł Lis,0000-0002-4978-7671,Key Personnel,Team Alessi,Paweł Lis
1825.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5086146440,María Teresa Periñán,0000-0001-7412-7440,,,María Periñán
1826.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5069738625,Rim Amouri,0000-0001-5641-5748,,,Rim Amouri
1827.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5080861807,Samia Ben Sassi,0000-0002-1002-5979,,,Samia Sassi
1828.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5087318432,F. Hentati,,,,F. Hentati
1829.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5029388712,Francesca Tonelli,0000-0002-4600-6630,Key Personnel,Team Alessi,Francesca Tonelli
1830.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
1831.0,"RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses","GP2, Alessi (+Hardy, Wood)",10.1101/2024.01.17.24300927,10.1016/S1474-4422(24)00121-2,1.0,W4394695501,A5050824228,Matthew J. Farrer,0000-0003-1159-5321,,,Matthew Farrer
1832.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5082378291,Joseph C. Boktor,0000-0003-2456-1913,,Team Sulzer,Joseph Boktor
1833.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5015135158,Gil Sharon,0000-0002-4605-9943,,,Gil Sharon
1834.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5087670887,Leo Verhagen Metman,0000-0002-5503-1475,,,Leo Metman
1835.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5101571010,Deborah A. Hall,0000-0003-2772-7851,,,Deborah Hall
1836.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5088776895,Phillip A. Engen,0000-0002-5276-5174,,,Phillip Engen
1837.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5048424545,Zoe J. Zreloff,,,,Zoe Zreloff
1838.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5034889945,Daniel Hakim,0000-0002-8467-5413,,,Daniel Hakim
1839.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5025238358,John W. Bostick,0000-0001-8925-2447,,,John Bostick
1840.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5023594398,James Ousey,0000-0003-4886-0053,,,James Ousey
1841.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5065716783,Danielle Lange,,,,Danielle Lange
1842.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5082559708,Gregory Humphrey,0000-0003-3930-1663,,,Gregory Humphrey
1843.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5077137639,Gail Ackermann,0000-0002-3901-4931,,,Gail Ackermann
1844.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5009381464,Martha Carlin,0000-0001-5115-1974,,,Martha Carlin
1845.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5033881627,Rob Knight,0000-0002-0975-9019,,,Rob Knight
1846.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5002619544,Ali Keshavarzian,0000-0002-7969-3369,,,Ali Keshavarzian
1847.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Gradinaru,Sarkis Mazmanian
1848.0,Integrated Multi-Cohort Analysis of the Parkinson's Disease Gut Metagenome,Gradinaru,10.1101/2022.07.20.500694,10.1002/mds.29300,1.0,W4317830385,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Sulzer,Sarkis Mazmanian
1849.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5057677268,Lillian Campos,0000-0003-0839-0288,Key Personnel,Team Gradinaru,Lillian Campos
1850.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5044178593,Cynthia M. Arokiaraj,0000-0003-3201-9868,Key Personnel,Team Gradinaru,Cynthia Arokiaraj
1851.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5054743790,Miguel R. Chuapoco,0000-0001-5397-996X,,,Miguel Chuapoco
1852.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5103159490,Xinhong Chen,0000-0003-0408-0813,Key Personnel,Team Gradinaru,Xinhong Chen
1853.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5039431916,Nick Goeden,,,,Nick Goeden
1854.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5050240445,Viviana Gradinaru,0000-0001-5868-348X,Lead-PI,Team Gradinaru,Viviana Gradinaru
1855.0,Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system,Gradinaru,review,10.1016/j.crneur.2023.100086,0.0,W4362699913,A5101580701,Andrew S. Fox,0000-0003-0695-3323,Co-PI,Team Gradinaru,Andrew Fox
1856.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5066850713,Leonardo A Parra‐Rivas,0000-0002-6707-1255,Key Personnel,Team Gradinaru,Leonardo Parra‐Rivas
1857.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5076599015,Kayalvizhi Madhivanan,0000-0002-4241-2922,,,Kayalvizhi Madhivanan
1858.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5019635765,Brent Aulston,0000-0001-6865-0577,Key Personnel,Team Gradinaru,Brent Aulston
1859.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5100385918,Lina Wang,0000-0001-6294-7310,,,Lina Wang
1860.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5036307323,Dube Dheeraj Prakashchand,,,,Dube Prakashchand
1861.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5090021123,Nicholas P. Boyer,0000-0001-8283-1710,,,Nicholas Boyer
1862.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5029791890,Verônica M. Saia‐Cereda,0000-0002-6285-1201,Key Personnel,Team Gradinaru,Verônica Saia‐Cereda
1863.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5013913174,Kristen Branes‐Guerrero,0000-0002-2181-2425,,,Kristen Branes‐Guerrero
1864.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5048339270,Donald Pizzo,0000-0002-8022-3604,,,Donald Pizzo
1865.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5004797092,Pritha Bagchi,0000-0001-7229-9476,,,Pritha Bagchi
1866.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5017520956,V. S. Sundar,,,,V. Sundar
1867.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5110632252,Yong Tang,0000-0002-3686-8990,,,Yong Tang
1868.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5051343863,Utpal Das,0000-0003-2239-7400,,,Utpal Das
1869.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5103434053,David A. Scott,,,,David Scott
1870.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5044701434,Padmini Rangamani,0000-0001-5953-4347,,,Padmini Rangamani
1871.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5080399663,Yuki Ogawa,0000-0003-2126-9087,,,Yuki Ogawa
1872.0,Serine-129 phosphorylation of α-synuclein is an activity-dependent trigger for physiologic protein-protein interactions and synaptic function: Neuron (cell.com),Gradinaru,10.1101/2022.12.22.521485,10.1016/j.neuron.2023.11.020,1.0,W4389992959,A5076742196,Subhojit Roy,0000-0002-1571-2735,Collaborating PI,Team Gradinaru,Subhojit Roy
1873.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5054743790,Miguel R. Chuapoco,0000-0001-5397-996X,,,Miguel Chuapoco
1874.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5038007344,Nicholas C. Flytzanis,0000-0002-7921-9392,,,Nicholas Flytzanis
1875.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5039431916,Nick Goeden,,,,Nick Goeden
1876.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5028809809,J. Christopher Octeau,0000-0001-6462-9439,,,J. Octeau
1877.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5077285514,Kristina M. Roxas,0009-0004-7462-0154,,,Kristina Roxas
1878.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5068542583,Ken Y. Chan,0000-0002-8853-5186,,,Ken Chan
1879.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5036676609,J Scherrer,0009-0008-8040-4860,,,J Scherrer
1880.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5018958986,Janet Winchester,,,,Janet Winchester
1881.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5033121696,Roy J. Blackburn,,,,Roy Blackburn
1882.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5057677268,Lillian Campos,0000-0003-0839-0288,Key Personnel,Team Gradinaru,Lillian Campos
1883.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5068243350,Kwun Nok Mimi Man,0000-0002-0132-9129,,,Kwun Man
1884.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5076380977,Junqing Sun,,,,Junqing Sun
1885.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5103159490,Xinhong Chen,0000-0003-0408-0813,Key Personnel,Team Gradinaru,Xinhong Chen
1886.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5065342764,Arthur Lefèvre,0000-0003-2847-0859,,,Arthur Lefèvre
1887.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5108141803,Vikram Pal Singh,,,,Vikram Singh
1888.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5044178593,Cynthia M. Arokiaraj,0000-0003-3201-9868,Key Personnel,Team Gradinaru,Cynthia Arokiaraj
1889.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5017919522,Timothy F. Shay,0000-0001-6591-3271,Key Personnel,Team Gradinaru,Timothy Shay
1890.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5018653405,Julia Vendemiatti,0000-0002-6547-9601,,,Julia Vendemiatti
1891.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5029757025,Min Jee Jang,0000-0002-1536-7177,Key Personnel,Team Gradinaru,Min Jang
1892.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5053088872,John K. Mich,0000-0002-1626-1139,,,John Mich
1893.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5079290355,Yemeserach Bishaw,0000-0002-8837-7827,,,Yemeserach Bishaw
1894.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5061805152,Bryan B. Gore,0000-0003-1721-4235,,,Bryan Gore
1895.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5080318812,Victoria Omstead,0000-0002-3796-970X,,,Victoria Omstead
1896.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5006766567,Naz Taskin,0009-0003-2417-8428,,,Naz Taskin
1897.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5008277955,Natalie Weed,0000-0003-0891-0327,,,Natalie Weed
1898.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5045882226,Boaz P. Levi,0000-0002-8346-872X,,,Boaz Levi
1899.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5013070422,Jonathan T. Ting,0000-0001-8266-0392,,,Jonathan Ting
1900.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5081532552,Cory T. Miller,0000-0001-8345-2720,,,Cory Miller
1901.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5014515859,Benjamin E. Deverman,0000-0002-6223-9303,,,Benjamin Deverman
1902.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5053346018,James Pickel,0000-0002-3617-3072,,,James Pickel
1903.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5080490976,Lin Tian,0000-0001-7012-6926,Collaborating PI,Team Gradinaru,Lin Tian
1904.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5101580701,Andrew S. Fox,0000-0003-0695-3323,Co-PI,Team Gradinaru,Andrew Fox
1905.0,Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain,Gradinaru,10.1101/2022.01.08.475342,10.1038/s41565-023-01419-x,1.0,W4383868431,A5050240445,Viviana Gradinaru,0000-0001-5868-348X,Lead-PI,Team Gradinaru,Viviana Gradinaru
1906.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5029769174,Alexandra Stavsky,0000-0002-8209-3524,,,Alexandra Stavsky
1907.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5066850713,Leonardo A Parra‐Rivas,0000-0002-6707-1255,Key Personnel,Team Gradinaru,Leonardo Parra‐Rivas
1908.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5058456570,Shani Tal,,,,Shani Tal
1909.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5101681653,Jen Riba,0009-0004-5016-5636,,,Jen Riba
1910.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5076599015,Kayalvizhi Madhivanan,0000-0002-4241-2922,,,Kayalvizhi Madhivanan
1911.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5076742196,Subhojit Roy,0000-0002-1571-2735,Collaborating PI,Team Gradinaru,Subhojit Roy
1912.0,Synapsin E-domain is essential for α-synuclein function,Gradinaru,10.1101/2023.06.24.546170,10.7554/elife.89687,1.0,W4385664850,A5071999088,Daniel Gitler,0000-0001-9544-3610,,,Daniel Gitler
1913.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5027763981,Lívia H. Morais,0000-0002-5738-2658,,Team Sulzer,Lívia Morais
1914.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5082378291,Joseph C. Boktor,0000-0003-2456-1913,,Team Sulzer,Joseph Boktor
1915.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5072914653,Siamak MahmoudianDehkordi,0000-0002-6843-1718,,,Siamak MahmoudianDehkordi
1916.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5025091889,Rima Kaddurah‐Daouk,0000-0003-1858-5732,,,Rima Kaddurah‐Daouk
1917.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Gradinaru,Sarkis Mazmanian
1918.0,α-Synuclein Overexpression and the Microbiome Shape the Gut and Brain Metabolome in Mice,Gradinaru/Sulzer,10.1101/2024.06.07.597975,,1.0,W4399484859,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Sulzer,Sarkis Mazmanian
1919.0,The immunology of Parkinson’s disease - PMC (nih.gov),Hafler,review,10.1007/s00281-022-00947-3,0.0,W4282921514,A5081651213,Biqing Zhu,0000-0002-7428-6297,personnel,Team Hafler,Biqing Zhu
1920.0,The immunology of Parkinson’s disease - PMC (nih.gov),Hafler,review,10.1007/s00281-022-00947-3,0.0,W4282921514,A5059401507,Dominic Yin,0000-0001-7733-9326,,,Dominic Yin
1921.0,The immunology of Parkinson’s disease - PMC (nih.gov),Hafler,review,10.1007/s00281-022-00947-3,0.0,W4282921514,A5074828414,Hongyu Zhao,0000-0003-1195-9607,,,Hongyu Zhao
1922.0,The immunology of Parkinson’s disease - PMC (nih.gov),Hafler,review,10.1007/s00281-022-00947-3,0.0,W4282921514,A5017375396,Le Zhang,0000-0002-4860-831X,Key Personnel (PI),Team De Camilli,Le Zhang
1923.0,The immunology of Parkinson’s disease - PMC (nih.gov),Hafler,review,10.1007/s00281-022-00947-3,0.0,W4282921514,A5017375396,Le Zhang,0000-0002-4860-831X,Collaborator,Team Hafler,Le Zhang
1924.0,Gut instincts in neuroimmunity from the eighteenth to twenty-first centuries,Hafler,NA Review,10.1007/s00281-022-00948-2,0.0,W4283796233,A5067698958,Mytien Nguyen,0000-0001-7343-6882,,,Mytien Nguyen
1925.0,Gut instincts in neuroimmunity from the eighteenth to twenty-first centuries,Hafler,NA Review,10.1007/s00281-022-00948-2,0.0,W4283796233,A5022058492,Noah W. Palm,0000-0001-7262-9455,Co-PI,Team Hafler,Noah Palm
1926.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5041656783,D. J. Vidyadhara,0000-0003-0974-0307,personnel,Team Hafler,D. Vidyadhara
1927.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5074818237,Mahalakshmi Somayaji,0000-0002-6209-9400,,,Mahalakshmi Somayaji
1928.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5091097058,Nigel Wade,0000-0003-3778-9263,,,Nigel Wade
1929.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5082936619,Betül Yücel,,,,Betül Yücel
1930.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5018351147,Helen R. Zhao,0000-0002-1333-9463,,,Helen Zhao
1931.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5070899335,N Shashaank,,,,N Shashaank
1932.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5051009457,Joseph Ribaudo,0000-0003-3381-9795,,,Joseph Ribaudo
1933.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5070828095,Jyoti Gupta,0000-0002-7211-3958,,,Jyoti Gupta
1934.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5009370559,TuKiet T. Lam,0000-0002-4850-3462,,,TuKiet Lam
1935.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5021452033,Dalibor Sameš,0000-0001-6911-2260,,,Dalibor Sameš
1936.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5004657382,Lois E. Greene,0000-0003-3786-8594,,,Lois Greene
1937.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
1938.0,Dopamine transporter and synaptic vesicle sorting defects underlie auxilin-associated Parkinson’s disease,Hafler,10.1101/2022.02.04.479203,10.1016/j.celrep.2023.112231,1.0,W4324145225,A5059606057,Sreeganga S. Chandra,0000-0001-9035-1733,Co-PI,Team Hafler,Sreeganga Chandra
1939.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5081651213,Biqing Zhu,0000-0002-7428-6297,personnel,Team Hafler,Biqing Zhu
1940.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5100402287,Hongyu Li,0000-0001-6525-9310,,,Hongyu Li
1941.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5017375396,Le Zhang,0000-0002-4860-831X,Key Personnel (PI),Team De Camilli,Le Zhang
1942.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5017375396,Le Zhang,0000-0002-4860-831X,Collaborator,Team Hafler,Le Zhang
1943.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5059606057,Sreeganga S. Chandra,0000-0001-9035-1733,Co-PI,Team Hafler,Sreeganga Chandra
1944.0,A Markov random field model-based approach for differentially expressed gene detection from single-cell RNA-seq data,Hafler,10.1101/2020.11.11.378976,10.1093/bib/bbac166,1.0,W4226113200,A5074828414,Hongyu Zhao,0000-0003-1195-9607,,,Hongyu Zhao
1945.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5081651213,Biqing Zhu,0000-0002-7428-6297,personnel,Team Hafler,Biqing Zhu
1946.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5040547491,Yuge Wang,0000-0001-7389-1519,,,Yuge Wang
1947.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5067130687,Li-Ting Ku,,,,Li-Ting Ku
1948.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5019679682,David van Dijk,0000-0003-3911-9925,Collaborator,Team Hafler,David Dijk
1949.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5017375396,Le Zhang,0000-0002-4860-831X,Key Personnel (PI),Team De Camilli,Le Zhang
1950.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5017375396,Le Zhang,0000-0002-4860-831X,Collaborator,Team Hafler,Le Zhang
1951.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5004216670,David A. Hafler,0000-0003-4664-535X,Lead PI,Team Hafler,David Hafler
1952.0,scNAT: a deep learning method for integrating paired single-cell RNA and T cell receptor sequencing profiles,Hafler,does_not_exist,10.1186/s13059-023-03129-y,1.0,W4389893752,A5074828414,Hongyu Zhao,0000-0003-1195-9607,,,Hongyu Zhao
1953.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5081651213,Biqing Zhu,0000-0002-7428-6297,personnel,Team Hafler,Biqing Zhu
1954.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5100645944,Jae Min Park,0000-0001-8873-8832,,,Jae Park
1955.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5021234473,Sarah Coffey,0000-0003-3631-2228,,,Sarah Coffey
1956.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5032627575,I‐Uen Hsu,0000-0002-4089-6601,,,I‐Uen Hsu
1957.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5009370559,TuKiet T. Lam,0000-0002-4850-3462,,,TuKiet Lam
1958.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5037063479,Pallavi P. Gopal,0000-0003-4708-8479,,,Pallavi Gopal
1959.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5047993013,Stephen D. Ginsberg,0000-0002-1797-4288,,,Stephen Ginsberg
1960.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5100388791,Jiawei Wang,0000-0003-2627-4897,,,Jiawei Wang
1961.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5045324437,Chang Su,0000-0002-8704-1512,,,Chang Su
1962.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5074828414,Hongyu Zhao,0000-0003-1195-9607,,,Hongyu Zhao
1963.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5004216670,David A. Hafler,0000-0003-4664-535X,Lead PI,Team Hafler,David Hafler
1964.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5059606057,Sreeganga S. Chandra,0000-0001-9035-1733,Co-PI,Team Hafler,Sreeganga Chandra
1965.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5017375396,Le Zhang,0000-0002-4860-831X,Key Personnel (PI),Team De Camilli,Le Zhang
1966.0,Single-cell transcriptomic and proteomic analysis of Parkinson’s disease Brains,Hafler,10.1101/2022.02.14.480397,,1.0,W4213123943,A5017375396,Le Zhang,0000-0002-4860-831X,Collaborator,Team Hafler,Le Zhang
1967.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5019530991,Nirosen Vijiaratnam,0000-0002-9671-0212,,,Nirosen Vijiaratnam
1968.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
1969.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
1970.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5073721007,Amanda Heslegrave,0000-0002-7290-6405,,,Amanda Heslegrave
1971.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5054185420,Tong Guo,0000-0001-9395-3617,,,Tong Guo
1972.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5043990676,Dilan Athauda,0000-0001-8594-2483,,,Dilan Athauda
1973.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
1974.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5064943801,Christine Girges,0000-0001-5019-6812,,,Christine Girges
1975.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
1976.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5079766290,Henrik Zetterberg,0000-0003-3930-4354,,,Henrik Zetterberg
1977.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
1978.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
1979.0,Diabetes and neuroaxonal damage in Parkinson’s disease,Hardy,10.1101/2022.04.19.22274027,10.1002/mds.29067,1.0,W4286268352,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
1980.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5009635974,Nikoleta Vavouraki,0000-0003-2581-4935,,,Nikoleta Vavouraki
1981.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5033209539,James E. Tomkins,0000-0003-3010-6634,Key Personnel,Team Wood,James Tomkins
1982.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5037544730,Eleanna Kara,0000-0001-5428-6743,,,Eleanna Kara
1983.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
1984.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1985.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5051202360,Marcus J. Tindall,0000-0001-6069-5260,,,Marcus Tindall
1986.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
1987.0,Integrating protein networks and machine learning for disease stratification in the Hereditary Spastic Paraplegias,Hardy,10.1101/2021.01.14.425874,10.1016/j.isci.2021.102484,1.0,W3157413169,A5005572028,Claudia Manzoni,0000-0001-5367-4023,Key Personnel,Team Hardy,Claudia Manzoni
1988.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
1989.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5045987441,Aaron Z. Wagen,0000-0002-7747-6870,Key Personnel,Team Wood,Aaron Wagen
1990.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5088297566,Frida Lona‐Durazo,0000-0003-2585-5710,,,Frida Lona‐Durazo
1991.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
1992.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
1993.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
1994.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5064487935,Sarah A. Gagliano Taliun,0000-0003-1306-1868,,,Sarah Taliun
1995.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
1996.0,Local genetic correlations exist among neurodegenerative and neuropsychiatric diseases,Hardy,10.1101/2022.05.30.22275781,10.1038/s41531-023-00504-1,1.0,W4367316359,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
1997.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
1998.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
1999.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2000.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
2001.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
2002.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5015597636,Lesley Wu,0000-0001-5464-5603,Key Personnel,Team Hardy,Lesley Wu
2003.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2004.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5050860301,Camille Carroll,0000-0001-7472-953X,,,Camille Carroll
2005.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2006.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2007.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2008.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2009.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2010.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
2011.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2012.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
2013.0,Genetic meta-analysis of levodopa induced dyskinesia in Parkinson’s disease | npj Parkinson's Disease (nature.com),Hardy,10.1101/2023.05.24.23290362,10.1038/s41531-023-00573-2,1.0,W4386316574,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2014.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
2015.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2016.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5106945264,Miriam I. Pollard,,,,Miriam Pollard
2017.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5022311239,Emmeline Brown,0000-0001-6222-0146,,,Emmeline Brown
2018.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
2019.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
2020.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5110682999,Samir Bekadar,,,,Samir Bekadar
2021.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5041010859,Edwin Jabbari,0000-0001-6844-882X,Key Personnel,Team Hardy,Edwin Jabbari
2022.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2023.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5091001932,Hirotaka Iwaki,0000-0002-8982-7885,,,Hirotaka Iwaki
2024.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
2025.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5009788111,Sofia Kanavou,0000-0001-8650-6667,,,Sofia Kanavou
2026.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5067765304,Leon Hubbard,,,,Leon Hubbard
2027.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5032765325,Naveed Malek,0000-0003-1138-4153,,,Naveed Malek
2028.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5103521164,Katherine A. Grosset,,,,Katherine Grosset
2029.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5103532491,Nin Bajaj,,,,Nin Bajaj
2030.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5084748006,Roger A. Barker,0000-0001-8843-7730,Co-PI,Team Jakobsson,Roger Barker
2031.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5010057774,David J. Burn,0000-0001-7658-1209,,,David Burn
2032.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5069748944,Catherine Bresner,0000-0003-2673-9762,,,Catherine Bresner
2033.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
2034.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
2035.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5005045661,Caroline H. Williams‐Gray,0000-0002-2648-9743,,,Caroline Williams‐Gray
2036.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5020215901,Ole A. Andreassen,0000-0002-4461-3568,,,Ole Andreassen
2037.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5075595619,Mathias Toft,0000-0002-6723-6865,,,Mathias Toft
2038.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5058392597,Alexis Elbaz,0000-0001-9724-5490,,,Alexis Elbaz
2039.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5005831289,Fanny Artaud,0000-0003-1899-8502,,,Fanny Artaud
2040.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
2041.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5004608080,Jean‐Christophe Corvol,0000-0001-7325-0199,,,Jean‐Christophe Corvol
2042.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5042029327,Jan Aasly,0000-0002-0558-7686,,,Jan Aasly
2043.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5050824228,Matthew J. Farrer,0000-0003-1159-5321,,,Matthew Farrer
2044.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5041676520,Mike A. Nalls,0000-0003-0319-4325,,,Mike Nalls
2045.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
2046.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2047.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2048.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2049.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2050.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2051.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
2052.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5061589783,Lasse Pihlstrøm,0000-0002-7635-8645,,,Lasse Pihlstrøm
2053.0,Genome-wide determinants of mortality and clinical progression in Parkinson’s disease,Hardy,10.1101/2022.07.07.22277297,10.1038/s41531-024-00729-8,1.0,W4399432024,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2054.0,KAT8 compound inhibition inhibits PINK1/Parkin-dependent mitophagy and initiates mitochondrial delivery to lysosomes | bioRxiv,Hardy,10.1101/2023.08.03.551835,10.1038/s41598-024-60602-9,1.0,W4398200995,A5097222057,Capucine de Talhouët,0000-0001-5958-0693,Key Personnel,Team Hardy,Capucine Talhouët
2055.0,KAT8 compound inhibition inhibits PINK1/Parkin-dependent mitophagy and initiates mitochondrial delivery to lysosomes | bioRxiv,Hardy,10.1101/2023.08.03.551835,10.1038/s41598-024-60602-9,1.0,W4398200995,A5038020678,Noemí Esteras,0000-0002-7938-6131,,,Noemí Esteras
2056.0,KAT8 compound inhibition inhibits PINK1/Parkin-dependent mitophagy and initiates mitochondrial delivery to lysosomes | bioRxiv,Hardy,10.1101/2023.08.03.551835,10.1038/s41598-024-60602-9,1.0,W4398200995,A5009136361,Marc P. M. Soutar,0000-0003-0008-9423,,,Marc Soutar
2057.0,KAT8 compound inhibition inhibits PINK1/Parkin-dependent mitophagy and initiates mitochondrial delivery to lysosomes | bioRxiv,Hardy,10.1101/2023.08.03.551835,10.1038/s41598-024-60602-9,1.0,W4398200995,A5059141377,Benjamin O’Callaghan,0000-0002-1323-6843,Key Personnel,Team Hardy,Benjamin O’Callaghan
2058.0,KAT8 compound inhibition inhibits PINK1/Parkin-dependent mitophagy and initiates mitochondrial delivery to lysosomes | bioRxiv,Hardy,10.1101/2023.08.03.551835,10.1038/s41598-024-60602-9,1.0,W4398200995,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656,Collaborating PI,Team Hardy,Hélène Plun‐Favreau
2059.0,Protein network analysis links the NSL complex to Parkinson’s disease and mitochondrial biology,Hardy,10.1101/2023.01.27.524249,10.1039/d2mo00325b,1.0,W4380683663,A5078740297,Katie Kelly,0000-0002-9466-1680,,,Katie Kelly
2060.0,Protein network analysis links the NSL complex to Parkinson’s disease and mitochondrial biology,Hardy,10.1101/2023.01.27.524249,10.1039/d2mo00325b,1.0,W4380683663,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2061.0,Protein network analysis links the NSL complex to Parkinson’s disease and mitochondrial biology,Hardy,10.1101/2023.01.27.524249,10.1039/d2mo00325b,1.0,W4380683663,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656,Collaborating PI,Team Hardy,Hélène Plun‐Favreau
2062.0,Protein network analysis links the NSL complex to Parkinson’s disease and mitochondrial biology,Hardy,10.1101/2023.01.27.524249,10.1039/d2mo00325b,1.0,W4380683663,A5005572028,Claudia Manzoni,0000-0001-5367-4023,Key Personnel,Team Hardy,Claudia Manzoni
2063.0,From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease | Biochemical Journal | Portland Press,Hardy,review,10.1042/BCJ20210383,0.0,W3184877446,A5077705939,Susanne Herbst,0000-0003-2255-7371,Key Personnel,Team Hardy,Susanne Herbst
2064.0,From structure to ætiology: a new window on the biology of leucine-rich repeat kinase 2 and Parkinson's disease | Biochemical Journal | Portland Press,Hardy,review,10.1042/BCJ20210383,0.0,W3184877446,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2065.0,The emerging role of LRRK2 in tauopathies,Hardy,review,10.1042/CS20220067,0.0,W4285040643,A5077705939,Susanne Herbst,0000-0003-2255-7371,Key Personnel,Team Hardy,Susanne Herbst
2066.0,The emerging role of LRRK2 in tauopathies,Hardy,review,10.1042/CS20220067,0.0,W4285040643,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2067.0,The emerging role of LRRK2 in tauopathies,Hardy,review,10.1042/CS20220067,0.0,W4285040643,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2068.0,Vesicular dysfunction and pathways to neurodegeneration | Essays in Biochemistry | Portland Press,Hardy,review,10.1042/EBC20210034,0.0,W4200025093,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2069.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
2070.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
2071.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5037391977,David Zhang,0000-0003-2382-8460,,,David Zhang
2072.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2073.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
2074.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2075.0,ggtranscript: an R package for the visualization and interpretation of transcript isoforms using ggplot2,Hardy,10.1101/2022.03.28.486050,10.1093/bioinformatics/btac409,1.0,W4283511977,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2076.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5009136361,Marc P. M. Soutar,0000-0003-0008-9423,,,Marc Soutar
2077.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5023202307,Daniela Melandri,0000-0002-3630-5143,,,Daniela Melandri
2078.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5059141377,Benjamin O’Callaghan,0000-0002-1323-6843,Key Personnel,Team Hardy,Benjamin O’Callaghan
2079.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5044305625,Emily Annuario,0000-0002-0342-1113,,,Emily Annuario
2080.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5047091121,Amy E. Monaghan,0000-0003-0302-6989,,,Amy Monaghan
2081.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5051992465,Natalie J. Welsh,0000-0002-2714-0367,Key personnel,Team Vila,Natalie Welsh
2082.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5008997142,Karishma D’Sa,,,,Karishma D’Sa
2083.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5051204041,Sebastian Guelfi,0000-0002-0256-2686,,,Sebastian Guelfi
2084.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5037391977,David Zhang,0000-0003-2382-8460,,,David Zhang
2085.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5021931896,Alan Pittman,0000-0002-8112-2987,,,Alan Pittman
2086.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5044516423,Daniah Trabzuni,0000-0003-4826-9570,,,Daniah Trabzuni
2087.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5031176489,Anouk H. A. Verboven,0000-0002-9252-6020,,,Anouk Verboven
2088.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5001480287,Kylie S. Pan,0000-0003-1057-9119,,,Kylie Pan
2089.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5110614420,Demis A. Kia,,,,Demis Kia
2090.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5041739625,Magda Bictash,0000-0002-7909-8076,,,Magda Bictash
2091.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
2092.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
2093.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5064191051,Mark Cookson,0000-0002-1058-3831,,,Mark Cookson
2094.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5049588515,Nael Nadif Kasri,0000-0002-7448-9289,,,Nael Kasri
2095.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
2096.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
2097.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2098.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5055408422,Paul J. Whiting,0000-0002-4121-1379,,,Paul Whiting
2099.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
2100.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5100762756,Alexander J. Whitworth,0000-0002-1154-6629,,,Alexander Whitworth
2101.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5005572028,Claudia Manzoni,0000-0001-5367-4023,Key Personnel,Team Hardy,Claudia Manzoni
2102.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2103.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2104.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2105.0,Regulation of mitophagy by the NSL complex underlies genetic risk for Parkinson’s disease at Chr16q11.2 and on the MAPT H1 allele,Hardy,10.1101/2020.01.06.896241,10.1093/brain/awac325,1.0,W4295078575,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656,Collaborating PI,Team Hardy,Hélène Plun‐Favreau
2106.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
2107.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
2108.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2109.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2110.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
2111.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
2112.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5004608080,Jean‐Christophe Corvol,0000-0001-7325-0199,,,Jean‐Christophe Corvol
2113.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2114.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2115.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5069748944,Catherine Bresner,0000-0003-2673-9762,,,Catherine Bresner
2116.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5056043498,Leon Hubbard,0000-0002-0064-6755,,,Leon Hubbard
2117.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
2118.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5072972205,Suzanne Lesage,0000-0003-4158-2601,,,Suzanne Lesage
2119.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5042271343,Johann Faouzi,0000-0003-0542-9968,,,Johann Faouzi
2120.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5058392597,Alexis Elbaz,0000-0001-9724-5490,,,Alexis Elbaz
2121.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5005831289,Fanny Artaud,0000-0003-1899-8502,,,Fanny Artaud
2122.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2123.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2124.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2125.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2126.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2127.0,Association between the LRP1B and APOE loci and the development of Parkinson’s disease dementia,Hardy,10.1101/2022.05.23.22275465,10.1093/brain/awac414,1.0,W4308571577,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2128.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5004778160,Amy R. Hicks,0000-0002-3965-5253,Key Personnel,Team Hardy,Amy Hicks
2129.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2130.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5059141377,Benjamin O’Callaghan,0000-0002-1323-6843,Key Personnel,Team Hardy,Benjamin O’Callaghan
2131.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
2132.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5045734117,Ana Luisa Gil-Martínez,0000-0001-8455-5676,Key Personnel,Team Hardy,Ana Gil-Martínez
2133.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5045734117,Ana Luisa Gil-Martínez,0000-0001-8455-5676,Key Personnel,Team Wood,Ana Gil-Martínez
2134.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5025988686,Juan A. Botía,0000-0002-6992-598X,Key Personnel,Team Hardy,Juan Botía
2135.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656,Collaborating PI,Team Hardy,Hélène Plun‐Favreau
2136.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2137.0,The chromatin modulating NSL complex regulates genes and pathways genetically linked to Parkinson’s disease,Hardy,10.1101/2023.01.16.523926,10.1093/brain/awad246,1.0,W4385406197,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2138.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5015597636,Lesley Wu,0000-0001-5464-5603,Key Personnel,Team Hardy,Lesley Wu
2139.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
2140.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
2141.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5018964271,Ruth Chia,0000-0002-4709-7423,,,Ruth Chia
2142.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2143.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
2144.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5069748944,Catherine Bresner,0000-0003-2673-9762,,,Catherine Bresner
2145.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
2146.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
2147.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2148.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2149.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5056047751,Yevgeniya Abramzon,,,,Yevgeniya Abramzon
2150.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5034702104,Sarah Ahmed,0000-0003-0247-2557,,,Sarah Ahmed
2151.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5011045049,Camille Alba,0000-0002-0458-1629,,,Camille Alba
2152.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5110247931,Marilyn S. Albert,,,,Marilyn Albert
2153.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5052709263,Dagmar Bačíková,,,,Dagmar Bačíková
2154.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107497745,Matthew J. Barrett,,,,Matthew Barrett
2155.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5104689962,Thomas G Beach,,,,Thomas Beach
2156.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5014075642,David A. Bennett,0000-0003-3689-554X,,,David Bennett
2157.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107834584,Lilah M. Besser,,,,Lilah Besser
2158.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107831437,Eileen H. Bigio,,,,Eileen Bigio
2159.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107398640,Bradley F Boeve,,,,Bradley Boeve
2160.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5086310908,Ryan C. Bohannan,,,,Ryan Bohannan
2161.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5039097710,Chad A. Caraway,,,,Chad Caraway
2162.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5050948560,Jose‐Alberto Palma,0000-0002-1345-6774,,,Jose‐Alberto Palma
2163.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5018964271,Ruth Chia,0000-0002-4709-7423,,,Ruth Chia
2164.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5007936453,Clifton L. Dalgard,0000-0003-2025-8239,,,Clifton Dalgard
2165.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5009533777,Dennis W. Dickson,0000-0001-7189-7917,,,Dennis Dickson
2166.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2167.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5106726039,Kelley Faber,,,,Kelley Faber
2168.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5036878959,Tanis J. Ferman,0000-0001-8377-6194,,,Tanis Ferman
2169.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5048196698,Luigi Ferrucci,0000-0002-6273-1613,,,Luigi Ferrucci
2170.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5004078745,Margaret E. Flanagan,0009-0008-7078-3545,,,Margaret Flanagan
2171.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
2172.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5047929315,Bernardino Ghetti,0000-0002-1842-8019,,,Bernardino Ghetti
2173.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5005340246,J. Raphael Gibbs,0000-0002-6985-0658,,,J. Gibbs
2174.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5090202716,Alison Goate,0000-0002-0576-2472,,,Alison Goate
2175.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5024558351,David B. Goldstein,0000-0002-1111-2820,,,David Goldstein
2176.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107398641,Neill R Graff-Radford,,,,Neill Graff-Radford
2177.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5101220224,Heng-Chen Hu,,,,Heng-Chen Hu
2178.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5078015895,Daniel Hupalo,0000-0001-7816-2948,,,Daniel Hupalo
2179.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5075871006,Scott M. Kaiser,,,,Scott Kaiser
2180.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5073518656,Horacio Kaufmann,0000-0002-1851-9981,,,Horacio Kaufmann
2181.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5032570790,Ronald C. Kim,,,,Ronald Kim
2182.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107632204,Gregory Klein,,,,Gregory Klein
2183.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5060014836,Walter A. Kukull,0000-0001-8761-9014,,,Walter Kukull
2184.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5039340118,Amanda B. Kuzma,0000-0002-6064-5420,,,Amanda Kuzma
2185.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5113557701,James B. Leverenz,,,,James Leverenz
2186.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5011772005,Grisel Lopez,0000-0001-7785-2197,Key Personnel,Team Vangheluwe,Grisel Lopez
2187.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5109726582,Qinwen Mao,,,,Qinwen Mao
2188.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5086423613,Elisa Martinez-McGrath,,,,Elisa Martinez-McGrath
2189.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5074775445,Eliezer Masliah,0000-0002-2117-5569,,,Eliezer Masliah
2190.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5105472870,Ed Monuki,,,,Ed Monuki
2191.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5064132072,Kathy L. Newell,,,,Kathy Newell
2192.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5067477244,Lucy Norcliffe‐Kaufmann,0000-0003-0702-1333,,,Lucy Norcliffe‐Kaufmann
2193.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5029603803,Matthew Perkins,0000-0001-7715-0638,,,Matthew Perkins
2194.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5106521650,Olga Pletnikova,,,,Olga Pletnikova
2195.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5106478912,Alan E. Renton,,,,Alan Renton
2196.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5003112344,Susan M. Resnick,0000-0003-1115-7145,,,Susan Resnick
2197.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5074593768,Owen A. Ross,0000-0003-4813-756X,,,Owen Ross
2198.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5017601590,Marya S. Sabir,0000-0001-6333-4049,Key Personnel,Team Hardy,Marya Sabir
2199.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
2200.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
2201.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5050607848,Geidy E. Serrano,0000-0002-9527-2011,Key Personnel,Team Scherzer,Geidy Serrano
2202.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5096290966,Vikram Shakkotai,,,,Vikram Shakkotai
2203.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
2204.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5103328069,Andrew B. Singleton,,,,Andrew Singleton
2205.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5079276216,Toshiko Tanaka,0000-0002-4161-3829,,,Toshiko Tanaka
2206.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
2207.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5035072440,Bryan J. Traynor,0000-0003-0527-2446,,,Bryan Traynor
2208.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5048570234,Juan C. Troncoso,0000-0001-9553-6673,,,Juan Troncoso
2209.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5035373313,Coralie Viollet,0000-0002-6182-8165,,,Coralie Viollet
2210.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5073233893,Ronald L. Walton,,,,Ronald Walton
2211.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5109438902,Randy Woltjer,,,,Randy Woltjer
2212.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5022481370,Zbigniew K. Wszołek,0000-0001-5487-1053,,,Zbigniew Wszołek
2213.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5040635626,Sandra E. Black,0000-0001-7093-8289,,,Sandra Black
2214.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5089452258,Ziv Gan‐Or,0000-0003-0332-234X,,,Ziv Gan‐Or
2215.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5062012597,Julia Keith,0000-0003-1519-6731,,,Julia Keith
2216.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5085497748,Mario Masellis,0000-0002-6244-2096,,,Mario Masellis
2217.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5012586710,Ekaterina Rogaeva,0000-0002-2852-0329,,,Ekaterina Rogaeva
2218.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5051934606,Dag Aarsland,0000-0001-6314-216X,,,Dag Aarsland
2219.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5011302176,Safa Al‐Sarraj,0000-0002-6783-3571,,,Safa Al‐Sarraj
2220.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5077963659,Johannes Attems,0000-0003-1636-1700,,,Johannes Attems
2221.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107908441,Raffaele Ferrari,,,,Raffaele Ferrari
2222.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5108937855,Steve Gentleman,,,,Steve Gentleman
2223.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2224.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5106722695,Angela Hodges,0000-0002-5565-6678,,,Angela Hodges
2225.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5016566297,Seth Love,0000-0001-8683-3625,,,Seth Love
2226.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5003002074,Ian G. McKeith,0000-0002-9250-0568,,,Ian McKeith
2227.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5079660167,Christopher M. Morris,0000-0002-3749-0993,,,Christopher Morris
2228.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2229.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5036671564,Lyle J. Palmer,0000-0002-1628-3055,,,Lyle Palmer
2230.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5054635855,Stuart Pickering‐Brown,0000-0003-1561-6054,,,Stuart Pickering‐Brown
2231.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2232.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2233.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2234.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5035122709,Alan Thomas,0000-0002-6667-9533,,,Alan Thomas
2235.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5041586473,Bension S. Tilley,,,,Bension Tilley
2236.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5029095625,Claire Troakes,0000-0002-1790-7376,,,Claire Troakes
2237.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5062891142,Francesca Brett,0000-0002-7453-4027,,,Francesca Brett
2238.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5027489586,Alexis Brice,0000-0002-0941-3990,,,Alexis Brice
2239.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5107329484,Charles Duyckaerts,,,,Charles Duyckaerts
2240.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5013639132,Suzanne Lesage,,,,Suzanne Lesage
2241.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5109465673,Maura Brunetti,,,,Maura Brunetti
2242.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5049549975,Andrea Calvo,0000-0002-5122-7243,,,Andrea Calvo
2243.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5013689467,Antonio Canosa,0000-0001-5876-4079,,,Antonio Canosa
2244.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5090628289,Adriano Chiò,0000-0001-9579-5341,,,Adriano Chiò
2245.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5056137794,Gianluca Floris,0000-0001-8821-123X,,,Gianluca Floris
2246.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5047104019,Giancarlo Logroscino,0000-0003-0423-3242,,,Giancarlo Logroscino
2247.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5102749429,Chiara Zecca,0000-0002-7855-5714,,,Chiara Zecca
2248.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5035872689,Jordi Clarimón,0000-0002-6824-6942,,,Jordi Clarimón
2249.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5085616253,Mónica Díez-Fairén,0000-0003-1882-0309,,,Mónica Díez-Fairén
2250.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5010797490,Juan Fortea,0000-0002-1340-638X,,,Juan Fortea
2251.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5014575752,Isabel González Aramburu,0000-0002-3696-4093,,,Isabel Aramburu
2252.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5028976895,Jon Infante,0000-0003-4025-4606,,,Jon Infante
2253.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5065646667,Carmen Lage,0000-0003-1703-121X,,,Carmen Lage
2254.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5012378779,Alberto Lleó,0000-0002-2568-5478,,,Alberto Lleó
2255.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5027347263,Pau Pástor,0000-0002-7493-8777,,,Pau Pástor
2256.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5096290967,Laura Porcel-Molina,,,,Laura Porcel-Molina
2257.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5025514852,Eloy Rodríguez‐Rodríguez,0000-0001-7742-677X,,,Eloy Rodríguez‐Rodríguez
2258.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5069432142,Pascual Sánchez‐Juan,,,,Pascual Sánchez‐Juan
2259.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5113669519,Rejko Krüger,,,,Rejko Krüger
2260.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5057437092,Patrick May,0000-0001-8698-3770,,,Patrick May
2261.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5015590373,Georgia Xiromerisiou,0000-0001-7162-3588,,,Georgia Xiromerisiou
2262.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
2263.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5035072440,Bryan J. Traynor,0000-0003-0527-2446,,,Bryan Traynor
2264.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2265.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2266.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2267.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2268.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2269.0,Investigation of the genetic aetiology of Lewy body diseases with and without dementia | medRxiv,Hardy,10.1101/2023.10.17.23297157,10.1093/braincomms/fcae190,1.0,W4399200646,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2270.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
2271.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
2272.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5047510188,Siddharth Sethi,0000-0002-4398-4295,,,Siddharth Sethi
2273.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5037635006,Yujing Gao,0000-0002-4542-7062,,,Yujing Gao
2274.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Hardy,Jonathan Brenton
2275.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Wood,Jonathan Brenton
2276.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
2277.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5100325058,David Zhang,0000-0002-5027-5286,,,David Zhang
2278.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5043873122,Raquel Garza,0000-0002-2524-3055,Key Personnel,Team Jakobsson,Raquel Garza
2279.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2280.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
2281.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5016118485,Zhongbo Chen,0000-0001-6668-7202,,,Zhongbo Chen
2282.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
2283.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5064844758,Hannah Macpherson,0000-0002-9535-4025,Key Personnel,Team Wood,Hannah Macpherson
2284.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5044470153,Kylie Montgomery,0000-0001-6090-0703,,,Kylie Montgomery
2285.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5058711274,Rhys Dore,0000-0001-8417-8743,,,Rhys Dore
2286.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5066839058,Anna I. Wernick,0000-0001-9048-9492,Key Personnel,Team Hardy,Anna Wernick
2287.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5055552839,Charles Arber,0000-0002-9743-8134,,,Charles Arber
2288.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5050181909,Selina Wray,0000-0003-3062-7050,,,Selina Wray
2289.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
2290.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5068613855,Julian Esselborn,0000-0002-3499-8417,,,Julian Esselborn
2291.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
2292.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5062661954,Christopher H. Douse,0000-0002-1604-8944,,,Christopher Douse
2293.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5069607564,Anita Adami,0000-0002-9421-7942,Key Personnel,Team Jakobsson,Anita Adami
2294.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5032604553,Diahann A. M. Atacho,0000-0002-6158-0235,,,Diahann Atacho
2295.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5006545376,Antonina Kouli,0000-0001-6553-6154,,,Antonina Kouli
2296.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5033125199,Annelies Quaegebeur,0000-0001-5357-9341,Key Personnel,Team Jakobsson,Annelies Quaegebeur
2297.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5084748006,Roger A. Barker,0000-0001-8843-7730,Co-PI,Team Jakobsson,Roger Barker
2298.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5063767082,Elisabet Englund,0000-0002-2708-2443,,,Elisabet Englund
2299.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5078895245,Frances M. Platt,0000-0001-7614-0403,Co-PI,Team Hardy,Frances Platt
2300.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5021760406,Johan Jakobsson,0000-0003-0669-7673,Lead PI,Team Jakobsson,Johan Jakobsson
2301.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
2302.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
2303.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5002104149,Harpreet K. Saini,0000-0002-3733-7657,,,Harpreet Saini
2304.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5069936095,Carla F. Bento,0000-0001-8377-4543,,,Carla Bento
2305.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2306.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2307.0,The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1,Hardy,10.1101/2022.10.21.513169,10.1126/sciadv.adk1296,1.0,W4400033871,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2308.0,A step forward for LRRK2 inhibitors in Parkinson’s disease,Hardy,review,10.1126/scitranslmed.abq7374,0.0,W4282928088,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2309.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5019530991,Nirosen Vijiaratnam,0000-0002-9671-0212,,,Nirosen Vijiaratnam
2310.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2311.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5073721007,Amanda Heslegrave,0000-0002-7290-6405,,,Amanda Heslegrave
2312.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5054185420,Tong Guo,0000-0001-9395-3617,,,Tong Guo
2313.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
2314.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5041010859,Edwin Jabbari,0000-0001-6844-882X,Key Personnel,Team Hardy,Edwin Jabbari
2315.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
2316.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5103878779,John Woodside,,,,John Woodside
2317.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5112248330,Katherine Grosset,,,,Katherine Grosset
2318.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5014701168,Viorica Chelban,0000-0002-5817-6290,,,Viorica Chelban
2319.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5043990676,Dilan Athauda,0000-0001-8594-2483,,,Dilan Athauda
2320.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5064943801,Christine Girges,0000-0001-5019-6812,,,Christine Girges
2321.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5084748006,Roger A. Barker,0000-0001-8843-7730,Co-PI,Team Jakobsson,Roger Barker
2322.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2323.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
2324.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5082436384,Henry Houlden,0000-0002-2866-7777,,,Henry Houlden
2325.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2326.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2327.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5111750310,Henrik Zetterberg,,,,Henrik Zetterberg
2328.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2329.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
2330.0,Combining biomarkers for prognostic modelling of Parkinson’s disease,Hardy,10.1101/2021.11.01.21265751,10.1136/jnnp-2021-328365,1.0,W4280560966,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2331.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5058366878,Alejandro Martínez-Carrasco,0000-0001-6191-1703,,,Alejandro Martínez-Carrasco
2332.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5000861365,Raquel Real,0000-0001-8117-742X,Key Personnel,Team Hardy,Raquel Real
2333.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5007778657,Michael Lawton,0000-0002-3419-0354,,,Michael Lawton
2334.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2335.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5046721666,Manuela Tan,0000-0001-5835-669X,,,Manuela Tan
2336.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5015597636,Lesley Wu,0000-0001-5464-5603,Key Personnel,Team Hardy,Lesley Wu
2337.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5073614894,Nigel Williams,0000-0003-1177-6931,,,Nigel Williams
2338.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5050860301,Camille Carroll,0000-0001-7472-953X,,,Camille Carroll
2339.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5004608080,Jean‐Christophe Corvol,0000-0001-7325-0199,,,Jean‐Christophe Corvol
2340.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5003673082,Joshua Shulman,0000-0001-6382-5841,,,Joshua Shulman
2341.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5059872338,Donald G. Grosset,0000-0002-2757-8203,,,Donald Grosset
2342.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2343.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2344.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2345.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5046617667,Yoav Ben‐Shlomo,0000-0001-6648-3007,,,Yoav Ben‐Shlomo
2346.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5071383564,Maryam Shoai,0000-0003-2499-8533,Key Personnel,Team Hardy,Maryam Shoai
2347.0,Association of genetic variation at the GJA5/ACP6 locus with motor progression in Parkinson’s,Hardy,10.1101/2022.10.28.22281645,10.1212/nxg.0000000000200092,1.0,W4385650789,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2348.0,Leucine-rich repeat kinase 2 at a glance,Hardy,review,10.1242/jcs.259724,0.0,W4386624202,A5034246730,Christiane Zhu,0009-0005-2908-824X,,,Christiane Zhu
2349.0,Leucine-rich repeat kinase 2 at a glance,Hardy,review,10.1242/jcs.259724,0.0,W4386624202,A5077705939,Susanne Herbst,0000-0003-2255-7371,Key Personnel,Team Hardy,Susanne Herbst
2350.0,Leucine-rich repeat kinase 2 at a glance,Hardy,review,10.1242/jcs.259724,0.0,W4386624202,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2351.0,PINK1: From Parkinson’s disease to mitophagy and back again,Hardy,review,10.1371/journal.pbio.3002196,0.0,W4382601233,A5059141377,Benjamin O’Callaghan,0000-0002-1323-6843,Key Personnel,Team Hardy,Benjamin O’Callaghan
2352.0,PINK1: From Parkinson’s disease to mitophagy and back again,Hardy,review,10.1371/journal.pbio.3002196,0.0,W4382601233,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
2353.0,PINK1: From Parkinson’s disease to mitophagy and back again,Hardy,review,10.1371/journal.pbio.3002196,0.0,W4382601233,A5045997682,Hélène Plun‐Favreau,0000-0002-1401-9656,Collaborating PI,Team Hardy,Hélène Plun‐Favreau
2354.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5086806177,MX Tan Manuela,,,,MX Manuela
2355.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5104205350,Real Raquel,,,,Real Raquel
2356.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5089848747,A Lawton Michael,,,,A Michael
2357.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5024719515,Catherine Bresner,,,,Catherine Bresner
2358.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5009788111,Sofia Kanavou,0000-0001-8650-6667,,,Sofia Kanavou
2359.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
2360.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
2361.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5023401809,Andrea Mike,0000-0002-5498-6843,,,Andrea Mike
2362.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5043537924,Nigel Maxted,0000-0002-2112-0947,,,Nigel Maxted
2363.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5103747873,Ben-Shlomo Yoav,,,,Ben-Shlomo Yoav
2364.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5049634450,TM Hu Michele,,,,TM Michele
2365.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5103989983,G Grosset Donald,,,,G Donald
2366.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5106696054,Hardy John,,,,Hardy John
2367.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5103989984,Shoai Maryam,,,,Shoai Maryam
2368.0,Evaluation Of The Rims2 Locus As A Risk Locus For Parkinson’s Disease Dementia,Hardy,10.1101/2021.07.26.21261131,,1.0,W3186738626,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2369.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
2370.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5037391977,David Zhang,0000-0003-2382-8460,,,David Zhang
2371.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
2372.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
2373.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5016758911,G Rocamora-Perez,,,,G Rocamora-Perez
2374.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
2375.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5054705865,Aine Fairbrother-Browne,0000-0002-7196-1410,Key Personnel,Team Wood,Aine Fairbrother-Browne
2376.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
2377.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Hardy,Jonathan Brenton
2378.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Wood,Jonathan Brenton
2379.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5045734117,Ana Luisa Gil-Martínez,0000-0001-8455-5676,Key Personnel,Team Hardy,Ana Gil-Martínez
2380.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5045734117,Ana Luisa Gil-Martínez,0000-0001-8455-5676,Key Personnel,Team Wood,Ana Gil-Martínez
2381.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5016118485,Zhongbo Chen,0000-0001-6668-7202,,,Zhongbo Chen
2382.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5034073565,Donald C. Rio,,Lead-PI,Team Rio,Donald Rio
2383.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5025988686,Juan A. Botía,0000-0002-6992-598X,Key Personnel,Team Hardy,Juan Botía
2384.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5051204041,Sebastian Guelfi,0000-0002-0256-2686,,,Sebastian Guelfi
2385.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5075979341,Leonardo Collado‐Torres,0000-0003-2140-308X,,,Leonardo Collado‐Torres
2386.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
2387.0,"Splicing accuracy varies across human introns, tissues and age",Hardy,10.1101/2023.03.29.534370,,1.0,W4361262952,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
2388.0,Mutations in GPNMB associated with Amyloid cutis dyschromica alter intracellular trafficking and processing of GPNMB | bioRxiv,Hardy,10.1101/2023.12.19.572409,,1.0,W4389986385,A5085158276,Erin C. Bogacki,0000-0001-9594-8272,,,Erin Bogacki
2389.0,Mutations in GPNMB associated with Amyloid cutis dyschromica alter intracellular trafficking and processing of GPNMB | bioRxiv,Hardy,10.1101/2023.12.19.572409,,1.0,W4389986385,A5000831279,Patrick A. Lewis,0000-0003-4537-0489,Collaborating PI,Team Hardy,Patrick Lewis
2390.0,Mutations in GPNMB associated with Amyloid cutis dyschromica alter intracellular trafficking and processing of GPNMB | bioRxiv,Hardy,10.1101/2023.12.19.572409,,1.0,W4389986385,A5077705939,Susanne Herbst,0000-0003-2255-7371,Key Personnel,Team Hardy,Susanne Herbst
2391.0,The pathogenesis of Parkinson's disease - The Lancet,Hardy/Kirik,review,10.1016/S0140-6736(23)01478-2,0.0,W4390964116,A5082416184,Huw R. Morris,0000-0002-5473-3774,Collaborating PI,Team Hardy,Huw Morris
2392.0,The pathogenesis of Parkinson's disease - The Lancet,Hardy/Kirik,review,10.1016/S0140-6736(23)01478-2,0.0,W4390964116,A5037609259,Maria Grazia Spillantini,0000-0002-8544-7332,Co-PI,Team Hardy,Maria Spillantini
2393.0,The pathogenesis of Parkinson's disease - The Lancet,Hardy/Kirik,review,10.1016/S0140-6736(23)01478-2,0.0,W4390964116,A5045037139,Carolyn M. Sue,0000-0003-1255-3617,,,Carolyn Sue
2394.0,The pathogenesis of Parkinson's disease - The Lancet,Hardy/Kirik,review,10.1016/S0140-6736(23)01478-2,0.0,W4390964116,A5005045661,Caroline H. Williams‐Gray,0000-0002-2648-9743,,,Caroline Williams‐Gray
2395.0,The chaperone Clusterin in neurodegeneration−friend or foe?,Harper,review,10.1002/bies.202100287,0.0,W4229006902,A5082805678,Patricia Yuste‐Checa,0000-0002-1056-3849,Key Personnel,Team Harper,Patricia Yuste‐Checa
2396.0,The chaperone Clusterin in neurodegeneration−friend or foe?,Harper,review,10.1002/bies.202100287,0.0,W4229006902,A5036116391,Andreas Bracher,0000-0001-8530-7594,,,Andreas Bracher
2397.0,The chaperone Clusterin in neurodegeneration−friend or foe?,Harper,review,10.1002/bies.202100287,0.0,W4229006902,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2398.0,Mechanisms Controlling Selective Elimination of Damaged Lysosomes - PMC (nih.gov),Harper,review,10.1016/j.cophys.2022.100590,0.0,W4293724281,A5085158845,Melissa Hoyer,0000-0003-0858-4998,,,Melissa Hoyer
2399.0,Mechanisms Controlling Selective Elimination of Damaged Lysosomes - PMC (nih.gov),Harper,review,10.1016/j.cophys.2022.100590,0.0,W4293724281,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2400.0,Mechanisms Controlling Selective Elimination of Damaged Lysosomes - PMC (nih.gov),Harper,review,10.1016/j.cophys.2022.100590,0.0,W4293724281,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2401.0,Mechanisms underlying ubiquitin-driven selective mitochondrial and bacterial autophagy: Molecular Cell,Harper,review,10.1016/j.molcel.2022.03.012,0.0,W4220684596,A5042803666,Ellen A. Goodall,0000-0001-9876-5973,Key Personnel,Team Harper,Ellen Goodall
2402.0,Mechanisms underlying ubiquitin-driven selective mitochondrial and bacterial autophagy: Molecular Cell,Harper,review,10.1016/j.molcel.2022.03.012,0.0,W4220684596,A5066628008,Felix Kraus,0000-0002-3757-541X,,,Felix Kraus
2403.0,Mechanisms underlying ubiquitin-driven selective mitochondrial and bacterial autophagy: Molecular Cell,Harper,review,10.1016/j.molcel.2022.03.012,0.0,W4220684596,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2404.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5021043258,Dorothy Yanling Zhao,0000-0002-3538-0926,,,Dorothy Zhao
2405.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5083461569,Felix J.B. Bäuerlein,0000-0002-8889-7371,,,Felix Bäuerlein
2406.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5027067913,Itika Saha,0000-0002-0289-4082,Key Personnel,Team Harper,Itika Saha
2407.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2408.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2409.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5006303094,Florian Wilfling,0000-0002-6559-7261,Key Personnel,Team Harper,Florian Wilfling
2410.0,Autophagy preferentially degrades non-fibrillar polyQ aggregates,Harper,10.1101/2023.08.08.552291,10.1016/j.molcel.2024.04.018,1.0,W4396980221,A5006303094,Florian Wilfling,0000-0002-6559-7261,Paid Collaborator,Team Hurley,Florian Wilfling
2411.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5089371716,Victoria A. Trinkaus,0000-0001-8964-6120,,,Victoria Trinkaus
2412.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5059509143,Irene Riera-Tur,0000-0002-2396-3921,,,Irene Riera-Tur
2413.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5035593262,Antonio Martínez-Sánchez,0000-0002-5865-2138,,,Antonio Martínez-Sánchez
2414.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5083461569,Felix J.B. Bäuerlein,0000-0002-8889-7371,,,Felix Bäuerlein
2415.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5100690472,Qiang Guo,0000-0003-3520-5439,,,Qiang Guo
2416.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5111873552,Thomas Arzberger,,,,Thomas Arzberger
2417.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2418.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5079468350,Irina Dudanova,0000-0003-1052-8485,,,Irina Dudanova
2419.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5062536186,Mark S. Hipp,0000-0002-0497-3016,,,Mark Hipp
2420.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2421.0,In situ architecture of neuronal α-Synuclein inclusions,Harper,10.1101/2020.08.07.234138,10.1038/s41467-021-22108-0,1.0,W3156701803,A5061030857,Rubén Fernández‐Busnadiego,0000-0002-8366-7622,Co-PI,Team Harper,Rubén Fernández‐Busnadiego
2422.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5082805678,Patricia Yuste‐Checa,0000-0002-1056-3849,Key Personnel,Team Harper,Patricia Yuste‐Checa
2423.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5089371716,Victoria A. Trinkaus,0000-0001-8964-6120,,,Victoria Trinkaus
2424.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5059509143,Irene Riera-Tur,0000-0002-2396-3921,,,Irene Riera-Tur
2425.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5021138927,Rahmi Imamoglu,0000-0002-7695-8317,,,Rahmi Imamoglu
2426.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5038644841,Theresa Schaller,0000-0002-1208-7823,,,Theresa Schaller
2427.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5066673597,Huping Wang,0000-0002-9639-5355,,,Huping Wang
2428.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5079468350,Irina Dudanova,0000-0003-1052-8485,,,Irina Dudanova
2429.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5062536186,Mark S. Hipp,0000-0002-0497-3016,,,Mark Hipp
2430.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5036116391,Andreas Bracher,0000-0001-8530-7594,,,Andreas Bracher
2431.0,The extracellular chaperone Clusterin enhances Tau aggregate seeding in a cellular model,Harper,10.1101/2021.07.16.452659,10.1038/s41467-021-25060-1,1.0,W3187288550,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2432.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5061097943,Matthias M. Schneider,0000-0002-1894-1859,Key Personnel,Team Harper,Matthias Schneider
2433.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5005940057,Saurabh Gautam,0000-0003-0366-6169,,,Saurabh Gautam
2434.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5061699771,Therese W. Herling,0000-0002-1332-3090,,,Therese Herling
2435.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5005057235,Ewa Andrzejewska,0000-0002-6940-1289,,,Ewa Andrzejewska
2436.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5019000351,Georg Krainer,0000-0002-9626-7636,,,Georg Krainer
2437.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5102864622,Alyssa Miller,0000-0002-6980-9794,,,Alyssa Miller
2438.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5089371716,Victoria A. Trinkaus,0000-0001-8964-6120,,,Victoria Trinkaus
2439.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5057736494,Quentin Peter,0000-0002-8018-3059,,,Quentin Peter
2440.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5022738294,Francesco Simone Ruggeri,0000-0002-1232-1907,,,Francesco Ruggeri
2441.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5038452125,Michele Vendruscolo,0000-0002-3616-1610,Co-PI,Team Wood,Michele Vendruscolo
2442.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5036116391,Andreas Bracher,0000-0001-8530-7594,,,Andreas Bracher
2443.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5091898546,Christopher M. Dobson,0000-0002-5445-680X,,,Christopher Dobson
2444.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2445.0,The Hsc70 disaggregation machinery removes monomer units directly from α-synuclein fibril ends,Harper,10.1101/2020.11.02.365825,10.1038/s41467-021-25966-w,1.0,W3206809879,A5041530719,Tuomas P. J. Knowles,0000-0002-7879-0140,,,Tuomas Knowles
2446.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5083726820,Sebastian Boland,0000-0002-6694-2039,,,Sebastian Boland
2447.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2448.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5086983262,Yohannes Abere Ambaw,0000-0002-1703-400X,,,Yohannes Ambaw
2449.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5074877384,Pedro Carpio Malia,0000-0003-1234-8103,,,Pedro Malia
2450.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5030740961,Ruth C. Richards,,,,Ruth Richards
2451.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5075402962,Alexander W. Fischer,0000-0001-6717-9090,,,Alexander Fischer
2452.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5045344077,Shubham Singh,0000-0002-2428-7718,,,Shubham Singh
2453.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5055646685,Geetika Aggarwal,0000-0002-1848-5056,,,Geetika Aggarwal
2454.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5025008902,Salvatore Spina,0000-0003-3570-9143,,,Salvatore Spina
2455.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5013515632,Alissa L. Nana,0000-0003-3474-8044,,,Alissa Nana
2456.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5003878251,Lea T. Grinberg,0000-0002-6809-0618,,,Lea Grinberg
2457.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5074694043,William W. Seeley,0000-0003-1410-2027,,,William Seeley
2458.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5056618033,Michał A. Surma,0000-0001-7833-2214,,,Michał Surma
2459.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5071326290,Christian Klose,0000-0003-2853-4533,,,Christian Klose
2460.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2461.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5100693033,Andrew D. Nguyen,0000-0002-9492-9472,,,Andrew Nguyen
2462.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2463.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5078087465,Tobias C. Walther,0000-0003-1442-1327,,,Tobias Walther
2464.0,Deficiency of the frontotemporal dementia gene GRN results in gangliosidosis,Harper,10.1101/2021.09.30.461806,10.1038/s41467-022-33500-9,1.0,W4303446525,A5083674919,Robert V. Farese,0000-0001-8103-2239,,,Robert Farese
2465.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5091866133,Hankum Park,0000-0001-5795-3249,,,Hankum Park
2466.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5079127441,Frances V Hundley,0000-0001-9469-301X,Project Manager,Team Harper,Frances Hundley
2467.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5040242042,Qing Yu,0000-0003-0468-5353,,,Qing Yu
2468.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5010446056,Katherine A. Overmyer,0000-0002-1929-1229,,,Katherine Overmyer
2469.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5031630272,Dain R. Brademan,0000-0002-0971-9711,,,Dain Brademan
2470.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5037217891,Lia R. Serrano,0000-0001-5662-5884,,,Lia Serrano
2471.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2472.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5023479457,Julia C. Paoli,0000-0001-8266-1766,,,Julia Paoli
2473.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2474.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5086840789,Joshua J. Coon,0000-0002-0004-8253,,,Joshua Coon
2475.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5079793809,Steven P. Gygi,0000-0001-7626-0034,,,Steven Gygi
2476.0,Spatial snapshots of amyloid precursor protein intramembrane processing via early endosome proteomics,Harper,10.1101/2022.03.31.486371,10.1038/s41467-022-33881-x,1.0,W4306353218,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2477.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5027067913,Itika Saha,0000-0002-0289-4082,Key Personnel,Team Harper,Itika Saha
2478.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5082805678,Patricia Yuste‐Checa,0000-0002-1056-3849,Key Personnel,Team Harper,Patricia Yuste‐Checa
2479.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5068009554,Miguel da Silva Padilha,0000-0001-8141-7163,,,Miguel Padilha
2480.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5100690472,Qiang Guo,0000-0003-3520-5439,,,Qiang Guo
2481.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5063314765,Roman Körner,0000-0001-9285-9290,,,Roman Körner
2482.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5008325885,Hauke Holthusen,0000-0002-2050-413X,,,Hauke Holthusen
2483.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5089371716,Victoria A. Trinkaus,0000-0001-8964-6120,,,Victoria Trinkaus
2484.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5079468350,Irina Dudanova,0000-0003-1052-8485,,,Irina Dudanova
2485.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5061030857,Rubén Fernández‐Busnadiego,0000-0002-8366-7622,Co-PI,Team Harper,Rubén Fernández‐Busnadiego
2486.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2487.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5090306646,David W. Sanders,0000-0002-1835-6895,,,David Sanders
2488.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5005940057,Saurabh Gautam,0000-0003-0366-6169,,,Saurabh Gautam
2489.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5013978422,Marc I. Diamond,0000-0002-8085-7770,,,Marc Diamond
2490.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5086048712,F. Ulrich Hartl,0000-0002-7941-135X,Co-PI,Team Harper,F. Hartl
2491.0,The AAA+ chaperone VCP disaggregates Tau fibrils and generates aggregate seeds in a cellular system,Harper,10.1101/2022.02.18.481043,10.1038/s41467-023-36058-2,1.0,W4319017939,A5062536186,Mark S. Hipp,0000-0002-0497-3016,,,Mark Hipp
2492.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5085158845,Melissa Hoyer,0000-0003-0858-4998,,,Melissa Hoyer
2493.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5045212954,Cristina Capitanio,0000-0002-5297-9156,Key Personnel,Team Harper,Cristina Capitanio
2494.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5035241621,Ian R. Smith,0000-0002-4966-9333,,,Ian Smith
2495.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5023479457,Julia C. Paoli,0000-0001-8266-1766,,,Julia Paoli
2496.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5037145890,Anna Bieber,0000-0001-5014-6620,Key Personnel,Team Harper,Anna Bieber
2497.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5108145366,Yizhi Jiang,,Key Personnel,Team Harper,Yizhi Jiang
2498.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2499.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5031687007,Miguel A. Gonzalez‐Lozano,0000-0002-7837-151X,Key Personnel,Team Harper,Miguel Gonzalez‐Lozano
2500.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2501.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5006303094,Florian Wilfling,0000-0002-6559-7261,Key Personnel,Team Harper,Florian Wilfling
2502.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5006303094,Florian Wilfling,0000-0002-6559-7261,Paid Collaborator,Team Hurley,Florian Wilfling
2503.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5023564164,Brenda A. Schulman,0000-0002-3083-1126,Co-PI,Team Harper,Brenda Schulman
2504.0,Combinatorial selective ER-phagy remodels the ER during neurogensis,Harper,10.1101/2023.06.26.546565,10.1038/s41556-024-01356-4,1.0,W4392356816,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2505.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5051742555,Kelsey Hickey,0000-0001-9904-0966,Key Personnel,Team Harper,Kelsey Hickey
2506.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2507.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5035241621,Ian R. Smith,0000-0002-4966-9333,,,Ian Smith
2508.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5023479457,Julia C. Paoli,0000-0001-8266-1766,,,Julia Paoli
2509.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5092952928,Enya Miguel Whelan,0000-0003-1525-7207,,,Enya Whelan
2510.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2511.0,Proteome census upon nutrient stress reveals Golgiphagy membrane receptors | Nature,Harper,10.1101/2022.12.06.519342,10.1038/s41586-023-06657-6,1.0,W4387095425,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2512.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5039241406,Frank Adolf,0000-0002-9812-5711,Key Personnel,Team Harper,Frank Adolf
2513.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5042396355,Jiale Du,0000-0003-1410-7020,Key Personnel,Team Harper,Jiale Du
2514.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5042803666,Ellen A. Goodall,0000-0001-9876-5973,Key Personnel,Team Harper,Ellen Goodall
2515.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5012541288,Richard M. Walsh,0000-0002-8939-8988,,,Richard Walsh
2516.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5016627841,Shaun Rawson,0000-0002-2973-2630,,,Shaun Rawson
2517.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5035481746,Susanne von Gronau,,,,Susanne Gronau
2518.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2519.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5039787720,John Hanna,0000-0003-2964-1058,,,John Hanna
2520.0,Visualizing chaperone-mediated multistep assembly of the human 20S proteasome,Harper,10.1101/2024.01.27.577538,10.1038/s41594-024-01268-9,1.0,W4394691490,A5023564164,Brenda A. Schulman,0000-0002-3083-1126,Co-PI,Team Harper,Brenda Schulman
2521.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5037145890,Anna Bieber,0000-0001-5014-6620,Key Personnel,Team Harper,Anna Bieber
2522.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5045212954,Cristina Capitanio,0000-0002-5297-9156,Key Personnel,Team Harper,Cristina Capitanio
2523.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5066605298,Philipp S. Erdmann,0000-0001-8289-9133,,,Philipp Erdmann
2524.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5076792820,Fabian Fiedler,,,,Fabian Fiedler
2525.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5014597115,Florian Beck,0000-0003-3183-2953,,,Florian Beck
2526.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5101504331,Chia‐Wei Lee,0000-0002-8925-7421,,,Chia‐Wei Lee
2527.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5017563110,Delong Li,0000-0002-6930-8391,Key Personnel,Team Harper,Delong Li
2528.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5059945365,Gerhard Hummer,0000-0001-7768-746X,Paid Collaborator,Team Hurley,Gerhard Hummer
2529.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5023564164,Brenda A. Schulman,0000-0002-3083-1126,Co-PI,Team Harper,Brenda Schulman
2530.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2531.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5006303094,Florian Wilfling,0000-0002-6559-7261,Key Personnel,Team Harper,Florian Wilfling
2532.0,In situ structural analysis reveals membrane shape transitions during autophagosome formation,Harper,10.1101/2022.05.02.490291,10.1073/pnas.2209823119,1.0,W4296297488,A5006303094,Florian Wilfling,0000-0002-6559-7261,Paid Collaborator,Team Hurley,Florian Wilfling
2533.0,UniProtExtractR: an app and R package for easily extracting protein-specific UniProtKB information and fine-tuning organelle resolution | Bioinformatics Advances | Oxford Academic (oup.com),Harper,review,10.1093/bioadv/vbad157,0.0,W4388422308,A5072980791,Alexandra Panov,,,,Alexandra Panov
2534.0,UniProtExtractR: an app and R package for easily extracting protein-specific UniProtKB information and fine-tuning organelle resolution | Bioinformatics Advances | Oxford Academic (oup.com),Harper,review,10.1093/bioadv/vbad157,0.0,W4388422308,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2535.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5066628008,Felix Kraus,0000-0002-3757-541X,,,Felix Kraus
2536.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5042803666,Ellen A. Goodall,0000-0001-9876-5973,Key Personnel,Team Harper,Ellen Goodall
2537.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5035241621,Ian R. Smith,0000-0002-4966-9333,,,Ian Smith
2538.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5054007595,Yizhi Jiang,0000-0001-9016-1104,Key Personnel,Team Harper,Yizhi Jiang
2539.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5023479457,Julia C. Paoli,0000-0001-8266-1766,,,Julia Paoli
2540.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5039241406,Frank Adolf,0000-0002-9812-5711,Key Personnel,Team Harper,Frank Adolf
2541.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5000219280,Jiuchun Zhang,,,,Jiuchun Zhang
2542.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2543.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5023564164,Brenda A. Schulman,0000-0002-3083-1126,Co-PI,Team Harper,Brenda Schulman
2544.0,PARK15/FBXO7 is dispensable for PINK1/Parkin mitophagy in iNeurons and HeLa cell systems,Harper,10.1101/2022.11.02.514817,10.15252/embr.202256399,1.0,W4381164613,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2545.0,Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy,Harper,10.1101/2021.07.19.452535,10.7554/eLife.72328,1.0,W3202373309,A5053069378,Vinay V. Eapen,0000-0002-8023-387X,,,Vinay Eapen
2546.0,Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy,Harper,10.1101/2021.07.19.452535,10.7554/eLife.72328,1.0,W3202373309,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2547.0,Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy,Harper,10.1101/2021.07.19.452535,10.7554/eLife.72328,1.0,W3202373309,A5085158845,Melissa Hoyer,0000-0003-0858-4998,,,Melissa Hoyer
2548.0,Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy,Harper,10.1101/2021.07.19.452535,10.7554/eLife.72328,1.0,W3202373309,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2549.0,Quantitative proteomics reveals the selectivity of ubiquitin-binding autophagy receptors in the turnover of damaged lysosomes by lysophagy,Harper,10.1101/2021.07.19.452535,10.7554/eLife.72328,1.0,W3202373309,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2550.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5004961303,Ching‐Chieh Chou,0000-0001-8302-2915,Key Personnel,Team Harper,Ching‐Chieh Chou
2551.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5048401301,Ryan T. Vest,,,,Ryan Vest
2552.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5021119423,Miguel A. Prado,0000-0002-4914-1619,,,Miguel Prado
2553.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5063538067,Joshua Wilson‐Grady,0000-0001-6919-0410,,,Joshua Wilson‐Grady
2554.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2555.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5011108715,Yohei Shibuya,0000-0002-8825-5440,,,Yohei Shibuya
2556.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5111624928,Patricia Moran‐Losada,,,,Patricia Moran‐Losada
2557.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5077274718,Ting-Ting Lee,0000-0003-1010-3292,Key Personnel,Team Harper,Ting-Ting Lee
2558.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5071756884,Jian Luo,0000-0002-2064-8467,,,Jian Luo
2559.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5079793809,Steven P. Gygi,0000-0001-7626-0034,,,Steven Gygi
2560.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5081499831,Jeffery W. Kelly,0000-0001-8943-3395,,,Jeffery Kelly
2561.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5084203383,Daniel Finley,0000-0003-2076-5863,,,Daniel Finley
2562.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5081385535,Marius Wernig,0000-0002-5309-515X,,,Marius Wernig
2563.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5027893468,Tony Wyss‐Coray,0000-0001-5893-0831,,,Tony Wyss‐Coray
2564.0,Proteostasis and lysosomal quality control deficits in Alzheimer’s disease neurons | bioRxiv,Harper,10.1101/2023.03.27.534444,,1.0,W4361215982,A5041204065,Judith Frydman,0000-0003-2302-6943,Co-PI,Team Harper,Judith Frydman
2565.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5066628008,Felix Kraus,0000-0002-3757-541X,,,Felix Kraus
2566.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5100642697,Yuchen He,0000-0002-6096-4915,,,Yuchen He
2567.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5035448367,Sharan Swarup,0000-0003-0226-5582,,,Sharan Swarup
2568.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5010446056,Katherine A. Overmyer,0000-0002-1929-1229,,,Katherine Overmyer
2569.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5108145366,Yizhi Jiang,,Key Personnel,Team Harper,Yizhi Jiang
2570.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5028364120,Johann Brenner,0000-0003-1306-3564,,,Johann Brenner
2571.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5045212954,Cristina Capitanio,0000-0002-5297-9156,Key Personnel,Team Harper,Cristina Capitanio
2572.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5037145890,Anna Bieber,0000-0001-5014-6620,Key Personnel,Team Harper,Anna Bieber
2573.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5070738917,Annie Jen,0000-0001-5569-8387,,,Annie Jen
2574.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5042181659,Nicole M. Nightingale,0009-0004-6917-2406,,,Nicole Nightingale
2575.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5008047821,Benton J. Anderson,0000-0001-6156-342X,,,Benton Anderson
2576.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5100663728,Chan Lee,0000-0002-5512-8146,,,Chan Lee
2577.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5026734370,João A. Paulo,0000-0002-4291-413X,,,João Paulo
2578.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5035241621,Ian R. Smith,0000-0002-4966-9333,,,Ian Smith
2579.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5080004495,Jürgen M. Plitzko,0000-0002-6402-8315,,,Jürgen Plitzko
2580.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5023564164,Brenda A. Schulman,0000-0002-3083-1126,Co-PI,Team Harper,Brenda Schulman
2581.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5006303094,Florian Wilfling,0000-0002-6559-7261,Key Personnel,Team Harper,Florian Wilfling
2582.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5006303094,Florian Wilfling,0000-0002-6559-7261,Paid Collaborator,Team Hurley,Florian Wilfling
2583.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5086840789,Joshua J. Coon,0000-0002-0004-8253,,,Joshua Coon
2584.0,Lysosomal storage disease proteo/lipidomic profiling using nMOST links ferritinophagy with mitochondrial iron deficiencies in cells lacking NPC2,Harper,10.1101/2024.03.26.586828,,1.0,W4393217948,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2585.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5051742555,Kelsey Hickey,0000-0001-9904-0966,Key Personnel,Team Harper,Kelsey Hickey
2586.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5072980791,Alexandra Panov,,,,Alexandra Panov
2587.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5092952928,Enya Miguel Whelan,0000-0003-1525-7207,,,Enya Whelan
2588.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5050460382,Tillman Schäfer,0000-0002-9992-2501,,,Tillman Schäfer
2589.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5000792752,Arda Mizrak,0000-0001-6524-4864,Key Personnel,Team Harper,Arda Mizrak
2590.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5058767055,Ron R. Kopito,0000-0001-5027-6935,,,Ron Kopito
2591.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5029559203,Wolfgang Baumeister,0000-0001-8154-8809,Key Collaborator,Team Harper,Wolfgang Baumeister
2592.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5061030857,Rubén Fernández‐Busnadiego,0000-0002-8366-7622,Co-PI,Team Harper,Rubén Fernández‐Busnadiego
2593.0,Temporal control of acute protein aggregate turnover by UBE3C and NRF1-dependent proteasomal pathways,Harper,10.1101/2024.08.30.610524,,1.0,W4402101311,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2594.0,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes",Hurley,10.1101/2022.11.14.516471,10.1016/j.celrep.2023.112448,1.0,W4367625974,A5087056018,Dan Dou,0000-0002-6939-4752,,,Dan Dou
2595.0,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes",Hurley,10.1101/2022.11.14.516471,10.1016/j.celrep.2023.112448,1.0,W4367625974,A5070127770,Erin Smith,0000-0002-6726-628X,,,Erin Smith
2596.0,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes",Hurley,10.1101/2022.11.14.516471,10.1016/j.celrep.2023.112448,1.0,W4367625974,A5033015769,Chantell S. Evans,0000-0001-9401-8604,Collaborating PI,Team Calakos,Chantell Evans
2597.0,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes",Hurley,10.1101/2022.11.14.516471,10.1016/j.celrep.2023.112448,1.0,W4367625974,A5072866258,C. Alexander Boecker,0000-0001-9701-5273,,,C. Boecker
2598.0,"Regulatory imbalance between LRRK2 kinase, PPM1H phosphatase, and ARF6 GTPase disrupts the axonal transport of autophagosomes",Hurley,10.1101/2022.11.14.516471,10.1016/j.celrep.2023.112448,1.0,W4367625974,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2599.0,Orchestration of selective autophagy by cargo receptors,Hurley,review,10.1016/j.cub.2022.11.002,0.0,W4312094513,A5067997102,Elias Adriaenssens,0000-0001-9430-917X,Key Personnel,Team Hurley,Elias Adriaenssens
2600.0,Orchestration of selective autophagy by cargo receptors,Hurley,review,10.1016/j.cub.2022.11.002,0.0,W4312094513,A5078271011,Luca Ferrari,0000-0003-1934-157X,,,Luca Ferrari
2601.0,Orchestration of selective autophagy by cargo receptors,Hurley,review,10.1016/j.cub.2022.11.002,0.0,W4312094513,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2602.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2603.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5065987196,Justyna Sawa‐Makarska,0000-0002-9321-976X,Key Personnel,Team Hurley,Justyna Sawa‐Makarska
2604.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2605.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5080220622,Wai Kit Lam,0000-0002-7433-9205,Key Personnel,Team Hurley,Wai Lam
2606.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5067997102,Elias Adriaenssens,0000-0001-9430-917X,Key Personnel,Team Hurley,Elias Adriaenssens
2607.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5038589622,Dorotea Fracchiolla,0000-0002-1612-5225,Project Manager,Team Hurley,Dorotea Fracchiolla
2608.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5045624897,Stephen Shoebridge,0000-0002-3555-2855,,,Stephen Shoebridge
2609.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5075781636,Daniel Bernklau,,,,Daniel Bernklau
2610.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5078421822,Benjamin Scott Padman,0000-0002-5710-6100,,,Benjamin Padman
2611.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014,,,Marvin Skulsuppaisarn
2612.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5082909714,Runa Lindblom,0000-0001-6755-8744,Key Personnel,Team Hurley,Runa Lindblom
2613.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2614.0,Unconventional Initiation of PINK1/Parkin Mitophagy by Optineurin,Hurley,10.1101/2022.08.14.503930,10.1016/j.molcel.2023.04.021,1.0,W4377047698,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2615.0,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling: Molecular Cell,Hurley,10.1101/2022.06.21.496850,10.1016/j.molcel.2023.08.005,1.0,W4386496532,A5066177476,Olivia Harding,0000-0002-0719-2901,,,Olivia Harding
2616.0,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling: Molecular Cell,Hurley,10.1101/2022.06.21.496850,10.1016/j.molcel.2023.08.005,1.0,W4386496532,A5045960186,Elisabeth Holzer,0000-0003-1806-737X,Key Personnel,Team Hurley,Elisabeth Holzer
2617.0,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling: Molecular Cell,Hurley,10.1101/2022.06.21.496850,10.1016/j.molcel.2023.08.005,1.0,W4386496532,A5011795650,Julia F. Riley,0000-0001-8518-9786,Key Personnel,Team Hurley,Julia Riley
2618.0,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling: Molecular Cell,Hurley,10.1101/2022.06.21.496850,10.1016/j.molcel.2023.08.005,1.0,W4386496532,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2619.0,Damaged mitochondria recruit the effector NEMO to activate NF-κB signaling: Molecular Cell,Hurley,10.1101/2022.06.21.496850,10.1016/j.molcel.2023.08.005,1.0,W4386496532,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2620.0,Mitochondrial degradation: Mitophagy and beyond: Molecular Cell,Hurley,review,10.1016/j.molcel.2023.08.021,0.0,W4386757254,A5046225091,Louise Uoselis,0000-0001-8538-9817,Key Personnel,Team Hurley,Louise Uoselis
2621.0,Mitochondrial degradation: Mitophagy and beyond: Molecular Cell,Hurley,review,10.1016/j.molcel.2023.08.021,0.0,W4386757254,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2622.0,Mitochondrial degradation: Mitophagy and beyond: Molecular Cell,Hurley,review,10.1016/j.molcel.2023.08.021,0.0,W4386757254,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2623.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5067997102,Elias Adriaenssens,0000-0001-9430-917X,Key Personnel,Team Hurley,Elias Adriaenssens
2624.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2625.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5065987196,Justyna Sawa‐Makarska,0000-0002-9321-976X,Key Personnel,Team Hurley,Justyna Sawa‐Makarska
2626.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2627.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5028534248,Martina Schuschnig,0000-0002-8926-6432,,,Martina Schuschnig
2628.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5045624897,Stephen Shoebridge,0000-0002-3555-2855,,,Stephen Shoebridge
2629.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014,,,Marvin Skulsuppaisarn
2630.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5032318558,Emily Maria Watts,,,,Emily Watts
2631.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5028882845,Kitti Csályi,0000-0002-0853-8257,,,Kitti Csályi
2632.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5078421822,Benjamin Scott Padman,0000-0002-5710-6100,,,Benjamin Padman
2633.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2634.0,Control of mitophagy initiation and progression by the TBK1 adaptors NAP1 and SINTBAD,Hurley,10.1101/2023.09.25.559255,10.1038/s41594-024-01338-y,1.0,W4400007735,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2635.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5066177476,Olivia Harding,0000-0002-0719-2901,,,Olivia Harding
2636.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5033015769,Chantell S. Evans,0000-0001-9401-8604,Collaborating PI,Team Calakos,Chantell Evans
2637.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5051236194,Junqiang Ye,0000-0002-4529-0713,,,Junqiang Ye
2638.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5050439123,Jonah Cheung,0000-0002-1014-0707,,,Jonah Cheung
2639.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5091116725,Tom Maniatis,0000-0002-2722-8633,,,Tom Maniatis
2640.0,ALS and FTD-associated missense mutations in TBK1 differentially disrupt mitophagy,Hurley,10.1101/2021.04.12.439050,10.1073/pnas.2025053118,1.0,W3156864965,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2641.0,Toward a standard model for autophagosome biogenesis | Journal of Cell Biology | Rockefeller University Press (rupress.org),Hurley,review,10.1083/jcb.202304011,0.0,W4379376257,A5054466750,Annan SI Cook,0000-0001-6415-9107,Key Personnel,Team Hurley,Annan Cook
2642.0,Toward a standard model for autophagosome biogenesis | Journal of Cell Biology | Rockefeller University Press (rupress.org),Hurley,review,10.1083/jcb.202304011,0.0,W4379376257,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2643.0,RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors,Hurley,10.1101/2023.07.25.550521,10.1083/jcb.202307092,1.0,W4393040800,A5087056018,Dan Dou,0000-0002-6939-4752,,,Dan Dou
2644.0,RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors,Hurley,10.1101/2023.07.25.550521,10.1083/jcb.202307092,1.0,W4393040800,A5059846654,Jayne Aiken,0000-0002-6084-602X,,,Jayne Aiken
2645.0,RAB3 phosphorylation by pathogenic LRRK2 impairs trafficking of synaptic vesicle precursors,Hurley,10.1101/2023.07.25.550521,10.1083/jcb.202307092,1.0,W4393040800,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2646.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5060714245,Dan Tudorica,0000-0003-0337-5150,Key Personnel,Team Hurley,Dan Tudorica
2647.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5063984041,Bishal Basak,0000-0003-4496-4162,Key Personnel,Team Hurley,Bishal Basak
2648.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5103109315,Alexia S. Puerta Cordova,,,,Alexia Cordova
2649.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2650.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5074128852,Kevin Rose,0000-0002-9373-4147,Key Personnel,Team Hurley,Kevin Rose
2651.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2652.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2653.0,A RAB7A Phosphoswitch Coordinates Rubicon Homology Protein Regulation of PINK1/Parkin-Dependent Mitophagy,Hurley,10.1101/2023.08.28.555228,10.1083/jcb.202309015,1.0,W4396811660,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2654.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5002623700,Chunmei Chang,0000-0002-5607-7985,,,Chunmei Chang
2655.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5019802538,Xiaoshan Shi,0000-0001-7931-8684,,,Xiaoshan Shi
2656.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5040157507,Liv Jensen,0000-0003-1492-1743,,,Liv Jensen
2657.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5048244508,Adam L. Yokom,0000-0002-3746-7961,,,Adam Yokom
2658.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5038589622,Dorotea Fracchiolla,0000-0002-1612-5225,Project Manager,Team Hurley,Dorotea Fracchiolla
2659.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2660.0,Reconstitution of cargo-induced LC3 lipidation in mammalian selective autophagy,Hurley,10.1101/2021.01.08.425958,10.1126/sciadv.abg4922,1.0,W3153643350,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2661.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5040157507,Liv Jensen,0000-0003-1492-1743,,,Liv Jensen
2662.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5028861095,Shanlin Rao,0000-0003-4892-5523,,,Shanlin Rao
2663.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5028534248,Martina Schuschnig,0000-0002-8926-6432,,,Martina Schuschnig
2664.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5080423176,A. King Cada,0000-0002-9284-0941,,,A. Cada
2665.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2666.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5059945365,Gerhard Hummer,0000-0001-7768-746X,Paid Collaborator,Team Hurley,Gerhard Hummer
2667.0,Membrane curvature sensing and stabilization by the autophagic LC3 lipidation machinery,Hurley,10.1101/2022.05.03.490522,10.1126/sciadv.add1436,1.0,W4311441084,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2668.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2669.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2670.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5080220622,Wai Kit Lam,0000-0002-7433-9205,Key Personnel,Team Hurley,Wai Lam
2671.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5023002262,Cosmo Z. Buffalo,0000-0002-8187-4660,,,Cosmo Buffalo
2672.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2673.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5048244508,Adam L. Yokom,0000-0002-3746-7961,,,Adam Yokom
2674.0,Structural basis for ATG9A recruitment to the ULK1 complex in mitophagy initiation,Hurley,10.1101/2022.07.12.499634,10.1126/sciadv.adg2997,1.0,W4320896717,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2675.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5046225091,Louise Uoselis,0000-0001-8538-9817,Key Personnel,Team Hurley,Louise Uoselis
2676.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5082909714,Runa Lindblom,0000-0001-6755-8744,Key Personnel,Team Hurley,Runa Lindblom
2677.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5080220622,Wai Kit Lam,0000-0002-7433-9205,Key Personnel,Team Hurley,Wai Lam
2678.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5019073167,Catharina J. Küng,0009-0008-0175-7810,,,Catharina Küng
2679.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014,,,Marvin Skulsuppaisarn
2680.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2681.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2682.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5009876179,Danielle L. Rudler,0000-0002-5540-6548,,,Danielle Rudler
2683.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5050949179,Aleksandra Filipovska,0000-0002-6998-8403,,,Aleksandra Filipovska
2684.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5087390081,Ralf B. Schittenhelm,0000-0001-8738-1878,,,Ralf Schittenhelm
2685.0,Temporal landscape of mitochondrial proteostasis governed by the UPRmt,Hurley,10.1101/2022.11.30.518286,10.1126/sciadv.adh8228,1.0,W4386952060,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2686.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5028861095,Shanlin Rao,0000-0003-4892-5523,,,Shanlin Rao
2687.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014,,,Marvin Skulsuppaisarn
2688.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5071900726,Lisa Strong,0000-0002-4293-8131,,,Lisa Strong
2689.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2690.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2691.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2692.0,"Three-step docking by WIPI2, ATG16L1 and ATG3 delivers LC3 to the phagophore",Hurley,10.1101/2023.07.17.549391,10.1126/sciadv.adj8027,1.0,W4391629214,A5059945365,Gerhard Hummer,0000-0001-7768-746X,Paid Collaborator,Team Hurley,Gerhard Hummer
2693.0,A unifying model for the role of the ATG8 system in autophagy,Hurley,review,10.1242/jcs.258997,0.0,W4282006334,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2694.0,A unifying model for the role of the ATG8 system in autophagy,Hurley,review,10.1242/jcs.258997,0.0,W4282006334,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2695.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5071900726,Lisa Strong,0000-0002-4293-8131,,,Lisa Strong
2696.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5002623700,Chunmei Chang,0000-0002-5607-7985,,,Chunmei Chang
2697.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5011795650,Julia F. Riley,0000-0001-8518-9786,Key Personnel,Team Hurley,Julia Riley
2698.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5072866258,C. Alexander Boecker,0000-0001-9701-5273,,,C. Boecker
2699.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5042332218,Thomas G. Flower,0000-0002-7890-6473,,,Thomas Flower
2700.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5023002262,Cosmo Z. Buffalo,0000-0002-8187-4660,,,Cosmo Buffalo
2701.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2702.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5014643816,Andrea KH Stavoe,0000-0002-4073-4565,,,Andrea Stavoe
2703.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2704.0,Structural Basis for Membrane Recruitment of ATG16L1 by WIPI2 in Autophagy,Hurley,10.1101/2021.05.14.444175,10.7554/eLife.70372,1.0,W3196608509,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2705.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5035221045,Juliet Goldsmith,0000-0002-6935-1744,,,Juliet Goldsmith
2706.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5050948158,Alban Ordureau,0000-0002-4924-8520,,,Alban Ordureau
2707.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5072866258,C. Alexander Boecker,0000-0001-9701-5273,,,C. Boecker
2708.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5038798770,Madeleine Arany,,,,Madeleine Arany
2709.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5047746208,J. Wade Harper,0000-0002-6944-7236,Lead PI,Team Harper,J. Harper
2710.0,Distinct adaptations revealed by unbiased proteomic analysis of autophagy cargos in the brain in PINK1 and LRRK2 models of Parkinson’s disease,Hurley,10.1101/2022.10.03.510717,,1.0,W4301373231,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2711.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5011701850,Minghao Chen,0000-0002-7668-3974,Key Personnel,Team Hurley,Minghao Chen
2712.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2713.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2714.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2715.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5054466750,Annan SI Cook,0000-0001-6415-9107,Key Personnel,Team Hurley,Annan Cook
2716.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5024632884,Yuanchang Zhao,0000-0003-1458-5321,,,Yuanchang Zhao
2717.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5100784937,Ahmet Yıldız,0000-0003-4792-174X,,,Ahmet Yıldız
2718.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2719.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2720.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5011701850,Minghao Chen,0000-0002-7668-3974,Key Personnel,Team Hurley,Minghao Chen
2721.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2722.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2723.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2724.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5054466750,Annan SI Cook,0000-0001-6415-9107,Key Personnel,Team Hurley,Annan Cook
2725.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5024632884,Yuanchang Zhao,0000-0003-1458-5321,,,Yuanchang Zhao
2726.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5100784937,Ahmet Yıldız,0000-0003-4792-174X,,,Ahmet Yıldız
2727.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2728.0,Structure and activation of the human autophagy-initiating ULK1C:PI3KC3-C1 supercomplex,Hurley,10.1101/2023.06.01.543278,,1.0,W4379145226,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2729.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5054466750,Annan SI Cook,0000-0001-6415-9107,Key Personnel,Team Hurley,Annan Cook
2730.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5011701850,Minghao Chen,0000-0002-7668-3974,Key Personnel,Team Hurley,Minghao Chen
2731.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2732.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5028861095,Shanlin Rao,0000-0003-4892-5523,,,Shanlin Rao
2733.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5102555809,Samantha N. Garcia,0000-0001-5668-5609,,,Samantha Garcia
2734.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5005119863,Ainara Claveras Cabezudo,0000-0003-1400-4929,Key Personnel,Team Hurley,Ainara Cabezudo
2735.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5025340342,Anthony T. Iavarone,,,,Anthony Iavarone
2736.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5059945365,Gerhard Hummer,0000-0001-7768-746X,Paid Collaborator,Team Hurley,Gerhard Hummer
2737.0,Structural pathway for class III PI 3-kinase activation by the myristoylated GTP-binding pseudokinase VPS15 | bioRxiv,Hurley,10.1101/2023.09.28.559894,,1.0,W4387184698,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2738.0,Mitochondrial damage triggers concerted degradation of negative regulators of neuronal autophagy,Hurley,10.1101/2024.06.12.598718,,1.0,W4399602719,A5063984041,Bishal Basak,0000-0003-4496-4162,Key Personnel,Team Hurley,Bishal Basak
2739.0,Mitochondrial damage triggers concerted degradation of negative regulators of neuronal autophagy,Hurley,10.1101/2024.06.12.598718,,1.0,W4399602719,A5075390520,Erika L.F. Holzbaur,0000-0001-5389-4114,Co-PI,Team Hurley,Erika Holzbaur
2740.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5067997102,Elias Adriaenssens,0000-0001-9430-917X,Key Personnel,Team Hurley,Elias Adriaenssens
2741.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5106830915,Stefan Schaar,0009-0009-6733-7277,,,Stefan Schaar
2742.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5054466750,Annan SI Cook,0000-0001-6415-9107,Key Personnel,Team Hurley,Annan Cook
2743.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5106778092,Jan F. M. Stuke,,,,Jan Stuke
2744.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5065987196,Justyna Sawa‐Makarska,0000-0002-9321-976X,Key Personnel,Team Hurley,Justyna Sawa‐Makarska
2745.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2746.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5041244181,Xuefeng Ren,0000-0002-4822-4316,Key Personnel,Team Hurley,Xuefeng Ren
2747.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5028534248,Martina Schuschnig,0000-0002-8926-6432,,,Martina Schuschnig
2748.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5078834887,Julia Romanov,0000-0002-2875-9487,,,Julia Romanov
2749.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2750.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2751.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5059945365,Gerhard Hummer,0000-0001-7768-746X,Paid Collaborator,Team Hurley,Gerhard Hummer
2752.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5061450716,James H. Hurley,0000-0001-5054-5445,Lead PI,Team Hurley,James Hurley
2753.0,Reconstitution of BNIP3/NIX-mediated autophagy reveals two pathways and hierarchical flexibility of the initiation machinery,Hurley,10.1101/2024.08.28.609967,,1.0,W4401944929,A5029002091,Sascha Martens,0000-0003-3786-8199,Co-PI,Team Hurley,Sascha Martens
2754.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5080220622,Wai Kit Lam,0000-0002-7433-9205,Key Personnel,Team Hurley,Wai Lam
2755.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5082909714,Runa Lindblom,0000-0001-6755-8744,Key Personnel,Team Hurley,Runa Lindblom
2756.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5051142559,Bridget Milky,0000-0003-3851-9564,,,Bridget Milky
2757.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5055892178,Paris Mazzachi,0009-0006-5974-7901,,,Paris Mazzachi
2758.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5044402690,Marjan Hadian-Jazi,0000-0002-1948-7491,,,Marjan Hadian-Jazi
2759.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5019073167,Catharina J. Küng,0009-0008-0175-7810,,,Catharina Küng
2760.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5084050236,Grace Khuu,0000-0002-2550-0605,Key Personnel,Team Hurley,Grace Khuu
2761.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5046225091,Louise Uoselis,0000-0001-8538-9817,Key Personnel,Team Hurley,Louise Uoselis
2762.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5027374290,Thanh Ngoc Nguyen,0000-0001-9698-0020,Key Personnel,Team Hurley,Thanh Nguyen
2763.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5033276727,Marvin Skulsuppaisarn,0000-0003-4041-7014,,,Marvin Skulsuppaisarn
2764.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5012843058,Tahnee L. Saunders,0000-0001-5286-1695,,,Tahnee Saunders
2765.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5008028464,Marlene F. Schmidt,,,,Marlene Schmidt
2766.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5073982345,Grant Dewson,0000-0003-4251-8898,,,Grant Dewson
2767.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5078029361,Adam I. Fogel,0009-0002-6210-537X,,,Adam Fogel
2768.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5051105644,Cédric Bardy,0000-0001-8321-0852,,,Cédric Bardy
2769.0,Presynapses are mitophagy pit stops that prevent axon degeneration,Hurley,10.1101/2024.09.09.611943,,1.0,W4402420172,A5061877082,Michael Lazarou,0000-0003-2150-5545,Co-PI,Team Hurley,Michael Lazarou
2770.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5043873122,Raquel Garza,0000-0002-2524-3055,Key Personnel,Team Jakobsson,Raquel Garza
2771.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5032604553,Diahann A. M. Atacho,0000-0002-6158-0235,,,Diahann Atacho
2772.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5069607564,Anita Adami,0000-0002-9421-7942,Key Personnel,Team Jakobsson,Anita Adami
2773.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5034281734,Patricia Gerdes,0000-0002-1148-9134,,,Patricia Gerdes
2774.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5034449910,Meghna Vinod,0009-0008-9057-6834,,,Meghna Vinod
2775.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5061843819,PingHsun Hsieh,0000-0001-8294-6227,,,PingHsun Hsieh
2776.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5001477091,Ofelia Karlsson,0000-0003-0679-8204,Key Personnel,Team Jakobsson,Ofelia Karlsson
2777.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5080116525,Vivien Horváth,0000-0001-6536-1710,,,Vivien Horváth
2778.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5043496124,Pia A. Johansson,0000-0002-6938-4060,,,Pia Johansson
2779.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5091482811,Ninoslav Pandiloski,0000-0002-1204-5359,,,Ninoslav Pandiloski
2780.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5059001655,Jon Matas-Fuentes,0009-0000-9253-1172,,,Jon Matas-Fuentes
2781.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5033125199,Annelies Quaegebeur,0000-0001-5357-9341,Key Personnel,Team Jakobsson,Annelies Quaegebeur
2782.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5006545376,Antonina Kouli,0000-0001-6553-6154,,,Antonina Kouli
2783.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5045289748,Yogita Sharma,0000-0001-9702-1809,Key Personnel,Team Jakobsson,Yogita Sharma
2784.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5075396241,Marie E. Jönsson,0000-0002-1184-6269,,,Marie Jönsson
2785.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5000947992,Emanuela Monni,0000-0003-0083-1050,,,Emanuela Monni
2786.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5063767082,Elisabet Englund,0000-0002-2708-2443,,,Elisabet Englund
2787.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5014870107,Evan E. Eichler,0000-0002-8246-4014,,,Evan Eichler
2788.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5032075946,Molly Hammell,0000-0003-0405-8392,Co-PI,Team Jakobsson,Molly Hammell
2789.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5084748006,Roger A. Barker,0000-0001-8843-7730,Co-PI,Team Jakobsson,Roger Barker
2790.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5066365730,Zaal Kokaia,0000-0003-2296-2449,,,Zaal Kokaia
2791.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5062661954,Christopher H. Douse,0000-0002-1604-8944,,,Christopher Douse
2792.0,LINE-1 retrotransposons drive human neuronal transcriptome complexity and functional diversification | Science Advances,Jakobsson,10.1101/2023.03.04.531072,10.1126/sciadv.adh9543,1.0,W4388173917,A5021760406,Johan Jakobsson,0000-0003-0669-7673,Lead PI,Team Jakobsson,Johan Jakobsson
2793.0,State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us,Kaplitt,NA Review,10.3389/fnagi.2022.971007,0.0,W4306943613,A5003692234,Santiago R. Unda,0000-0001-7319-6794,Key Personnel,Team Kaplitt,Santiago Unda
2794.0,State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us,Kaplitt,NA Review,10.3389/fnagi.2022.971007,0.0,W4306943613,A5052771182,Sabina Marciano,0000-0002-0899-0454,Key Personnel,Team Kaplitt,Sabina Marciano
2795.0,State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us,Kaplitt,NA Review,10.3389/fnagi.2022.971007,0.0,W4306943613,A5030629278,Teresa A. Milner,0000-0002-0458-6569,,,Teresa Milner
2796.0,State-of-the-art review of the clinical research on menopause and hormone replacement therapy association with Parkinson’s disease: What meta-analysis studies cannot tell us,Kaplitt,NA Review,10.3389/fnagi.2022.971007,0.0,W4306943613,A5000487408,Roberta Marongiu,0000-0002-7609-7000,Co-PI,Team Kaplitt,Roberta Marongiu
2797.0,Cognitive dysfunction in animal models of human lewy-body dementia,Kaplitt,,10.3389/fnagi.2024.1369733,0.0,W4400896439,A5063110440,Caroline Haikal,0000-0002-9066-5940,Key Personnel,Team Kaplitt,Caroline Haikal
2798.0,Cognitive dysfunction in animal models of human lewy-body dementia,Kaplitt,,10.3389/fnagi.2024.1369733,0.0,W4400896439,A5113300015,Graham M. Winston,,Key Personnel,Team Kaplitt,Graham Winston
2799.0,Cognitive dysfunction in animal models of human lewy-body dementia,Kaplitt,,10.3389/fnagi.2024.1369733,0.0,W4400896439,A5027250646,Michael G. Kaplitt,0000-0002-8979-2459,Lead-PI,Team Kaplitt,Michael Kaplitt
2800.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5030544727,Daniel Dautan,0000-0003-1001-5727,Key Personnel,Team Kaplitt,Daniel Dautan
2801.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5026281113,Wojciech Pasławski,0000-0003-2141-4547,Key Personnel,Team Kaplitt,Wojciech Pasławski
2802.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5095902166,Sergio Montejo,,,,Sergio Montejo
2803.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5109313536,D Doyon,,,,D Doyon
2804.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5109709484,Roberta Marangiu,,,,Roberta Marangiu
2805.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5027250646,Michael G. Kaplitt,0000-0002-8979-2459,Lead-PI,Team Kaplitt,Michael Kaplitt
2806.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5100419005,Rong Chen,0000-0001-9291-5539,Key Personnel,Team Kaplitt,Rong Chen
2807.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5025568267,Valina L. Dawson,0000-0002-2915-3970,Collaborating PI,Team Kaplitt,Valina Dawson
2808.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5052123856,Xiaoqun Zhang,0000-0002-2723-4451,,,Xiaoqun Zhang
2809.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5021759485,Ted M. Dawson,0000-0002-6459-0893,Co-PI,Team Kaplitt,Ted Dawson
2810.0,Gut-Initiated Alpha Synuclein Fibrils Drive Parkinson’s Disease Phenotypes: Temporal Mapping of non-Motor Symptoms and REM Sleep Behavior Disorder,Kaplitt,10.1101/2024.04.22.590542,,1.0,W4395660291,A5036364090,Per Svenningsson,0000-0001-6727-3802,Co-PI,Team Kaplitt,Per Svenningsson
2811.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5007371335,Chiara Pavan,0000-0002-2890-7021,Key Personnel,Team Kirik,Chiara Pavan
2812.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5035485086,Jian‐Ping Jin,0000-0001-9932-1063,,,Jian‐Ping Jin
2813.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5104805463,Sanne de Jong,0009-0004-6148-2346,,,Sanne Jong
2814.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5033872539,Dario Strbenac,0000-0001-9234-3243,,,Dario Strbenac
2815.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5001979226,Richard L. Davis,0000-0002-6175-9200,,,Richard Davis
2816.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5045037139,Carolyn M. Sue,0000-0003-1255-3617,,,Carolyn Sue
2817.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5032550349,Jean M. Johnston,,,,Jean Johnston
2818.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5000457783,Timothy Lynch,0000-0002-7096-541X,,,Timothy Lynch
2819.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Collaborating PI,Team Edwards,Glenda Halliday
2820.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Kirik,Glenda Halliday
2821.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Vila,Glenda Halliday
2822.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5083016310,Deniz Kirik,0000-0002-1360-1265,Lead-PI,Team Kirik,Deniz Kirik
2823.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5044118193,Clare L. Parish,0000-0001-8212-9884,Co-PI,Team Kirik,Clare Parish
2824.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5067345526,Lachlan H. Thompson,0000-0003-2632-0304,Co-PI,Team Kirik,Lachlan Thompson
2825.0,Generation of the iPSC line FINi002-A from a male Parkinson's disease patient carrying compound heterozygous mutations in the PRKN gene - ScienceDirect,Kirik,NA (lab resource),10.1016/j.scr.2023.103211,0.0,W4387711107,A5064216415,Dmitry A. Ovchinnikov,0000-0001-9603-8385,Key Personnel,Team Kirik,Dmitry Ovchinnikov
2826.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5022317877,Gautam Wali,0000-0003-2961-3954,,,Gautam Wali
2827.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5100685328,Yan Li,0000-0002-5938-8519,,,Yan Li
2828.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5005036101,Dad Abu-Bonsrah,0000-0002-2687-3526,,,Dad Abu-Bonsrah
2829.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5083016310,Deniz Kirik,0000-0002-1360-1265,Lead-PI,Team Kirik,Deniz Kirik
2830.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5044118193,Clare L. Parish,0000-0001-8212-9884,Co-PI,Team Kirik,Clare Parish
2831.0,Generation of human-induced pluripotent-stem-cell-derived cortical neurons for high-throughput imaging of neurite morphology and neuron maturation,Kirik,NA (protocol),10.1016/j.xpro.2023.102325,0.0,W4380204562,A5045037139,Carolyn M. Sue,0000-0003-1255-3617,,,Carolyn Sue
2832.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5102720235,Sara Walton,0000-0002-4981-0309,,,Sara Walton
2833.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5049642756,Alexis Fenyi,0000-0003-3270-2085,,,Alexis Fenyi
2834.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5062045682,Tyler Tittle,0000-0001-9195-4958,,,Tyler Tittle
2835.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
2836.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5072516098,Gian Pal,0000-0003-1048-6182,,,Gian Pal
2837.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5023291758,Solji Choi,0000-0002-0216-109X,,,Solji Choi
2838.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5084373973,Ronald Melki,0000-0003-0000-7096,,,Ronald Melki
2839.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5021829625,Bryan A. Killinger,0000-0002-8043-8517,,,Bryan Killinger
2840.0,Neither alpha-synuclein fibril strain nor host murine genotype influences seeding efficacy,Kordower,10.1101/2023.08.24.554646,10.1038/s41531-024-00679-1,1.0,W4398172122,A5074765508,Jeffrey H. Kordower,0000-0001-8629-3294,Lead-PI,Team Kordower,Jeffrey Kordower
2841.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5077753619,Yaping Chu,0000-0001-6573-9496,Key Personnel,Team Kordower,Yaping Chu
2842.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5020699970,Warren D. Hirst,0000-0003-0389-8891,Co-PI,Team Kordower,Warren Hirst
2843.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5003466529,Howard J. Federoff,0000-0002-7595-6520,,,Howard Federoff
2844.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Kordower,Ashley Harms
2845.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Sulzer,Ashley Harms
2846.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5066908279,A. Jon Stoessl,0000-0002-9778-7246,,,A. Stoessl
2847.0,Nigrostriatal tau pathology in parkinsonism and Parkinson’s disease,Kordower,10.1101/2022.08.04.502831,10.1093/brain/awad388,1.0,W4388994083,A5103177177,Jeffrey H. Kordower,0000-0003-0407-1861,Lead-PI,Team Kordower,Jeffrey Kordower
2848.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5104317489,S. G. Choi,,,,S. Choi
2849.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5062045682,Tyler Tittle,0000-0001-9195-4958,,,Tyler Tittle
2850.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5096857711,D. Garcia-Prada,,,,D. Garcia-Prada
2851.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5103177177,Jeffrey H. Kordower,0000-0003-0407-1861,Lead-PI,Team Kordower,Jeffrey Kordower
2852.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5084373973,Ronald Melki,0000-0003-0000-7096,,,Ronald Melki
2853.0,Alpha-synuclein aggregates are phosphatase resistant,Kordower,10.1101/2023.11.20.567854,10.1186/s40478-024-01785-0,1.0,W4399230878,A5021829625,Bryan A. Killinger,0000-0002-8043-8517,,,Bryan Killinger
2854.0,Adult-Onset Deletion of ATP13A2 in Mice Induces Progressive Nigrostriatal Pathway Dopaminergic Degeneration and Lysosomal Abnormalities,Lee,10.1101/2024.01.25.577280,10.1038/s41531-024-00748-5,1.0,W4400859109,A5048443244,Madalynn Erb,0000-0002-7651-6826,Key Personnel,Team Lee,Madalynn Erb
2855.0,Adult-Onset Deletion of ATP13A2 in Mice Induces Progressive Nigrostriatal Pathway Dopaminergic Degeneration and Lysosomal Abnormalities,Lee,10.1101/2024.01.25.577280,10.1038/s41531-024-00748-5,1.0,W4400859109,A5093793466,Kayla Sipple,,,,Kayla Sipple
2856.0,Adult-Onset Deletion of ATP13A2 in Mice Induces Progressive Nigrostriatal Pathway Dopaminergic Degeneration and Lysosomal Abnormalities,Lee,10.1101/2024.01.25.577280,10.1038/s41531-024-00748-5,1.0,W4400859109,A5033733203,Nathan Levine,,,,Nathan Levine
2857.0,Adult-Onset Deletion of ATP13A2 in Mice Induces Progressive Nigrostriatal Pathway Dopaminergic Degeneration and Lysosomal Abnormalities,Lee,10.1101/2024.01.25.577280,10.1038/s41531-024-00748-5,1.0,W4400859109,A5100329981,Xi Chen,0000-0002-7995-6202,,,Xi Chen
2858.0,Adult-Onset Deletion of ATP13A2 in Mice Induces Progressive Nigrostriatal Pathway Dopaminergic Degeneration and Lysosomal Abnormalities,Lee,10.1101/2024.01.25.577280,10.1038/s41531-024-00748-5,1.0,W4400859109,A5037205059,Darren J. Moore,0000-0003-2359-5679,Co-PI,Team Lee,Darren Moore
2859.0,Targeting cellular senescence with senotherapeutics: senolytics and senomorphics,Lee,NA Review,10.1111/febs.16350,0.0,W4205869028,A5100433830,Lei Zhang,0000-0001-7409-6090,,,Lei Zhang
2860.0,Targeting cellular senescence with senotherapeutics: senolytics and senomorphics,Lee,NA Review,10.1111/febs.16350,0.0,W4205869028,A5080814866,Louise E. Pitcher,,,,Louise Pitcher
2861.0,Targeting cellular senescence with senotherapeutics: senolytics and senomorphics,Lee,NA Review,10.1111/febs.16350,0.0,W4205869028,A5011590825,Vaishali Prahalad,,,,Vaishali Prahalad
2862.0,Targeting cellular senescence with senotherapeutics: senolytics and senomorphics,Lee,NA Review,10.1111/febs.16350,0.0,W4205869028,A5043039694,Laura J. Niedernhofer,0000-0002-1074-1385,Co-PI,Team Lee,Laura Niedernhofer
2863.0,Targeting cellular senescence with senotherapeutics: senolytics and senomorphics,Lee,NA Review,10.1111/febs.16350,0.0,W4205869028,A5040467127,Paul D. Robbins,0000-0003-1068-7099,Key Personnel,Team Lee,Paul Robbins
2864.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5100433830,Lei Zhang,0000-0001-7409-6090,,,Lei Zhang
2865.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5080814866,Louise E. Pitcher,,,,Louise Pitcher
2866.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5078174238,Matthew J. Yousefzadeh,0000-0003-2869-1029,,,Matthew Yousefzadeh
2867.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5043039694,Laura J. Niedernhofer,0000-0002-1074-1385,Co-PI,Team Lee,Laura Niedernhofer
2868.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5040467127,Paul D. Robbins,0000-0003-1068-7099,Key Personnel,Team Lee,Paul Robbins
2869.0,Cellular senescence: a key therapeutic target in aging and diseases,Lee,NA review,10.1172/JCI158450,0.0,W4289028880,A5107500736,Yi Zhu,0000-0002-3876-3156,,,Yi Zhu
2870.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5061285720,Scott Vermilyea,0000-0001-7827-8166,Key Personnel,Team Lee,Scott Vermilyea
2871.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5002949069,Anne Illemann Christensen,0000-0002-9924-7198,,,Anne Christensen
2872.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5010389487,Joyce Meints,0000-0002-9394-9631,Key Personnel,Team Lee,Joyce Meints
2873.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5080830277,Balvindar Singh,0000-0002-8288-553X,,,Balvindar Singh
2874.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5061243800,Héctor Martell-Martínez,,,,Héctor Martell-Martínez
2875.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5035000135,Md. Razaul Karim,0000-0002-0404-7290,,,Md. Karim
2876.0,Loss of Tau Expression Attenuates Neurodegeneration Associated with α-Synucleinopathy,Lee,10.21203/rs.3.rs-1150251/v1,10.1186/s40035-022-00309-x,1.0,W4283764255,A5021234825,Michael K. Lee,0000-0001-5865-9682,Lead-PI,Team Lee,Michael Lee
2877.0,"Immune Senescence, Immunosenescence and Aging",Lee,NA Review,10.3389/fragi.2022.900028,0.0,W4281680618,A5017895020,Kyoo-a Lee,,,,Kyoo-a Lee
2878.0,"Immune Senescence, Immunosenescence and Aging",Lee,NA Review,10.3389/fragi.2022.900028,0.0,W4281680618,A5050075073,Rafael R. Flores,0000-0002-5580-6381,,,Rafael Flores
2879.0,"Immune Senescence, Immunosenescence and Aging",Lee,NA Review,10.3389/fragi.2022.900028,0.0,W4281680618,A5062640954,In Hwa Jang,0009-0009-9448-8433,,,In Jang
2880.0,"Immune Senescence, Immunosenescence and Aging",Lee,NA Review,10.3389/fragi.2022.900028,0.0,W4281680618,A5062679752,Ashley Saathoff,,,,Ashley Saathoff
2881.0,"Immune Senescence, Immunosenescence and Aging",Lee,NA Review,10.3389/fragi.2022.900028,0.0,W4281680618,A5040467127,Paul D. Robbins,0000-0003-1068-7099,Key Personnel,Team Lee,Paul Robbins
2882.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5103234864,M.R. Karim,0000-0002-0058-1429,Key Personnel,Team Lee,M.R. Karim
2883.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5099063152,Emilie Gasparini,,,,Emilie Gasparini
2884.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5099063153,Elizabeth Tiegs,,Key Personnel,Team Lee,Elizabeth Tiegs
2885.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5099063154,Riley Schlichte,,Key Personnel,Team Lee,Riley Schlichte
2886.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5061285720,Scott Vermilyea,0000-0001-7827-8166,Key Personnel,Team Lee,Scott Vermilyea
2887.0,Internalized α-synuclein fibrils become truncated and resist degradation in neurons while glial cells rapidly degrade α-synuclein fibrils,Lee,10.1101/2024.06.05.597615,,1.0,W4399466972,A5021234825,Michael K. Lee,0000-0001-5865-9682,Lead-PI,Team Lee,Michael Lee
2888.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5084682696,Jake Boles,0000-0001-5501-2162,,,Jake Boles
2889.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5114154822,Maeve E. Krueger,,,,Maeve Krueger
2890.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5079636197,Janna Jernigan,0000-0003-0771-384X,Key Personnel,Team Liddle,Janna Jernigan
2891.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5079636197,Janna Jernigan,0000-0003-0771-384X,Key Personnel,Team Liddle,Janna Jernigan
2892.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5112979525,Cassandra L. Cole,0009-0006-9245-9960,,,Cassandra Cole
2893.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5092480911,Noelle Neighbarger,0009-0007-6649-0988,,,Noelle Neighbarger
2894.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5007526626,Oihane Uriarte Huarte,0000-0001-8460-0844,,,Oihane Huarte
2895.0,"A leaky gut dysregulates gene networks in the brain associated with immune activation, oxidative stress, and myelination in a mouse model of colitis",Liddle,10.1101/2023.08.10.552488,10.1016/j.bbi.2024.02.007,1.0,W4391656225,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2896.0,Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors - ScienceDirect,Liddle,review,10.1016/j.ceca.2023.102838,0.0,W4389331039,A5070734573,Alfonso Martín‐Peña,0000-0001-7598-0777,Key Personnel,Team Liddle,Alfonso Martín‐Peña
2897.0,Calcium influx into astrocytes plays a pivotal role in inflammation-driven behaviors - ScienceDirect,Liddle,review,10.1016/j.ceca.2023.102838,0.0,W4389331039,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2898.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5037780867,Zachary D. Wallen,0000-0002-2278-7348,Key Personnel,Team Liddle,Zachary Wallen
2899.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5001432320,Ayşe Demirkan,0000-0002-7546-0867,Key Personnel,Team Liddle,Ayşe Demirkan
2900.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5045056363,Guy Twa,0000-0002-8409-7844,Key Personnel,Team Liddle,Guy Twa
2901.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5026253406,Gwendolyn Cohen,0000-0002-5084-061X,,,Gwendolyn Cohen
2902.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5062505725,Marissa Dean,0000-0002-9318-769X,,,Marissa Dean
2903.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
2904.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5058647225,Timothy R. Sampson,0000-0002-2486-8766,Co-PI,Team Liddle,Timothy Sampson
2905.0,Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms,Liddle,10.1101/2022.06.08.495316,10.1038/s41467-022-34667-x,1.0,W4309109636,A5055969440,Haydeh Payami,0000-0001-9084-5338,Co-PI,Team Liddle,Haydeh Payami
2906.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5055969440,Haydeh Payami,0000-0001-9084-5338,Co-PI,Team Liddle,Haydeh Payami
2907.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5026253406,Gwendolyn Cohen,0000-0002-5084-061X,,,Gwendolyn Cohen
2908.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5075093941,Charles Murchison,0009-0007-5589-8144,Key Personnel,Team Liddle,Charles Murchison
2909.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5058647225,Timothy R. Sampson,0000-0002-2486-8766,Co-PI,Team Liddle,Timothy Sampson
2910.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
2911.0,Population fraction of Parkinson’s disease attributable to preventable risk factors - PMC (nih.gov),Liddle,10.1101/2023.05.19.23290231,10.1038/s41531-023-00603-z,1.0,W4389331336,A5037780867,Zachary D. Wallen,0000-0002-2278-7348,Key Personnel,Team Liddle,Zachary Wallen
2912.0,Microbial amyloids in neurodegenerative amyloid diseases (wiley.com),Liddle,review,10.1111/febs.17023,0.0,W4389264036,A5058647225,Timothy R. Sampson,0000-0002-2486-8766,Co-PI,Team Liddle,Timothy Sampson
2913.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5100355362,Zhiyong Liu,0000-0002-2959-5189,,,Zhiyong Liu
2914.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5072554284,Arpine Sokratian,0000-0001-6654-5773,Key Personnel,Team Liddle,Arpine Sokratian
2915.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5059484114,Addison M. Duda,0000-0002-8116-4714,,,Addison Duda
2916.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5032836941,Enquan Xu,0000-0003-3463-0337,,,Enquan Xu
2917.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5111075893,Christina M. Stanhope,,,,Christina Stanhope
2918.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5073389189,A Fu,0009-0008-0898-9067,,,A Fu
2919.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5060506940,Samuel Strader,0000-0003-4417-3707,,,Samuel Strader
2920.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5063490840,Huizhong Li,0009-0004-1228-0721,,,Huizhong Li
2921.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5103219876,Yuan Yuan,0009-0002-3810-6487,,,Yuan Yuan
2922.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5064488491,Benjamin G. Bobay,0000-0003-4775-3686,,,Benjamin Bobay
2923.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5041930216,Joana Marie Sipe,0000-0001-5602-0922,,,Joana Sipe
2924.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5015976754,Ketty Bai,0000-0002-9807-888X,,,Ketty Bai
2925.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5081024969,Iben Lundgaard,0000-0001-9613-3892,,,Iben Lundgaard
2926.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5100389767,Na Liu,0000-0002-3140-795X,,,Na Liu
2927.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5102873283,B. Hernández,0000-0001-5017-1447,,,B. Hernández
2928.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5051860617,Catherine Bowes Rickman,0000-0002-8555-9596,,,Catherine Rickman
2929.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5048514549,Sara Miller,0000-0002-9441-0101,,,Sara Miller
2930.0,Anionic nanoplastic contaminants promote Parkinson’s disease–associated α-synuclein aggregation | Science Advances,Liddle,10.21203/rs.3.rs-3439102/v1,10.1126/sciadv.adi8716,1.0,W4388757415,A5071278272,Andrew B. West,0000-0002-3034-4061,Co-PI,Team Liddle,Andrew West
2931.0,Central and peripheral innate and adaptive immunity in Parkinson’s disease | Science Translational Medicine,Liddle,review,10.1126/scitranslmed.adk3225,0.0,W4388486600,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Kordower,Ashley Harms
2932.0,Central and peripheral innate and adaptive immunity in Parkinson’s disease | Science Translational Medicine,Liddle,review,10.1126/scitranslmed.adk3225,0.0,W4388486600,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Sulzer,Ashley Harms
2933.0,Central and peripheral innate and adaptive immunity in Parkinson’s disease | Science Translational Medicine,Liddle,review,10.1126/scitranslmed.adk3225,0.0,W4388486600,A5101635495,Yating Yang,0000-0003-4671-8061,,Team Sulzer,Yating Yang
2934.0,Central and peripheral innate and adaptive immunity in Parkinson’s disease | Science Translational Medicine,Liddle,review,10.1126/scitranslmed.adk3225,0.0,W4388486600,A5101635495,Yating Yang,0000-0003-4671-8061,,Team Sulzer,Yating Yang
2935.0,Central and peripheral innate and adaptive immunity in Parkinson’s disease | Science Translational Medicine,Liddle,review,10.1126/scitranslmed.adk3225,0.0,W4388486600,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2936.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5026190664,Rashmi Chandra,0000-0001-9591-8997,,,Rashmi Chandra
2937.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5072554284,Arpine Sokratian,0000-0001-6654-5773,Key Personnel,Team Liddle,Arpine Sokratian
2938.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5024539060,Katherine Ramos Chavez,0000-0001-8952-385X,Key Personnel,Team Liddle,Katherine Chavez
2939.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5006733326,Stephanie L. King,0000-0003-2293-9185,,,Stephanie King
2940.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5065401534,Sandip M. Swain,0000-0002-2404-8186,,,Sandip Swain
2941.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5087580101,Joshua C. Snyder,0000-0002-9787-3371,,,Joshua Snyder
2942.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5071278272,Andrew B. West,0000-0002-3034-4061,Co-PI,Team Liddle,Andrew West
2943.0,Gut mucosal cells transfer α-synuclein to the vagus nerve,Liddle,10.1101/2023.08.14.553305,10.1172/jci.insight.172192,1.0,W4389429458,A5058874182,Rodger A. Liddle,0000-0002-5498-4151,Lead-PI,Team Liddle,Rodger Liddle
2944.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5092969782,Khondamir Imomnazarov,0009-0007-0808-7808,,,Khondamir Imomnazarov
2945.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5090538110,Joshua Lopez‐Scarim,0000-0003-3290-7670,,,Joshua Lopez‐Scarim
2946.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5093878043,Ila Bagheri,0009-0009-0624-4536,,,Ila Bagheri
2947.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5079474017,Valerie Joers,0000-0001-6743-6587,,,Valerie Joers
2948.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2949.0,Biochemical fractionation of human α-Synuclein in a Drosophila model of synucleinopathies,Liddle,10.1101/2024.02.05.579034,10.3390/ijms25073643,1.0,W4393142786,A5070734573,Alfonso Martín‐Peña,0000-0001-7598-0777,Key Personnel,Team Liddle,Alfonso Martín‐Peña
2950.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5072554284,Arpine Sokratian,0000-0001-6654-5773,Key Personnel,Team Liddle,Arpine Sokratian
2951.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5090978976,Ye Zhou,0000-0002-0489-3614,,,Ye Zhou
2952.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5032836941,Enquan Xu,0000-0003-3463-0337,,,Enquan Xu
2953.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5020705232,Elizabeth Viverette,0000-0002-5173-5838,Key Personnel,Team Liddle,Elizabeth Viverette
2954.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5064794383,Lucas Dillard,0000-0003-4325-8055,,,Lucas Dillard
2955.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5113577754,Yuan Yuan,0009-0002-9540-2100,,,Yuan Yuan
2956.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5085774574,Joshua Y. Li,,,,Joshua Li
2957.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5062040327,Ariana Matarangas,,,,Ariana Matarangas
2958.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5086360909,Jonathan Bouvette,0000-0003-3550-5319,,,Jonathan Bouvette
2959.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5038092347,Mario J. Borgnia,0000-0001-9159-1413,,,Mario Borgnia
2960.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5041098204,Alberto Bartesaghi,0000-0002-7360-1523,,,Alberto Bartesaghi
2961.0,Structural and functional landscape of α-synuclein fibril conformations amplified from cerebrospinal fluid,Liddle,10.1101/2022.07.13.499896,,1.0,W4285393454,A5071278272,Andrew B. West,0000-0002-3034-4061,Co-PI,Team Liddle,Andrew West
2962.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5034941377,Rebecca L. Wallings,0000-0003-0947-4459,Key Personnel,Team Liddle,Rebecca Wallings
2963.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5030150965,Karen N. McFarland,0000-0002-9952-8678,,,Karen McFarland
2964.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5035443988,Hannah A. Staley,,,,Hannah Staley
2965.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5092480911,Noelle Neighbarger,0009-0007-6649-0988,,,Noelle Neighbarger
2966.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5047799933,Susen Schaake,0009-0006-6021-3069,,,Susen Schaake
2967.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5076156979,Norbert Brüggemann,0000-0001-5969-6899,,,Norbert Brüggemann
2968.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5013050837,Simone Zittel,0000-0002-3767-6376,,,Simone Zittel
2969.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5073315197,Tatiana Usnich,0000-0001-7335-8888,,,Tatiana Usnich
2970.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5024773860,Christine Klein,0000-0003-2102-3431,,,Christine Klein
2971.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5067865589,Esther Sammler,0000-0003-3218-7116,Key Personnel,Team Alessi,Esther Sammler
2972.0,The R1441C-LRRK2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner | bioRxiv,Liddle,10.1101/2023.10.12.562063,,1.0,W4387705483,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2973.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5058647225,Timothy R. Sampson,0000-0002-2486-8766,Co-PI,Team Liddle,Timothy Sampson
2974.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5037780867,Zachary D. Wallen,0000-0002-2278-7348,Key Personnel,Team Liddle,Zachary Wallen
2975.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5050580520,Woong-Jai Won,0009-0007-3396-6572,,,Woong-Jai Won
2976.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
2977.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5055969440,Haydeh Payami,0000-0001-9084-5338,Co-PI,Team Liddle,Haydeh Payami
2978.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Kordower,Ashley Harms
2979.0,Alpha-synuclein overexpression can drive microbiome dysbiosis in mice,Liddle,10.1101/2024.02.01.578464,,1.0,W4391482318,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Sulzer,Ashley Harms
2980.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5084682696,Jake Boles,0000-0001-5501-2162,,,Jake Boles
2981.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5058866795,Jenny Holt,,,,Jenny Holt
2982.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5112979525,Cassandra L. Cole,0009-0006-9245-9960,,,Cassandra Cole
2983.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5092480911,Noelle Neighbarger,0009-0007-6649-0988,,,Noelle Neighbarger
2984.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5029290468,Nikhil M. Urs,0000-0003-1819-7836,,,Nikhil Urs
2985.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5007526626,Oihane Uriarte Huarte,0000-0001-8460-0844,,,Oihane Huarte
2986.0,Locus coeruleus injury modulates ventral midbrain neuroinflammation during DSS-induced colitis,Liddle,10.1101/2024.02.12.580010,,1.0,W4391770806,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
2987.0,Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease,Liddle,10.1101/2024.04.03.24305273,,1.0,W4393931755,A5055969440,Haydeh Payami,0000-0001-9084-5338,Co-PI,Team Liddle,Haydeh Payami
2988.0,Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease,Liddle,10.1101/2024.04.03.24305273,,1.0,W4393931755,A5058647225,Timothy R. Sampson,0000-0002-2486-8766,Co-PI,Team Liddle,Timothy Sampson
2989.0,Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease,Liddle,10.1101/2024.04.03.24305273,,1.0,W4393931755,A5075093941,Charles Murchison,0009-0007-5589-8144,Key Personnel,Team Liddle,Charles Murchison
2990.0,Microbiome-based biomarkers to guide personalized microbiome-based therapies for Parkinson's disease,Liddle,10.1101/2024.04.03.24305273,,1.0,W4393931755,A5037780867,Zachary D. Wallen,0000-0002-2278-7348,Key Personnel,Team Liddle,Zachary Wallen
2991.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5114154822,Maeve E. Krueger,,,,Maeve Krueger
2992.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5084682696,Jake Boles,0000-0001-5501-2162,,,Jake Boles
2993.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5031564422,Zachary D. Simon,0000-0001-9297-2971,,,Zachary Simon
2994.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5102656629,Stephan D. Alvarez,,,,Stephan Alvarez
2995.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5045713119,Nikolaus R. McFarland,0000-0002-8699-8857,,,Nikolaus McFarland
2996.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5056665061,Michael S. Okun,0000-0002-6247-9358,,,Michael Okun
2997.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5110316456,Ellen M. Zimmermann,0000-0002-7966-2837,,,Ellen Zimmermann
2998.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5030058343,Christopher E. Forsmark,,,,Christopher Forsmark
2999.0,A comparative analysis of Parkinson’s disease and inflammatory bowel disease gut microbiomes highlights shared depletions in key butyrate-producing bacteria,Liddle,10.1101/2024.04.26.591350,,1.0,W4396215826,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
3000.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5072554284,Arpine Sokratian,0000-0001-6654-5773,Key Personnel,Team Liddle,Arpine Sokratian
3001.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5100635764,Zhou Ye,0000-0001-9367-7608,,,Zhou Ye
3002.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5051076769,Meltem Tatlı,0000-0003-3632-6208,,,Meltem Tatlı
3003.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5037954223,Kevin Burbidge,0000-0003-1055-0199,,,Kevin Burbidge
3004.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5032836941,Enquan Xu,0000-0003-3463-0337,,,Enquan Xu
3005.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5020705232,Elizabeth Viverette,0000-0002-5173-5838,Key Personnel,Team Liddle,Elizabeth Viverette
3006.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5059484114,Addison M. Duda,0000-0002-8116-4714,,,Addison Duda
3007.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5103219876,Yuan Yuan,0009-0002-3810-6487,,,Yuan Yuan
3008.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5060506940,Samuel Strader,0000-0003-4417-3707,,,Samuel Strader
3009.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5041529324,Nirali Patel,,,,Nirali Patel
3010.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5098937937,Lauren Shiell,,,,Lauren Shiell
3011.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5089076069,Tuyana Malankhanova,0000-0002-5106-8465,,,Tuyana Malankhanova
3012.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5060960629,Olivia Chen,0000-0001-9323-8760,,,Olivia Chen
3013.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5080558971,Joseph R. Mazzulli,0000-0002-7692-2381,,,Joseph Mazzulli
3014.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5022509779,L. Perera,0000-0003-0823-1631,,,L. Perera
3015.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5022570818,Henning Stahlberg,0000-0002-1185-4592,,,Henning Stahlberg
3016.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5038092347,Mario J. Borgnia,0000-0001-9159-1413,,,Mario Borgnia
3017.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5041098204,Alberto Bartesaghi,0000-0002-7360-1523,,,Alberto Bartesaghi
3018.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5086170675,Hilal A. Lashuel,0000-0001-7682-8320,,,Hilal Lashuel
3019.0,Mouse α-synuclein fibrils are structurally and functionally distinct from human fibrils associated with Lewy body diseases,Liddle,10.1101/2024.05.09.593334,,1.0,W4396809691,A5071278272,Andrew B. West,0000-0002-3034-4061,Co-PI,Team Liddle,Andrew West
3020.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5035859489,MacKenzie L. Bolen,0000-0003-1973-3784,Key Personnel,Team Liddle,MacKenzie Bolen
3021.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5035859489,MacKenzie L. Bolen,0000-0003-1973-3784,Key Personnel,Team Liddle,MacKenzie Bolen
3022.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5070930245,Beatriz Maffini Gomes,0009-0004-2908-8672,,,Beatriz Gomes
3023.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5033737236,B. Gill,0009-0001-8624-7818,,,B. Gill
3024.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5077448441,Kelly B. Menees,0000-0003-4282-8546,Key Personnel,Team Liddle,Kelly Menees
3025.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5103108690,Hannah A. Staley,0009-0001-8284-6178,,,Hannah Staley
3026.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5079636197,Janna Jernigan,0000-0003-0771-384X,Key Personnel,Team Liddle,Janna Jernigan
3027.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5079636197,Janna Jernigan,0000-0003-0771-384X,Key Personnel,Team Liddle,Janna Jernigan
3028.0,Peripheral Blood Immune Cells from Individuals with Parkinson’s Disease or Inflammatory Bowel Disease Share Deficits in Iron Storage and Transport that are Modulated by Non-Steroidal Anti-Inflammatory Drugs,Liddle,10.1101/2024.08.19.608634,,1.0,W4401712885,A5008036209,Malú G. Tansey,0000-0002-1719-4708,Co-PI,Team Liddle,Malú Tansey
3029.0,Delivery of RNA Therapeutics: The Great Endosomal Escape!,Mobley,NA review,10.1089/nat.2022.0004,0.0,W4281486640,A5048054072,Steven F. Dowdy,0000-0003-3083-2257,Co-PI,Team Mobley,Steven Dowdy
3030.0,Delivery of RNA Therapeutics: The Great Endosomal Escape!,Mobley,NA review,10.1089/nat.2022.0004,0.0,W4281486640,A5057571496,Ryan L. Setten,0000-0002-0956-7084,,,Ryan Setten
3031.0,Delivery of RNA Therapeutics: The Great Endosomal Escape!,Mobley,NA review,10.1089/nat.2022.0004,0.0,W4281486640,A5017386190,Xian-Shu Cui,,,,Xian-Shu Cui
3032.0,Delivery of RNA Therapeutics: The Great Endosomal Escape!,Mobley,NA review,10.1089/nat.2022.0004,0.0,W4281486640,A5009803059,Satish Jadhav,,,,Satish Jadhav
3033.0,Therapeutic Potential of PTB Inhibition Through Converting Glial Cells to Neurons in the Brain | Annual Review of Neuroscience (annualreviews.org),Mobley,review,10.1146/annurev-neuro-083022-113120,0.0,W4383815147,A5103144746,Xiang‐Dong Fu,0000-0001-5499-8732,Lead-PI,Team Mobley,Xiang‐Dong Fu
3034.0,Therapeutic Potential of PTB Inhibition Through Converting Glial Cells to Neurons in the Brain | Annual Review of Neuroscience (annualreviews.org),Mobley,review,10.1146/annurev-neuro-083022-113120,0.0,W4383815147,A5009879178,William C. Mobley,0000-0002-6408-9548,Co-PI,Team Mobley,William Mobley
3035.0,Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem? (cshlp.org),Mobley,review,10.1261/rna.079507.122,0.0,W4317600205,A5048054072,Steven F. Dowdy,0000-0003-3083-2257,Co-PI,Team Mobley,Steven Dowdy
3036.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3037.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3038.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3039.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5061542163,Wolfgang H. Oertel,0000-0002-7582-8166,,,Wolfgang Oertel
3040.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3041.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5067845430,Amy W. Amara,0000-0003-0762-9656,Key Personnel (PI),Team Sulzer,Amy Amara
3042.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5075185919,Ana Fernández‐Arcos,,,,Ana Fernández‐Arcos
3043.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5078689202,Eduardo Tolosa,0000-0002-3781-0854,,,Eduardo Tolosa
3044.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5001487398,Cristina Simonet,0000-0002-5555-0283,,,Cristina Simonet
3045.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5042577463,Birgit Högl,0000-0003-1894-7641,,,Birgit Högl
3046.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5083282772,Aleksandar Videnović,0000-0002-9237-1516,Collaborator,Team Hafler,Aleksandar Videnović
3047.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3048.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3049.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3050.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5073918974,Elliot Burghardt,0000-0002-9921-7634,,,Elliot Burghardt
3051.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3052.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5084101739,Hyunkeun R. Cho,,,,Hyunkeun Cho
3053.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5109102258,Karl Kieburtz,,,,Karl Kieburtz
3054.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3055.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3056.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5072592799,Douglas Galasko,0000-0001-6195-3241,,,Douglas Galasko
3057.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3058.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3059.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3060.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3061.0,Dopamine transporter imaging predicts clinically-defined α-synucleinopathy in REM sleep behavior disorder,PPMI,missing,10.1002/acn3.51269,1.0,W3118160052,A5112292363,Álex Iranzo,,,,Álex Iranzo
3062.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3063.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5013496030,Marina Picillo,,,,Marina Picillo
3064.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5008108638,Hyunkeun Ryan Cho,0000-0003-2361-258X,,,Hyunkeun Cho
3065.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3066.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
3067.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5022778142,Ethan Brown,0000-0001-9744-8562,,,Ethan Brown
3068.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3069.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3070.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5082749398,Roseanne D. Dobkin,0000-0002-2535-5495,,,Roseanne Dobkin
3071.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3072.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5087907356,Doug Galasko,,,,Doug Galasko
3073.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5109102258,Karl Kieburtz,,,,Karl Kieburtz
3074.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3075.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3076.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3077.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3078.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3079.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3080.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5035490583,Andrew Singleton,0000-0002-5545-2149,,,Andrew Singleton
3081.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3082.0,Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study,PPMI,missing,10.1002/mdc3.13751,1.0,W4364360245,A5048664606,Caroline M. Tanner,,,,Caroline Tanner
3083.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5103202968,Thomas Kremer,0000-0002-5999-5183,,,Thomas Kremer
3084.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5006066023,Kirsten I. Taylor,0000-0002-2480-3137,,,Kirsten Taylor
3085.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5043312189,Juliane Siebourg‐Polster,0000-0002-1759-3223,,,Juliane Siebourg‐Polster
3086.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5084403760,Thomas Gerken,0000-0002-7919-7613,,,Thomas Gerken
3087.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5035828502,Andreas Staempfli,,,,Andreas Staempfli
3088.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5065043368,Christian Czech,0000-0001-7746-0134,,,Christian Czech
3089.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5059906003,Juergen Dukart,0000-0003-0492-5644,,,Juergen Dukart
3090.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5072592799,Douglas Galasko,0000-0001-6195-3241,,,Douglas Galasko
3091.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3092.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3093.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3094.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3095.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3096.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3097.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3098.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5102799042,Arthur W. Toga,0000-0003-1454-8643,,,Arthur Toga
3099.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3100.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3101.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3102.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5027177608,Sebastian Dziadek,0000-0002-2397-5412,,,Sebastian Dziadek
3103.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5022630766,Claudia Trenkwalder,0000-0001-6407-1199,,,Claudia Trenkwalder
3104.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5048882944,Gennaro Pagano,0000-0002-6247-8988,,,Gennaro Pagano
3105.0,Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease,PPMI,missing,10.1002/mds.28608,1.0,W3157129664,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3106.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3107.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5079646874,Carly M. Farris,0000-0002-8277-8531,,,Carly Farris
3108.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5089118521,Bret Holguin,,,,Bret Holguin
3109.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5044524827,Yihua Ma,,,,Yihua Ma
3110.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3111.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5088555176,Marco J. Russo,0000-0001-8064-6685,,,Marco Russo
3112.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5079876124,Un Jung Kang,0000-0002-5970-6839,,,Un Kang
3113.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3114.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3115.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5073319054,Mohammad Shahnawaz,0000-0001-9322-3577,,,Mohammad Shahnawaz
3116.0,Seed Amplification Assay to Diagnose Early Parkinson's and Predict Dopaminergic Deficit Progression,PPMI,NA_review,10.1002/mds.28715,0.0,W3178164773,A5085647135,Claudio Soto,0000-0002-3412-0524,,,Claudio Soto
3117.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3118.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3119.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5082065342,David-Erick Lafontant,0000-0003-2157-7151,,,David-Erick Lafontant
3120.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5079646874,Carly M. Farris,0000-0002-8277-8531,,,Carly Farris
3121.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5044524827,Yihua Ma,,,,Yihua Ma
3122.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5041531247,Paula A. Urenia,,,,Paula Urenia
3123.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5033372584,Hieu Nguyen,,,,Hieu Nguyen
3124.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
3125.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3126.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3127.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5072592799,Douglas Galasko,0000-0001-6195-3241,,,Douglas Galasko
3128.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5109102258,Karl Kieburtz,,,,Karl Kieburtz
3129.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3130.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3131.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3132.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3133.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3134.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3135.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3136.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5083282772,Aleksandar Videnović,0000-0002-9237-1516,Collaborator,Team Hafler,Aleksandar Videnović
3137.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5026114705,Seung Ho Choi,,,,Seung Choi
3138.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5070199032,Ryan Kurth,0009-0004-4569-5763,,,Ryan Kurth
3139.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3140.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3141.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5086836720,Mark Frasier,0000-0002-1730-0603,,,Mark Frasier
3142.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5014508198,Luís M. A. Oliveira,0000-0002-2958-181X,,,Luís Oliveira
3143.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3144.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
3145.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3146.0,Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study,PPMI,10.1101/2023.02.27.23286156,10.1016/S1474-4422(23)00109-6,1.0,W4365459497,A5085647135,Claudio Soto,0000-0002-3412-0524,,,Claudio Soto
3147.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3148.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3149.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3150.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3151.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5066655367,Teresa Buracchio,,,,Teresa Buracchio
3152.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5022740813,Michelle Campbell,0000-0002-9502-8529,,,Michelle Campbell
3153.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5080665846,Sohini Chowdhury,0009-0009-8321-0081,,,Sohini Chowdhury
3154.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3155.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3156.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5091463368,Tien Dam,0000-0002-7786-5825,,,Tien Dam
3157.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5092534244,Peter DiBiaso,,,,Peter DiBiaso
3158.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3159.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5086836720,Mark Frasier,0000-0002-1730-0603,,,Mark Frasier
3160.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5092534245,Caroline Gochanour,0009-0009-3263-8344,,,Caroline Gochanour
3161.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5044504228,Danna Jennings,0000-0003-0753-6281,,,Danna Jennings
3162.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5109102258,Karl Kieburtz,,,,Karl Kieburtz
3163.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5020663082,Catherine Kopil,0000-0001-8678-7550,,,Catherine Kopil
3164.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3165.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3166.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5067728043,Thomas J. Montine,0000-0002-1346-2728,,,Thomas Montine
3167.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5070191350,Kelly Nudelman,0000-0003-4040-1717,,,Kelly Nudelman
3168.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5048882944,Gennaro Pagano,0000-0002-6247-8988,,,Gennaro Pagano
3169.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3170.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
3171.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
3172.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5073027575,Diane Stephenson,0000-0002-4262-436X,,,Diane Stephenson
3173.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5067906113,Matthew Stern,0000-0001-8278-6374,,,Matthew Stern
3174.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5085647135,Claudio Soto,0000-0002-3412-0524,,,Claudio Soto
3175.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3176.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5078689202,Eduardo Tolosa,0000-0002-3781-0854,,,Eduardo Tolosa
3177.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3178.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5102664467,Yuge Xiao,,,,Yuge Xiao
3179.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3180.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5023830624,Billy Dunn,0000-0002-4314-5993,,,Billy Dunn
3181.0,A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research - The Lancet Neurology,PPMI,commentary,10.1016/S1474-4422(23)00405-2,0.0,W4391090353,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3182.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5088555176,Marco J. Russo,0000-0001-8064-6685,,,Marco Russo
3183.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5040502772,Christina D. Orrú,0000-0001-7253-2944,,,Christina Orrú
3184.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3185.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5057795641,Simone Giaisi,,,,Simone Giaisi
3186.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5010907811,Bradley R. Groveman,0000-0002-5059-7672,,,Bradley Groveman
3187.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5079646874,Carly M. Farris,0000-0002-8277-8531,,,Carly Farris
3188.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5089118521,Bret Holguin,,,,Bret Holguin
3189.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5016183452,Andrew G. Hughson,0000-0002-0725-4017,,,Andrew Hughson
3190.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5110815847,David-Erick Lafontant,,,,David-Erick Lafontant
3191.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3192.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3193.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5030708947,J Mollon,0000-0002-0788-9442,,,J Mollon
3194.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3195.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3196.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5053105888,Roland G. Heym,0009-0003-4682-3061,,,Roland Heym
3197.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5085647135,Claudio Soto,0000-0002-3412-0524,,,Claudio Soto
3198.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5015110041,Byron Caughey,0000-0002-3928-6101,,,Byron Caughey
3199.0,High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease,PPMI,missing,10.1186/s40478-021-01282-8,1.0,W3212865892,A5079876124,Un Jung Kang,0000-0002-5970-6839,,,Un Kang
3200.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3201.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5082917142,Kerri A. Pierz,0009-0002-1892-3164,,,Kerri Pierz
3202.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5082065342,David-Erick Lafontant,0000-0003-2157-7151,,,David-Erick Lafontant
3203.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3204.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5101963138,Christopher S. Coffey,0000-0002-8130-5484,,,Christopher Coffey
3205.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3206.0,Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older,PPMI,missing,10.1212/WNL.0000000000207077,1.0,W4322489360,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3207.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5039840375,Michael Bartl,0000-0002-7752-2443,Key Personnel,Team Schlossmacher,Michael Bartl
3208.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5010902538,Mohammed Dakna,0000-0001-8341-0360,,,Mohammed Dakna
3209.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5072592799,Douglas Galasko,0000-0001-6195-3241,,,Douglas Galasko
3210.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3211.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3212.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5007413633,Marian Quan,,,,Marian Quan
3213.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3214.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3215.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5086570784,Jonas Franz,0000-0001-7523-6622,Key Personnel,Team Schlossmacher,Jonas Franz
3216.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5022630766,Claudia Trenkwalder,0000-0001-6407-1199,,,Claudia Trenkwalder
3217.0,Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease,PPMI,missing,10.1371/journal.pone.0257372,1.0,W3201883528,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3218.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5032335167,Christos Koros,0000-0001-5806-0717,,,Christos Koros
3219.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5052068068,Athina‐Maria Simitsi,0000-0002-7130-6256,,,Athina‐Maria Simitsi
3220.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5022634059,Nikolaos Papagiannakis,0000-0002-8401-8472,,,Nikolaos Papagiannakis
3221.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5042650138,Anastasia Bougea,0000-0003-3006-8711,,,Anastasia Bougea
3222.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5029997531,Andreas Prentakis,0000-0001-9194-2447,,,Andreas Prentakis
3223.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5005420378,Dimitra Papadimitriou,0000-0002-3125-6223,,,Dimitra Papadimitriou
3224.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5052990676,Ioanna Pachi,0000-0001-7488-4425,,,Ioanna Pachi
3225.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5001937624,Ion Beratis,0000-0003-2379-4571,,,Ion Beratis
3226.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5053694772,Evangelia Stanitsa,0000-0001-5448-3675,,,Evangelia Stanitsa
3227.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5030161367,Efthalia Angelopoulou,0000-0002-1426-3384,,,Efthalia Angelopoulou
3228.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5024234619,Roubina Antonelou,0000-0003-1485-3496,,,Roubina Antonelou
3229.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5039549926,Marianna Bregianni,,,,Marianna Bregianni
3230.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5022480300,Konstantinos Lourentzos,,,,Konstantinos Lourentzos
3231.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5082581713,Sokratis G. Papageorgiou,0000-0001-8863-3635,,,Sokratis Papageorgiou
3232.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5059645877,Anastasios Bonakis,0000-0003-0509-5910,,,Anastasios Bonakis
3233.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5086375776,Xenia Geronicola Trapali,,,,Xenia Trapali
3234.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5062015847,María Stamelou,0000-0003-1668-9925,,,María Stamelou
3235.0,Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson’s Disease: Longitudinal Data from the PPMI Study,PPMI,,10.3233/jpd-230007,1.0,W4383101796,A5089947731,Leonidas Stefanis,0000-0003-3569-8990,,,Leonidas Stefanis
3236.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5032661753,Charlotte B. Stewart,,,,Charlotte Stewart
3237.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5076378015,David Ledingham,0000-0002-6474-2666,,,David Ledingham
3238.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5011463293,Victoria K. Foster,,,,Victoria Foster
3239.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5081011489,Kirstie N. Anderson,0000-0001-5767-918X,,,Kirstie Anderson
3240.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5087198324,Sahana Sathyanarayana,,,,Sahana Sathyanarayana
3241.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5024441926,Debra Galley,,,,Debra Galley
3242.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5021159009,Nicola Pavese,0000-0002-6801-6194,,,Nicola Pavese
3243.0,The longitudinal progression of autonomic dysfunction in Parkinson's disease: A 7-year study,PPMI,missing,10.3389/fneur.2023.1155669,1.0,W4365148465,A5057313797,Jacopo Pasquini,0000-0003-1856-2995,,,Jacopo Pasquini
3244.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5070191350,Kelly Nudelman,0000-0003-4040-1717,,,Kelly Nudelman
3245.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5075190278,Yajing Yan Yan Xiong,,,,Yajing Xiong
3246.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5073577553,Lola Cook,0000-0001-6109-4598,,,Lola Cook
3247.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5050774865,Jeanine Schulze,0000-0001-9163-3425,,,Jeanine Schulze
3248.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5108405938,Marco Abreu,,,,Marco Abreu
3249.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3250.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
3251.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3252.0,Dystonia-Parkinsonism Gene Variants in Individuals with Parkinsonism and Brain Scans without Evidence for Dopaminergic Deficit (SWEDD),PPMI,10.1101/2022.03.21.22271781,,1.0,W4220883817,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3253.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3254.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3255.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3256.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5073918974,Elliot Burghardt,0000-0002-9921-7634,,,Elliot Burghardt
3257.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5026114705,Seung Ho Choi,,,,Seung Choi
3258.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3259.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3260.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3261.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3262.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5072592799,Douglas Galasko,0000-0001-6195-3241,,,Douglas Galasko
3263.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3264.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5006414261,Vanessa Arnedo,0000-0002-6444-6752,,,Vanessa Arnedo
3265.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3266.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5112921681,Alyssa O’Grady,,,,Alyssa O’Grady
3267.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3268.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3269.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3270.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5030324367,Karl Kieburtz,0000-0002-1645-6921,,,Karl Kieburtz
3271.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3272.0,Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression,PPMI,10.1101/2023.05.23.23290344,,1.0,W4377967472,A5101963138,Christopher S. Coffey,0000-0002-8130-5484,,,Christopher Coffey
3273.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5091463368,Tien Dam,0000-0002-7786-5825,,,Tien Dam
3274.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5048882944,Gennaro Pagano,0000-0002-6247-8988,,,Gennaro Pagano
3275.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3276.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5092534245,Caroline Gochanour,0009-0009-3263-8344,,,Caroline Gochanour
3277.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5053689920,Kathleen L. Poston,0000-0003-3424-7143,,,Kathleen Poston
3278.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3279.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3280.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5101963138,Christopher S. Coffey,0000-0002-8130-5484,,,Christopher Coffey
3281.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3282.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5020663082,Catherine Kopil,0000-0001-8678-7550,,,Catherine Kopil
3283.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5034373129,Yuge Xiao,0009-0003-0382-8014,,,Yuge Xiao
3284.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5080665846,Sohini Chowdhury,0009-0009-8321-0081,,,Sohini Chowdhury
3285.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3286.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5092534244,Peter DiBiaso,,,,Peter DiBiaso
3287.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3288.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5086836720,Mark Frasier,0000-0002-1730-0603,,,Mark Frasier
3289.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5044504228,Danna Jennings,0000-0003-0753-6281,,,Danna Jennings
3290.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5030324367,Karl Kieburtz,0000-0002-1645-6921,,,Karl Kieburtz
3291.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3292.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3293.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5067728043,Thomas J. Montine,0000-0002-1346-2728,,,Thomas Montine
3294.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5070191350,Kelly Nudelman,0000-0003-4040-1717,,,Kelly Nudelman
3295.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5037230816,John Seibyl,0000-0002-4917-5413,,,John Seibyl
3296.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
3297.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
3298.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5073027575,Diane Stephenson,0000-0002-4262-436X,,,Diane Stephenson
3299.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5067906113,Matthew Stern,0000-0001-8278-6374,,,Matthew Stern
3300.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5085647135,Claudio Soto,0000-0002-3412-0524,,,Claudio Soto
3301.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5078689202,Eduardo Tolosa,0000-0002-3781-0854,,,Eduardo Tolosa
3302.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3303.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5023830624,Billy Dunn,0000-0002-4314-5993,,,Billy Dunn
3304.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5112325034,Tanya Simuni,,,,Tanya Simuni
3305.0,"Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts",PPMI,10.1101/2024.02.14.24302818,,1.0,W4391846234,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3306.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5070024100,Silvia Paola Caminiti,0000-0003-4568-1738,,,Silvia Caminiti
3307.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
3308.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5085580106,Alice Galli,0009-0009-7804-5106,,,Alice Galli
3309.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5094353945,Rachele Malito,,,,Rachele Malito
3310.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5092939508,Giada Cuconato,,,,Giada Cuconato
3311.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5023465330,Andrea Pilotto,0000-0003-2029-6606,,,Andrea Pilotto
3312.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5089967868,Alessandro Padovani,0000-0002-0119-3639,,,Alessandro Padovani
3313.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5109698730,Fabio Blandini,,,,Fabio Blandini
3314.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5039017810,Daniela Perani,0000-0002-3421-204X,,,Daniela Perani
3315.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5053749762,Cristina Tassorelli,0000-0003-1513-2113,,,Cristina Tassorelli
3316.0,Combined detrimental effect of male sex and GBA1 variants on cognitive decline in Parkinson’s Disease,PPMI,10.1101/2024.04.02.24305191,,1.0,W4393852992,A5068582387,Enza Maria Valente,0000-0002-0600-6820,Key Personnel,Team Schapira,Enza Valente
3317.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5022778142,Ethan Brown,0000-0001-9744-8562,,,Ethan Brown
3318.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3319.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3320.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5092534245,Caroline Gochanour,0009-0009-3263-8344,,,Caroline Gochanour
3321.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5070199032,Ryan Kurth,0009-0004-4569-5763,,,Ryan Kurth
3322.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5109729775,Micah J. Marshall,,,,Micah Marshall
3323.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3324.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3325.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5108121050,Christopher S. Coffey,,,,Christopher Coffey
3326.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5087800771,Craig Stanley,,,,Craig Stanley
3327.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5023605199,Monica Korell,,,,Monica Korell
3328.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5112925252,Bridget McMahon,,,,Bridget McMahon
3329.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5091461490,Maggie Kuhl,,,,Maggie Kuhl
3330.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5092971505,Kimberly Fabrizio,,,,Kimberly Fabrizio
3331.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5089975024,Laura Heathers,0009-0008-1097-2678,,,Laura Heathers
3332.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3333.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3334.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5090494025,Claudio Soto,,,,Claudio Soto
3335.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5080665846,Sohini Chowdhury,0009-0009-8321-0081,,,Sohini Chowdhury
3336.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3337.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3338.0,A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease,PPMI,10.1101/2024.06.03.24308229,,1.0,W4399319883,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3339.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5062401170,Kalpana Merchant,0000-0003-1118-9403,,,Kalpana Merchant
3340.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5070950034,Tanya Simuni,0000-0002-2347-1644,,,Tanya Simuni
3341.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5082223284,Janel Fedler,0000-0002-2361-6604,,,Janel Fedler
3342.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5072297287,Chelsea Caspell‐Garcia,0000-0002-0933-1039,,,Chelsea Caspell‐Garcia
3343.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5008562274,Michael C. Brumm,0000-0002-3173-9989,,,Michael Brumm
3344.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5070191350,Kelly Nudelman,0000-0003-4040-1717,,,Kelly Nudelman
3345.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5035603169,Elizabeth Tengstrand,,,,Elizabeth Tengstrand
3346.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5046229459,F. Hsieh,0000-0001-5203-8922,,,F. Hsieh
3347.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
3348.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5008462596,Christopher S. Coffey,0009-0002-8892-2626,,,Christopher Coffey
3349.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5025515809,Lana M. Chahine,0000-0003-2521-7196,,,Lana Chahine
3350.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5048034644,Tatiana Foroud,0000-0002-5549-2212,,,Tatiana Foroud
3351.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5100694605,Andrew Singleton,0000-0001-5606-700X,,,Andrew Singleton
3352.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5037362183,Daniel Weintraub,0000-0003-0633-7168,,,Daniel Weintraub
3353.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5017406329,Samantha J. Hutten,0000-0002-8435-744X,,,Samantha Hutten
3354.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5088732447,Todd Sherer,0000-0001-9667-6600,,,Todd Sherer
3355.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5073135371,Andrew Siderowf,0000-0002-1750-7698,,,Andrew Siderowf
3356.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3357.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5080273687,Caroline M. Tanner,0000-0002-3775-5082,,,Caroline Tanner
3358.0,Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts,PPMI,10.21203/rs.3.rs-2065993/v1,,1.0,W4302007502,A5091194111,Kenneth Marek,0000-0002-4197-5627,,,Kenneth Marek
3359.0,Scientific Perspectives: Structural Biology of LRRK2 and its Interaction with Microtubules,Reck-Peterson,review,10.1002/mds.28755,0.0,W3196071261,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3360.0,Scientific Perspectives: Structural Biology of LRRK2 and its Interaction with Microtubules,Reck-Peterson,review,10.1002/mds.28755,0.0,W3196071261,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X,Lead-PI,Team Reck-Peterson,Samara Reck‐Peterson
3361.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5019965194,Verena Dederer,0000-0002-7877-4706,Key Personnel,Team Reck-Peterson,Verena Dederer
3362.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315,Key Personnel,Team Reck-Peterson,Marta Murillo
3363.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5076988745,Eva Karasmanis,0000-0002-0139-0210,Key Personnel,Team Reck-Peterson,Eva Karasmanis
3364.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5072876433,Kathryn S. Hatch,0000-0002-8629-0939,Key Personnel,Team Reck-Peterson,Kathryn Hatch
3365.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5086343829,Deep Chatterjee,0000-0001-8190-9213,Key Personnel,Team Reck-Peterson,Deep Chatterjee
3366.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5043108531,Franziska Preuß,0000-0003-1616-4811,,,Franziska Preuß
3367.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5044887346,K.R. Abdul Azeez,0000-0001-9985-0336,,,K.R. Azeez
3368.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5114099949,Landon Vu Nguyen,0000-0001-7482-4668,Key Personnel,Team Reck-Peterson,Landon Nguyen
3369.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5039124196,Christian Galicia,0000-0001-6080-7533,,,Christian Galicia
3370.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5016483675,Birgit Dreier,0000-0002-5124-9346,,,Birgit Dreier
3371.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5083658123,Andreas Plückthun,0000-0003-4191-5306,,,Andreas Plückthun
3372.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5057791434,Wim Versées,0000-0002-4695-696X,,,Wim Versées
3373.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5042127936,Sebastian Mathea,0000-0001-8500-4569,Key Personnel,Team Reck-Peterson,Sebastian Mathea
3374.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3375.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X,Lead-PI,Team Reck-Peterson,Samara Reck‐Peterson
3376.0,Development of LRRK2 designed ankyrin-repeat proteins,Reck-Peterson,10.1101/2023.11.14.567123,10.1016/j.jbc.2024.107469,1.0,W4399566509,A5013336817,Stefan Knapp,0000-0001-5995-6494,Co-PI,Team Reck-Peterson,Stefan Knapp
3377.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5000947783,Nanjun Chen,0000-0003-4074-5229,,,Nanjun Chen
3378.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5045296531,Carolin Sailer,0000-0001-7735-6070,,,Carolin Sailer
3379.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5009764050,Kai Michael Kammer,,,,Kai Kammer
3380.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5022134059,Julius Fürsch,,,,Julius Fürsch
3381.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5062381761,Markus R. Eisele,,,,Markus Eisele
3382.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5001692218,Eri Sakata,0000-0002-8580-3683,,,Eri Sakata
3383.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5001802857,Riccardo Pellarin,0000-0002-1054-7400,,,Riccardo Pellarin
3384.0,Mono- and Intralink Filter (Mi-Filter) To Reduce False Identifications in Cross-Linking Mass Spectrometry Data | Analytical Chemistry (acs.org),Reck-Peterson,10.1101/2022.02.03.478943,10.1021/acs.analchem.2c00494,1.0,W4311220075,A5006736501,Florian Stengel,0000-0003-1447-4509,Collaborating PI,Team Reck-Peterson,Florian Stengel
3385.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5021363544,David Snead,0000-0001-7839-452X,,,David Snead
3386.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5084097252,Mariusz Matyszewski,0000-0003-1033-9270,,,Mariusz Matyszewski
3387.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5057238552,Andrea M. Dickey,0000-0001-8725-0982,,,Andrea Dickey
3388.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5044141143,Yu Xuan Lin,0000-0002-1016-4776,,,Yu Lin
3389.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3390.0,Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules,Reck-Peterson,10.1101/2022.01.21.477284,10.1038/s41594-022-00863-y,1.0,W4311901922,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X,Lead-PI,Team Reck-Peterson,Samara Reck‐Peterson
3391.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5068874193,Janice M. Reimer,0000-0002-2664-5523,,,Janice Reimer
3392.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5057238552,Andrea M. Dickey,0000-0001-8725-0982,,,Andrea Dickey
3393.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5044141143,Yu Xuan Lin,0000-0002-1016-4776,,,Yu Lin
3394.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5086277887,Robert G. Abrisch,0000-0002-4231-9971,Key Personnel,Team Reck-Peterson,Robert Abrisch
3395.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5042127936,Sebastian Mathea,0000-0001-8500-4569,Key Personnel,Team Reck-Peterson,Sebastian Mathea
3396.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5086343829,Deep Chatterjee,0000-0001-8190-9213,Key Personnel,Team Reck-Peterson,Deep Chatterjee
3397.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5070756331,Elizabeth J. Fay,0000-0003-1712-757X,,,Elizabeth Fay
3398.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5013336817,Stefan Knapp,0000-0001-5995-6494,Co-PI,Team Reck-Peterson,Stefan Knapp
3399.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5071307291,Matthew D. Daugherty,0000-0002-4879-9603,,,Matthew Daugherty
3400.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5021023250,Samara L. Reck‐Peterson,0000-0002-1553-465X,Lead-PI,Team Reck-Peterson,Samara Reck‐Peterson
3401.0,Structure of LRRK1 and mechanisms of autoinhibition and activation,Reck-Peterson,10.1101/2022.11.22.517582,10.1038/s41594-023-01109-1,1.0,W4387782462,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3402.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315,Key Personnel,Team Reck-Peterson,Marta Murillo
3403.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5092762755,Amalia Villagran Suarez,0000-0003-3400-2330,Key Personnel,Team Reck-Peterson,Amalia Suarez
3404.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5102848969,Verena Dederer,0009-0006-7557-5388,Key Personnel,Team Reck-Peterson,Verena Dederer
3405.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5086343829,Deep Chatterjee,0000-0001-8190-9213,Key Personnel,Team Reck-Peterson,Deep Chatterjee
3406.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5068728058,Jaime Alegrio Louro,0000-0002-2800-923X,Key Personnel,Team Reck-Peterson,Jaime Louro
3407.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5013336817,Stefan Knapp,0000-0001-5995-6494,Co-PI,Team Reck-Peterson,Stefan Knapp
3408.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5042127936,Sebastian Mathea,0000-0001-8500-4569,Key Personnel,Team Reck-Peterson,Sebastian Mathea
3409.0,Inhibition of Parkinson’s Disease-related LRRK2 by type-I and type-II kinase inhibitors: activity and structures | bioRxiv,Reck-Peterson,10.1101/2023.09.07.556689,10.1126/sciadv.adk6191,1.0,W4389233086,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3410.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5100325198,Siyu Chen,0000-0003-4565-4772,Key Personnel,Team Reck-Peterson,Siyu Chen
3411.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5013862228,Tamar Basiashvili,0000-0003-0394-3832,Key Personnel,Team Reck-Peterson,Tamar Basiashvili
3412.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5006107445,Joshua Hutchings,0000-0001-6841-8583,Key Personnel,Team Reck-Peterson,Joshua Hutchings
3413.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5053245720,Marta Sanz Murillo,0000-0002-6175-9315,Key Personnel,Team Reck-Peterson,Marta Murillo
3414.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5092762755,Amalia Villagran Suarez,0000-0003-3400-2330,Key Personnel,Team Reck-Peterson,Amalia Suarez
3415.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5068728058,Jaime Alegrio Louro,0000-0002-2800-923X,Key Personnel,Team Reck-Peterson,Jaime Louro
3416.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5011173483,Andres E. Leschziner,0000-0002-7732-7023,Co-PI,Team Reck-Peterson,Andres Leschziner
3417.0,Cryo-electron tomography reveals the microtubule-bound form of inactive LRRK2,Reck-Peterson,10.1101/2024.06.18.599606,,1.0,W4399852907,A5087861735,Elizabeth Villa,0000-0003-4677-9809,Co-PI,Team Reck-Peterson,Elizabeth Villa
3418.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5038944590,Hanqin Li,0000-0001-7995-1084,Key Personnel,Team Rio,Hanqin Li
3419.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5000495585,Oriol Busquets,0000-0002-1372-9699,Key Personnel,Team Rio,Oriol Busquets
3420.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5088126377,Yogendra Verma,0000-0003-3380-6089,,,Yogendra Verma
3421.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5013626934,Khaja Syed,0000-0002-7682-7608,Key Personnel,Team Rio,Khaja Syed
3422.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5004265638,Nitzan Kutnowski,0000-0002-3012-4616,,,Nitzan Kutnowski
3423.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5038011560,Gabriella Pangilinan,0000-0003-2662-7883,,,Gabriella Pangilinan
3424.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5035219354,Luke A. Gilbert,0000-0001-5854-0825,,,Luke Gilbert
3425.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5089305536,Helen S. Bateup,0000-0002-0135-0972,Co-PI,Team Rio,Helen Bateup
3426.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5034073565,Donald C. Rio,,Lead-PI,Team Rio,Donald Rio
3427.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092,Co-PI,Team Rio,Dirk Hockemeyer
3428.0,Highly efficient generation of isogenic pluripotent stem cell models using prime editing,Rio,10.1101/2022.02.15.480601,10.7554/eLife.79208,1.0,W4294904866,A5070152031,Frank Soldner,0000-0002-7102-8655,Co-PI,Team Rio,Frank Soldner
3429.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5000495585,Oriol Busquets,0000-0002-1372-9699,Key Personnel,Team Rio,Oriol Busquets
3430.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5038944590,Hanqin Li,0000-0001-7995-1084,Key Personnel,Team Rio,Hanqin Li
3431.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5013626934,Khaja Syed,0000-0002-7682-7608,Key Personnel,Team Rio,Khaja Syed
3432.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5027391800,Pilar Álvarez Jerez,0000-0002-5812-1898,,,Pilar Jerez
3433.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5082840733,Jesse Dunnack,0000-0002-0387-0090,Key Personnel,Team Rio,Jesse Dunnack
3434.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5045635967,Riana Lo Bu,0000-0002-1732-5878,,,Riana Bu
3435.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5088126377,Yogendra Verma,0000-0003-3380-6089,,,Yogendra Verma
3436.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5038011560,Gabriella Pangilinan,0000-0003-2662-7883,,,Gabriella Pangilinan
3437.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5083708337,Annika Martin,0009-0006-3369-1495,,,Annika Martin
3438.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5032393653,Jannes Straub,0000-0002-7178-1663,Key Personnel,Team Voet,Jannes Straub
3439.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5101643259,YuXin Du,0000-0001-5212-5372,,,YuXin Du
3440.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5027065485,V Simon,0009-0001-1976-0937,,,V Simon
3441.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5082161278,Steven Poser,0000-0003-4868-1389,Key Personnel,Team Rio,Steven Poser
3442.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5093929327,Zipporiah Bush,0000-0002-6304-9579,,,Zipporiah Bush
3443.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5002224349,Jessica Diaz,0000-0001-7165-6590,Key Personnel,Team Rio,Jessica Diaz
3444.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5068055115,Atehsa Sahagun,0000-0001-7521-3279,Key Personnel,Team Rio,Atehsa Sahagun
3445.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5083449579,J M Gao,0009-0007-4535-6587,,,J Gao
3446.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5029141074,Samantha Hong,0009-0001-8968-6461,,,Samantha Hong
3447.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5101776731,Dena Hernández,0000-0002-0188-9927,,,Dena Hernández
3448.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5016889750,Kristin Levine,0000-0002-5702-0980,,,Kristin Levine
3449.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5060890812,Ezgi O. Booth,0000-0001-9213-8426,Project Manager,Team Rio,Ezgi Booth
3450.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5010146665,Marco Blanchette,0009-0005-5592-7166,,,Marco Blanchette
3451.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5089305536,Helen S. Bateup,0000-0002-0135-0972,Co-PI,Team Rio,Helen Bateup
3452.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5034073565,Donald C. Rio,,Lead-PI,Team Rio,Donald Rio
3453.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5072627174,Cornelis Blauwendraat,0000-0001-9358-8111,,,Cornelis Blauwendraat
3454.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092,Co-PI,Team Rio,Dirk Hockemeyer
3455.0,iSCORE-PD: an isogenic stem cell collection to research Parkinson’s Disease,Rio,10.1101/2024.02.12.579917,,1.0,W4391820161,A5070152031,Frank Soldner,0000-0002-7102-8655,Co-PI,Team Rio,Frank Soldner
3456.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5077348858,Yeon J. Lee,,Key Personnel,Team Rio,Yeon Lee
3457.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5013626934,Khaja Syed,0000-0002-7682-7608,Key Personnel,Team Rio,Khaja Syed
3458.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5000495585,Oriol Busquets,0000-0002-1372-9699,Key Personnel,Team Rio,Oriol Busquets
3459.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5038944590,Hanqin Li,0000-0001-7995-1084,Key Personnel,Team Rio,Hanqin Li
3460.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5082840733,Jesse Dunnack,0000-0002-0387-0090,Key Personnel,Team Rio,Jesse Dunnack
3461.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5068055115,Atehsa Sahagun,0000-0001-7521-3279,Key Personnel,Team Rio,Atehsa Sahagun
3462.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5089305536,Helen S. Bateup,0000-0002-0135-0972,Co-PI,Team Rio,Helen Bateup
3463.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5070152031,Frank Soldner,0000-0002-7102-8655,Co-PI,Team Rio,Frank Soldner
3464.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092,Co-PI,Team Rio,Dirk Hockemeyer
3465.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5034073565,Donald C. Rio,,Lead-PI,Team Rio,Donald Rio
3466.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5077348858,Yeon J. Lee,,Key Personnel,Team Rio,Yeon Lee
3467.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5013626934,Khaja Syed,0000-0002-7682-7608,Key Personnel,Team Rio,Khaja Syed
3468.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5000495585,Oriol Busquets,0000-0002-1372-9699,Key Personnel,Team Rio,Oriol Busquets
3469.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5038944590,Hanqin Li,0000-0001-7995-1084,Key Personnel,Team Rio,Hanqin Li
3470.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5082840733,Jesse Dunnack,0000-0002-0387-0090,Key Personnel,Team Rio,Jesse Dunnack
3471.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5068055115,Atehsa Sahagun,0000-0001-7521-3279,Key Personnel,Team Rio,Atehsa Sahagun
3472.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5089305536,Helen S. Bateup,0000-0002-0135-0972,Co-PI,Team Rio,Helen Bateup
3473.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5070152031,Frank Soldner,0000-0002-7102-8655,Co-PI,Team Rio,Frank Soldner
3474.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5045835078,Dirk Hockemeyer,0000-0002-5598-5092,Co-PI,Team Rio,Dirk Hockemeyer
3475.0,Comparison of Alternative pre-mRNA Splicing and Gene Expression Patterns in Midbrain Lineage Cells Carrying Familial Parkinson’s Disease Mutations,Rio,10.1101/2024.02.28.582420,,1.0,W4392342300,A5034073565,Donald C. Rio,,Lead-PI,Team Rio,Donald Rio
3476.0,Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease - Toffoli - 2023 - Movement Disorders - Wiley Online Library,Schapira,review,10.1002/mds.29609,0.0,W4386945332,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
3477.0,Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease - Toffoli - 2023 - Movement Disorders - Wiley Online Library,Schapira,review,10.1002/mds.29609,0.0,W4386945332,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3478.0,Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease - Toffoli - 2023 - Movement Disorders - Wiley Online Library,Schapira,review,10.1002/mds.29609,0.0,W4386945332,A5012157016,Christos Proukakis,0000-0001-6423-6539,Co-PI,Team Voet,Christos Proukakis
3479.0,"Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach",Schapira,review,10.1007/s11910-023-01259-1,0.0,W4323348262,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3480.0,"Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach",Schapira,review,10.1007/s11910-023-01259-1,0.0,W4323348262,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3481.0,"Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach",Schapira,review,10.1007/s11910-023-01259-1,0.0,W4323348262,A5007019878,Fabio Blandini,0000-0002-0178-1289,Co-PI,Team Schapira,Fabio Blandini
3482.0,"Who is at Risk of Parkinson Disease? Refining the Preclinical Phase of GBA1 and LRRK2 Variant Carriers: a Clinical, Biochemical, and Imaging Approach",Schapira,review,10.1007/s11910-023-01259-1,0.0,W4323348262,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
3483.0,The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications,Schapira,NA_review,10.1007/s40263-024-01073-4,0.0,W4393901714,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3484.0,The Gut Microbiota in Parkinson Disease: Interactions with Drugs and Potential for Therapeutic Applications,Schapira,NA_review,10.1007/s40263-024-01073-4,0.0,W4393901714,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3485.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
3486.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5085397310,Harneek Chohan,0000-0003-0561-758X,,,Harneek Chohan
3487.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5087576419,Stephen Mullin,0000-0002-1936-394X,,,Stephen Mullin
3488.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5038790922,Aaron Jesuthasan,0000-0002-7699-8853,,,Aaron Jesuthasan
3489.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5092551126,Selen Yalkic,0000-0002-9811-6612,Key Personnel,Team Schapira,Selen Yalkic
3490.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5080523651,Sofia Koletsi,0000-0002-6661-7797,Project Manager,Team Schapira,Sofia Koletsi
3491.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3492.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5092551127,Soraya Rahall,,,,Soraya Rahall
3493.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5052995870,Naomi Limbachiya,,,,Naomi Limbachiya
3494.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5090002183,Nadine Loefflad,0000-0002-9940-7753,Key Personnel,Team Schapira,Nadine Loefflad
3495.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5082724626,Abigail Higgins,0000-0003-1908-5721,,,Abigail Higgins
3496.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5056651699,Jonathan P. Bestwick,0000-0002-3088-8616,,,Jonathan Bestwick
3497.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5051189127,Sara Lucas Del Pozo,0000-0002-5431-8204,Key Personnel,Team Schapira,Sara Pozo
3498.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5092551125,Federico Fierli,0000-0002-8259-2067,Key Personnel,Team Schapira,Federico Fierli
3499.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5049802730,Audrey Farbos,0009-0008-5230-4272,,,Audrey Farbos
3500.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5084077878,Roxana Mezabrovschi,0000-0001-8580-0629,Key Personnel,Team Schapira,Roxana Mezabrovschi
3501.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5008407091,Chiao‐Yin Lee,0000-0003-1117-3006,Key Personnel,Team Schapira,Chiao‐Yin Lee
3502.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5071609742,Anette Schrag,0000-0002-9872-6680,,,Anette Schrag
3503.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5067029380,David Moreno-Martínez,0000-0001-9777-7796,,,David Moreno-Martínez
3504.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5016812185,Derralynn Hughes,0000-0003-4531-9173,,,Derralynn Hughes
3505.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5052101031,Alastair Noyce,0000-0003-3027-5497,,,Alastair Noyce
3506.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5005466365,Kevin Colclough,0000-0003-0566-4853,,,Kevin Colclough
3507.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5063570563,Aaron R. Jeffries,0000-0002-1235-8291,,,Aaron Jeffries
3508.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5012157016,Christos Proukakis,0000-0001-6423-6539,Co-PI,Team Voet,Christos Proukakis
3509.0,Phenotypic effect of GBA1 variants in individuals with and without Parkinson's disease: The RAPSODI study - PubMed (nih.gov),Schapira,10.1101/2023.07.25.23291637,10.1016/j.nbd.2023.106343,1.0,W4388304230,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3510.0,Bile acids and neurological disease,Schapira,review,10.1016/j.pharmthera.2022.108311,0.0,W4309413381,A5058322950,Michael J. Hurley,0000-0001-8022-9283,,,Michael Hurley
3511.0,Bile acids and neurological disease,Schapira,review,10.1016/j.pharmthera.2022.108311,0.0,W4309413381,A5031944389,Rachel Bates,0000-0002-4768-6869,,,Rachel Bates
3512.0,Bile acids and neurological disease,Schapira,review,10.1016/j.pharmthera.2022.108311,0.0,W4309413381,A5002329761,Jane Macnaughtan,0000-0003-1211-9298,Collaborating PI,Team Schapira,Jane Macnaughtan
3513.0,Bile acids and neurological disease,Schapira,review,10.1016/j.pharmthera.2022.108311,0.0,W4309413381,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3514.0,"Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues",Schapira,review,10.1016/j.pharmthera.2023.108419,0.0,W4366256886,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3515.0,"Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues",Schapira,review,10.1016/j.pharmthera.2023.108419,0.0,W4366256886,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
3516.0,"Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues",Schapira,review,10.1016/j.pharmthera.2023.108419,0.0,W4366256886,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3517.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5091287609,Pascale Baden,,,,Pascale Baden
3518.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5100614696,María José Pérez,0000-0001-8842-4286,Key Personnel,Team Schapira,María Pérez
3519.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5002880244,Hariam Raji,0000-0002-2705-8857,Key Personnel,Team Schapira,Hariam Raji
3520.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5078024953,Federico Bertoli,0000-0001-5600-1190,Key Personnel,Team Schapira,Federico Bertoli
3521.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5021231719,Stefanie Kalb,,,,Stefanie Kalb
3522.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5014496858,M. E. Banegas Illescas,0000-0003-0198-1106,,,M. Illescas
3523.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5064872080,Fokion Spanos,0000-0002-0753-4561,Key Personnel,Team Schapira,Fokion Spanos
3524.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5107444116,Claudio Giuliano,0000-0003-3274-0903,,,Claudio Giuliano
3525.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5023721480,Alessandra Maria Calogero,0000-0003-2262-4992,,,Alessandra Calogero
3526.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5032912195,Marvin Oldrati,0000-0001-6205-3042,,,Marvin Oldrati
3527.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5081768282,Hannah Hebestreit,,,,Hannah Hebestreit
3528.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5012729392,Graziella Cappelletti,0000-0003-0903-5392,,,Graziella Cappelletti
3529.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5004204996,Kathrin Brockmann,0000-0002-7515-8596,,,Kathrin Brockmann
3530.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5067744605,Thomas Gasser,0000-0002-1069-1146,,,Thomas Gasser
3531.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3532.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5023707841,Cristina Ugalde,0000-0002-9742-1877,,,Cristina Ugalde
3533.0,Glucocerebrosidase is imported into mitochondria and preserves complex I integrity and energy metabolism,Schapira,10.21203/rs.3.rs-1521848/v1,10.1038/s41467-023-37454-4,1.0,W4362692584,A5056933907,Michela Deleidi,0000-0003-0357-0124,Co-PI,Team Schapira,Michela Deleidi
3534.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5002756707,Maria Kedariti,0000-0002-6311-5273,,,Maria Kedariti
3535.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5076898403,Emanuele Frattini,0000-0002-5375-2404,,,Emanuele Frattini
3536.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5091287609,Pascale Baden,,,,Pascale Baden
3537.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5021299206,Susanna Cogo,0000-0002-5792-6897,,,Susanna Cogo
3538.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5042931876,Laura Civiero,0000-0002-5334-155X,,,Laura Civiero
3539.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5082938949,Elena Ziviani,0000-0002-0864-8309,,,Elena Ziviani
3540.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5079224173,Gianluca Zilio,0000-0002-4801-7237,,,Gianluca Zilio
3541.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5078024953,Federico Bertoli,0000-0001-5600-1190,Key Personnel,Team Schapira,Federico Bertoli
3542.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5079021237,Massimo Aureli,0000-0003-1916-2440,,,Massimo Aureli
3543.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5079926109,Alice Kaganovich,0000-0003-2981-1731,,,Alice Kaganovich
3544.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5064191051,Mark Cookson,0000-0002-1058-3831,,,Mark Cookson
3545.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5089947731,Leonidas Stefanis,0000-0003-3569-8990,,,Leonidas Stefanis
3546.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5046848981,Matthew Surface,0000-0002-4933-2618,,,Matthew Surface
3547.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5056933907,Michela Deleidi,0000-0003-0357-0124,Co-PI,Team Schapira,Michela Deleidi
3548.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5064861919,Alessio Di Fonzo,0000-0001-6478-026X,,,Alessio Fonzo
3549.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
3550.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5028502903,Hardy J. Rideout,0000-0003-4597-9489,,,Hardy Rideout
3551.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5056455938,Elisa Greggio,0000-0002-8172-3598,,,Elisa Greggio
3552.0,LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease,Schapira,10.1101/2021.09.27.461935,10.1038/s41531-022-00354-3,1.0,W4285797163,A5033878743,Nicoletta Plotegher,0000-0001-7421-8705,,,Nicoletta Plotegher
3553.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5021024576,Céline Galvagnion,0000-0001-9753-3310,,,Céline Galvagnion
3554.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5000174219,Frederik Ravnkilde Marlet,0000-0003-3781-6022,,,Frederik Marlet
3555.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5059283344,Silvia Cerri,0000-0002-6466-5381,Key Personnel,Team Schapira,Silvia Cerri
3556.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3557.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5007019878,Fabio Blandini,0000-0002-0178-1289,Co-PI,Team Schapira,Fabio Blandini
3558.0,Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation,Schapira,10.1101/2020.11.09.375048,10.1093/brain/awab371,1.0,W4205299346,A5035849217,Donato A. Di Monte,0000-0002-8296-836X,Co-PI,Team Schapira,Donato Monte
3559.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5058322950,Michael J. Hurley,0000-0001-8022-9283,,,Michael Hurley
3560.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3561.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5080523651,Sofia Koletsi,0000-0002-6661-7797,Project Manager,Team Schapira,Sofia Koletsi
3562.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5031944389,Rachel Bates,0000-0002-4768-6869,,,Rachel Bates
3563.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5070560226,Matthew E. Gegg,0000-0001-8093-0723,Key Personnel,Team Schapira,Matthew Gegg
3564.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922,Key Personnel,Team Schapira,Kai‐Yin Chau
3565.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5081742118,Hervé M. Blottière,0000-0002-8390-0607,Collaborating PI,Team Schapira,Hervé Blottière
3566.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5002329761,Jane Macnaughtan,0000-0003-1211-9298,Collaborating PI,Team Schapira,Jane Macnaughtan
3567.0,α-synuclein expression in response to bacterial ligands and metabolites in gut enteroendocrine cells,Schapira,10.1101/2023.04.02.535274,10.1093/braincomms/fcad285,1.0,W4387928799,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3568.0,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines,Schapira,10.1101/2022.06.01.494130,10.1093/hmg/ddac233,1.0,W4296974338,A5050495296,Laura Smith,0000-0002-1108-2991,,,Laura Smith
3569.0,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines,Schapira,10.1101/2022.06.01.494130,10.1093/hmg/ddac233,1.0,W4296974338,A5045059502,Magdalena M. Bolsinger,0000-0002-3020-9943,,,Magdalena Bolsinger
3570.0,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines,Schapira,10.1101/2022.06.01.494130,10.1093/hmg/ddac233,1.0,W4296974338,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922,Key Personnel,Team Schapira,Kai‐Yin Chau
3571.0,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines,Schapira,10.1101/2022.06.01.494130,10.1093/hmg/ddac233,1.0,W4296974338,A5070560226,Matthew E. Gegg,0000-0001-8093-0723,Key Personnel,Team Schapira,Matthew Gegg
3572.0,The GBA variant E326K is associated with alpha-synuclein aggregation and lipid droplet accumulation in human cell lines,Schapira,10.1101/2022.06.01.494130,10.1093/hmg/ddac233,1.0,W4296974338,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3573.0,Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes,Schapira,review,10.1111/jnc.15524,0.0,W3204540093,A5008407091,Chiao‐Yin Lee,0000-0003-1117-3006,Key Personnel,Team Schapira,Chiao‐Yin Lee
3574.0,Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes,Schapira,review,10.1111/jnc.15524,0.0,W3204540093,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3575.0,Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes,Schapira,review,10.1111/jnc.15524,0.0,W3204540093,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922,Key Personnel,Team Schapira,Kai‐Yin Chau
3576.0,Glucocerebrosidase 1 and leucine-rich repeat kinase 2 in Parkinson disease and interplay between the two genes,Schapira,review,10.1111/jnc.15524,0.0,W3204540093,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3577.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5068969030,Michael Helwig,0000-0001-6371-7082,,,Michael Helwig
3578.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5050850243,Ayşe Ulusoy,0000-0003-2840-3429,Key Personnel,Team Schapira,Ayşe Ulusoy
3579.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5058661760,Angela Rollar,0000-0003-1016-6912,Key Personnel,Team Schapira,Angela Rollar
3580.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5071630632,Sinéad A. O’Sullivan,0000-0003-1909-0803,Key Personnel,Team Schapira,Sinéad O’Sullivan
3581.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5067600809,Shirley S. L. Lee,0000-0002-5349-8450,,,Shirley Lee
3582.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5046281491,Helia Aboutalebi,,,,Helia Aboutalebi
3583.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5034492694,Rita Pinto‐Costa,0000-0002-4920-4739,,,Rita Pinto‐Costa
3584.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5067136914,Benjamin Jevans,0000-0002-2885-9912,,,Benjamin Jevans
3585.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5027560244,Michael Klinkenberg,0000-0002-0241-4712,,,Michael Klinkenberg
3586.0,Neuronal hyperactivity–induced oxidant stress promotes in vivo α-synuclein brain spreading,Schapira,,10.1126/sciadv.abn0356,0.0,W4293783041,A5035849217,Donato A. Di Monte,0000-0002-8296-836X,Co-PI,Team Schapira,Donato Monte
3587.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5082724626,Abigail Higgins,0000-0003-1908-5721,,,Abigail Higgins
3588.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
3589.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5087576419,Stephen Mullin,0000-0002-1936-394X,,,Stephen Mullin
3590.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5008407091,Chiao‐Yin Lee,0000-0003-1117-3006,Key Personnel,Team Schapira,Chiao‐Yin Lee
3591.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5080523651,Sofia Koletsi,0000-0002-6661-7797,Project Manager,Team Schapira,Sofia Koletsi
3592.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5091396775,Micol Avenali,0000-0002-7880-9921,Key Personnel,Team Schapira,Micol Avenali
3593.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5007019878,Fabio Blandini,0000-0002-0178-1289,Co-PI,Team Schapira,Fabio Blandini
3594.0,The remote assessment of parkinsonism supporting the ongoing development of interventions in Gaucher disease,Schapira,10.1101/2021.07.21.21260533,10.2217/nmt-2021-0032,0.0,W3206328474,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3595.0,Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease,Schapira,review,10.3389/fneur.2022.971252,0.0,W4290830810,A5050495296,Laura Smith,0000-0002-1108-2991,,,Laura Smith
3596.0,Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease,Schapira,review,10.3389/fneur.2022.971252,0.0,W4290830810,A5008407091,Chiao‐Yin Lee,0000-0003-1117-3006,Key Personnel,Team Schapira,Chiao‐Yin Lee
3597.0,Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease,Schapira,review,10.3389/fneur.2022.971252,0.0,W4290830810,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3598.0,Genetic variations in GBA1 and LRRK2 genes: Biochemical and clinical consequences in Parkinson disease,Schapira,review,10.3389/fneur.2022.971252,0.0,W4290830810,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3599.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5002977326,Victoria Meslier,0000-0003-2699-0092,Key Personnel,Team Schapira,Victoria Meslier
3600.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5062367843,Elisa Menozzi,0000-0003-3565-7910,Key Personnel,Team Schapira,Elisa Menozzi
3601.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5058448475,Aymeric David,,,,Aymeric David
3602.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5032540310,Christian Morabito,0000-0002-3193-7299,Key Personnel,Team Schapira,Christian Morabito
3603.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5051189127,Sara Lucas Del Pozo,0000-0002-5431-8204,Key Personnel,Team Schapira,Sara Pozo
3604.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5017390096,Alexandre Famechon,0009-0009-6298-3755,Key Personnel,Team Schapira,Alexandre Famechon
3605.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5111028510,Janet North,,,,Janet North
3606.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5082132149,Benoît Quinquis,0000-0002-7573-969X,Key Personnel,Team Schapira,Benoît Quinquis
3607.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5080523651,Sofia Koletsi,0000-0002-6661-7797,Project Manager,Team Schapira,Sofia Koletsi
3608.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5002329761,Jane Macnaughtan,0000-0003-1211-9298,Collaborating PI,Team Schapira,Jane Macnaughtan
3609.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5084077878,Roxana Mezabrovschi,0000-0001-8580-0629,Key Personnel,Team Schapira,Roxana Mezabrovschi
3610.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5109572271,S. Dusko Ehrlich,,,,S. Ehrlich
3611.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3612.0,Evaluation of an adapted semi-automated DNA extraction for human salivary shotgun metagenomics,Schapira,10.21203/rs.3.rs-2762553/v1,10.3390/biom13101505,1.0,W4387531995,A5067904253,Mathieu Almeida,0000-0003-4971-0049,Co-PI,Team Schapira,Mathieu Almeida
3613.0,GBA Variants and Parkinson Disease: Mechanisms and Treatments,Schapira,review,10.3390/cells11081261,0.0,W4224297855,A5050495296,Laura Smith,0000-0002-1108-2991,,,Laura Smith
3614.0,GBA Variants and Parkinson Disease: Mechanisms and Treatments,Schapira,review,10.3390/cells11081261,0.0,W4224297855,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3615.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5003538295,Electra Brunialti,0000-0002-0247-3819,,,Electra Brunialti
3616.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5016070892,Alessandro Villa,0000-0002-7445-916X,,,Alessandro Villa
3617.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5024237726,Marco Toffoli,0000-0002-3255-9648,Key Personnel,Team Schapira,Marco Toffoli
3618.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5051189127,Sara Lucas Del Pozo,0000-0002-5431-8204,Key Personnel,Team Schapira,Sara Pozo
3619.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5060234266,Nicoletta Rizzi,0000-0001-7075-2759,,,Nicoletta Rizzi
3620.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5020425919,Clara Meda,0000-0003-3524-2010,,,Clara Meda
3621.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5055666393,Adriana Maggi,0000-0001-5700-5273,,,Adriana Maggi
3622.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3623.0,Sex-specific microglial responses to glucocerebrosidase inhibition: relevance to GBA1-linked Parkinson disease,Schapira,10.1101/2022.12.05.519143,10.3390/cells12030343,1.0,W4316690364,A5052037610,Paolo Ciana,0000-0001-5771-5638,,,Paolo Ciana
3624.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5060842798,Carmela Giachino,0000-0003-3650-8677,Key Personnel,Team Schapira,Carmela Giachino
3625.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5075407827,Cataldo Tirolo,0000-0003-1747-8134,,,Cataldo Tirolo
3626.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5021181399,Salvatore Caniglia,0000-0002-9416-8458,,,Salvatore Caniglia
3627.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5074264245,Maria Francesca Serapide,0000-0001-6332-4772,,,Maria Serapide
3628.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5031496401,Francesca L’Episcopo,0000-0003-3292-9677,,,Francesca L’Episcopo
3629.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5078024953,Federico Bertoli,0000-0001-5600-1190,Key Personnel,Team Schapira,Federico Bertoli
3630.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5107444116,Claudio Giuliano,0000-0003-3274-0903,,,Claudio Giuliano
3631.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5003743419,Marika Mearelli,,,,Marika Mearelli
3632.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5050011017,Meike Jakobi,0000-0003-2025-4385,,,Meike Jakobi
3633.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5025026489,Nicole Schneiderhan‐Marra,0000-0001-6785-181X,,,Nicole Schneiderhan‐Marra
3634.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5056933907,Michela Deleidi,0000-0003-0357-0124,Co-PI,Team Schapira,Michela Deleidi
3635.0,LRRK2-G2019S Synergizes with Ageing and Low-Grade Inflammation to Promote Gut and Peripheral Immune Cell Activation that Precede Nigrostriatal Degeneration,Schapira,10.1101/2022.09.01.505977,,1.0,W4295067826,A5020938978,Bianca Marchetti,0000-0002-9287-8448,,,Bianca Marchetti
3636.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5051189127,Sara Lucas Del Pozo,0000-0002-5431-8204,Key Personnel,Team Schapira,Sara Pozo
3637.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5061010988,Giuseppe Uras,0000-0003-3494-8521,,,Giuseppe Uras
3638.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5092551125,Federico Fierli,0000-0002-8259-2067,Key Personnel,Team Schapira,Federico Fierli
3639.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5089153209,Veronica Lentini,0009-0000-6060-0321,,,Veronica Lentini
3640.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5080523651,Sofia Koletsi,0000-0002-6661-7797,Project Manager,Team Schapira,Sofia Koletsi
3641.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5052572031,Kai‐Yin Chau,0000-0002-5797-2922,Key Personnel,Team Schapira,Kai‐Yin Chau
3642.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5016812185,Derralynn Hughes,0000-0003-4531-9173,,,Derralynn Hughes
3643.0,Reduction of a-synuclein aggregates by PIKfyve inhibition via TFEB-mediated lysosomal biogenesis in a Parkinson disease model | bioRxiv,Schapira,10.1101/2023.10.23.563557,,1.0,W4387908165,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3644.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5035922000,Pietro La Vitola,0000-0001-7415-0739,Key Personnel,Team Schapira,Pietro Vitola
3645.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5053300892,Èva M. Szegő,0000-0002-2629-2131,Key Personnel,Team Schapira,Èva Szegő
3646.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5114177669,Rita Pinto-Costa,,,,Rita Pinto-Costa
3647.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5058661760,Angela Rollar,0000-0003-1016-6912,Key Personnel,Team Schapira,Angela Rollar
3648.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5058420581,Eugenia Harbachova,0000-0001-9639-4849,Key Personnel,Team Schapira,Eugenia Harbachova
3649.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5059770430,Anthony H.V. Schapira,0000-0002-3018-3966,Lead-PI,Team Schapira,Anthony Schapira
3650.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5050850243,Ayşe Ulusoy,0000-0003-2840-3429,Key Personnel,Team Schapira,Ayşe Ulusoy
3651.0,Mitochondrial oxidant stress promotes α-synuclein aggregation and spreading in mice with mutated glucocerebrosidase,Schapira,10.1101/2024.06.13.598820,,1.0,W4399693312,A5035849217,Donato A. Di Monte,0000-0002-8296-836X,Co-PI,Team Schapira,Donato Monte
3652.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5100614696,María José Pérez,0000-0001-8842-4286,Key Personnel,Team Schapira,María Pérez
3653.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5078024953,Federico Bertoli,0000-0001-5600-1190,Key Personnel,Team Schapira,Federico Bertoli
3654.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5002880244,Hariam Raji,0000-0002-2705-8857,Key Personnel,Team Schapira,Hariam Raji
3655.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5067020549,Alicia Lam,,,,Alicia Lam
3656.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5088596026,Mariella Bosch,,,,Mariella Bosch
3657.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5016900497,Christin Weissleder,0000-0001-8858-9590,Key Personnel,Team Schapira,Christin Weissleder
3658.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5033772913,Ivan Nemazanyy,0000-0001-8080-839X,,,Ivan Nemazanyy
3659.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5021231719,Stefanie Kalb,,,,Stefanie Kalb
3660.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5083847708,Insa Hirschberg,,,,Insa Hirschberg
3661.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5087383118,Dario Brunetti,0000-0002-2740-9370,,,Dario Brunetti
3662.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5006156963,Indra Heckenbach,0000-0001-7038-4677,,,Indra Heckenbach
3663.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5069851925,Morten Scheibye‐Knudsen,0000-0002-6637-1280,,,Morten Scheibye‐Knudsen
3664.0,The mitochondrial unfolded protein response promotes senescence in human microglia by increasing S-adenosylmethionine availability for polyamine synthesis,Schapira,10.1101/2024.09.03.610925,,1.0,W4402178515,A5056933907,Michela Deleidi,0000-0003-0357-0124,Co-PI,Team Schapira,Michela Deleidi
3665.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5032196561,Sonia Donzelli,,,,Sonia Donzelli
3666.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5071630632,Sinéad A. O’Sullivan,0000-0003-1909-0803,Key Personnel,Team Schapira,Sinéad O’Sullivan
3667.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5014891788,Anne‐Laure Mahul‐Mellier,0000-0002-7830-5483,,,Anne‐Laure Mahul‐Mellier
3668.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5050850243,Ayşe Ulusoy,0000-0003-2840-3429,Key Personnel,Team Schapira,Ayşe Ulusoy
3669.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5050837148,Giuliana Fusco,0000-0002-3644-9809,,,Giuliana Fusco
3670.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5112462194,Senthil T. Kumar,,,,Senthil Kumar
3671.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5082880868,Anass Chiki,0000-0002-5675-9644,,,Anass Chiki
3672.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5027768846,Johannes Burtscher,0000-0002-2889-0151,,,Johannes Burtscher
3673.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5062732970,Manel Boussouf,,,,Manel Boussouf
3674.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5058066072,Iman Rostami,0000-0002-1344-0748,,,Iman Rostami
3675.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5078520379,Alfonso De Simone,0000-0001-8789-9546,,,Alfonso Simone
3676.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5035849217,Donato A. Di Monte,0000-0002-8296-836X,Co-PI,Team Schapira,Donato Monte
3677.0,Post-fibrillization nitration of alpha-synuclein abolishes its seeding activity and pathology formation in primary neurons and in vivo,Schapira,10.1101/2023.03.24.534149,,1.0,W4360951881,A5103249273,Hilal A. Lashuel,0000-0002-3737-1054,,,Hilal Lashuel
3678.0,Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila,Scherzer,10.1101/2022.07.26.501592,10.1002/mds.29283,1.0,W4309748707,A5008890762,Abby L. Olsen,0000-0002-7680-1758,,,Abby Olsen
3679.0,Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila,Scherzer,10.1101/2022.07.26.501592,10.1002/mds.29283,1.0,W4309748707,A5061999530,Sabrina G. Clemens,,,,Sabrina Clemens
3680.0,Nicotine-Mediated Rescue of α-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila,Scherzer,10.1101/2022.07.26.501592,10.1002/mds.29283,1.0,W4309748707,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3681.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5067787152,Yuanwei Yan,,,,Yuanwei Yan
3682.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5100381624,Xueyan Li,0000-0003-0457-7846,,,Xueyan Li
3683.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5004535291,Yu Gao,0000-0001-5090-8250,,,Yu Gao
3684.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5002377995,Sakthikumar Mathivanan,0000-0002-6647-8774,Key Personnel,Team Scherzer,Sakthikumar Mathivanan
3685.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5054021355,Linghai Kong,0000-0002-8015-5971,,,Linghai Kong
3686.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5004034878,Yunlong Tao,0000-0003-0377-7133,,,Yunlong Tao
3687.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5082505578,Yi Dong,0000-0001-9898-9571,,,Yi Dong
3688.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5100331057,Xiang Li,0000-0002-4916-524X,,,Xiang Li
3689.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5014311864,Anita Bhattacharyya,0000-0002-0360-7145,,,Anita Bhattacharyya
3690.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5100709184,Xinyu Zhao,0000-0002-5128-4424,,,Xinyu Zhao
3691.0,3D Bioprinting of Human Neural Tissues with Functional Connectivity | bioRxiv,Scherzer,10.1101/2024.01.18.576289,10.1016/j.stem.2023.12.009,1.0,W4391450102,A5101605513,Su‐Chun Zhang,,,,Su‐Chun Zhang
3692.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3693.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5042168221,Yunfei Bai,0000-0002-4088-4117,,,Yunfei Bai
3694.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5090291379,Zhixiang Liao,0000-0001-7014-5465,,,Zhixiang Liao
3695.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5036599897,David Gritsch,,,,David Gritsch
3696.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5100386602,Xiaoli Liu,0000-0003-2904-4413,,,Xiaoli Liu
3697.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5100453553,Tao Wang,0000-0002-5728-6463,,,Tao Wang
3698.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5059988595,Rebeca Borges-Monroy,0000-0001-5821-7630,,,Rebeca Borges-Monroy
3699.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5072857466,Alyssa Ehrlich,,,,Alyssa Ehrlich
3700.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5050607848,Geidy E. Serrano,0000-0002-9527-2011,Key Personnel,Team Scherzer,Geidy Serrano
3701.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3702.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5072613176,Thomas G. Beach,0000-0003-3296-6128,Key Personnel,Team Scherzer,Thomas Beach
3703.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5072613176,Thomas G. Beach,0000-0003-3296-6128,Collaborating PI,Team Voet,Thomas Beach
3704.0,Circular RNAs in the human brain are tailored to neuron identity and neuropsychiatric disease,Scherzer,10.1101/2023.04.01.535194,10.1038/s41467-023-40348-0,1.0,W4386833452,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3705.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5090309070,Vanitha Nithianandam,0000-0002-0740-0758,Key Personnel,Team Scherzer,Vanitha Nithianandam
3706.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5052272787,Hassan Bukhari,0000-0003-3328-8234,Key Personnel,Team Scherzer,Hassan Bukhari
3707.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5002405280,Matthew Leventhal,0000-0002-5995-5202,,,Matthew Leventhal
3708.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5086190348,Rachel A. Battaglia,0000-0003-3187-6964,,,Rachel Battaglia
3709.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3710.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5043876367,Ernest Fraenkel,0000-0001-9249-8181,,,Ernest Fraenkel
3711.0,Integrative analysis reveals a conserved role for the amyloid precursor protein in proteostasis during aging,Scherzer,10.1101/2023.10.06.560646,10.1038/s41467-023-42822-1,1.0,W4388288214,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3712.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5023428054,Brett K. Beaulieu‐Jones,0000-0002-6700-1468,,,Brett Beaulieu‐Jones
3713.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5015991866,Francesca Frau,,,,Francesca Frau
3714.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5066023568,Sylvie Bozzi,,,,Sylvie Bozzi
3715.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5088334273,Karen J. Chandross,0000-0002-1346-2162,,,Karen Chandross
3716.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5062886426,Michel Peterschmitt,0000-0003-4686-0412,,,Michel Peterschmitt
3717.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5015327085,Caroline Cohen,,,,Caroline Cohen
3718.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5093950713,Catherine Coulovrat,,,,Catherine Coulovrat
3719.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5100771341,Dinesh Kumar,0000-0002-6143-2507,,,Dinesh Kumar
3720.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5089922910,Mark J Kruger,,,,Mark Kruger
3721.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5061817429,Scott Lipnick,0000-0002-4271-746X,,,Scott Lipnick
3722.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5000076976,Lane Fitzsimmons,,,,Lane Fitzsimmons
3723.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5088509061,Isaac S. Kohane,0000-0003-2192-5160,,,Isaac Kohane
3724.0,Disease progression strikingly differs in research and real-world Parkinson’s populations,Scherzer,10.1101/2024.02.17.24302981,10.1038/s41531-024-00667-5,1.0,W4392740577,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3725.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5004034878,Yunlong Tao,0000-0003-0377-7133,,,Yunlong Tao
3726.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5100381627,Xueyan Li,0000-0003-2251-710X,,,Xueyan Li
3727.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5102885505,Qiping Dong,0000-0003-4668-9264,,,Qiping Dong
3728.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5054021355,Linghai Kong,0000-0002-8015-5971,,,Linghai Kong
3729.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5012208420,Andrew J. Petersen,0000-0002-3626-816X,,,Andrew Petersen
3730.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5067787152,Yuanwei Yan,,,,Yuanwei Yan
3731.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5078312537,Ke Xu,0000-0002-0621-4507,,,Ke Xu
3732.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5092421446,Seth R. T. Zima,,,,Seth Zima
3733.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5100767636,Yanru Li,0000-0002-8048-7220,,,Yanru Li
3734.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5040143457,Danielle Schmidt,0000-0001-7131-9738,,,Danielle Schmidt
3735.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5023140063,Melvin Ayala,0000-0002-8669-1046,,,Melvin Ayala
3736.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5002377995,Sakthikumar Mathivanan,0000-0002-6647-8774,Key Personnel,Team Scherzer,Sakthikumar Mathivanan
3737.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5088177310,André M. M. Sousa,0000-0003-1740-5066,,,André Sousa
3738.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5035294678,Qiang Chang,0000-0002-7625-2170,,,Qiang Chang
3739.0,Generation of locus coeruleus norepinephrine neurons from human pluripotent stem cells | Nature Biotechnology,Scherzer,missing,10.1038/s41587-023-01977-4,1.0,W4388728640,A5030394012,Su‐Chun Zhang,,Co-PI,Team Scherzer,Su‐Chun Zhang
3740.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3741.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5100634700,Xiaoqi Li,0000-0002-4125-5726,,,Xiaoqi Li
3742.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5049831541,Tzuu-Wang Chang,,,,Tzuu-Wang Chang
3743.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3744.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5073763243,Scott T. Weiss,0000-0001-7196-303X,,,Scott Weiss
3745.0,powerEQTL: An R package and shiny application for sample size and power calculation of bulk tissue and single-cell eQTL analysis,Scherzer,10.1101/2020.12.15.422954,10.1093/bioinformatics/btab385,1.0,W3162394046,A5052479679,Weiliang Qiu,0000-0002-9155-6957,,,Weiliang Qiu
3746.0,Pathways controlling neurotoxicity and proteostasis in mitochondrial complex I deficiency | bioRxiv,Scherzer,10.1101/2024.01.08.574634,10.1093/hmg/ddae018,1.0,W4391592420,A5090309070,Vanitha Nithianandam,0000-0002-0740-0758,Key Personnel,Team Scherzer,Vanitha Nithianandam
3747.0,Pathways controlling neurotoxicity and proteostasis in mitochondrial complex I deficiency | bioRxiv,Scherzer,10.1101/2024.01.08.574634,10.1093/hmg/ddae018,1.0,W4391592420,A5002011992,Souvarish Sarkar,0000-0002-7384-0508,,,Souvarish Sarkar
3748.0,Pathways controlling neurotoxicity and proteostasis in mitochondrial complex I deficiency | bioRxiv,Scherzer,10.1101/2024.01.08.574634,10.1093/hmg/ddae018,1.0,W4391592420,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3749.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5052272787,Hassan Bukhari,0000-0003-3328-8234,Key Personnel,Team Scherzer,Hassan Bukhari
3750.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5090309070,Vanitha Nithianandam,0000-0002-0740-0758,Key Personnel,Team Scherzer,Vanitha Nithianandam
3751.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5086190348,Rachel A. Battaglia,0000-0003-3187-6964,,,Rachel Battaglia
3752.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5038972728,Anthony Cicalo,,,,Anthony Cicalo
3753.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5002011992,Souvarish Sarkar,0000-0002-7384-0508,,,Souvarish Sarkar
3754.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5077922022,Aram Comjean,0000-0003-4125-0703,,,Aram Comjean
3755.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5025902765,Yanhui Hu,0000-0003-1494-1402,,,Yanhui Hu
3756.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5002405280,Matthew Leventhal,0000-0002-5995-5202,,,Matthew Leventhal
3757.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3758.0,Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a Drosophila knock-in tauopathy model,Scherzer,10.1101/2024.02.02.578624,10.1101/gr.278576.123,1.0,W4394676908,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3759.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5079331697,Ali Fathi,0000-0002-1570-8883,,,Ali Fathi
3760.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5002377995,Sakthikumar Mathivanan,0000-0002-6647-8774,Key Personnel,Team Scherzer,Sakthikumar Mathivanan
3761.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5054021355,Linghai Kong,0000-0002-8015-5971,,,Linghai Kong
3762.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5012208420,Andrew J. Petersen,0000-0002-3626-816X,,,Andrew Petersen
3763.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5035248560,Cole R. K. Harder,0000-0002-8967-9114,,,Cole Harder
3764.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5091817768,Jasper Block,,,,Jasper Block
3765.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5014190768,Julia M. Miller,,,,Julia Miller
3766.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5014311864,Anita Bhattacharyya,0000-0002-0360-7145,,,Anita Bhattacharyya
3767.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5053240500,Daifeng Wang,0000-0001-9190-3704,,,Daifeng Wang
3768.0,Chemically induced senescence in human stem cell‐derived neurons promotes phenotypic presentation of neurodegeneration,Scherzer,10.1101/2021.07.11.451956,10.1111/acel.13541,1.0,W4200380426,A5030394012,Su‐Chun Zhang,,Co-PI,Team Scherzer,Su‐Chun Zhang
3769.0,α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin,Scherzer,10.1101/2023.06.02.543481,10.1523/JNEUROSCI.1922-22.2022,1.0,W4317384288,A5071891906,Gali Maor,,,,Gali Maor
3770.0,α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin,Scherzer,10.1101/2023.06.02.543481,10.1523/JNEUROSCI.1922-22.2022,1.0,W4317384288,A5051469930,Ronald R. Dubreuil,,,,Ronald Dubreuil
3771.0,α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin,Scherzer,10.1101/2023.06.02.543481,10.1523/JNEUROSCI.1922-22.2022,1.0,W4317384288,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
3772.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5008890762,Abby L. Olsen,0000-0002-7680-1758,,,Abby Olsen
3773.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5107847656,Joseph J. Locascio,,Key Personnel,Team Scherzer,Joseph Locascio
3774.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5018300263,Idil Tuncali,0000-0001-7437-285X,,,Idil Tuncali
3775.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5091698794,Nada Laroussi,,,,Nada Laroussi
3776.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5052533842,Elena Abatzis,,,,Elena Abatzis
3777.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5066790748,Polina Kamenskaya,,,,Polina Kamenskaya
3778.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5024908746,Yuliya I. Kuras,0000-0001-5388-3669,,,Yuliya Kuras
3779.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5089904167,Tom Yi,,,,Tom Yi
3780.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5083282772,Aleksandar Videnović,0000-0002-9237-1516,Collaborator,Team Hafler,Aleksandar Videnović
3781.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5111596943,Michael T. Hayes,,,,Michael Hayes
3782.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5021042548,Gary P. H. Ho,0000-0001-7004-8630,,,Gary Ho
3783.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5022402858,Jordan Paulson,,,,Jordan Paulson
3784.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5055136563,Vikram Khurana,0000-0002-4018-5527,Co-PI,Team Studer,Vikram Khurana
3785.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5025328947,Todd Herrington,0000-0001-9489-7418,,,Todd Herrington
3786.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5068688487,Bradley T. Hyman,0000-0002-7959-9401,,,Bradley Hyman
3787.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5087935119,Dennis J. Selkoe,0000-0001-8846-9767,,,Dennis Selkoe
3788.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5111694111,John H. Growdon,,,,John Growdon
3789.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5039757131,Stephen N. Gomperts,0000-0002-0083-0077,,,Stephen Gomperts
3790.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5023596841,Trond Riise,0000-0001-9644-5140,,,Trond Riise
3791.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5041777746,Michael A. Schwarzschild,0000-0001-6019-8280,Co-PI,Team Chen,Michael Schwarzschild
3792.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5003702843,Albert Y. Hung,0000-0003-3658-571X,,,Albert Hung
3793.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5062713774,Anne‐Marie Wills,0000-0002-0901-4711,,,Anne‐Marie Wills
3794.0,Towards a phenome-wide view of Parkinson’s disease,Scherzer,10.1101/2022.02.01.22270276,,1.0,W4210801458,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3795.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5092920123,Maggie J. Sodders,0000-0001-6009-1264,,,Maggie Sodders
3796.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5029384804,Julián Ávila-Pacheco,0000-0001-9388-3946,,,Julián Ávila-Pacheco
3797.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5060362786,E. Okorie,0009-0003-6600-3677,,,E. Okorie
3798.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5100763967,Ming Shen,,,,Ming Shen
3799.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5104152324,Namrata Kumari,0000-0002-3239-7220,,,Namrata Kumari
3800.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5098666887,Archana Marathi,,,,Archana Marathi
3801.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5111197774,Mehek Lakhani,,,,Mehek Lakhani
3802.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5045264328,Kevin Bullock,0000-0002-6494-7290,,,Kevin Bullock
3803.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5091441079,Kerry A. Pierce,0000-0001-8078-640X,,,Kerry Pierce
3804.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5052652125,Courtney Dennis,0000-0002-3565-3904,,,Courtney Dennis
3805.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5047843651,Sarah Jeanfavre,,,,Sarah Jeanfavre
3806.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5002011992,Souvarish Sarkar,0000-0002-7384-0508,,,Souvarish Sarkar
3807.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3808.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5057221073,Clary B. Clish,0000-0001-8259-9245,,,Clary Clish
3809.0,Genetic screening and metabolomics identify glial adenosine metabolism as a therapeutic target in Parkinson’s disease,Scherzer,10.1101/2024.05.15.594309,,1.0,W4396973832,A5008890762,Abby L. Olsen,0000-0002-7680-1758,,,Abby Olsen
3810.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5014283519,Ruifeng Hu,0000-0001-5549-3082,Key Personnel,Team Scherzer,Ruifeng Hu
3811.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5111236143,Ruoxuan Wang,,,,Ruoxuan Wang
3812.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5101720692,Jie Yuan,0000-0002-3857-4152,Key Personnel,Team Scherzer,Jie Yuan
3813.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5000457670,Zechuan Lin,0000-0003-2270-5194,Key Personnel,Team Scherzer,Zechuan Lin
3814.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5019518841,Elizabeth Hutchins,0000-0003-2543-0798,,,Elizabeth Hutchins
3815.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5078256109,Barry Landin,,,,Barry Landin
3816.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5090291379,Zhixiang Liao,0000-0001-7014-5465,,,Zhixiang Liao
3817.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5036062144,Ganqiang Liu,0000-0002-1921-9542,,,Ganqiang Liu
3818.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3819.0,Transcriptional pathobiology and multi-omics predictors for Parkinson’s disease,Scherzer,10.1101/2024.06.18.599639,,1.0,W4399907545,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3820.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5017886169,Sean Simmons,,Key Personnel,Team Scherzer,Sean Simmons
3821.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5080948604,Xian Adiconis,0000-0002-4052-2503,,,Xian Adiconis
3822.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5086382225,Nathan Haywood,0000-0003-2213-5080,,,Nathan Haywood
3823.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5063059245,Jacob J. Parker,0000-0001-9425-6418,Key Personnel,Team Scherzer,Jacob Parker
3824.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5000457670,Zechuan Lin,0000-0003-2270-5194,Key Personnel,Team Scherzer,Zechuan Lin
3825.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5090291379,Zhixiang Liao,0000-0001-7014-5465,,,Zhixiang Liao
3826.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5018300263,Idil Tuncali,0000-0001-7437-285X,,,Idil Tuncali
3827.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5085440029,Aziz Al’Khafaji,0000-0002-4677-5667,,,Aziz Al’Khafaji
3828.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5111294243,Asa Shin,,,,Asa Shin
3829.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5034446085,Karthik A. Jagadeesh,0000-0002-0957-812X,,,Karthik Jagadeesh
3830.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5080377515,Kirk Gosik,0000-0001-7612-2176,,,Kirk Gosik
3831.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5023411745,Michael Gatzen,0000-0001-5390-0705,,,Michael Gatzen
3832.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5065665626,Jonathan T. Smith,,,,Jonathan Smith
3833.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5009482508,Daniel N. El-Kodsi,0000-0002-8896-0043,Key Personnel,Team Studer,Daniel El-Kodsi
3834.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5024908746,Yuliya I. Kuras,0000-0001-5388-3669,,,Yuliya Kuras
3835.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5055928333,Clare Baecher‐Allan,0000-0003-2405-8525,,,Clare Baecher‐Allan
3836.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5050607848,Geidy E. Serrano,0000-0002-9527-2011,Key Personnel,Team Scherzer,Geidy Serrano
3837.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5072613176,Thomas G. Beach,0000-0003-3296-6128,Key Personnel,Team Scherzer,Thomas Beach
3838.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5072613176,Thomas G. Beach,0000-0003-3296-6128,Collaborating PI,Team Voet,Thomas Beach
3839.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5063557800,Kiran Garimella,0000-0002-6212-5736,,,Kiran Garimella
3840.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5071415389,Orit Rozenblatt–Rosen,0000-0001-6313-3570,,,Orit Rozenblatt–Rosen
3841.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5004067604,Aviv Regev,0000-0003-3293-3158,,,Aviv Regev
3842.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
3843.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
3844.0,Experimental and Computational Methods for Allelic Imbalance Analysis from Single-Nucleus RNA-seq Data,Scherzer,10.1101/2024.08.13.607784,,1.0,W4401669789,A5024425176,Joshua Z. Levin,0000-0002-0170-3598,Co-PI,Team Scherzer,Joshua Levin
3845.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5071045440,Jean-Louis Parmasad,0000-0001-5013-2317,,,Jean-Louis Parmasad
3846.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5057641857,Konrad M. Ricke,0000-0002-9425-0603,Key Personnel,Team Schlossmacher,Konrad Ricke
3847.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5060016186,Benjamin Nguyen,0000-0001-5485-0308,Key Personnel,Team Schlossmacher,Benjamin Nguyen
3848.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5079997009,Morgan G. Stykel,0000-0002-4799-4220,,,Morgan Stykel
3849.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5079690501,Brodie Buchner-Duby,,,,Brodie Buchner-Duby
3850.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5058209602,Amanda S. Bruce,,,,Amanda Bruce
3851.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5037659953,Haley Geertsma,0000-0003-2434-5057,,,Haley Geertsma
3852.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5005590576,Eric Lian,0000-0002-2147-5422,,,Eric Lian
3853.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5077923670,Nathalie A. Lengacher,0000-0002-2536-1895,Key Personnel,Team Schlossmacher,Nathalie Lengacher
3854.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5079871962,Steve Callaghan,0000-0001-6692-4060,Key Personnel,Team Schlossmacher,Steve Callaghan
3855.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5038045962,Alvin Joselin,0000-0002-9010-0421,,,Alvin Joselin
3856.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3857.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3858.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5030159931,William L. Stanford,0000-0002-5813-8016,,,William Stanford
3859.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5038011017,Jiyan Ma,0000-0001-7150-1898,,,Jiyan Ma
3860.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5072622786,Patrik Brundin,0000-0003-2924-5186,,,Patrik Brundin
3861.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5004497226,Scott D. Ryan,0000-0001-9829-4649,,,Scott Ryan
3862.0,Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy,Schlossmacher,10.1101/2022.05.02.490309,10.1038/s41419-024-06534-8,1.0,W4393941511,A5054577159,Maxime W.C. Rousseaux,0000-0002-2737-6193,Co-PI,Team Schlossmacher,Maxime Rousseaux
3863.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5037659953,Haley Geertsma,0000-0003-2434-5057,,,Haley Geertsma
3864.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5047731142,Zoe Fisk,0000-0002-2185-0819,,,Zoe Fisk
3865.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5093027876,Lillian Sauline,,,,Lillian Sauline
3866.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5023271415,Alice Prigent,0000-0002-7270-4512,,,Alice Prigent
3867.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5091973419,Kevin Kurgat,0000-0003-3237-7390,Key Personnel,Team Biederer,Kevin Kurgat
3868.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5079871962,Steve Callaghan,0000-0001-6692-4060,Key Personnel,Team Schlossmacher,Steve Callaghan
3869.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5047948555,Benjamin R. Arenkiel,0000-0001-9047-2420,Co-PI,Team Schlossmacher,Benjamin Arenkiel
3870.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3871.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3872.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5036052976,Christine Stadelmann,0000-0003-1766-5458,Co-PI,Team Schlossmacher,Christine Stadelmann
3873.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3874.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Biederer,Michael Henderson
3875.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Lee,Michael Henderson
3876.0,A topographical atlas of αSyn dosage and cell-type expression in the mouse brain and periphery | bioRxiv,Schlossmacher,10.1101/2023.10.05.559770,10.1038/s41531-024-00672-8,1.0,W4392963971,A5054577159,Maxime W.C. Rousseaux,0000-0002-2737-6193,Co-PI,Team Schlossmacher,Maxime Rousseaux
3877.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5037659953,Haley Geertsma,0000-0003-2434-5057,,,Haley Geertsma
3878.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5066671830,Terry R. Suk,0000-0001-7694-4823,,,Terry Suk
3879.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5057641857,Konrad M. Ricke,0000-0002-9425-0603,Key Personnel,Team Schlossmacher,Konrad Ricke
3880.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5086488677,Kyra Horsthuis,,,,Kyra Horsthuis
3881.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5071045440,Jean-Louis Parmasad,0000-0001-5013-2317,,,Jean-Louis Parmasad
3882.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5047731142,Zoe Fisk,0000-0002-2185-0819,,,Zoe Fisk
3883.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5079871962,Steve Callaghan,0000-0001-6692-4060,Key Personnel,Team Schlossmacher,Steve Callaghan
3884.0,"Constitutive nuclear accumulation of endogenous alpha-synuclein in mice causes motor impairment and cortical dysfunction, independent of protein aggregation",Schlossmacher,10.1101/2021.10.13.464123,10.1093/hmg/ddac035,1.0,W4213320742,A5054577159,Maxime W.C. Rousseaux,0000-0002-2737-6193,Co-PI,Team Schlossmacher,Maxime Rousseaux
3885.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5077923670,Nathalie A. Lengacher,0000-0002-2536-1895,Key Personnel,Team Schlossmacher,Nathalie Lengacher
3886.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3887.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5013766186,Ann-Kristin Jochum,0000-0002-6981-1384,,,Ann-Kristin Jochum
3888.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5086570784,Jonas Franz,0000-0001-7523-6622,Key Personnel,Team Schlossmacher,Jonas Franz
3889.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5064134027,Omar Hasan Ali,0000-0001-5185-7520,Key Personnel,Team Schlossmacher,Omar Ali
3890.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5087984672,Lukas Flatz,0000-0001-9683-8390,,,Lukas Flatz
3891.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5019107852,Wolfram Jochum,0000-0001-6170-2020,,,Wolfram Jochum
3892.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5114228209,Josef Penninger,,Collaborating PI,Team Schlossmacher,Josef Penninger
3893.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5047948555,Benjamin R. Arenkiel,0000-0001-9047-2420,Co-PI,Team Schlossmacher,Benjamin Arenkiel
3894.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5004947640,Zhandong Liu,0000-0002-7608-0831,Collaborating PI,Team Schlossmacher,Zhandong Liu
3895.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3896.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5059310975,Josef Penninger,0000-0002-8194-3777,Collaborating PI,Team Schlossmacher,Josef Penninger
3897.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5054577159,Maxime W.C. Rousseaux,0000-0002-2737-6193,Co-PI,Team Schlossmacher,Maxime Rousseaux
3898.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5091123067,Armen Saghatelyan,0000-0003-4962-0465,Collaborating PI,Team Schlossmacher,Armen Saghatelyan
3899.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5089514184,Natalina Salmaso,0000-0002-9661-5194,Collaborating PI,Team Schlossmacher,Natalina Salmaso
3900.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5036052976,Christine Stadelmann,0000-0003-1766-5458,Co-PI,Team Schlossmacher,Christine Stadelmann
3901.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3902.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3903.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5090917194,John Woulfe,0000-0002-7382-6343,Collaborating PI,Team Schlossmacher,John Woulfe
3904.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5036052976,Christine Stadelmann,0000-0003-1766-5458,Co-PI,Team Schlossmacher,Christine Stadelmann
3905.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5090917194,John Woulfe,0000-0002-7382-6343,Collaborating PI,Team Schlossmacher,John Woulfe
3906.0,Neuropathological assessment of the olfactory bulb and tract in individuals with COVID-19,Schlossmacher,10.1101/2023.12.18.572180,10.1186/s40478-024-01761-8,1.0,W4396622582,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3907.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3908.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5002039998,Juan Li,0000-0003-1565-2477,Key Personnel,Team Schlossmacher,Juan Li
3909.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5070826694,Sebastian Schade,0000-0002-6316-6804,,,Sebastian Schade
3910.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5008858542,Sandrina Weber,0000-0001-5713-2141,,,Sandrina Weber
3911.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5022630766,Claudia Trenkwalder,0000-0001-6407-1199,,,Claudia Trenkwalder
3912.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5038754906,Luis Concha‐Marambio,0000-0002-9454-8389,,,Luis Concha‐Marambio
3913.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3914.0,Persistent Hyposmia as Surrogate for a-Synuclein-Linked Brain Pathology,Schlossmacher,10.1101/2023.12.19.23300164,,1.0,W4390008521,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3915.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5025948444,Jakob Reichmann,0000-0002-6597-1831,,,Jakob Reichmann
3916.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5086570784,Jonas Franz,0000-0001-7523-6622,Key Personnel,Team Schlossmacher,Jonas Franz
3917.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5081825312,Marina Eckermann,0000-0001-6418-4310,,,Marina Eckermann
3918.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5113765051,Katja Schulz,,,,Katja Schulz
3919.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5110690838,Brit Mollenhauer,,Co-PI,Team Schlossmacher,Brit Mollenhauer
3920.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5036052976,Christine Stadelmann,0000-0003-1766-5458,Co-PI,Team Schlossmacher,Christine Stadelmann
3921.0,3D imaging of neuronal inclusions and protein aggregates in human neurodegeneration by multiscale X-ray phase-contrast tomography,Schlossmacher,10.1101/2024.03.26.24304193,,1.0,W4393214864,A5010972337,Tim Salditt,0000-0003-4636-0813,,,Tim Salditt
3922.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5002039998,Juan Li,0000-0003-1565-2477,Key Personnel,Team Schlossmacher,Juan Li
3923.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5113327390,Kelsey Grimes,,,,Kelsey Grimes
3924.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5026894888,Joseph Saade,,,,Joseph Saade
3925.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5080762163,Julianna J. Tomlinson,0000-0003-2997-5162,Project Manager,Team Schlossmacher,Julianna Tomlinson
3926.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5067113888,Tiago Mestre,0000-0002-6973-7479,,,Tiago Mestre
3927.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5070826694,Sebastian Schade,0000-0002-6316-6804,,,Sebastian Schade
3928.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5008858542,Sandrina Weber,0000-0001-5713-2141,,,Sandrina Weber
3929.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5010902538,Mohammed Dakna,0000-0001-8341-0360,,,Mohammed Dakna
3930.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5060437091,Tamara Wicke,0000-0001-9779-4692,,,Tamara Wicke
3931.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5028000508,Elisabeth Lang,0000-0001-5748-1376,,,Elisabeth Lang
3932.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5022630766,Claudia Trenkwalder,0000-0001-6407-1199,,,Claudia Trenkwalder
3933.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5089514184,Natalina Salmaso,0000-0002-9661-5194,Collaborating PI,Team Schlossmacher,Natalina Salmaso
3934.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5088691231,Andrew Frank,0009-0009-2368-2538,,,Andrew Frank
3935.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5007444643,Tim Ramsay,0000-0001-8478-8170,,,Tim Ramsay
3936.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5034701753,Douglas G. Manuel,0000-0003-0912-0845,,,Douglas Manuel
3937.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5082185657,Brit Mollenhauer,0000-0001-8437-3645,Co-PI,Team Schlossmacher,Brit Mollenhauer
3938.0,"Development of a Simplified Smell Test to Identify Patients with Typical Parkinson’s as Informed by Multiple Cohorts, Machine Learning and External Validation",Schlossmacher,10.1101/2024.08.09.24311696,,1.0,W4401450240,A5000268173,Michael G. Schlossmacher,0000-0002-0394-0300,Lead-PI,Team Schlossmacher,Michael Schlossmacher
3939.0,Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration,"Senescence WG (Studer, Mobley, Lee)",NA_review,10.1038/s43587-024-00586-3,0.0,W4392356353,A5040956324,Isabelle R. de Luzy,0000-0003-0672-0829,,,Isabelle Luzy
3940.0,Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration,"Senescence WG (Studer, Mobley, Lee)",NA_review,10.1038/s43587-024-00586-3,0.0,W4392356353,A5021234825,Michael K. Lee,0000-0001-5865-9682,,,Michael Lee
3941.0,Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration,"Senescence WG (Studer, Mobley, Lee)",NA_review,10.1038/s43587-024-00586-3,0.0,W4392356353,A5009879178,William C. Mobley,0000-0002-6408-9548,Co-PI,Team Mobley,William Mobley
3942.0,Lessons from inducible pluripotent stem cell models on neuronal senescence in aging and neurodegeneration,"Senescence WG (Studer, Mobley, Lee)",NA_review,10.1038/s43587-024-00586-3,0.0,W4392356353,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
3943.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5011836535,Mingyi Xia,0000-0003-0861-419X,,,Mingyi Xia
3944.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5056817782,Busra Nur Agca,0000-0003-1145-9899,,,Busra Agca
3945.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5103221437,Tomoko Yoshida,0000-0003-3961-0095,,,Tomoko Yoshida
3946.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5005054739,Jiwon Choi,0000-0002-2801-7854,,,Jiwon Choi
3947.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5045944438,Usamma Amjad,0000-0001-5455-3207,Key Personnel,Team Strick,Usamma Amjad
3948.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5000246911,Kade Bose,0000-0002-0593-0392,,,Kade Bose
3949.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5025434731,Nikol Keren,0000-0001-9071-9710,,,Nikol Keren
3950.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5008841667,Shahar Zukerman,,,,Shahar Zukerman
3951.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5061683153,Michael J. Cima,0000-0003-2379-6139,,,Michael Cima
3952.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5081686751,Ann M. Graybiel,0000-0002-4326-7720,,,Ann Graybiel
3953.0,"Scalable, flexible carbon fiber electrode thread arrays for three-dimensional spatial profiling of neurochemical activity in deep brain structures of rodents",Strick,10.1101/2023.04.15.537033,10.1016/j.bios.2023.115625,1.0,W4386034921,A5035254479,Helen N. Schwerdt,,Co-PI,Team Strick,Helen Schwerdt
3954.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5062343908,Lucy Liang,0009-0003-5462-832X,,,Lucy Liang
3955.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5092044785,Isabela Zimmermann Rollin,0009-0005-0048-3967,,,Isabela Rollin
3956.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5076743721,Aydin Alikaya,0009-0003-8876-5103,Key Personnel,Team Strick,Aydin Alikaya
3957.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5102962580,Jonathan Ho,0009-0007-9463-6884,,,Jonathan Ho
3958.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5074796537,Tales Santini,0000-0003-4533-9190,,,Tales Santini
3959.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5091037945,Andreea C. Bostan,0000-0003-4376-3836,Project Manager,Team Strick,Andreea Bostan
3960.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5035254479,Helen N. Schwerdt,,Co-PI,Team Strick,Helen Schwerdt
3961.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5070330500,William R. Stauffer,0000-0003-1031-8824,Co-PI,Team Strick,William Stauffer
3962.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5074729401,Tamer S. Ibrahim,0000-0001-6738-5855,,,Tamer Ibrahim
3963.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5018322134,Elvira Pirondini,0000-0002-8078-3951,,,Elvira Pirondini
3964.0,An open-source MRI compatible frame for multimodal presurgical mapping in macaque and capuchin monkeys,Strick,10.1101/2024.02.17.580767,10.1016/j.jneumeth.2024.110133,1.0,W4394014279,A5103180866,David J. Schaeffer,0000-0003-2201-7092,Collaborating PI,Team Strick,David Schaeffer
3965.0,Detecting rhythmic spiking through the power spectra of point process model residuals,Strick,10.1101/2023.09.08.556120,10.1088/1741-2552/ad6188,1.0,W4400482301,A5088047514,Karin Cox,0000-0002-5418-0508,Key Personnel,Team Strick,Karin Cox
3966.0,Detecting rhythmic spiking through the power spectra of point process model residuals,Strick,10.1101/2023.09.08.556120,10.1088/1741-2552/ad6188,1.0,W4400482301,A5079873167,Daisuke Kase,0000-0001-6787-5862,Key Personnel,Team Strick,Daisuke Kase
3967.0,Detecting rhythmic spiking through the power spectra of point process model residuals,Strick,10.1101/2023.09.08.556120,10.1088/1741-2552/ad6188,1.0,W4400482301,A5051806341,Taieb Znati,0000-0002-9389-3033,,,Taieb Znati
3968.0,Detecting rhythmic spiking through the power spectra of point process model residuals,Strick,10.1101/2023.09.08.556120,10.1088/1741-2552/ad6188,1.0,W4400482301,A5018445297,Robert S. Turner,0000-0002-6074-4365,Co-PI,Team Strick,Robert Turner
3969.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5027803927,Jordan L. Manes,0000-0001-6596-4423,,,Jordan Manes
3970.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5017228751,Latané Bullock,0000-0003-1257-7221,,,Latané Bullock
3971.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5083906112,Andrew M. Meier,0000-0002-2125-4179,,,Andrew Meier
3972.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5018445297,Robert S. Turner,0000-0002-6074-4365,Co-PI,Team Strick,Robert Turner
3973.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5027666885,R. Mark Richardson,0000-0003-2620-7387,,,R. Richardson
3974.0,A neurocomputational view of the effects of Parkinson’s disease on speech production,Strick,NA_Review,10.3389/fnhum.2024.1383714,0.0,W4396934609,A5025328957,Frank H. Guenther,0000-0003-1161-1555,,,Frank Guenther
3975.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5089278299,Neil M. Dundon,0000-0001-6246-1775,Key Personnel,Team Strick,Neil Dundon
3976.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5018083960,Elizabeth Rizor,0000-0002-5833-4471,Key Personnel,Team Strick,Elizabeth Rizor
3977.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5081162895,Joanne Stasiak,0000-0003-3854-345X,Key Personnel,Team Strick,Joanne Stasiak
3978.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5055333965,Jingyi Wang,0000-0002-7903-0952,Key Personnel,Team Strick,Jingyi Wang
3979.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5099421945,Kiana Sabugo,,,,Kiana Sabugo
3980.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5099421946,Christina Villaneuva,,,,Christina Villaneuva
3981.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5099421947,Parker Barandon,,,,Parker Barandon
3982.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5091037945,Andreea C. Bostan,0000-0003-4376-3836,Project Manager,Team Strick,Andreea Bostan
3983.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5021968379,Regina C. Lapate,0000-0002-1835-2309,Collaborating PI,Team Strick,Regina Lapate
3984.0,Dissociation of novel open loop from ventral putamen to motor areas from classic closed loop in humans II: task-based function,Strick,10.1101/2024.06.18.599622,,1.0,W4399929404,A5082140726,Scott T. Grafton,0000-0003-4015-3151,Co-PI,Team Strick,Scott Grafton
3985.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5018083960,Elizabeth Rizor,0000-0002-5833-4471,Key Personnel,Team Strick,Elizabeth Rizor
3986.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5089278299,Neil M. Dundon,0000-0001-6246-1775,Key Personnel,Team Strick,Neil Dundon
3987.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5055333965,Jingyi Wang,0000-0002-7903-0952,Key Personnel,Team Strick,Jingyi Wang
3988.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5081162895,Joanne Stasiak,0000-0003-3854-345X,Key Personnel,Team Strick,Joanne Stasiak
3989.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5113359616,Taylor L Li,,,,Taylor Li
3990.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5091037945,Andreea C. Bostan,0000-0003-4376-3836,Project Manager,Team Strick,Andreea Bostan
3991.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5021968379,Regina C. Lapate,0000-0002-1835-2309,Collaborating PI,Team Strick,Regina Lapate
3992.0,Dissociation of putative open loop circuit from ventral putamen to motor cortical areas in humans I: high-resolution connectomics,Strick,10.1101/2024.08.28.610129,,1.0,W4402077132,A5082140726,Scott T. Grafton,0000-0003-4015-3151,Co-PI,Team Strick,Scott Grafton
3993.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5079873167,Daisuke Kase,0000-0001-6787-5862,Key Personnel,Team Strick,Daisuke Kase
3994.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5090851725,Andrew J. Zimnik,0000-0002-8313-2476,,,Andrew Zimnik
3995.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5101702818,Han Yan,0000-0001-7570-3884,,,Han Yan
3996.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5039075900,D. Harsch,0000-0001-6267-2871,Key Personnel,Team Strick,D. Harsch
3997.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5033135125,Sarah Bacha,,,,Sarah Bacha
3998.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5088047514,Karin Cox,0000-0002-5418-0508,Key Personnel,Team Strick,Karin Cox
3999.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5091037945,Andreea C. Bostan,0000-0003-4376-3836,Project Manager,Team Strick,Andreea Bostan
4000.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5027666885,R. Mark Richardson,0000-0003-2620-7387,,,R. Richardson
4001.0,Movement-related activity in the internal globus pallidus of the parkinsonian macaque,Strick,10.1101/2024.08.29.610310,,1.0,W4402049473,A5018445297,Robert S. Turner,0000-0002-6074-4365,Co-PI,Team Strick,Robert Turner
4002.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4003.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5051289855,Yoland Smith,0000-0002-8700-878X,Co-PI,Team Wichmann,Yoland Smith
4004.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5082122443,William W. Lytton,0000-0002-3727-2849,,,William Lytton
4005.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5082140726,Scott T. Grafton,0000-0003-4015-3151,Co-PI,Team Strick,Scott Grafton
4006.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5038017663,Rosa M. Villalba,0000-0001-6156-3606,Key Personnel,Team Wichmann,Rosa Villalba
4007.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5022089750,Gunasingh Masilamoni,0000-0003-2813-1195,Key Personnel,Team Wichmann,Gunasingh Masilamoni
4008.0,Dysfunction of Motor Cortices in Parkinson’s disease,"Strick, Wichmann",NA_Review,10.1093/cercor/bhae294,0.0,W4401103245,A5042569468,Thomas Wichmann,0000-0002-2751-9545,Lead-PI,Team Wichmann,Thomas Wichmann
4009.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5041870481,Erinc Hallacli,0000-0002-5850-6974,,,Erinc Hallacli
4010.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5083357729,Can Kayatekin,0000-0002-4367-9645,,,Can Kayatekin
4011.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5038328241,Sumaiya Nazeen,,Key Personnel,Team Studer,Sumaiya Nazeen
4012.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5003203426,Xiou H. Wang,0000-0003-3569-3073,,,Xiou Wang
4013.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5030457951,Zoe Sheinkopf,,,,Zoe Sheinkopf
4014.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5038490590,Shubhangi Sathyakumar,0000-0002-5115-6254,,,Shubhangi Sathyakumar
4015.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5002011992,Souvarish Sarkar,0000-0002-7384-0508,,,Souvarish Sarkar
4016.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5047830370,Xin Jiang,0000-0002-7288-8278,,,Xin Jiang
4017.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5053690577,Xianjun Dong,0000-0002-8052-9320,Co-PI,Team Scherzer,Xianjun Dong
4018.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5048107151,Roberto Di Maio,0000-0003-2162-1781,,,Roberto Maio
4019.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5100757620,Wen Wang,0000-0002-5812-6744,,,Wen Wang
4020.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5042674015,Matthew T. Keeney,0000-0003-4968-3722,,,Matthew Keeney
4021.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5069094037,Daniel Felsky,0000-0003-1831-9848,,,Daniel Felsky
4022.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5052184376,Jackson Sandoe,,,,Jackson Sandoe
4023.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5037167340,Aazam Vahdatshoar,,,,Aazam Vahdatshoar
4024.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5026162401,Namrata D. Udeshi,0000-0001-5312-1402,,,Namrata Udeshi
4025.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5015184631,D.R. Mani,0000-0003-3914-133X,,,D.R. Mani
4026.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5036255260,Steven A. Carr,0000-0002-7203-4299,,,Steven Carr
4027.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5108447414,Susan Lindquist,,,,Susan Lindquist
4028.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5049324919,Philip L. De Jager,0000-0002-8057-2505,,,Philip Jager
4029.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5087589263,David P. Bartel,0000-0002-3872-2856,,,David Bartel
4030.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5022226374,Chad L. Myers,0000-0002-1026-5972,,,Chad Myers
4031.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5016806788,J. Timothy Greenamyre,0000-0003-3468-7878,,,J. Greenamyre
4032.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
4033.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5068462201,Shamil Sunyaev,0000-0001-5715-5677,,,Shamil Sunyaev
4034.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5037236878,Chee Yeun Chung,0000-0002-5515-650X,,,Chee Chung
4035.0,The Parkinson's disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability,Studer,missing,10.1016/j.cell.2022.05.008,1.0,W4281832698,A5055136563,Vikram Khurana,0000-0002-4018-5527,Co-PI,Team Studer,Vikram Khurana
4036.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5100670572,Tae Wan Kim,0000-0002-0831-6881,,,Tae Kim
4037.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5029736315,So Yeon Koo,0000-0001-8634-7643,,,So Koo
4038.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5064249491,Markus Rießland,0000-0003-2592-5045,,,Markus Rießland
4039.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5025716602,Fayzan Chaudhry,0000-0002-4295-8570,,,Fayzan Chaudhry
4040.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5001504885,Benjamin Kolisnyk,0000-0003-3990-0340,,,Benjamin Kolisnyk
4041.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5101854464,Hyunwoo Cho,0000-0003-3166-585X,,,Hyunwoo Cho
4042.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5091301746,Marco Russo,0000-0002-0550-0608,,,Marco Russo
4043.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5082319537,Nathalie Saurat,0000-0002-6439-5166,Key Personnel,Team Studer,Nathalie Saurat
4044.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5042323995,Sanjoy Mehta,0009-0006-8991-8425,,,Sanjoy Mehta
4045.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5086601654,Ralph Garippa,0000-0003-3917-0739,,,Ralph Garippa
4046.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5072909840,Doron Betel,0000-0002-8006-7752,,,Doron Betel
4047.0,TNF-NF-κB-p53 axis restricts in vivo survival of hPSC-derived dopamine neurons,Studer,10.1101/2023.03.29.534819,10.1016/j.cell.2024.05.030,1.0,W4399538948,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4048.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5077337251,Isabel Lam,0000-0002-6247-8080,Key Personnel,Team Studer,Isabel Lam
4049.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5084102235,Alain Ndayisaba,0000-0001-7611-7115,Key Personnel,Team Studer,Alain Ndayisaba
4050.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5063400815,Amanda J. Lewis,0000-0001-7257-5848,,,Amanda Lewis
4051.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Edwards,YuHong Fu
4052.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5014280534,YuHong Fu,0000-0003-4539-2039,Key Personnel,Team Kirik,YuHong Fu
4053.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5014280534,YuHong Fu,0000-0003-4539-2039,Key personnel,Team Vila,YuHong Fu
4054.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5019016310,Giselle T. Sagredo,,,,Giselle Sagredo
4055.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047502254,Anastasia Kuzkina,0000-0001-5443-8540,Unpaid Collaborator,Team Studer,Anastasia Kuzkina
4056.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047680284,Ludovica Zaccagnini,,,,Ludovica Zaccagnini
4057.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5030885388,Meral Celikag,0000-0003-4462-3819,,,Meral Celikag
4058.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5052184376,Jackson Sandoe,,,,Jackson Sandoe
4059.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5108961921,Ricardo L. Sanz,,,,Ricardo Sanz
4060.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5037167340,Aazam Vahdatshoar,,,,Aazam Vahdatshoar
4061.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5065679671,Timothy D. Martin,0000-0002-4870-3624,,,Timothy Martin
4062.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5055791602,Nader Morshed,,,,Nader Morshed
4063.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5039229943,Toru Ichihashi,0000-0001-8235-6585,,,Toru Ichihashi
4064.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5033546515,Arati Tripathi,0000-0003-0108-2223,,,Arati Tripathi
4065.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5002535841,Nagendran Ramalingam,0000-0002-9459-3593,,,Nagendran Ramalingam
4066.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5071838425,Charlotte Oettgen-Suazo,,,,Charlotte Oettgen-Suazo
4067.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5014655101,Theresa Bartels,0000-0003-4100-0608,,,Theresa Bartels
4068.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5062732970,Manel Boussouf,,,,Manel Boussouf
4069.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5097193984,Max Schäbinger,,,,Max Schäbinger
4070.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5041870481,Erinc Hallacli,0000-0002-5850-6974,,,Erinc Hallacli
4071.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047830370,Xin Jiang,0000-0002-7288-8278,,,Xin Jiang
4072.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5100914741,Amrita Verma,,,,Amrita Verma
4073.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5028821173,Challana Tea,0009-0004-4646-6081,,,Challana Tea
4074.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5100784336,Zichen Wang,0000-0002-1415-1286,,,Zichen Wang
4075.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047916481,Hiroyuki Hakozaki,0009-0008-2503-0480,,,Hiroyuki Hakozaki
4076.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5111272428,Xiao Yu,,,,Xiao Yu
4077.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5072532397,Kelly Hyles,,,,Kelly Hyles
4078.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5074429583,Chansaem Park,,,,Chansaem Park
4079.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5100634214,Xinyuan Wang,0000-0002-3107-8359,Key Personnel,Team Studer,Xinyuan Wang
4080.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5069702912,Thorold W. Theunissen,0000-0001-6943-7858,,,Thorold Theunissen
4081.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5060956929,Haoyi Wang,0000-0003-2135-1769,,,Haoyi Wang
4082.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5087185533,Rudolf Jaenisch,0000-0002-2540-7099,,,Rudolf Jaenisch
4083.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5108447414,Susan Lindquist,,,,Susan Lindquist
4084.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5019182420,Beth Stevens,0000-0003-4226-1201,,,Beth Stevens
4085.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5008859868,Nadia Stefanova,,,,Nadia Stefanova
4086.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5064715109,Gregor K. Wenning,0000-0001-9077-1666,,,Gregor Wenning
4087.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5071946210,Wilma D. J. van de Berg,0000-0002-6175-5357,,,Wilma Berg
4088.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5026208351,Kelvin C. Luk,0000-0002-6591-6269,,,Kelvin Luk
4089.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5053568588,Rosario Sánchez‐Pernaute,0000-0003-1144-9025,,,Rosario Sánchez‐Pernaute
4090.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5072960017,Juan Carlos Gómez‐Esteban,0000-0002-4697-3890,,,Juan Gómez‐Esteban
4091.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5069094037,Daniel Felsky,0000-0003-1831-9848,,,Daniel Felsky
4092.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5060116100,Yasujiro Kiyota,0000-0002-0212-7318,,,Yasujiro Kiyota
4093.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5063425934,Nidhi Sahni,0000-0002-9155-5882,,,Nidhi Sahni
4094.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5063496035,S. Stephen Yi,0000-0003-0047-8103,,,S. Yi
4095.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5037236878,Chee Yeun Chung,0000-0002-5515-650X,,,Chee Chung
4096.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5022570818,Henning Stahlberg,0000-0002-1185-4592,,,Henning Stahlberg
4097.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5010636987,Isidró Ferrer,0000-0001-9888-8754,,,Isidró Ferrer
4098.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5005646392,Johannes Schöneberg,0000-0001-7083-1828,,,Johannes Schöneberg
4099.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5025914907,Stephen J. Elledge,0000-0001-7923-6283,,,Stephen Elledge
4100.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5036811345,Ulf Dettmer,0000-0001-6676-0107,,,Ulf Dettmer
4101.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Collaborating PI,Team Edwards,Glenda Halliday
4102.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Kirik,Glenda Halliday
4103.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5047141421,Glenda M. Halliday,0000-0003-0422-8398,Co-PI,Team Vila,Glenda Halliday
4104.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5054829961,Tim Bartels,0000-0002-4071-5612,,,Tim Bartels
4105.0,"Rapid iPSC inclusionopathy models shed light on formation, consequence and molecular subtype of α-synuclein inclusions",Studer,10.1101/2022.11.08.515615,10.1016/j.neuron.2024.06.002,1.0,W4401078278,A5055136563,Vikram Khurana,0000-0002-4018-5527,Co-PI,Team Studer,Vikram Khurana
4106.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5072933321,Liuliu Yang,0000-0003-0121-4214,,,Liuliu Yang
4107.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5100670572,Tae Wan Kim,0000-0002-0831-6881,,,Tae Kim
4108.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5101608323,Yuling Han,0000-0002-6805-4094,,,Yuling Han
4109.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5054630199,Manoj S. Nair,0000-0002-5994-3957,,,Manoj Nair
4110.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5080771881,Oliver Harschnitz,0000-0001-6496-881X,,,Oliver Harschnitz
4111.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5029498896,Jiajun Zhu,0000-0003-2357-267X,,,Jiajun Zhu
4112.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5100399590,Pengfei Wang,0000-0003-2454-7652,,,Pengfei Wang
4113.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5029736315,So Yeon Koo,0000-0001-8634-7643,,,So Koo
4114.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5083098289,Lauretta A. Lacko,0000-0003-1648-2772,,,Lauretta Lacko
4115.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5091106561,Vasuretha Chandar,0000-0001-8631-3347,,,Vasuretha Chandar
4116.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5044409020,Yaron Bram,0000-0001-9711-575X,,,Yaron Bram
4117.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5100665419,Tuo Zhang,0000-0001-5396-918X,,,Tuo Zhang
4118.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5073787755,Wei Zhang,0000-0003-3113-9577,,,Wei Zhang
4119.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5101741705,Feng He,0000-0003-3207-1295,,,Feng He
4120.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5003481933,Chendong Pan,0000-0003-3058-7247,,,Chendong Pan
4121.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5001019377,Junjie Wu,0000-0002-4000-7026,,,Junjie Wu
4122.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5053171428,Yaoxing Huang,0000-0001-6270-1644,,,Yaoxing Huang
4123.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5003411069,Todd Evans,0000-0002-7148-9849,,,Todd Evans
4124.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5086717130,Paul van der Valk,0000-0001-5292-166X,,,Paul Valk
4125.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5055333491,Maarten J. Titulaer,0000-0002-1033-3840,,,Maarten Titulaer
4126.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5057421655,Jochem K. H. Spoor,0000-0003-1183-4775,,,Jochem Spoor
4127.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5061892862,Robert L. Furler,0000-0001-5706-4871,,,Robert Furler
4128.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5030595673,Marianna Bugiani,0000-0001-7689-3042,,,Marianna Bugiani
4129.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5071946210,Wilma D. J. van de Berg,0000-0002-6175-5357,,,Wilma Berg
4130.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5047735728,Robert E. Schwartz,0000-0002-5417-5995,,,Robert Schwartz
4131.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5047929823,David D. Ho,0000-0003-1627-149X,,,David Ho
4132.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4133.0,SARS-CoV-2 infection causes dopaminergic neuron senescence: Cell Stem Cell,Studer,10.21203/rs.3.rs-513461/v1,10.1016/j.stem.2023.12.012,1.0,W4390942359,A5024015568,Shuibing Chen,0000-0002-6294-5187,,,Shuibing Chen
4134.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5082319537,Nathalie Saurat,0000-0002-6439-5166,Key Personnel,Team Studer,Nathalie Saurat
4135.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5011430458,Andrew P. Minotti,,,,Andrew Minotti
4136.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5101838547,Maliha T. Rahman,0000-0002-0429-9762,,,Maliha Rahman
4137.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5097685934,Trisha Sikder,,,,Trisha Sikder
4138.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5060215226,Chao Zhang,0000-0001-8019-7998,,,Chao Zhang
4139.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5062179210,Daniela Cornacchia,0000-0003-0897-8161,,,Daniela Cornacchia
4140.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5025345912,Johannes Jungverdorben,0000-0002-7227-1139,Project Manager,Team Studer,Johannes Jungverdorben
4141.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5084028446,Gabriele Ciceri,0000-0002-8481-9771,,,Gabriele Ciceri
4142.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5072909840,Doron Betel,0000-0002-8006-7752,,,Doron Betel
4143.0,Genome-wide CRISPR screen identifies neddylation as a regulator of neuronal aging and AD neurodegeneration,Studer,,10.1016/j.stem.2024.06.001,1.0,W4399970235,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4144.0,Induced pluripotent stem cells: a tool for modeling Parkinson’s disease,Studer,NA Review,10.1016/j.tins.2022.05.001,0.0,W4281977146,A5101957335,Anindita Bose,0000-0002-9172-6127,,,Anindita Bose
4145.0,Induced pluripotent stem cells: a tool for modeling Parkinson’s disease,Studer,NA Review,10.1016/j.tins.2022.05.001,0.0,W4281977146,A5007934367,Gregory A. Petsko,0000-0003-3668-3694,,,Gregory Petsko
4146.0,Induced pluripotent stem cells: a tool for modeling Parkinson’s disease,Studer,NA Review,10.1016/j.tins.2022.05.001,0.0,W4281977146,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4147.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5034404707,Nona Farbehi,0000-0001-8461-236X,Key Personnel,Team Studer,Nona Farbehi
4148.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5077634295,Drew Neavin,0000-0002-1783-6491,Key Personnel,Team Studer,Drew Neavin
4149.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5069441404,Anna Cuomo,0000-0001-5168-6979,,,Anna Cuomo
4150.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4151.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5003038390,Daniel G. MacArthur,0000-0002-5771-2290,,,Daniel MacArthur
4152.0,"Integrating population genetics, stem cell biology and cellular genomics to study complex human diseases",Studer,NA_review,10.1038/s41588-024-01731-9,0.0,W4396870546,A5063458641,Joseph E. Powell,0000-0002-5070-4124,Co-PI,Team Studer,Joseph Powell
4153.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5064417807,Taylor Russo,0000-0003-4564-5366,,,Taylor Russo
4154.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5001504885,Benjamin Kolisnyk,0000-0003-3990-0340,,,Benjamin Kolisnyk
4155.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5063859984,B.S. Aswathy,,,,B.S. Aswathy
4156.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5092510829,Jonathan Plessis‐Belair,0000-0002-3997-0421,,,Jonathan Plessis‐Belair
4157.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5100670572,Tae Wan Kim,0000-0002-0831-6881,,,Tae Kim
4158.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5066273213,Jacqueline Martin,0000-0001-6060-5632,,,Jacqueline Martin
4159.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5058921922,Jason Ni,,,,Jason Ni
4160.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5087826176,Jordan A. Pearson,0000-0002-2669-8801,,,Jordan Pearson
4161.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5039425833,Emily J. Park,0000-0001-8770-9239,,,Emily Park
4162.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5026421450,Roger B. Sher,0000-0003-3327-537X,,,Roger Sher
4163.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4164.0,The SATB1-MIR22-GBA axis mediates glucocerebroside accumulation inducing a cellular senescence-like phenotype in dopaminergic neurons,Studer,10.1101/2023.07.19.549710,10.1111/acel.14077,1.0,W4391483361,A5064249491,Markus Rießland,0000-0003-2592-5045,,,Markus Rießland
4165.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5038328241,Sumaiya Nazeen,,Key Personnel,Team Studer,Sumaiya Nazeen
4166.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5100634214,Xinyuan Wang,0000-0002-3107-8359,Key Personnel,Team Studer,Xinyuan Wang
4167.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5084581814,Dina Zielinski,0000-0002-6188-9590,,,Dina Zielinski
4168.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5077337251,Isabel Lam,0000-0002-6247-8080,Key Personnel,Team Studer,Isabel Lam
4169.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5041870481,Erinc Hallacli,0000-0002-5850-6974,,,Erinc Hallacli
4170.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5008058822,Ping Xu,0000-0001-9031-9004,,,Ping Xu
4171.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5018721045,Elizabeth Ethier,,,,Elizabeth Ethier
4172.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5111140468,Ronya Strom,,,,Ronya Strom
4173.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5090377961,Camila A. Zanella,0000-0002-2448-5765,,,Camila Zanella
4174.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5090309070,Vanitha Nithianandam,0000-0002-0740-0758,Key Personnel,Team Scherzer,Vanitha Nithianandam
4175.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5068045411,Dylan Ritter,0000-0002-8704-908X,Key Personnel,Team Studer,Dylan Ritter
4176.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5009491997,Alexander Henderson,,,,Alexander Henderson
4177.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5082319537,Nathalie Saurat,0000-0002-6439-5166,Key Personnel,Team Studer,Nathalie Saurat
4178.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5098279884,Jalwa Afroz,,Key Personnel,Team Studer,Jalwa Afroz
4179.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5090888671,Andrew Nutter-Upham,,,,Andrew Nutter-Upham
4180.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5028325060,Hadar Benyamini,,,,Hadar Benyamini
4181.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5026626302,Joseph Copty,0000-0002-8602-119X,,,Joseph Copty
4182.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5050536137,Shyamsundar Ravishankar,0000-0003-3006-6134,,,Shyamsundar Ravishankar
4183.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5029403792,Autumn Morrow,0000-0002-2301-9869,,,Autumn Morrow
4184.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5110844502,Jonathan Mitchel,,,,Jonathan Mitchel
4185.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5077634295,Drew Neavin,0000-0002-1783-6491,Key Personnel,Team Studer,Drew Neavin
4186.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5105297633,Renuka Gupta,,Key Personnel,Team Studer,Renuka Gupta
4187.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5034404707,Nona Farbehi,0000-0001-8461-236X,Key Personnel,Team Studer,Nona Farbehi
4188.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5079062478,Jennifer Grundman,0000-0003-2266-277X,,,Jennifer Grundman
4189.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5000345809,Richard H. Myers,0000-0002-8365-2674,,,Richard Myers
4190.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5008377476,Clemens R. Scherzer,0000-0002-0567-9193,Lead-PI,Team Scherzer,Clemens Scherzer
4191.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5021394368,John Q. Trojanowski,0000-0002-9239-8794,,,John Trojanowski
4192.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5041309484,Vivianna M. Van Deerlin,0000-0002-7400-9097,,,Vivianna Deerlin
4193.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5046356609,Antony A. Cooper,0000-0002-6027-2353,,,Antony Cooper
4194.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5061968243,Edward B. Lee,0000-0002-4589-1180,,,Edward Lee
4195.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5059774133,Yaniv Erlich,0000-0003-3257-8387,,,Yaniv Erlich
4196.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5108447414,Susan Lindquist,,,,Susan Lindquist
4197.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5061177999,Jian Peng,0000-0002-1736-2978,,,Jian Peng
4198.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5018481303,Daniel H. Geschwind,0000-0003-2896-3450,,,Daniel Geschwind
4199.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5063458641,Joseph E. Powell,0000-0002-5070-4124,Co-PI,Team Studer,Joseph Powell
4200.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5065135570,Lorenz Studer,0000-0003-0741-7987,Lead PI,Team Studer,Lorenz Studer
4201.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5002571663,Mel Β. Feany,0000-0003-0315-7970,Co-PI,Team Scherzer,Mel Feany
4202.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5068462201,Shamil Sunyaev,0000-0001-5715-5677,,,Shamil Sunyaev
4203.0,Deep sequencing of proteotoxicity modifier genes uncovers a Presenilin-2/beta-amyloid-actin genetic risk module shared among alpha-synucleinopathies,Studer,10.1101/2024.03.03.583145,,1.0,W4392449058,A5055136563,Vikram Khurana,0000-0002-4018-5527,Co-PI,Team Studer,Vikram Khurana
4204.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5072833710,Benjamin D. Hobson,0000-0002-2745-5318,,,Benjamin Hobson
4205.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5026251120,Adrien Stanley,0000-0002-3870-1422,,,Adrien Stanley
4206.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5031583395,Mark B. De Los Santos,0000-0002-7195-5141,,,Mark Santos
4207.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5063398311,Bruce Culbertson,0000-0002-1489-1348,,,Bruce Culbertson
4208.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5004169353,Eugene V. Mosharov,0000-0002-0229-7114,Key Personnel (PI),Team Sulzer,Eugene Mosharov
4209.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5066080208,Peter A. Sims,0000-0002-3921-4837,Key Personnel (PI),Team Sulzer,Peter Sims
4210.0,Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain,Sulzer,10.1101/2022.12.14.520294,10.1016/j.bbi.2023.04.008,1.0,W4366814678,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4211.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5072833710,Benjamin D. Hobson,0000-0002-2745-5318,,,Benjamin Hobson
4212.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5045364623,Linghao Kong,0000-0001-6108-3725,,,Linghao Kong
4213.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5029253641,María Florencia Angelo,,,,María Angelo
4214.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5009389618,Ori J. Lieberman,0000-0002-0467-0875,,,Ori Lieberman
4215.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5004169353,Eugene V. Mosharov,0000-0002-0229-7114,Key Personnel (PI),Team Sulzer,Eugene Mosharov
4216.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5080728926,Étienne Herzog,0000-0002-0058-6959,,,Étienne Herzog
4217.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4218.0,Subcellular and regional localization of mRNA translation in midbrain dopamine neurons,Sulzer,10.1101/2021.07.30.454065,10.1016/j.celrep.2021.110208,1.0,W4226101007,A5066080208,Peter A. Sims,0000-0002-3921-4837,Key Personnel (PI),Team Sulzer,Peter Sims
4219.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5085532824,Jessica Griffiths,0000-0002-5586-1567,Key Personnel,Team Gradinaru,Jessica Griffiths
4220.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5102436254,Bryan B. Yoo,,,,Bryan Yoo
4221.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5015913306,Peter Thuy-Boun,0000-0003-3285-4273,,,Peter Thuy-Boun
4222.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5072780768,Victor Cantu,,,,Victor Cantu
4223.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5027323292,Kelly C. Weldon,0000-0003-1064-8153,,,Kelly Weldon
4224.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5070576811,Collin Challis,0000-0003-4716-6086,,,Collin Challis
4225.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5007039952,Michael J. Sweredoski,0000-0003-0878-3831,,,Michael Sweredoski
4226.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5068542583,Ken Y. Chan,0000-0002-8853-5186,,,Ken Chan
4227.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5064324943,Taren Thron,0000-0001-9577-2617,,,Taren Thron
4228.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5015135158,Gil Sharon,0000-0002-4605-9943,,,Gil Sharon
4229.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5058433588,Annie Moradian,0000-0002-0407-2031,,,Annie Moradian
4230.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5082559708,Gregory Humphrey,0000-0003-3930-1663,,,Gregory Humphrey
4231.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5100616517,Qiyun Zhu,0000-0003-3748-948X,,,Qiyun Zhu
4232.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5078091883,Justin P. Shaffer,0000-0002-9371-6336,,,Justin Shaffer
4233.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5012051565,Dennis W. Wolan,0000-0001-9879-8353,,,Dennis Wolan
4234.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5082720301,Pieter C. Dorrestein,0000-0002-3003-1030,,,Pieter Dorrestein
4235.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5033881627,Rob Knight,0000-0002-0975-9019,,,Rob Knight
4236.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5050240445,Viviana Gradinaru,0000-0001-5868-348X,Lead-PI,Team Gradinaru,Viviana Gradinaru
4237.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Gradinaru,Sarkis Mazmanian
4238.0,Peripheral neuronal activation shapes the microbiome and alters gut physiology,Sulzer,10.1101/2021.04.12.439539,10.1016/j.celrep.2024.113953,1.0,W4393040330,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Sulzer,Sarkis Mazmanian
4239.0,Gut microbiome-mediated regulation of neuroinflammation,Sulzer,NA Review,10.1016/j.coi.2022.102177,0.0,W4224232095,A5025238358,John W. Bostick,0000-0001-8925-2447,,,John Bostick
4240.0,Gut microbiome-mediated regulation of neuroinflammation,Sulzer,NA Review,10.1016/j.coi.2022.102177,0.0,W4224232095,A5084083600,Aubrey M. Schonhoff,,,Team Sulzer,Aubrey Schonhoff
4241.0,Gut microbiome-mediated regulation of neuroinflammation,Sulzer,NA Review,10.1016/j.coi.2022.102177,0.0,W4224232095,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Gradinaru,Sarkis Mazmanian
4242.0,Gut microbiome-mediated regulation of neuroinflammation,Sulzer,NA Review,10.1016/j.coi.2022.102177,0.0,W4224232095,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Sulzer,Sarkis Mazmanian
4243.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5046678361,Gregory P. Williams,0000-0001-9523-1781,,,Gregory Williams
4244.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5052801583,Kaylin Muskat,,,,Kaylin Muskat
4245.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5044515449,April Frazier,0000-0002-4722-7304,Key Personnel,Team Sulzer,April Frazier
4246.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5075915109,Yaqian Xu,0000-0001-5890-3446,,,Yaqian Xu
4247.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5063444034,José Mateus,0000-0002-1402-3452,,,José Mateus
4248.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5083647614,Alba Grifoni,0000-0002-0369-1746,,,Alba Grifoni
4249.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5075614639,Ricardo da Silva Antunes,0000-0001-9785-5272,,,Ricardo Antunes
4250.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5071431150,Daniela Weiskopf,0000-0003-2968-7371,,,Daniela Weiskopf
4251.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5067845430,Amy W. Amara,0000-0003-0762-9656,Key Personnel (PI),Team Sulzer,Amy Amara
4252.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
4253.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535,,,Jennifer Goldman
4254.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5006709022,Irene Litvan,0000-0002-3485-3445,,,Irene Litvan
4255.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
4256.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4257.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002,Co-PI,Team Sulzer,Cecilia Arlehamn
4258.0,Unaltered T cell responses to common antigens in individuals with Parkinson’s disease,Sulzer,10.1101/2022.04.05.487195,10.1016/j.jns.2022.120510,1.0,W4309938596,A5010966529,Alessandro Sette,0000-0001-7013-2250,Key Personnel (PI),Team Sulzer,Alessandro Sette
4259.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5016441474,Rachel M. Wise,0000-0001-8432-2725,,,Rachel Wise
4260.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5062185787,Annika Wagener,,,,Annika Wagener
4261.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5052236648,Urban M. Fietzek,0000-0002-4323-9930,,,Urban Fietzek
4262.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5026565602,Thomas Klopstock,0000-0003-2805-4652,,,Thomas Klopstock
4263.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5004169353,Eugene V. Mosharov,0000-0002-0229-7114,Key Personnel (PI),Team Sulzer,Eugene Mosharov
4264.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5040986998,Fabio A. Zucca,0000-0003-1230-1129,,,Fabio Zucca
4265.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4266.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5030347715,Luigi Zecca,0000-0002-7409-6653,,,Luigi Zecca
4267.0,"Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders",Sulzer,NA Review,10.1016/j.nbd.2022.105920,0.0,W4308293006,A5061501546,Lena F. Burbulla,0000-0002-6548-905X,,,Lena Burbulla
4268.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5012875579,Francesca Garretti,0000-0002-6609-8034,,,Francesca Garretti
4269.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5084707089,Connor Monahan,0000-0003-3245-6187,Key Personnel,Team Sulzer,Connor Monahan
4270.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5084885571,Nicholas Sloan,,,,Nicholas Sloan
4271.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5113981476,Jamie Bergen,,,,Jamie Bergen
4272.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5022786763,Sanjid Shahriar,0000-0003-4911-9742,,,Sanjid Shahriar
4273.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5037333942,Seon Woo Kim,0000-0002-5774-0224,,,Seon Kim
4274.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5010966529,Alessandro Sette,0000-0001-7013-2250,Key Personnel (PI),Team Sulzer,Alessandro Sette
4275.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5043267221,Tyler Cutforth,,,,Tyler Cutforth
4276.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5040490050,Ellen Kanter,0000-0002-7475-5006,Key Personnel,Team Sulzer,Ellen Kanter
4277.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5103243942,Dritan Agalliu,0000-0002-1365-6450,Key Personnel (PI),Team Sulzer,Dritan Agalliu
4278.0,Interaction of an α-synuclein epitope with HLA-DRB1*15:01 initiates early enteric features of Parkinson’s disease in humanized mice,Sulzer,10.1101/2022.02.03.479014,10.1016/j.neuron.2023.07.015,1.0,W4385989451,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4279.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5014185718,Aubrey M Schonhoff,0000-0002-1801-1125,,Team Sulzer,Aubrey Schonhoff
4280.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5001789757,D. A. Figge,,,,D. Figge
4281.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5046678361,Gregory P. Williams,0000-0001-9523-1781,,,Gregory Williams
4282.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5036034462,Asta Jurkuvenaite,0000-0002-9193-5797,Key Personnel,Team Kordower,Asta Jurkuvenaite
4283.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5036034462,Asta Jurkuvenaite,0000-0002-9193-5797,Key Personnel,Team Sulzer,Asta Jurkuvenaite
4284.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5110746996,Nicole J Gallups,,,,Nicole Gallups
4285.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5034853308,Gabrielle Childers,0000-0003-1195-4750,,,Gabrielle Childers
4286.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5069788322,J. Webster,0000-0001-8230-6174,Key Personnel,Team Kordower,J. Webster
4287.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
4288.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5011457832,James E. Goldman,0000-0003-2135-8936,Key Personnel (PI),Team Sulzer,James Goldman
4289.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Kordower,Ashley Harms
4290.0,Border-associated macrophages mediate the neuroinflammatory response in an alpha-synuclein model of Parkinson disease,Sulzer,10.1101/2022.10.12.511960,10.1038/s41467-023-39060-w,1.0,W4382059965,A5046016738,Ashley S. Harms,0000-0002-7054-2812,Co-PI,Team Sulzer,Ashley Harms
4291.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5077060611,Rekha Dhanwani,0000-0002-6592-8657,,,Rekha Dhanwani
4292.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5057542377,João Rodrigues Lima-Júnior,,,,João Lima-Júnior
4293.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5109476794,Ashu Sethi,,,,Ashu Sethi
4294.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5114235233,John Pham,,,,John Pham
4295.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5046678361,Gregory P. Williams,0000-0001-9523-1781,,,Gregory Williams
4296.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5044515449,April Frazier,0000-0002-4722-7304,Key Personnel,Team Sulzer,April Frazier
4297.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5075915109,Yaqian Xu,0000-0001-5890-3446,,,Yaqian Xu
4298.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5067845430,Amy W. Amara,0000-0003-0762-9656,Key Personnel (PI),Team Sulzer,Amy Amara
4299.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5000374325,David G. Standaert,0000-0003-2921-8348,Key Personnel (PI),Team Sulzer,David Standaert
4300.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535,,,Jennifer Goldman
4301.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5006709022,Irene Litvan,0000-0002-3485-3445,,,Irene Litvan
4302.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
4303.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5023547268,Bjoern Peters,0000-0002-8457-6693,,,Bjoern Peters
4304.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4305.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002,Co-PI,Team Sulzer,Cecilia Arlehamn
4306.0,Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures,Sulzer,10.1101/2021.05.28.446215,10.1038/s41531-022-00282-2,1.0,W4221115508,A5010966529,Alessandro Sette,0000-0001-7013-2250,Key Personnel (PI),Team Sulzer,Alessandro Sette
4307.0,Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s diseas,Sulzer,NA Review,10.1038/s41531-022-00308-9,0.0,W4224305265,A5087013195,Alcmène Chalazonitis,0000-0003-4035-1764,,,Alcmène Chalazonitis
4308.0,Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s diseas,Sulzer,NA Review,10.1038/s41531-022-00308-9,0.0,W4224305265,A5013440829,Meenakshi Rao,0000-0002-8194-9204,,,Meenakshi Rao
4309.0,Similarities and differences between nigral and enteric dopaminergic neurons unravel distinctive involvement in Parkinson’s diseas,Sulzer,NA Review,10.1038/s41531-022-00308-9,0.0,W4224305265,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4310.0,Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease,Sulzer,review,10.3233/JPD-223153,0.0,W4214855533,A5072833710,Benjamin D. Hobson,0000-0002-2745-5318,,,Benjamin Hobson
4311.0,Neuronal Presentation of Antigen and Its Possible Role in Parkinson’s Disease,Sulzer,review,10.3233/JPD-223153,0.0,W4214855533,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4312.0,Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease,Sulzer,review,10.3233/JPD-223241,0.0,W4283364966,A5046678361,Gregory P. Williams,0000-0001-9523-1781,,,Gregory Williams
4313.0,Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease,Sulzer,review,10.3233/JPD-223241,0.0,W4283364966,A5084083600,Aubrey M. Schonhoff,,,Team Sulzer,Aubrey Schonhoff
4314.0,Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease,Sulzer,review,10.3233/JPD-223241,0.0,W4283364966,A5010966529,Alessandro Sette,0000-0001-7013-2250,Key Personnel (PI),Team Sulzer,Alessandro Sette
4315.0,Central and Peripheral Inflammation: Connecting the Immune Responses of Parkinson’s Disease,Sulzer,review,10.3233/JPD-223241,0.0,W4283364966,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002,Co-PI,Team Sulzer,Cecilia Arlehamn
4316.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5072833710,Benjamin D. Hobson,0000-0002-2745-5318,,,Benjamin Hobson
4317.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5065913149,Se Joon Choi,0000-0002-5486-7326,,,Se Choi
4318.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5004169353,Eugene V. Mosharov,0000-0002-0229-7114,Key Personnel (PI),Team Sulzer,Eugene Mosharov
4319.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5079956746,Rajesh K. Soni,0000-0002-4556-4358,,,Rajesh Soni
4320.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4321.0,Subcellular proteomics of dopamine neurons in the mouse brain reveals axonal enrichment of proteins encoded by Parkinson’s disease-linked genes,Sulzer,10.1101/2021.06.01.446584,10.7554/eLife.70921,1.0,W4220677882,A5066080208,Peter A. Sims,0000-0002-3921-4837,Key Personnel (PI),Team Sulzer,Peter Sims
4322.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5034575260,Reem Abdel-Haq,0000-0002-7418-5736,,,Reem Abdel-Haq
4323.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5017206227,Johannes C. M. Schlachetzki,0000-0002-7801-9743,,,Johannes Schlachetzki
4324.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5082378291,Joseph C. Boktor,0000-0003-2456-1913,,Team Sulzer,Joseph Boktor
4325.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5014061199,Thaisa M. Cantu-Jungles,0000-0001-8928-9717,,,Thaisa Cantu-Jungles
4326.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5064324943,Taren Thron,0000-0001-9577-2617,,,Taren Thron
4327.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5103166723,Mengying Zhang,0000-0003-0674-9437,,,Mengying Zhang
4328.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5025238358,John W. Bostick,0000-0001-8925-2447,,,John Bostick
4329.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5023642382,Tahmineh Khazaei,0000-0002-4743-2383,,,Tahmineh Khazaei
4330.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5008275014,Sujatha Chilakala,0000-0003-1581-3381,,,Sujatha Chilakala
4331.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5027763981,Lívia H. Morais,0000-0002-5738-2658,,Team Sulzer,Lívia Morais
4332.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5087126302,Greg Humphrey,,,,Greg Humphrey
4333.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5002619544,Ali Keshavarzian,0000-0002-7969-3369,,,Ali Keshavarzian
4334.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5022615394,Jonathan E. Katz,0000-0001-8175-790X,,,Jonathan Katz
4335.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5110505826,Matthew Thomson,,,,Matthew Thomson
4336.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5033881627,Rob Knight,0000-0002-0975-9019,,,Rob Knight
4337.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5050240445,Viviana Gradinaru,0000-0001-5868-348X,Lead-PI,Team Gradinaru,Viviana Gradinaru
4338.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5089760163,Bruce R. Hamaker,0000-0001-6591-942X,,,Bruce Hamaker
4339.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5039839135,Christopher K. Glass,0000-0003-4344-3592,,,Christopher Glass
4340.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Gradinaru,Sarkis Mazmanian
4341.0,A prebiotic diet modulates microglial states and motor deficits in α-synuclein overexpressing mice,Sulzer,10.1101/2022.06.27.497828,10.7554/eLife.81453,1.0,W4308633748,A5053569958,Sarkis K. Mazmanian,0000-0003-2713-1513,Co-PI,Team Sulzer,Sarkis Mazmanian
4342.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5092351288,Kelly Jakubiak,0009-0002-6932-4460,,Team Sulzer,Kelly Jakubiak
4343.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5028338461,Fahad Paryani,0000-0003-1418-1386,,,Fahad Paryani
4344.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5028156146,Adithya Kannan,0000-0001-7359-184X,,,Adithya Kannan
4345.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5030642016,Jaeseung Lee,0009-0003-0806-093X,,,Jaeseung Lee
4346.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5070840229,Nacoya Madden,,,,Nacoya Madden
4347.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5100648021,Juncheng Li,0009-0008-0934-1027,,,Juncheng Li
4348.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5002365816,David Chen,0000-0002-9710-1857,,,David Chen
4349.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5057263352,Aayushi Mahajan,0000-0003-3966-2936,,,Aayushi Mahajan
4350.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5103106252,Shengnan Xia,0000-0003-4940-2345,,,Shengnan Xia
4351.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5012650292,Xena Flowers,,,,Xena Flowers
4352.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5013606443,Vilas Menon,0000-0002-4096-8601,,,Vilas Menon
4353.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4354.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5011457832,James E. Goldman,0000-0003-2135-8936,Key Personnel (PI),Team Sulzer,James Goldman
4355.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5066080208,Peter A. Sims,0000-0002-3921-4837,Key Personnel (PI),Team Sulzer,Peter Sims
4356.0,The spatial landscape of glial pathology and T-cell response in Parkinson’s disease substantia nigra,Sulzer,10.1101/2024.01.08.574736,,1.0,W4390691959,A5068791795,Osama Al‐Dalahmah,0000-0002-3442-5459,Key Personnel,Team Sulzer,Osama Al‐Dalahmah
4357.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5046678361,Gregory P. Williams,0000-0001-9523-1781,,,Gregory Williams
4358.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5109682219,T. Michaelis,,,,T. Michaelis
4359.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5057542377,João Rodrigues Lima-Júnior,,,,João Lima-Júnior
4360.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5044515449,April Frazier,0000-0002-4722-7304,Key Personnel,Team Sulzer,April Frazier
4361.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5063421071,Ngan K. Tran,0000-0002-6106-2833,,,Ngan Tran
4362.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5080985934,Elizabeth J. Phillips,0000-0002-7623-3383,,,Elizabeth Phillips
4363.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5070165631,S. Mallal,0000-0002-7036-1309,,,S. Mallal
4364.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5006709022,Irene Litvan,0000-0002-3485-3445,,,Irene Litvan
4365.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5061596611,Jennifer G. Goldman,0000-0001-5014-7535,,,Jennifer Goldman
4366.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5037098776,Roy N. Alcalay,0000-0002-5717-4875,,,Roy Alcalay
4367.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5037285448,John Sidney,0000-0002-0987-405X,,,John Sidney
4368.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5026787858,David Sulzer,0000-0001-7632-0439,Lead PI,Team Sulzer,David Sulzer
4369.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5010966529,Alessandro Sette,0000-0001-7013-2250,Key Personnel (PI),Team Sulzer,Alessandro Sette
4370.0,PINK1 is a target of T cell responses in Parkinson's disease,Sulzer,10.1101/2024.02.09.579465,,1.0,W4391744684,A5066674783,Cecilia S. Lindestam Arlehamn,0000-0001-7302-8002,Co-PI,Team Sulzer,Cecilia Arlehamn
4371.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5086555383,Marcelo Mendonça,0000-0003-3587-8553,Key Personnel,Team Surmeier,Marcelo Mendonça
4372.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5055317786,Joaquim Alves da Silva,0000-0002-3967-3603,Key Personnel,Team Surmeier,Joaquim Silva
4373.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5031983930,Ledia F. Hernández,0000-0002-5293-3748,,,Ledia Hernández
4374.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5065746258,Iván Castela,0000-0002-5436-6716,,,Iván Castela
4375.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5062838955,José Á. Obeso,0000-0002-6996-8613,Co-PI,Team Vila,José Obeso
4376.0,Dopamine neuron activity encodes the length of upcoming contralateral movement sequences,Surmeier,10.1101/2021.04.20.440527,10.1016/j.cub.2024.01.067,1.0,W4391934167,A5060965799,Rui M. Costa,0000-0003-0495-8374,Co-PI,Team Surmeier,Rui Costa
4377.0,Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons,Surmeier,10.1101/2023.08.05.552108,10.1016/j.nbd.2023.106328,1.0,W4387675855,A5057169237,Cecilia Tubert,0000-0001-6766-5849,,,Cecilia Tubert
4378.0,Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons,Surmeier,10.1101/2023.08.05.552108,10.1016/j.nbd.2023.106328,1.0,W4387675855,A5022357653,Enrico Zampese,0000-0002-8851-2566,Key Personnel,Team Surmeier,Enrico Zampese
4379.0,Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons,Surmeier,10.1101/2023.08.05.552108,10.1016/j.nbd.2023.106328,1.0,W4387675855,A5061051142,Tristano Pancani,,,,Tristano Pancani
4380.0,Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons,Surmeier,10.1101/2023.08.05.552108,10.1016/j.nbd.2023.106328,1.0,W4387675855,A5005081394,Tatiana Tkatch,0000-0001-6626-7435,Key Personnel,Team Surmeier,Tatiana Tkatch
4381.0,Feed-forward metabotropic signaling by Cav1 Ca2+ channels supports pacemaking in pedunculopontine cholinergic neurons,Surmeier,10.1101/2023.08.05.552108,10.1016/j.nbd.2023.106328,1.0,W4387675855,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4382.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5031664190,Fuu-Jiun Hwang,0000-0003-0477-986X,Key Personnel,Team Surmeier,Fuu-Jiun Hwang
4383.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5064570319,Richard H. Roth,0000-0002-6855-999X,Key Personnel,Team Surmeier,Richard Roth
4384.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5022025026,Yu‐Wei Wu,0000-0002-4459-087X,,,Yu‐Wei Wu
4385.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5041659919,Yue Sun,0000-0002-5681-130X,Key Personnel,Team Surmeier,Yue Sun
4386.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5083711186,Destany K. Kwon,,,,Destany Kwon
4387.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5100345838,Yu Liu,0000-0002-7384-6176,,,Yu Liu
4388.0,Motor learning selectively strengthens cortical and striatal synapses of motor engram neurons,Surmeier,10.1101/2021.10.28.466357,10.1016/j.neuron.2022.06.006,1.0,W4284973744,A5070396294,Jun Ding,0000-0003-0690-1312,Co-PI,Team Surmeier,Jun Ding
4389.0,Cortico-basal ganglia plasticity in motor learning,Surmeier,NA_Review,10.1016/j.neuron.2024.06.014,0.0,W4400582704,A5064570319,Richard H. Roth,0000-0002-6855-999X,Key Personnel,Team Surmeier,Richard Roth
4390.0,Cortico-basal ganglia plasticity in motor learning,Surmeier,NA_Review,10.1016/j.neuron.2024.06.014,0.0,W4400582704,A5070396294,Jun Ding,0000-0003-0690-1312,Co-PI,Team Surmeier,Jun Ding
4391.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5026205750,Keith C. Summa,0000-0001-9541-8458,,,Keith Summa
4392.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5100622418,Pu Jiang,0000-0002-1942-5960,,,Pu Jiang
4393.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5026310676,Patricia González‐Rodríguez,0000-0002-2561-3984,Key Personnel,Team Surmeier,Patricia González‐Rodríguez
4394.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5101465278,Xiaolin Huang,0000-0001-7367-8347,Key Personnel,Team Surmeier,Xiaolin Huang
4395.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5081619588,Xiaojun Lin,0000-0003-4284-2401,,,Xiaojun Lin
4396.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5003825512,Martha Hotz Vitaterna,0000-0001-6243-2093,,,Martha Vitaterna
4397.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5036365985,Yang Dan,0000-0002-3818-877X,Co-PI,Team Surmeier,Yang Dan
4398.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4399.0,Disrupted sleep-wake regulation in the MCI-Park mouse model of Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.11.09.566376,10.1038/s41531-024-00670-w,1.0,W4392639128,A5084820716,Fred W. Turek,0000-0002-4031-4229,,,Fred Turek
4400.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5039142692,Jonathan C. Y. Tang,0000-0002-2376-6901,,,Jonathan Tang
4401.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5058819661,Vítor Paixão,0000-0003-3722-0747,,,Vítor Paixão
4402.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5005970339,Filipe Carvalho,0000-0002-8834-7062,,,Filipe Carvalho
4403.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5047503542,Artur Silva,0000-0002-1955-6944,,,Artur Silva
4404.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5031348495,Andreas Klaus,0000-0002-4133-351X,,,Andreas Klaus
4405.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5055317786,Joaquim Alves da Silva,0000-0002-3967-3603,Key Personnel,Team Surmeier,Joaquim Silva
4406.0,Dynamic behaviour restructuring mediates dopamine-dependent credit assignment | Nature,Surmeier,10.1101/2022.09.22.507905,10.1038/s41586-023-06941-5,1.0,W4389671970,A5060965799,Rui M. Costa,0000-0003-0495-8374,Co-PI,Team Surmeier,Rui Costa
4407.0,Neural heterogeneity controls computations in spiking neural networks,Surmeier,10.48550/arXiv.2206.08813,10.1073/pnas.2311885121,1.0,W4390691678,A5012329126,Richard Gast,0000-0002-4445-0340,Key Personnel,Team Surmeier,Richard Gast
4408.0,Neural heterogeneity controls computations in spiking neural networks,Surmeier,10.48550/arXiv.2206.08813,10.1073/pnas.2311885121,1.0,W4390691678,A5050281483,Sara A. Solla,0000-0001-7696-447X,,,Sara Solla
4409.0,Neural heterogeneity controls computations in spiking neural networks,Surmeier,10.48550/arXiv.2206.08813,10.1073/pnas.2311885121,1.0,W4390691678,A5071419759,Ann Kennedy,0000-0002-3782-0518,Co-PI,Team Surmeier,Ann Kennedy
4410.0,Macroscopic dynamics of neural networks with heterogeneous spiking thresholds,Surmeier,10.48550/arXiv.2209.03501,10.1103/PhysRevE.107.024306,1.0,W4321111295,A5012329126,Richard Gast,0000-0002-4445-0340,Key Personnel,Team Surmeier,Richard Gast
4411.0,Macroscopic dynamics of neural networks with heterogeneous spiking thresholds,Surmeier,10.48550/arXiv.2209.03501,10.1103/PhysRevE.107.024306,1.0,W4321111295,A5050281483,Sara A. Solla,0000-0001-7696-447X,,,Sara Solla
4412.0,Macroscopic dynamics of neural networks with heterogeneous spiking thresholds,Surmeier,10.48550/arXiv.2209.03501,10.1103/PhysRevE.107.024306,1.0,W4321111295,A5071419759,Ann Kennedy,0000-0002-3782-0518,Co-PI,Team Surmeier,Ann Kennedy
4413.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5022357653,Enrico Zampese,0000-0002-8851-2566,Key Personnel,Team Surmeier,Enrico Zampese
4414.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5044172289,David L. Wokosin,,,,David Wokosin
4415.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5026310676,Patricia González‐Rodríguez,0000-0002-2561-3984,Key Personnel,Team Surmeier,Patricia González‐Rodríguez
4416.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5111645731,Jaime N. Guzmán,0000-0002-7142-8384,,,Jaime Guzmán
4417.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5005081394,Tatiana Tkatch,0000-0001-6626-7435,Key Personnel,Team Surmeier,Tatiana Tkatch
4418.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5009047210,Jyothisri Kondapalli,,,,Jyothisri Kondapalli
4419.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5110964195,William C. Surmeier,,,,William Surmeier
4420.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5091095249,Karis B. D’Alessandro,0000-0003-1572-1321,,,Karis D’Alessandro
4421.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5014388603,Diego De Stefani,0000-0003-3796-8907,,,Diego Stefani
4422.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5027748782,Rosario Rizzuto,0000-0001-7044-5097,,,Rosario Rizzuto
4423.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5009491639,Masamitsu Iino,0000-0001-6426-4206,,,Masamitsu Iino
4424.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5075550603,Jeffery D. Molkentin,0000-0002-3558-6529,,,Jeffery Molkentin
4425.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5046518034,Navdeep S. Chandel,0000-0001-7208-3886,,,Navdeep Chandel
4426.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5081897750,Paul T. Schumacker,0000-0001-9591-2034,,,Paul Schumacker
4427.0,Ca2+ channels couple spiking to mitochondrial metabolism in substantia nigra dopainergic neurons,Surmeier,missing,10.1126/sciadv.abp8701,1.0,W4298126240,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4428.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5057888897,Michelle Day,,,,Michelle Day
4429.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5063704897,Marziyeh Belal,0000-0001-8778-0617,,,Marziyeh Belal
4430.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5110964195,William C. Surmeier,,,,William Surmeier
4431.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5064095603,Alexandria E. Melendez‐Zaidi,0000-0001-6057-0206,,,Alexandria Melendez‐Zaidi
4432.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5044172289,David L. Wokosin,,,,David Wokosin
4433.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5005081394,Tatiana Tkatch,0000-0001-6626-7435,Key Personnel,Team Surmeier,Tatiana Tkatch
4434.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5018658974,Vernon R. J. Clarke,0000-0002-6154-6555,Key Personnel,Team Surmeier,Vernon Clarke
4435.0,GABAergic regulation of striatal spiny projection neurons depends upon their activity state,Surmeier,10.1101/2023.03.14.532627,10.1371/journal.pbio.3002483,1.0,W4391381044,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4436.0,PyRates—A code-generation tool for modeling dynamical systems in biology and beyond | PLOS Computational Biology,Surmeier,10.48550/arXiv.2302.03763,10.1371/journal.pcbi.1011761,1.0,W4390264077,A5012329126,Richard Gast,0000-0002-4445-0340,Key Personnel,Team Surmeier,Richard Gast
4437.0,PyRates—A code-generation tool for modeling dynamical systems in biology and beyond | PLOS Computational Biology,Surmeier,10.48550/arXiv.2302.03763,10.1371/journal.pcbi.1011761,1.0,W4390264077,A5008548871,Thomas R. Knösche,0000-0001-9668-3261,,,Thomas Knösche
4438.0,PyRates—A code-generation tool for modeling dynamical systems in biology and beyond | PLOS Computational Biology,Surmeier,10.48550/arXiv.2302.03763,10.1371/journal.pcbi.1011761,1.0,W4390264077,A5075478892,Ann R. Kennedy,0000-0002-1602-2015,Co-PI,Team Surmeier,Ann Kennedy
4439.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5045944438,Usamma Amjad,0000-0001-5455-3207,Key Personnel,Team Strick,Usamma Amjad
4440.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5005054739,Jiwon Choi,0000-0002-2801-7854,,,Jiwon Choi
4441.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5104335276,Daniel J. Gibson,0000-0003-4376-6041,,,Daniel Gibson
4442.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5088086543,Raymond Murray,0009-0007-1529-9243,Key Personnel,Team Strick,Raymond Murray
4443.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5081686751,Ann M. Graybiel,0000-0002-4326-7720,,,Ann Graybiel
4444.0,Synchronous Measurements of Extracellular Action Potentials and Neurochemical Activity with Carbon Fiber Electrodes in Nonhuman Primates | bioRxiv,Surmeier,10.1101/2023.12.23.573130,10.1523/ENEURO.0001-24.2024,1.0,W4400018516,A5035254479,Helen N. Schwerdt,,Co-PI,Team Strick,Helen Schwerdt
4445.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5072086462,Fanni F. Geibl,0000-0002-5480-0463,,,Fanni Geibl
4446.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5068641130,Martin T. Henrich,0000-0001-8295-4884,,,Martin Henrich
4447.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5007465381,Zhong Xie,0000-0002-8348-4455,Key Personnel,Team Surmeier,Zhong Xie
4448.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5022357653,Enrico Zampese,0000-0002-8851-2566,Key Personnel,Team Surmeier,Enrico Zampese
4449.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5005081394,Tatiana Tkatch,0000-0001-6626-7435,Key Personnel,Team Surmeier,Tatiana Tkatch
4450.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5044172289,David L. Wokosin,,,,David Wokosin
4451.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5051713723,Elena Nasiri,,,,Elena Nasiri
4452.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5093468938,Constantin A. Grotmann,,,,Constantin Grotmann
4453.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5025568267,Valina L. Dawson,0000-0002-2915-3970,Collaborating PI,Team Kaplitt,Valina Dawson
4454.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5021759485,Ted M. Dawson,0000-0002-6459-0893,Co-PI,Team Kaplitt,Ted Dawson
4455.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5046518034,Navdeep S. Chandel,0000-0001-7208-3886,,,Navdeep Chandel
4456.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5061542163,Wolfgang H. Oertel,0000-0002-7582-8166,,,Wolfgang Oertel
4457.0,α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease | bioRxiv,Surmeier,10.1101/2023.12.11.571045,,1.0,W4389580093,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4458.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5055251836,DeNard V. Simmons,0000-0002-9829-4312,Key Personnel,Team Surmeier,DeNard Simmons
4459.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5029079965,Oscar Andrés Moreno-Ramos,0000-0002-1378-2545,Key Personnel,Team Awatramani,Oscar Moreno-Ramos
4460.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5003004688,Divya Raj,0000-0001-9369-3181,,,Divya Raj
4461.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5069459623,Konstantin Kaganovsky,0000-0002-1577-109X,,,Konstantin Kaganovsky
4462.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5070396294,Jun Ding,0000-0003-0690-1312,Co-PI,Team Surmeier,Jun Ding
4463.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5082378596,Rajeshwar Awatramani,0000-0002-0713-2140,Lead-PI,Team Awatramani,Rajeshwar Awatramani
4464.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5038386507,Charles J. Wilson,0000-0002-9004-2145,,,Charles Wilson
4465.0,Tonic dendritic GABA release by substantia nigra dopaminergic neurons,Surmeier,10.1101/2024.03.27.586699,,1.0,W4393338914,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4466.0,Refinement of efficient encodings of movement in the dorsolateral striatum throughout learning,Surmeier,10.1101/2024.06.06.596654,,1.0,W4399443539,A5087486056,Omar Jáidar,0000-0001-7317-6355,,,Omar Jáidar
4467.0,Refinement of efficient encodings of movement in the dorsolateral striatum throughout learning,Surmeier,10.1101/2024.06.06.596654,,1.0,W4399443539,A5051709838,Eddy Albarran,0000-0002-1638-100X,Key Personnel,Team Surmeier,Eddy Albarran
4468.0,Refinement of efficient encodings of movement in the dorsolateral striatum throughout learning,Surmeier,10.1101/2024.06.06.596654,,1.0,W4399443539,A5104322675,Eli Nathan Albarran,,,,Eli Albarran
4469.0,Refinement of efficient encodings of movement in the dorsolateral striatum throughout learning,Surmeier,10.1101/2024.06.06.596654,,1.0,W4399443539,A5100458048,Yuwei Wu,0000-0003-4926-2530,,,Yuwei Wu
4470.0,Refinement of efficient encodings of movement in the dorsolateral striatum throughout learning,Surmeier,10.1101/2024.06.06.596654,,1.0,W4399443539,A5070396294,Jun Ding,0000-0003-0690-1312,Co-PI,Team Surmeier,Jun Ding
4471.0,Activity-Dependent Remodeling of Corticostriatal Axonal Boutons During Motor Learning,Surmeier,10.1101/2024.06.10.598366,,1.0,W4399516825,A5072165527,Mengjun Sheng,0000-0002-1440-3447,Key Personnel,Team Surmeier,Mengjun Sheng
4472.0,Activity-Dependent Remodeling of Corticostriatal Axonal Boutons During Motor Learning,Surmeier,10.1101/2024.06.10.598366,,1.0,W4399516825,A5101643305,Di Lu,0000-0003-1177-5672,,,Di Lu
4473.0,Activity-Dependent Remodeling of Corticostriatal Axonal Boutons During Motor Learning,Surmeier,10.1101/2024.06.10.598366,,1.0,W4399516825,A5104248554,Kaiwen Sheng,,,,Kaiwen Sheng
4474.0,Activity-Dependent Remodeling of Corticostriatal Axonal Boutons During Motor Learning,Surmeier,10.1101/2024.06.10.598366,,1.0,W4399516825,A5111498304,Jun B. Ding,,Co-PI,Team Surmeier,Jun Ding
4475.0,Frontiers | Rethinking the network determinants of motor disability in Parkinson’s disease (frontiersin.org),Surmerier,review,10.3389/fnsyn.2023.1186484,0.0,W4382399915,A5033742239,D. James Surmeier,0000-0002-6376-5225,Lead-PI,Team Surmeier,D. Surmeier
4476.0,Frontiers | Rethinking the network determinants of motor disability in Parkinson’s disease (frontiersin.org),Surmerier,review,10.3389/fnsyn.2023.1186484,0.0,W4382399915,A5026010405,Shenyu Zhai,0000-0002-7097-9387,Key Personnel,Team Surmeier,Shenyu Zhai
4477.0,Frontiers | Rethinking the network determinants of motor disability in Parkinson’s disease (frontiersin.org),Surmerier,review,10.3389/fnsyn.2023.1186484,0.0,W4382399915,A5018267763,Qiaoling Cui,0000-0002-1632-4208,Key Personnel,Team Surmeier,Qiaoling Cui
4478.0,Frontiers | Rethinking the network determinants of motor disability in Parkinson’s disease (frontiersin.org),Surmerier,review,10.3389/fnsyn.2023.1186484,0.0,W4382399915,A5055251836,DeNard V. Simmons,0000-0002-9829-4312,Key Personnel,Team Surmeier,DeNard Simmons
4479.0,No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance,Vangheluwe,NA_review,10.1002/mds.28935,0.0,W4210466597,A5053970218,Adenrele M. Gleason,,,,Adenrele Gleason
4480.0,No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance,Vangheluwe,NA_review,10.1002/mds.28935,0.0,W4210466597,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
4481.0,No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance,Vangheluwe,NA_review,10.1002/mds.28935,0.0,W4210466597,A5011772005,Grisel Lopez,0000-0001-7785-2197,Key Personnel,Team Vangheluwe,Grisel Lopez
4482.0,No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance,Vangheluwe,NA_review,10.1002/mds.28935,0.0,W4210466597,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4483.0,CRISPR/Cas9-Based Functional Genomics in Human Induced Pluripotent Stem Cell–Derived Models: Can “the Stars Align” for Neurodegenerative Diseases?,Vangheluwe,review,10.1002/mds.28998,0.0,W4221130945,A5100401933,Yu Chen,0000-0001-5438-7309,Key Personnel,Team Vangheluwe,Yu Chen
4484.0,CRISPR/Cas9-Based Functional Genomics in Human Induced Pluripotent Stem Cell–Derived Models: Can “the Stars Align” for Neurodegenerative Diseases?,Vangheluwe,review,10.1002/mds.28998,0.0,W4221130945,A5065422276,Tiffany Jong,0000-0003-2277-4042,,,Tiffany Jong
4485.0,CRISPR/Cas9-Based Functional Genomics in Human Induced Pluripotent Stem Cell–Derived Models: Can “the Stars Align” for Neurodegenerative Diseases?,Vangheluwe,review,10.1002/mds.28998,0.0,W4221130945,A5035727257,Chase Chen,0000-0003-1016-0844,,,Chase Chen
4486.0,CRISPR/Cas9-Based Functional Genomics in Human Induced Pluripotent Stem Cell–Derived Models: Can “the Stars Align” for Neurodegenerative Diseases?,Vangheluwe,review,10.1002/mds.28998,0.0,W4221130945,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4487.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5079324419,Mark Ainsley Colijn,0000-0002-8151-1173,,,Mark Colijn
4488.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5018011138,Stephanie Vrijsen,0000-0002-2601-510X,Key Personnel,Team Vangheluwe,Stephanie Vrijsen
4489.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5021590955,Ping Yee Billie Au,0000-0002-9533-7217,,,Ping Au
4490.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5052958046,Rania Abou El Asrar,0000-0001-9947-2697,Key Personnel,Team Vangheluwe,Rania Asrar
4491.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5014957051,Marine Houdou,0000-0002-9766-3163,,,Marine Houdou
4492.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4493.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5088317967,Justyna R. Sarna,0000-0003-3308-1540,,,Justyna Sarna
4494.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5084445661,Gregory S. Montgomery,0000-0002-4232-2070,,,Gregory Montgomery
4495.0,Kufor-Rakeb Syndrome-Associated Psychosis: A Novel Loss-of-Function ATP13A2 Variant and Response to Treatment | medRxiv,Vangheluwe,10.1101/2024.01.12.23300401,10.1007/s10048-024-00767-7,1.0,W4400785253,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4496.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5002813232,Mujahid Azfar,0000-0001-5822-3969,Key Personnel,Team Vangheluwe,Mujahid Azfar
4497.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5024492574,Sarah van Veen,0000-0002-7639-7847,Key Personnel,Team Vangheluwe,Sarah Veen
4498.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5014957051,Marine Houdou,0000-0002-9766-3163,,,Marine Houdou
4499.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5032282577,Norin Nabil Hamouda,0000-0003-1898-3597,,,Norin Hamouda
4500.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4501.0,P5B-ATPases in the mammalian polyamine transport system and their role in disease,Vangheluwe,review,10.1016/j.bbamcr.2022.119354,0.0,W4294190937,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4502.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5031613860,Rosanne Wouters,0000-0001-7398-0351,,,Rosanne Wouters
4503.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5062934942,Igor Beletchi,0000-0002-0190-7881,,,Igor Beletchi
4504.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4505.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4506.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5053595396,Shaun Martin,0000-0003-4018-1507,,,Shaun Martin
4507.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4508.0,The lipid flippase ATP10B enables cellular lipid uptake under stress conditions,Vangheluwe,10.1101/2023.06.01.543059,10.1016/j.bbamcr.2023.119652,1.0,W4389570670,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4509.0,Rodent models based on endolysosomal genes involved in Parkinson's disease,Vangheluwe,review,10.1016/j.conb.2021.09.004,0.0,W3204682936,A5074178397,María Sanchiz-Calvo,0000-0003-1773-8696,Key Personnel,Team Vangheluwe,María Sanchiz-Calvo
4510.0,Rodent models based on endolysosomal genes involved in Parkinson's disease,Vangheluwe,review,10.1016/j.conb.2021.09.004,0.0,W3204682936,A5043034445,Eduard Bentea,0000-0003-2527-6997,,,Eduard Bentea
4511.0,Rodent models based on endolysosomal genes involved in Parkinson's disease,Vangheluwe,review,10.1016/j.conb.2021.09.004,0.0,W3204682936,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4512.0,The lysosome as a master regulator of iron metabolism,Vangheluwe,NA Review,10.1016/j.tibs.2021.07.003,0.0,W3192249208,A5060658897,Francesca Rizzollo,0000-0002-5211-7281,,,Francesca Rizzollo
4513.0,The lysosome as a master regulator of iron metabolism,Vangheluwe,NA Review,10.1016/j.tibs.2021.07.003,0.0,W3192249208,A5031848518,Sanket More,0000-0003-3482-4414,,,Sanket More
4514.0,The lysosome as a master regulator of iron metabolism,Vangheluwe,NA Review,10.1016/j.tibs.2021.07.003,0.0,W3192249208,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4515.0,The lysosome as a master regulator of iron metabolism,Vangheluwe,NA Review,10.1016/j.tibs.2021.07.003,0.0,W3192249208,A5091862786,Patrizia Agostinis,0000-0003-1314-2115,,,Patrizia Agostinis
4516.0,Lysosomal dysfunction in neurodegeneration: emerging concepts and methods,Vangheluwe,NA Review,10.1016/j.tins.2021.12.004,0.0,W4205593204,A5052458149,Vinod Udayar,0000-0001-8705-0649,,,Vinod Udayar
4517.0,Lysosomal dysfunction in neurodegeneration: emerging concepts and methods,Vangheluwe,NA Review,10.1016/j.tins.2021.12.004,0.0,W4205593204,A5100401933,Yu Chen,0000-0001-5438-7309,Key Personnel,Team Vangheluwe,Yu Chen
4518.0,Lysosomal dysfunction in neurodegeneration: emerging concepts and methods,Vangheluwe,NA Review,10.1016/j.tins.2021.12.004,0.0,W4205593204,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4519.0,Lysosomal dysfunction in neurodegeneration: emerging concepts and methods,Vangheluwe,NA Review,10.1016/j.tins.2021.12.004,0.0,W4205593204,A5049461821,Ravi Jagasia,0000-0001-9477-7643,,,Ravi Jagasia
4520.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5049357772,Gustavo Morrone Parfitt,0000-0003-0168-4099,,,Gustavo Parfitt
4521.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5018315371,Elena Coccia,0000-0002-9849-2423,Key Personnel,Team Vangheluwe,Elena Coccia
4522.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5081282444,Camille Goldman,0000-0002-9089-7290,Key Personnel,Team Vangheluwe,Camille Goldman
4523.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5084927815,Kristen Whitney,0000-0002-1578-6339,,,Kristen Whitney
4524.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5103047337,Ricardo Reyes,0000-0003-0371-2348,,,Ricardo Reyes
4525.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5055471641,Lily Sarrafha,0000-0002-6168-2119,Key Personnel,Team Vangheluwe,Lily Sarrafha
4526.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5075869161,Ki Hong Nam,,,,Ki Nam
4527.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5104113705,Soha Sohail,,Key Personnel,Team Vangheluwe,Soha Sohail
4528.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5018879076,Drew R. Jones,0000-0001-8732-9818,,,Drew Jones
4529.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5066548665,John F. Crary,0000-0002-0556-293X,,,John Crary
4530.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5050948158,Alban Ordureau,0000-0002-4924-8520,,,Alban Ordureau
4531.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5027087812,Joel Blanchard,0000-0003-3142-2970,Co-PI,Team Vangheluwe,Joel Blanchard
4532.0,Disruption of lysosomal proteolysis in astrocytes facilitates midbrain organoid proteostasis failure in an early-onset Parkinson’s disease model | Nature Communications,Vangheluwe,10.1101/2022.08.26.505472,10.1038/s41467-024-44732-2,1.0,W4390691315,A5044070205,Tim Ahfeldt,0000-0001-6377-7376,,,Tim Ahfeldt
4533.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5018011138,Stephanie Vrijsen,0000-0002-2601-510X,Key Personnel,Team Vangheluwe,Stephanie Vrijsen
4534.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5032555407,Laura Besora-Casals,0000-0001-5113-957X,,,Laura Besora-Casals
4535.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5024492574,Sarah van Veen,0000-0002-7639-7847,Key Personnel,Team Vangheluwe,Sarah Veen
4536.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5060975734,Jeffrey Zielich,0000-0003-4879-0649,,,Jeffrey Zielich
4537.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4538.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5032282577,Norin Nabil Hamouda,0000-0003-1898-3597,,,Norin Hamouda
4539.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5102736533,Christian Fischer,,,,Christian Fischer
4540.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5028713739,Bart Ghesquière,0000-0003-1547-1705,,,Bart Ghesquière
4541.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5012385354,Ivailo Tournev,0000-0002-2399-9297,,,Ivailo Tournev
4542.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5091862786,Patrizia Agostinis,0000-0003-1314-2115,,,Patrizia Agostinis
4543.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4544.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4545.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5036306949,Eric J. Lambie,0000-0002-7371-128X,,,Eric Lambie
4546.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5053595396,Shaun Martin,0000-0003-4018-1507,,,Shaun Martin
4547.0,ATP13A2 -mediated endo-lysosomal polyamine export counters mitochondrial oxidative stress,Vangheluwe,missing,10.1073/pnas.1922342117,1.0,W3110543229,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4548.0,Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection - PubMed (nih.gov),Vangheluwe,review,10.1146/annurev-biochem-071322-021330,0.0,W4362632568,A5018011138,Stephanie Vrijsen,0000-0002-2601-510X,Key Personnel,Team Vangheluwe,Stephanie Vrijsen
4549.0,Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection - PubMed (nih.gov),Vangheluwe,review,10.1146/annurev-biochem-071322-021330,0.0,W4362632568,A5014957051,Marine Houdou,0000-0002-9766-3163,,,Marine Houdou
4550.0,Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection - PubMed (nih.gov),Vangheluwe,review,10.1146/annurev-biochem-071322-021330,0.0,W4362632568,A5087249913,Ana Cascalho,0000-0003-3534-9723,,,Ana Cascalho
4551.0,Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection - PubMed (nih.gov),Vangheluwe,review,10.1146/annurev-biochem-071322-021330,0.0,W4362632568,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4552.0,Polyamines in Parkinson's Disease: Balancing Between Neurotoxicity and Neuroprotection - PubMed (nih.gov),Vangheluwe,review,10.1146/annurev-biochem-071322-021330,0.0,W4362632568,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4553.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5018011138,Stephanie Vrijsen,0000-0002-2601-510X,Key Personnel,Team Vangheluwe,Stephanie Vrijsen
4554.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5071168601,Céline Vrancx,0000-0003-2594-9020,,,Céline Vrancx
4555.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5035363726,Mara Del Vecchio,,,,Mara Vecchio
4556.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5016435003,Johannes V. Swinnen,0000-0002-7720-5077,,,Johannes Swinnen
4557.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5091862786,Patrizia Agostinis,0000-0003-1314-2115,,,Patrizia Agostinis
4558.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5026407068,Joris Winderickx,0000-0003-3133-7733,,,Joris Winderickx
4559.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4560.0,Inter-organellar Communication in Parkinson's and Alzheimer's Disease: Looking Beyond Endoplasmic Reticulum-Mitochondria Contact Sites,Vangheluwe,review,10.3389/fnins.2022.900338,0.0,W4283206225,A5014570685,Wim Annaert,0000-0003-0150-9661,,,Wim Annaert
4561.0,Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction - PubMed (nih.gov),Vangheluwe,review,10.3390/biom12050616,0.0,W4224241428,A5035727257,Chase Chen,0000-0003-1016-0844,,,Chase Chen
4562.0,Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction - PubMed (nih.gov),Vangheluwe,review,10.3390/biom12050616,0.0,W4224241428,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4563.0,Lyso-IP: Uncovering Pathogenic Mechanisms of Lysosomal Dysfunction - PubMed (nih.gov),Vangheluwe,review,10.3390/biom12050616,0.0,W4224241428,A5100401933,Yu Chen,0000-0001-5438-7309,Key Personnel,Team Vangheluwe,Yu Chen
4564.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5014957051,Marine Houdou,0000-0002-9766-3163,,,Marine Houdou
4565.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5015022025,Nathalie Jacobs,0000-0003-2087-5720,,,Nathalie Jacobs
4566.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5048174649,Jonathan Coene,0000-0002-0502-0890,,,Jonathan Coene
4567.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5002813232,Mujahid Azfar,0000-0001-5822-3969,Key Personnel,Team Vangheluwe,Mujahid Azfar
4568.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5004804151,Roeland Vanhoutte,0000-0001-9797-620X,,,Roeland Vanhoutte
4569.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4570.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4571.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5005377294,Veronique Daniëls,0000-0003-3403-8106,Project Manager,Team Vangheluwe,Veronique Daniëls
4572.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5017438536,Steven H. L. Verhelst,0000-0002-7400-1319,,,Steven Verhelst
4573.0,Novel green fluorescent polyamines to analyze ATP13A2 and ATP13A3 activity in the mammalian polyamine transport system,Vangheluwe,10.1101/2022.12.15.520427,10.3390/biom13020337,1.0,W4319971674,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4574.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5102809874,Jianmin Si,,,,Jianmin Si
4575.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4576.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5089341251,Evy Lobbestael,0000-0002-6417-4670,,,Evy Lobbestael
4577.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5053595396,Shaun Martin,0000-0003-4018-1507,,,Shaun Martin
4578.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5024492574,Sarah van Veen,0000-0002-7639-7847,Key Personnel,Team Vangheluwe,Sarah Veen
4579.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4580.0,"ATP13A2 regulates cellular α-synuclein multimerization, membrane association, and externalization",Vangheluwe,missing,10.3390/ijms22052689,1.0,W3135554717,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4581.0,Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism,Vangheluwe,review,10.3390/ijms23105842,0.0,W4281390096,A5020496784,Makaila L. Furderer,0000-0002-4328-6657,,,Makaila Furderer
4582.0,Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism,Vangheluwe,review,10.3390/ijms23105842,0.0,W4281390096,A5019095083,Ellen Hertz,0000-0002-0916-3557,Key Personnel,Team Vangheluwe,Ellen Hertz
4583.0,Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism,Vangheluwe,review,10.3390/ijms23105842,0.0,W4281390096,A5011772005,Grisel Lopez,0000-0001-7785-2197,Key Personnel,Team Vangheluwe,Grisel Lopez
4584.0,Neuropathological Features of Gaucher Disease and Gaucher Disease with Parkinsonism,Vangheluwe,review,10.3390/ijms23105842,0.0,W4281390096,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4585.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5020496784,Makaila L. Furderer,0000-0002-4328-6657,,,Makaila Furderer
4586.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5021774873,Bahafta Berhe,,Key Personnel,Team Vangheluwe,Bahafta Berhe
4587.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5111108535,Tiffany C. Chen,,Key Personnel,Team Vangheluwe,Tiffany Chen
4588.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5001748471,Stephen Wincovitch,,,,Stephen Wincovitch
4589.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5091851465,Xuntian Jiang,0000-0001-9048-7294,,,Xuntian Jiang
4590.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
4591.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4592.0,A Comparative Biochemical and Pathological Evaluation of Brain Samples from Knock-In Murine Models of Gaucher Disease,Vangheluwe,,10.3390/ijms25031827,1.0,W4391472513,A5101764645,Tae‐Un Han,0000-0002-0287-0160,Key Personnel,Team Vangheluwe,Tae‐Un Han
4593.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5018011138,Stephanie Vrijsen,0000-0002-2601-510X,Key Personnel,Team Vangheluwe,Stephanie Vrijsen
4594.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5052958046,Rania Abou El Asrar,0000-0001-9947-2697,Key Personnel,Team Vangheluwe,Rania Asrar
4595.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5014957051,Marine Houdou,0000-0002-9766-3163,,,Marine Houdou
4596.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4597.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4598.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5086345439,Joseph A. Lyons,0000-0003-0218-4862,Co-PI,Team Vangheluwe,Joseph Lyons
4599.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5016643155,Jan Eggermont,0000-0002-8497-1159,,,Jan Eggermont
4600.0,Functional characterization of ATP13A2 variants associated with distinct neurodegenerative disorders,Vangheluwe,10.1101/2023.08.21.552829,,1.0,W4386050476,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4601.0,Is Gauchian genotyping of GBA1 variants reliable? | medRxiv,Vangheluwe,10.1101/2023.10.26.23297627,,1.0,W4387973789,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
4602.0,Is Gauchian genotyping of GBA1 variants reliable? | medRxiv,Vangheluwe,10.1101/2023.10.26.23297627,,1.0,W4387973789,A5035593562,Jens Lichtenberg,0000-0002-0023-4937,Key Personnel,Team Vangheluwe,Jens Lichtenberg
4603.0,Is Gauchian genotyping of GBA1 variants reliable? | medRxiv,Vangheluwe,10.1101/2023.10.26.23297627,,1.0,W4387973789,A5019095083,Ellen Hertz,0000-0002-0916-3557,Key Personnel,Team Vangheluwe,Ellen Hertz
4604.0,Is Gauchian genotyping of GBA1 variants reliable? | medRxiv,Vangheluwe,10.1101/2023.10.26.23297627,,1.0,W4387973789,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4605.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5019095083,Ellen Hertz,0000-0002-0916-3557,Key Personnel,Team Vangheluwe,Ellen Hertz
4606.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5034928193,Gani Perez,,,,Gani Perez
4607.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5100691930,Ying Hao,0000-0001-5053-4850,,,Ying Hao
4608.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5006325493,Krystyna Rytel,,Key Personnel,Team Vangheluwe,Krystyna Rytel
4609.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5100583784,Charis Ma,,,,Charis Ma
4610.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5083761823,Martha Kirby,0000-0001-7157-7964,,,Martha Kirby
4611.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5109131253,Stacie Anderson,,,,Stacie Anderson
4612.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5001748471,Stephen Wincovitch,,,,Stephen Wincovitch
4613.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5094022320,Kate Andersh,,,,Kate Andersh
4614.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5044070205,Tim Ahfeldt,0000-0001-6377-7376,,,Tim Ahfeldt
4615.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5027087812,Joel Blanchard,0000-0003-3142-2970,Co-PI,Team Vangheluwe,Joel Blanchard
4616.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5039117237,Yue Qi,0000-0003-1914-8710,,,Yue Qi
4617.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5011772005,Grisel Lopez,0000-0001-7785-2197,Key Personnel,Team Vangheluwe,Grisel Lopez
4618.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5032921133,Nahid Tayebi,0000-0002-1007-4957,Key Personnel,Team Vangheluwe,Nahid Tayebi
4619.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5009140419,Ellen Sidransky,0000-0002-3019-8500,Co-PI,Team Vangheluwe,Ellen Sidransky
4620.0,Comparative study of enriched dopaminergic neurons from siblings with Gaucher disease discordant for parkinsonism,Vangheluwe,10.1101/2024.02.25.581985,,1.0,W4392243974,A5100401933,Yu Chen,0000-0001-5438-7309,Key Personnel,Team Vangheluwe,Yu Chen
4621.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5081282444,Camille Goldman,0000-0002-9089-7290,Key Personnel,Team Vangheluwe,Camille Goldman
4622.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5031127834,Tatyana Kareva,0000-0002-6625-0243,Key Personnel,Team Vangheluwe,Tatyana Kareva
4623.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5055471641,Lily Sarrafha,0000-0002-6168-2119,Key Personnel,Team Vangheluwe,Lily Sarrafha
4624.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5008878552,Braxton R. Schuldt,0000-0002-1737-707X,,,Braxton Schuldt
4625.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5071149293,Abhishek Sahasrabudhe,0000-0002-0889-6185,,,Abhishek Sahasrabudhe
4626.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5044070205,Tim Ahfeldt,0000-0001-6377-7376,,,Tim Ahfeldt
4627.0,Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout,Vangheluwe,10.1101/2024.05.21.594886,,1.0,W4398160425,A5027087812,Joel Blanchard,0000-0003-3142-2970,Co-PI,Team Vangheluwe,Joel Blanchard
4628.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5074178397,María Sanchiz-Calvo,0000-0003-1773-8696,Key Personnel,Team Vangheluwe,María Sanchiz-Calvo
4629.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5018315371,Elena Coccia,0000-0002-9849-2423,Key Personnel,Team Vangheluwe,Elena Coccia
4630.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5011822215,Christopher Cawthorne,0000-0002-5975-0354,,,Christopher Cawthorne
4631.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5049357772,Gustavo Morrone Parfitt,0000-0003-0168-4099,,,Gustavo Parfitt
4632.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5081304921,Koen Van Laere,0000-0001-5200-7245,,,Koen Laere
4633.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5045378304,Teresa Torre-Muruzabal,0000-0002-8003-5187,,,Teresa Torre-Muruzabal
4634.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5051555731,Diego Cabezudo,0000-0001-6898-7225,,,Diego Cabezudo
4635.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5047396863,George Tsafaras,0000-0001-9297-0730,,,George Tsafaras
4636.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5087249913,Ana Cascalho,0000-0003-3534-9723,,,Ana Cascalho
4637.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5040886525,Chris Van den Haute,0000-0002-6650-3845,Key Personnel,Team Vangheluwe,Chris Haute
4638.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5008583951,Peter Vangheluwe,0000-0002-7822-2944,Lead-PI,Team Vangheluwe,Peter Vangheluwe
4639.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5027087812,Joel Blanchard,0000-0003-3142-2970,Co-PI,Team Vangheluwe,Joel Blanchard
4640.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5043034445,Eduard Bentea,0000-0003-2527-6997,,,Eduard Bentea
4641.0,Loss of the lysosomal lipid flippase ATP10B leads to progressive dopaminergic neurodegeneration and Parkinsonian motor deficits,Vangheluwe,10.1101/2024.07.09.602700,,1.0,W4400665181,A5081531120,Veerle Baekelandt,0000-0001-8966-2921,Co-PI,Team Vangheluwe,Veerle Baekelandt
4642.0,Local diffusion in the extracellular space of the brain - ScienceDirect,Vila,review,10.1016/j.nbd.2022.105981,0.0,W4313529249,A5023479832,Jan Tønnesen,0000-0003-3663-8463,Collaborator,Team Vila,Jan Tønnesen
4643.0,Local diffusion in the extracellular space of the brain - ScienceDirect,Vila,review,10.1016/j.nbd.2022.105981,0.0,W4313529249,A5043885663,Sabina Hrabětová,0000-0001-9211-5099,,,Sabina Hrabětová
4644.0,Local diffusion in the extracellular space of the brain - ScienceDirect,Vila,review,10.1016/j.nbd.2022.105981,0.0,W4313529249,A5102897836,Federico N. Soria,0000-0003-1229-9663,Collaborator,Team Vila,Federico Soria
4645.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5026847057,Claudia Ceci,0000-0002-5958-7497,,,Claudia Ceci
4646.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5005666712,Pedro Miguel Lacal,0000-0003-1166-4593,,,Pedro Lacal
4647.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5029278885,Maria Luisa Barbaccia,0000-0002-5378-3972,,,Maria Barbaccia
4648.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5082528797,Nicola Biagio Mercuri,0000-0001-6700-7491,Co-PI,Team Vila,Nicola Mercuri
4649.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5036918847,Grazia Graziani,0000-0002-0221-768X,,,Grazia Graziani
4650.0,The VEGFs/VEGFRs system in Alzheimer’s and Parkinson’s diseases: Pathophysiological roles and therapeutic implications,Vila,NA_review,10.1016/j.phrs.2024.107101,0.0,W4391605343,A5046897266,Ada Ledonne,0000-0001-6302-207X,Key personnel,Team Vila,Ada Ledonne
4651.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5049186987,Miguel López‐Aguirre,0000-0002-7788-3660,Collaborator,Team Vila,Miguel López‐Aguirre
4652.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5031025016,Michele Matarazzo,0000-0002-2907-8667,,,Michele Matarazzo
4653.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5082130741,Javier Blesa,0000-0002-4257-1325,Collaborator,Team Vila,Javier Blesa
4654.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5004745128,Mariana H.G. Monje,0000-0002-0730-4061,,,Mariana Monje
4655.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5086418742,Rafael Rodríguez‐Rojas,0000-0002-2903-199X,,,Rafael Rodríguez‐Rojas
4656.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5070150597,Álvaro Sánchez‐Ferro,0000-0003-2461-2485,,,Álvaro Sánchez‐Ferro
4657.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5062838955,José Á. Obeso,0000-0002-6996-8613,Co-PI,Team Vila,José Obeso
4658.0,Dopaminergic denervation and associated MRI microstructural changes in the nigrostriatal projection in early Parkinson’s disease patients | npj Parkinson's Disease (nature.com),Vila,missing,10.1038/s41531-023-00586-x,1.0,W4387765831,A5023850435,José A. Pineda‐Pardo,0000-0002-8776-0031,Collaborator,Team Vila,José Pineda‐Pardo
4659.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5089831492,Tiziano Balzano,0000-0001-6523-2206,,,Tiziano Balzano
4660.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5010398014,Natalia López‐González del Rey,,,,Natalia Rey
4661.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5084740875,Noelia Esteban‐Garcia,0000-0002-2741-3054,Collaborator,Team Vila,Noelia Esteban‐Garcia
4662.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5029025646,Alejandro Reinares-Sebastián,0000-0003-1632-4432,Collaborator,Team Vila,Alejandro Reinares-Sebastián
4663.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5023850435,José A. Pineda‐Pardo,0000-0002-8776-0031,Collaborator,Team Vila,José Pineda‐Pardo
4664.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5047198741,Inés Trigo‐Damas,0000-0002-7821-2973,Key personnel,Team Vila,Inés Trigo‐Damas
4665.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5062838955,José Á. Obeso,0000-0002-6996-8613,Co-PI,Team Vila,José Obeso
4666.0,Neurovascular and immune factors of vulnerability of substantia nigra dopaminergic neurons in non-human primates,Vila,,10.1038/s41531-024-00735-w,1.0,W4399754101,A5082130741,Javier Blesa,0000-0002-4257-1325,Collaborator,Team Vila,Javier Blesa
4667.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5013260183,Marta González-Sepúlveda,0000-0002-5627-847X,Key personnel,Team Vila,Marta González-Sepúlveda
4668.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5063862942,Joan Compte,0000-0001-5447-5122,,,Joan Compte
4669.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5006417995,Thaïs Cuadros,,,,Thaïs Cuadros
4670.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5021245587,Alba Nicolau,0000-0002-0836-2802,Key personnel,Team Vila,Alba Nicolau
4671.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5012546198,Camille Guillard-Sirieix,0000-0002-2645-1892,Key personnel,Team Vila,Camille Guillard-Sirieix
4672.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5088743556,Núria Peñuelas,0000-0001-6443-9790,,,Núria Peñuelas
4673.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5090842506,Marina Lorente Picón,0000-0002-3629-9804,Key personnel,Team Vila,Marina Picón
4674.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5057918981,Annabelle Parent,0000-0002-6195-812X,Key personnel,Team Vila,Annabelle Parent
4675.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5081551825,Jordi Romero‐Giménez,0000-0002-8459-9895,,,Jordi Romero‐Giménez
4676.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5002959173,Joana M. Cladera-Sastre,0000-0002-5680-5057,Key personnel,Team Vila,Joana Cladera-Sastre
4677.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5022347865,Ariadna Laguna,0000-0002-9732-6677,Key personnel,Team Vila,Ariadna Laguna
4678.0,In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson's disease,Vila,10.1101/2022.08.08.503142,10.1093/brain/awac445,1.0,W4318592048,A5059189782,Miquel Vila,0000-0002-1352-989X,Lead-PI,Team Vila,Miquel Vila
4679.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5055196927,Julia Chocarro,0000-0002-3670-3459,Key personnel Lanciego,Team Vila,Julia Chocarro
4680.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5029237737,Alberto J. Rico,0000-0002-9067-5444,Key personnel Lanciego,Team Vila,Alberto Rico
4681.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5046597231,Goiaz Ariznabarreta,0000-0002-8975-8971,Key personnel Lanciego,Team Vila,Goiaz Ariznabarreta
4682.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5002584391,Elvira Roda,0000-0002-2229-3639,Key personnel Lanciego,Team Vila,Elvira Roda
4683.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5001636938,Adriana Honrubia,0000-0001-7850-5234,Key personnel Lanciego,Team Vila,Adriana Honrubia
4684.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5007339532,María Collantes,0000-0003-1162-1470,,,María Collantes
4685.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5013934560,Iván Peñuelas,0000-0001-8008-976X,,,Iván Peñuelas
4686.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5110850822,Alfonso Vázquez,,,,Alfonso Vázquez
4687.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5048432018,Ana I. Rodríguez‐Pérez,0000-0003-1354-8799,,,Ana Rodríguez‐Pérez
4688.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5005884041,José L. Labandeira‐García,0000-0002-8243-9791,,,José Labandeira‐García
4689.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5059189782,Miquel Vila,0000-0002-1352-989X,Lead-PI,Team Vila,Miquel Vila
4690.0,Neuromelanin accumulation drives endogenous synucleinopathy in non-human primates,Vila,10.1101/2023.08.04.551615,10.1093/brain/awad331,1.0,W4387125046,A5079288330,José L. Lanciego,0000-0003-2301-5419,Collaborator,Team Vila,José Lanciego
4691.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5029237737,Alberto J. Rico,0000-0002-9067-5444,Key personnel Lanciego,Team Vila,Alberto Rico
4692.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5093197281,Almudena Corcho,0009-0007-6198-7354,,,Almudena Corcho
4693.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5055196927,Julia Chocarro,0000-0002-3670-3459,Key personnel Lanciego,Team Vila,Julia Chocarro
4694.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5046597231,Goiaz Ariznabarreta,0000-0002-8975-8971,Key personnel Lanciego,Team Vila,Goiaz Ariznabarreta
4695.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5002584391,Elvira Roda,0000-0002-2229-3639,Key personnel Lanciego,Team Vila,Elvira Roda
4696.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5001636938,Adriana Honrubia,0000-0001-7850-5234,Key personnel Lanciego,Team Vila,Adriana Honrubia
4697.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5109272125,Patricia Arnaiz,,Key personnel Lanciego,Team Vila,Patricia Arnaiz
4698.0,Development And Characterization Of A Non-Human Primate Model Of Disseminated Synucleinopathy,Vila,10.1101/2023.12.15.571818,10.3389/fnana.2024.1355940,1.0,W4393229431,A5079288330,José L. Lanciego,0000-0003-2301-5419,Collaborator,Team Vila,José Lanciego
4699.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5103731786,Mónica Pardo,,,,Mónica Pardo
4700.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5043006921,Sara Gregorio,,,,Sara Gregorio
4701.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5001420330,Enrica Montalban,0000-0001-7625-7820,,,Enrica Montalban
4702.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5010405097,Lluı́s Pujadas,0000-0003-3890-8279,,,Lluı́s Pujadas
4703.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5032947897,Alba Elias-Tersa,0000-0002-6416-1677,,,Alba Elias-Tersa
4704.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5014639853,Núria Masachs,,,,Núria Masachs
4705.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5033144356,Alba Vílchez-Acosta,0000-0001-8268-591X,,,Alba Vílchez-Acosta
4706.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5057918981,Annabelle Parent,0000-0002-6195-812X,Key personnel,Team Vila,Annabelle Parent
4707.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5002621185,Carme Auladell,0000-0001-8345-1859,,,Carme Auladell
4708.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5065550629,Jean‐Antoine Girault,0000-0002-7900-1705,,,Jean‐Antoine Girault
4709.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5059189782,Miquel Vila,0000-0002-1352-989X,Lead-PI,Team Vila,Miquel Vila
4710.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5032456571,Angus C. Nairn,0000-0002-7075-0195,,,Angus Nairn
4711.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5011542402,Yasmina Manso,0000-0002-5788-4180,,,Yasmina Manso
4712.0,Adult-specific Reelin expression alters striatal neuronal organization: implications for neuropsychiatric disorders,Vila,10.1101/2023.01.21.525025,10.3389/fncel.2023.1143319,1.0,W4366547833,A5107632676,Eduardo Soriano,0000-0001-9260-9291,,,Eduardo Soriano
4713.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5032067791,Rosaria Meccariello,0000-0003-2174-1118,,,Rosaria Meccariello
4714.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5062499648,Gian Carlo Bellenchi,0000-0002-9302-0021,,,Gian Bellenchi
4715.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5003693303,Salvatore Pulcrano,0000-0002-5324-8689,,,Salvatore Pulcrano
4716.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5084442661,Sebastian Luca D’Addario,0000-0001-9467-9584,Key personnel,Team Vila,Sebastian D’Addario
4717.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5089300322,Domenico Tafuri,0000-0002-5948-1414,,,Domenico Tafuri
4718.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5082528797,Nicola Biagio Mercuri,0000-0001-6700-7491,Co-PI,Team Vila,Nicola Mercuri
4719.0,Frontiers | Neuronal dysfunction and gene modulation by non-coding RNA in Parkinson’s disease and synucleinopathies (frontiersin.org),Vila,review,10.3389/fncel.2023.1328269,0.0,W4390611441,A5048708355,Ezia Guatteo,0000-0001-6338-1793,Collaborator,Team Vila,Ezia Guatteo
4720.0,Fluorescence Microscopy Shadow Imaging for Neuroscience,Vila,review,10.3389/fncel.2024.1330100,0.0,W4391841711,A5002959610,V. V. G. Krishna Inavalli,0000-0002-7100-0214,,,V. Inavalli
4721.0,Fluorescence Microscopy Shadow Imaging for Neuroscience,Vila,review,10.3389/fncel.2024.1330100,0.0,W4391841711,A5076027069,Virginia Puente‐Muñoz,0000-0002-4860-9312,,,Virginia Puente‐Muñoz
4722.0,Fluorescence Microscopy Shadow Imaging for Neuroscience,Vila,review,10.3389/fncel.2024.1330100,0.0,W4391841711,A5047796812,Jonathan E. Draffin,0000-0002-1686-8504,Key personnel,Team Vila,Jonathan Draffin
4723.0,Fluorescence Microscopy Shadow Imaging for Neuroscience,Vila,review,10.3389/fncel.2024.1330100,0.0,W4391841711,A5023479832,Jan Tønnesen,0000-0003-3663-8463,Collaborator,Team Vila,Jan Tønnesen
4724.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5022347865,Ariadna Laguna,0000-0002-9732-6677,Key personnel,Team Vila,Ariadna Laguna
4725.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5088743556,Núria Peñuelas,0000-0001-6443-9790,,,Núria Peñuelas
4726.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5013260183,Marta González-Sepúlveda,0000-0002-5627-847X,Key personnel,Team Vila,Marta González-Sepúlveda
4727.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5021245587,Alba Nicolau,0000-0002-0836-2802,Key personnel,Team Vila,Alba Nicolau
4728.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5042765445,Sébastien Arthaud,0000-0001-7271-5468,,,Sébastien Arthaud
4729.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5012546198,Camille Guillard-Sirieix,0000-0002-2645-1892,Key personnel,Team Vila,Camille Guillard-Sirieix
4730.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5090842506,Marina Lorente Picón,0000-0002-3629-9804,Key personnel,Team Vila,Marina Picón
4731.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5063862942,Joan Compte,0000-0001-5447-5122,,,Joan Compte
4732.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5033153774,Lluís Miquel-Rio,0000-0002-3547-6004,,,Lluís Miquel-Rio
4733.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5064586919,Helena Xicoy,0000-0001-6641-1222,,,Helena Xicoy
4734.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5106405528,Jiong Liu,0009-0001-2208-2882,,,Jiong Liu
4735.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5057918981,Annabelle Parent,0000-0002-6195-812X,Key personnel,Team Vila,Annabelle Parent
4736.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5006417995,Thaïs Cuadros,,,,Thaïs Cuadros
4737.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5081551825,Jordi Romero‐Giménez,0000-0002-8459-9895,,,Jordi Romero‐Giménez
4738.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5113429651,Gemma Pujol,,,,Gemma Pujol
4739.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5069412405,Lydia Giménez‐Llort,0000-0002-4091-489X,,,Lydia Giménez‐Llort
4740.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5043257734,Patrice Fort,0000-0003-1211-8631,,,Patrice Fort
4741.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5067561723,Analı́a Bortolozzi,0000-0002-2069-9192,,,Analı́a Bortolozzi
4742.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5068882014,Iria Carballo‐Carbajal,0000-0002-4403-8006,,,Iria Carballo‐Carbajal
4743.0,Modelling human brain-wide pigmentation in rodents recapitulates age-related multisystem neurodegenerative deficits,Vila,10.1101/2023.08.08.552400,,1.0,W4385649180,A5059189782,Miquel Vila,0000-0002-1352-989X,Lead-PI,Team Vila,Miquel Vila
4744.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5063862942,Joan Compte,0000-0001-5447-5122,,,Joan Compte
4745.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5076494986,Marion Tible,0000-0001-5067-3711,,,Marion Tible
4746.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5006417995,Thaïs Cuadros,,,,Thaïs Cuadros
4747.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5081551825,Jordi Romero‐Giménez,0000-0002-8459-9895,,,Jordi Romero‐Giménez
4748.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5022347865,Ariadna Laguna,0000-0002-9732-6677,Key personnel,Team Vila,Ariadna Laguna
4749.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5047550032,Jean‐François Aubry,0000-0003-2644-3945,,,Jean‐François Aubry
4750.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5011243086,Erik Dumont,0000-0003-1002-8667,,,Erik Dumont
4751.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5014519406,Charlotte Constans,0000-0001-6378-9158,,,Charlotte Constans
4752.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5050621857,Thomas Tiennot,0000-0002-5486-3165,,,Thomas Tiennot
4753.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5038917187,Mathieu Santin,0000-0003-4251-0538,,,Mathieu Santin
4754.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5029597969,Stéphane Lehéricy,0000-0002-5802-3518,,,Stéphane Lehéricy
4755.0,Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents,Vila,10.1101/2023.08.08.552410,,1.0,W4385782167,A5059189782,Miquel Vila,0000-0002-1352-989X,Lead-PI,Team Vila,Miquel Vila
4756.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5013626188,Mariangela Massaro Cenere,0000-0001-7758-8082,Key personnel Lanciego,Team Vila,Mariangela Cenere
4757.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5064062765,Marta Tiberi,0000-0002-5287-424X,,,Marta Tiberi
4758.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5057335357,Emanuela Paldino,0000-0002-8483-543X,,,Emanuela Paldino
4759.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5084442661,Sebastian Luca D’Addario,0000-0001-9467-9584,Key personnel,Team Vila,Sebastian D’Addario
4760.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5076918566,Mauro Federici,0000-0003-4563-1677,,,Mauro Federici
4761.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5065183720,Cecilia Giacomet,0000-0001-7210-5619,Key personnel Lanciego,Team Vila,Cecilia Giacomet
4762.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5041223053,Debora Cutuli,0000-0003-4788-2461,,,Debora Cutuli
4763.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5016067194,Alessandro Matteocci,0009-0007-4556-1257,,,Alessandro Matteocci
4764.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5072683224,Francesca Cossa,0000-0002-8072-1910,Key personnel Lanciego,Team Vila,Francesca Cossa
4765.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5013851008,Beatrice Zarrilli,,Key personnel Lanciego,Team Vila,Beatrice Zarrilli
4766.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5050352104,Nicolas Casadei,0000-0003-2209-0580,,,Nicolas Casadei
4767.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5046897266,Ada Ledonne,0000-0001-6302-207X,Key personnel,Team Vila,Ada Ledonne
4768.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5024301232,Laura Petrosini,0000-0001-7464-5168,,,Laura Petrosini
4769.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5017967055,Nicola Berretta,0000-0001-8097-6238,Collaborator,Team Vila,Nicola Berretta
4770.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5051764819,Francesca R. Fusco,0000-0003-2226-523X,,,Francesca Fusco
4771.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5026859621,Valerio Chiurchiù,0000-0002-0316-7311,,,Valerio Chiurchiù
4772.0,Systemic inflammation triggers long-lasting neuroinflammation and accelerates neurodegeneration in a rat model of Parkinson’s disease overexpressing human α-synuclein,Vila,10.1101/2024.01.30.577912,,1.0,W4391400026,A5082528797,Nicola Biagio Mercuri,0000-0001-6700-7491,Co-PI,Team Vila,Nicola Mercuri
4773.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5013851008,Beatrice Zarrilli,,Key personnel Lanciego,Team Vila,Beatrice Zarrilli
4774.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5065183720,Cecilia Giacomet,0000-0001-7210-5619,Key personnel Lanciego,Team Vila,Cecilia Giacomet
4775.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5072683224,Francesca Cossa,0000-0002-8072-1910,Key personnel Lanciego,Team Vila,Francesca Cossa
4776.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5076918566,Mauro Federici,0000-0003-4563-1677,,,Mauro Federici
4777.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5017967055,Nicola Berretta,0000-0001-8097-6238,Collaborator,Team Vila,Nicola Berretta
4778.0,Functional efficacy of the MAO-B inhibitor safinamide in murine substantia nigra pars compacta dopaminergic neurons in vitro: a comparative study with tranylcypromine,Vila,10.1101/2024.05.28.596142,,1.0,W4399255251,A5082528797,Nicola Biagio Mercuri,0000-0001-6700-7491,Co-PI,Team Vila,Nicola Mercuri
4779.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5064977245,Suresh Poovathingal,0000-0002-3236-2255,Key Personnel,Team Voet,Suresh Poovathingal
4780.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5012454695,Kristofer Davie,0000-0003-2182-1249,,,Kristofer Davie
4781.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5058580972,Lars E. Borm,0000-0002-1764-6057,,,Lars Borm
4782.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5070098454,Roel Vandepoel,0000-0002-0876-2179,,,Roel Vandepoel
4783.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5000198915,Nicolas Poulvellarie,0000-0001-7712-2477,,,Nicolas Poulvellarie
4784.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5058201575,Annelien Verfaillie,,,,Annelien Verfaillie
4785.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5084434004,Nikky Corthout,0000-0003-1176-7277,,,Nikky Corthout
4786.0,Nova-ST: Nano-Patterned Ultra-Dense platform for spatial transcriptomics,Voet,10.1101/2024.02.22.581576,10.1016/j.crmeth.2024.100831,1.0,W4401364144,A5002137087,Stein Aerts,0000-0002-8006-0315,Co-PI,Team Voet,Stein Aerts
4787.0,More of less: Novel multi-ome profiling of single human neurons,Voet,NA Review,10.1016/j.xgen.2022.100110,0.0,W4221026466,A5033501843,Huiwen Che,0000-0002-3651-069X,,,Huiwen Che
4788.0,More of less: Novel multi-ome profiling of single human neurons,Voet,NA Review,10.1016/j.xgen.2022.100110,0.0,W4221026466,A5081498592,Bernard Thienpont,0000-0002-8772-6845,Co-PI,Team Voet,Bernard Thienpont
4789.0,Methods and applications for single-cell and spatial multi-omics,Voet,NA Review,10.1038/s41576-023-00580-2,0.0,W4322768301,A5032850044,Katy Vandereyken,0000-0002-4477-5866,Key Personnel,Team Voet,Katy Vandereyken
4790.0,Methods and applications for single-cell and spatial multi-omics,Voet,NA Review,10.1038/s41576-023-00580-2,0.0,W4322768301,A5045411063,Alejandro Sifrim,0000-0001-8247-4020,Collaborating PI,Team Voet,Alejandro Sifrim
4791.0,Methods and applications for single-cell and spatial multi-omics,Voet,NA Review,10.1038/s41576-023-00580-2,0.0,W4322768301,A5081498592,Bernard Thienpont,0000-0002-8772-6845,Co-PI,Team Voet,Bernard Thienpont
4792.0,Methods and applications for single-cell and spatial multi-omics,Voet,NA Review,10.1038/s41576-023-00580-2,0.0,W4322768301,A5033632636,Thierry Voet,0000-0003-1204-9963,Lead-PI,Team Voet,Thierry Voet
4793.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5050972881,Ibrahim Ihsan Taskiran,0000-0002-5077-5264,,,Ibrahim Taskiran
4794.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5051456216,Katina I. Spanier,0000-0002-1375-4157,,,Katina Spanier
4795.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5093472326,Hannah Dickmänken,0000-0001-9707-9293,,,Hannah Dickmänken
4796.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5093400185,Niklas Kempynck,0000-0002-0104-4844,Key Personnel,Team Voet,Niklas Kempynck
4797.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5069791579,Alexandra Pančíková,0000-0002-0693-132X,Key Personnel,Team Voet,Alexandra Pančíková
4798.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5093472327,Eren Çan Eksi,0000-0002-3122-9858,,,Eren Eksi
4799.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5001053440,Gert Hulselmans,0000-0003-2205-1899,Key Personnel,Team Voet,Gert Hulselmans
4800.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5017523286,Joy N. Ismail,0000-0002-7128-7040,,,Joy Ismail
4801.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5057448724,Koen Theunis,0000-0002-0699-6676,Key Personnel,Team Voet,Koen Theunis
4802.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5070098454,Roel Vandepoel,0000-0002-0876-2179,,,Roel Vandepoel
4803.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5015651743,Valerie Christiaens,0000-0002-5024-8691,Key Personnel,Team Voet,Valerie Christiaens
4804.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5075153586,David Mauduit,0000-0002-2045-227X,,,David Mauduit
4805.0,Cell-type-directed design of synthetic enhancers,Voet,10.1101/2022.07.26.501466,10.1038/s41586-023-06936-2,1.0,W4389613138,A5002137087,Stein Aerts,0000-0002-8006-0315,Co-PI,Team Voet,Stein Aerts
4806.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5013657567,Moritz Smolka,0000-0002-8621-600X,,,Moritz Smolka
4807.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5008831442,Luis F. Paulin,0000-0003-2567-3773,,,Luis Paulin
4808.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5002204513,Christopher M. Grochowski,0000-0002-3884-7720,,,Christopher Grochowski
4809.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5102910372,Dominic W. Horner,0009-0002-1988-3838,,,Dominic Horner
4810.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5039165370,Medhat Mahmoud,0000-0002-2553-4231,,,Medhat Mahmoud
4811.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5011002061,Sairam Behera,0000-0002-9047-0203,,,Sairam Behera
4812.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5000508972,Ester Kalef-Ezra,0000-0002-1297-3315,,,Ester Kalef-Ezra
4813.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5027933156,Mira Gandhi,,,,Mira Gandhi
4814.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5035392494,Karl Hong,,,,Karl Hong
4815.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5023261072,Davut Pehli̇van,0000-0001-5788-0270,,,Davut Pehli̇van
4816.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
4817.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5083240572,Claudia M.B. Carvalho,0000-0002-2090-298X,,,Claudia Carvalho
4818.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5012157016,Christos Proukakis,0000-0001-6423-6539,Co-PI,Team Voet,Christos Proukakis
4819.0,Comprehensive structural variant detection: From mosaic to population-level,Voet,10.1101/2022.04.04.487055,10.1038/s41587-023-02024-y,1.0,W4390500910,A5037440162,Fritz J. Sedlazeck,0000-0001-6040-2691,Collaborating PI,Team Voet,Fritz Sedlazeck
4820.0,Multiple genome alignment in the telomere-to-telomere assembly era | Genome Biology | Full Text (biomedcentral.com),Voet,review,10.1186/s13059-022-02735-6,0.0,W4293680421,A5072499401,Bryce Kille,0000-0003-2946-6915,,,Bryce Kille
4821.0,Multiple genome alignment in the telomere-to-telomere assembly era | Genome Biology | Full Text (biomedcentral.com),Voet,review,10.1186/s13059-022-02735-6,0.0,W4293680421,A5083401418,Advait Balaji,0000-0001-9858-9578,,,Advait Balaji
4822.0,Multiple genome alignment in the telomere-to-telomere assembly era | Genome Biology | Full Text (biomedcentral.com),Voet,review,10.1186/s13059-022-02735-6,0.0,W4293680421,A5037440162,Fritz J. Sedlazeck,0000-0001-6040-2691,Collaborating PI,Team Voet,Fritz Sedlazeck
4823.0,Multiple genome alignment in the telomere-to-telomere assembly era | Genome Biology | Full Text (biomedcentral.com),Voet,review,10.1186/s13059-022-02735-6,0.0,W4293680421,A5025825738,Michael Nute,0000-0003-4129-6525,,,Michael Nute
4824.0,Multiple genome alignment in the telomere-to-telomere assembly era | Genome Biology | Full Text (biomedcentral.com),Voet,review,10.1186/s13059-022-02735-6,0.0,W4293680421,A5054369332,Todd J. Treangen,0000-0002-3760-564X,,,Todd Treangen
4825.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5072934627,Florian De Rop,0000-0001-5241-924X,,,Florian Rop
4826.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5017523286,Joy N. Ismail,0000-0002-7128-7040,,,Joy Ismail
4827.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5061687284,Carmen Bravo González‐Blas,0000-0003-0973-9410,,,Carmen González‐Blas
4828.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5001053440,Gert Hulselmans,0000-0003-2205-1899,Key Personnel,Team Voet,Gert Hulselmans
4829.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5075978549,Christopher Campbell Flerin,,,,Christopher Flerin
4830.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5018784559,Jasper Janssens,0000-0001-9264-0782,,,Jasper Janssens
4831.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5057448724,Koen Theunis,0000-0002-0699-6676,Key Personnel,Team Voet,Koen Theunis
4832.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5015651743,Valerie Christiaens,0000-0002-5024-8691,Key Personnel,Team Voet,Valerie Christiaens
4833.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5052205823,Jasper Wouters,0000-0002-7129-2990,,,Jasper Wouters
4834.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5055239746,Gabriele Marcassa,0000-0001-8848-2136,,,Gabriele Marcassa
4835.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5043338272,Joris de Wit,0000-0003-1120-1089,,,Joris Wit
4836.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5064977245,Suresh Poovathingal,0000-0002-3236-2255,Key Personnel,Team Voet,Suresh Poovathingal
4837.0,Hydrop enables droplet-based single-cell ATAC-seq and single-cell RNA-seq using dissolvable hydrogel beads,Voet,10.1101/2021.06.04.447104,10.7554/eLife.73971,1.0,W4212780233,A5002137087,Stein Aerts,0000-0002-8006-0315,Co-PI,Team Voet,Stein Aerts
4838.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5000508972,Ester Kalef-Ezra,0000-0002-1297-3315,,,Ester Kalef-Ezra
4839.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5001979869,Zeliha Gözde Turan,0000-0001-8312-7725,Key Personnel,Team Voet,Zeliha Turan
4840.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5052309034,Diego Pérez‐Rodríguez,0000-0003-4903-3914,,,Diego Pérez‐Rodríguez
4841.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5092614113,Ida Bomann,0009-0004-3628-8023,,,Ida Bomann
4842.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5011002061,Sairam Behera,0000-0002-9047-0203,,,Sairam Behera
4843.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5074615141,Caoimhe Morley,0000-0001-6258-9250,Key Personnel,Team Voet,Caoimhe Morley
4844.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5046814636,Sonja W. Scholz,0000-0002-6623-0429,,,Sonja Scholz
4845.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5063134863,Zane Jaunmuktane,0000-0001-7738-8881,Co-PI,Team Hardy,Zane Jaunmuktane
4846.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5063134863,Zane Jaunmuktane,0000-0001-7738-8881,Collaborating PI,Team Voet,Zane Jaunmuktane
4847.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5021604609,Jonas Demeulemeester,0000-0002-2660-2478,Collaborating PI,Team Voet,Jonas Demeulemeester
4848.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5037440162,Fritz J. Sedlazeck,0000-0001-6040-2691,Collaborating PI,Team Voet,Fritz Sedlazeck
4849.0,Single-cell somatic copy number variants in brain using different amplification methods and reference genomes | bioRxiv,Voet,10.1101/2023.08.07.552289,,1.0,W4385667615,A5012157016,Christos Proukakis,0000-0001-6423-6539,Co-PI,Team Voet,Christos Proukakis
4850.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5053538648,Natalie Kaempf,0000-0002-5466-3972,Key Personnel,Team Voet,Natalie Kaempf
4851.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5027782677,Jorge S. Valadas,0000-0002-2126-9485,,,Jorge Valadas
4852.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5020825067,Pieter Robberechts,0000-0002-3734-0047,,,Pieter Robberechts
4853.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5065096295,Nils Schoovaerts,0000-0003-0990-6784,,,Nils Schoovaerts
4854.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5066788526,Roman Praschberger,0000-0001-7162-2403,,,Roman Praschberger
4855.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5044662708,Antonio Ortega,0000-0002-6617-341X,,,Antonio Ortega
4856.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5106801012,Ayse Kilic,0000-0002-9369-8377,,,Ayse Kilic
4857.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5081972058,Dries Chabot,,,,Dries Chabot
4858.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5067528977,Ulrike Pech,0009-0009-6985-9300,,,Ulrike Pech
4859.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5055747324,Sabine Kuenen,0000-0001-9135-5293,,,Sabine Kuenen
4860.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5035170115,Sven Vilain,0000-0002-9166-2792,,,Sven Vilain
4861.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5082210414,El‐Sayed Baz,0000-0003-1382-6090,,,El‐Sayed Baz
4862.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5057044252,Jeevanjot Singh,,,,Jeevanjot Singh
4863.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5029479248,Jesse Davis,0000-0002-3748-9263,,,Jesse Davis
4864.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5100402709,Sha Liu,0000-0002-7168-330X,,,Sha Liu
4865.0,Behavioral screening defines three molecular Parkinsonism subgroups in Drosophila | bioRxiv,Voet,10.1101/2024.08.27.609924,,1.0,W4401933640,A5040983698,Patrik Verstreken,0000-0002-5073-5393,Collaborating PI,Team Voet,Patrik Verstreken
4866.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5056426700,Salvador Durá-Bernal,0000-0002-8561-5324,,,Salvador Durá-Bernal
4867.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5055042639,Samuel A. Neymotin,0000-0003-3646-5195,,,Samuel Neymotin
4868.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5016045126,Benjamin A. Suter,0000-0002-9885-6936,,,Benjamin Suter
4869.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5029394770,Joshua Dacre,0000-0001-9643-7597,,,Joshua Dacre
4870.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5089900934,João Vitor da Silva Moreira,0000-0001-6888-2642,,,João Moreira
4871.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5027931249,Eugenio Urdapilleta,0000-0002-1656-3188,,,Eugenio Urdapilleta
4872.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5084882656,Julia Schiemann,0009-0001-3983-2002,,,Julia Schiemann
4873.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5030694323,Ian Duguid,0000-0001-6966-2641,,,Ian Duguid
4874.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5052931874,Gordon M. Shepherd,0000-0002-1455-8262,,,Gordon Shepherd
4875.0,"Multiscale model of primary motor cortex circuits predicts in vivo cell type-specific, behavioral state-dependent dynamics",Wichmann,10.1101/2022.02.03.479040,10.1016/j.celrep.2023.112574,1.0,W4380077829,A5082122443,William W. Lytton,0000-0002-3727-2849,,,William Lytton
4876.0,Open-Source Platform for Kinematic Analysis of Mouse Forelimb Movement,Wichmann,10.1101/2024.01.31.578239,10.1016/j.xpro.2024.103140,1.0,W4399857718,A5111146575,Daniil Berezhnoi,,Key Personnel,Team Wichmann,Daniil Berezhnoi
4877.0,Open-Source Platform for Kinematic Analysis of Mouse Forelimb Movement,Wichmann,10.1101/2024.01.31.578239,10.1016/j.xpro.2024.103140,1.0,W4399857718,A5094147299,Hiba Douja Chehade,,,,Hiba Chehade
4878.0,Open-Source Platform for Kinematic Analysis of Mouse Forelimb Movement,Wichmann,10.1101/2024.01.31.578239,10.1016/j.xpro.2024.103140,1.0,W4399857718,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4879.0,Reduced Thalamic Excitation to Motor Cortical Pyramidal Tract Neurons in Parkinsonism,Wichmann,10.1101/2022.09.24.509340,10.1126/sciadv.adg3038,1.0,W4386090431,A5071290415,Liqiang Chen,0000-0003-3236-1129,Key Personnel,Team Wichmann,Liqiang Chen
4880.0,Reduced Thalamic Excitation to Motor Cortical Pyramidal Tract Neurons in Parkinsonism,Wichmann,10.1101/2022.09.24.509340,10.1126/sciadv.adg3038,1.0,W4386090431,A5052036575,Samuel Daniels,0000-0003-4985-3787,,,Samuel Daniels
4881.0,Reduced Thalamic Excitation to Motor Cortical Pyramidal Tract Neurons in Parkinsonism,Wichmann,10.1101/2022.09.24.509340,10.1126/sciadv.adg3038,1.0,W4386090431,A5041373147,Rachel Dvorak,0000-0002-1245-710X,,,Rachel Dvorak
4882.0,Reduced Thalamic Excitation to Motor Cortical Pyramidal Tract Neurons in Parkinsonism,Wichmann,10.1101/2022.09.24.509340,10.1126/sciadv.adg3038,1.0,W4386090431,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4883.0,Simulations predict differing phase responses to excitation vs. inhibition intheta-resonant pyramidal neurons,Wichmann,10.1101/2023.03.20.533519,10.1152/jn.00160.2023,1.0,W4386084524,A5033120907,Craig Kelley,0000-0001-7978-5688,,,Craig Kelley
4884.0,Simulations predict differing phase responses to excitation vs. inhibition intheta-resonant pyramidal neurons,Wichmann,10.1101/2023.03.20.533519,10.1152/jn.00160.2023,1.0,W4386084524,A5044060170,Srdjan D. Antic,0000-0001-7102-4710,,,Srdjan Antic
4885.0,Simulations predict differing phase responses to excitation vs. inhibition intheta-resonant pyramidal neurons,Wichmann,10.1101/2023.03.20.533519,10.1152/jn.00160.2023,1.0,W4386084524,A5054280386,Nicholas T. Carnevale,,,,Nicholas Carnevale
4886.0,Simulations predict differing phase responses to excitation vs. inhibition intheta-resonant pyramidal neurons,Wichmann,10.1101/2023.03.20.533519,10.1152/jn.00160.2023,1.0,W4386084524,A5047980835,John L. Kubie,0000-0001-6900-2168,,,John Kubie
4887.0,Simulations predict differing phase responses to excitation vs. inhibition intheta-resonant pyramidal neurons,Wichmann,10.1101/2023.03.20.533519,10.1152/jn.00160.2023,1.0,W4386084524,A5082122443,William W. Lytton,0000-0002-3727-2849,,,William Lytton
4888.0,Basal ganglia neurons in healthy and parkinsonian primates generate recurring sequences of spikes,Wichmann,10.1101/2022.05.25.493476,10.1152/jn.00265.2022,1.0,W4362602509,A5056482545,Adriana Galván,0000-0001-9939-0130,Co-PI,Team Wichmann,Adriana Galván
4889.0,Basal ganglia neurons in healthy and parkinsonian primates generate recurring sequences of spikes,Wichmann,10.1101/2022.05.25.493476,10.1152/jn.00265.2022,1.0,W4362602509,A5042569468,Thomas Wichmann,0000-0002-2751-9545,Lead-PI,Team Wichmann,Thomas Wichmann
4890.0,Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE,Wichmann,10.1101/2022.02.03.479029,10.3389/fninf.2022.884245,1.0,W4296672472,A5015644536,Fernando S. Borges,0000-0002-7647-2341,,,Fernando Borges
4891.0,Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE,Wichmann,10.1101/2022.02.03.479029,10.3389/fninf.2022.884245,1.0,W4296672472,A5089900934,João Vitor da Silva Moreira,0000-0001-6888-2642,,,João Moreira
4892.0,Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE,Wichmann,10.1101/2022.02.03.479029,10.3389/fninf.2022.884245,1.0,W4296672472,A5037332166,Lavinia Mitiko Takarabe,0000-0001-8493-7033,,,Lavinia Takarabe
4893.0,Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE,Wichmann,10.1101/2022.02.03.479029,10.3389/fninf.2022.884245,1.0,W4296672472,A5082122443,William W. Lytton,0000-0002-3727-2849,,,William Lytton
4894.0,Large-scale biophysically detailed model of somatosensory thalamocortical circuits in NetPyNE,Wichmann,10.1101/2022.02.03.479029,10.3389/fninf.2022.884245,1.0,W4296672472,A5056426700,Salvador Durá-Bernal,0000-0002-8561-5324,,,Salvador Durá-Bernal
4895.0,Motor cortical circuit adaptations in parkinsonism,Wichmann,NA_review,10.4103/1673-5374.392884,0.0,W4390730026,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4896.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5071290415,Liqiang Chen,0000-0003-3236-1129,Key Personnel,Team Wichmann,Liqiang Chen
4897.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5081721044,Chetan Nagaraja,0000-0001-9768-9462,,,Chetan Nagaraja
4898.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5052036575,Samuel Daniels,0000-0003-4985-3787,,,Samuel Daniels
4899.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5047731142,Zoe Fisk,0000-0002-2185-0819,,,Zoe Fisk
4900.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5041373147,Rachel Dvorak,0000-0002-1245-710X,,,Rachel Dvorak
4901.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5036594161,Lindsay Meyerdirk,0000-0003-4640-9517,Key Personnel,Team Biederer,Lindsay Meyerdirk
4902.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5074237697,Jennifer A. Steiner,0000-0003-0953-1310,,,Jennifer Steiner
4903.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5023099454,Martha L. Escobar Galvis,0000-0001-8400-9392,,,Martha Galvis
4904.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Biederer,Michael Henderson
4905.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5034385515,Michael X. Henderson,0000-0001-9710-0726,Co-PI,Team Lee,Michael Henderson
4906.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5054577159,Maxime W.C. Rousseaux,0000-0002-2737-6193,Co-PI,Team Schlossmacher,Maxime Rousseaux
4907.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5072622786,Patrik Brundin,0000-0003-2924-5186,,,Patrik Brundin
4908.0,Synaptic location is a determinant of the detrimental effects of α-synuclein pathology to glutamatergic transmission in the basolateral amygdala,Wichmann,10.1101/2022.02.20.481207,10.7554/eLife.78055,1.0,W4283741897,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4909.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5101866473,Wei Zhou,0000-0002-2548-6348,Key Personnel,Team Wichmann,Wei Zhou
4910.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5052036575,Samuel Daniels,0000-0003-4985-3787,,,Samuel Daniels
4911.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5076365007,Vijay Paul Singh,0000-0002-5163-0876,Key Personnel,Team Biederer,Vijay Singh
4912.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5062983023,Marissa Menard,,,,Marissa Menard
4913.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5023099454,Martha L. Escobar Galvis,0000-0001-8400-9392,,,Martha Galvis
4914.0,Impaired Functional Connectivity of Cortico-Amygdala Pathway Can Drive Social Behavior Deficits in Synucleinopathies,Wichmann,10.1101/2024.05.20.594995,,1.0,W4398181948,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4915.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5053818945,Donald Doherty,0000-0002-4973-6225,Collaborating PI,Team Wichmann,Donald Doherty
4916.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5053818945,Donald Doherty,0000-0002-4973-6225,Key Personnel,Team Wichmann,Donald Doherty
4917.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5071290415,Liqiang Chen,0000-0003-3236-1129,Key Personnel,Team Wichmann,Liqiang Chen
4918.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5051289855,Yoland Smith,0000-0002-8700-878X,Co-PI,Team Wichmann,Yoland Smith
4919.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5042569468,Thomas Wichmann,0000-0002-2751-9545,Lead-PI,Team Wichmann,Thomas Wichmann
4920.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4921.0,Decreased cellular excitability of pyramidal tract neurons in primary motor cortex leads to paradoxically increased network activity in simulated parkinsonian motor cortex,Wichmann,10.1101/2024.05.23.595566,,1.0,W4398778789,A5082122443,William W. Lytton,0000-0002-3727-2849,,,William Lytton
4922.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5023335764,Anne‐Caroline Martel,0000-0001-6590-0323,Key Personnel,Team Wichmann,Anne‐Caroline Martel
4923.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5044246558,Damien Pittard,0000-0002-1169-8964,Key Personnel,Team Wichmann,Damien Pittard
4924.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5013254201,Annaelle Devergnas,0000-0002-0461-6422,Collaborating PI,Team Wichmann,Annaelle Devergnas
4925.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5035960168,Benjamin B. Risk,0000-0003-1090-0777,Collaborating PI,Team Wichmann,Benjamin Risk
4926.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5049719969,Jonathan J. Nassi,0000-0002-3144-3846,Key Personnel,Team Wichmann,Jonathan Nassi
4927.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5009573867,Waylin Yu,0000-0001-5489-3260,,,Waylin Yu
4928.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5011773329,Joshua D. Downer,0000-0003-3817-6733,Key Personnel,Team Wichmann,Joshua Downer
4929.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5042569468,Thomas Wichmann,0000-0002-2751-9545,Lead-PI,Team Wichmann,Thomas Wichmann
4930.0,Microendoscopic Calcium Imaging In Supplementary Motor Area And Primary Motor Cortex Of Rhesus Macaques At Rest And During Arm Movement,Wichmann,10.1101/2024.06.20.599918,,1.0,W4399992138,A5056482545,Adriana Galván,0000-0001-9939-0130,Co-PI,Team Wichmann,Adriana Galván
4931.0,Motor Cortical Neuronal Hyperexcitability Associated with α-Synuclein Aggregation,Wichmann,10.1101/2024.07.24.604995,,1.0,W4400995943,A5071290415,Liqiang Chen,0000-0003-3236-1129,Key Personnel,Team Wichmann,Liqiang Chen
4932.0,Motor Cortical Neuronal Hyperexcitability Associated with α-Synuclein Aggregation,Wichmann,10.1101/2024.07.24.604995,,1.0,W4400995943,A5058625347,Hiba Douja Chehade,0000-0002-5959-7900,Key Personnel,Team Wichmann,Hiba Chehade
4933.0,Motor Cortical Neuronal Hyperexcitability Associated with α-Synuclein Aggregation,Wichmann,10.1101/2024.07.24.604995,,1.0,W4400995943,A5073427053,Hong‐Yuan Chu,0000-0003-0923-683X,Co-PI,Team Wichmann,Hong‐Yuan Chu
4934.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5028218464,Bin Fu,0000-0002-8816-2906,Key Personnel,Team Wood,Bin Fu
4935.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5103220774,Emma E. Brock,0000-0002-7683-0153,Key Personnel,Team Wood,Emma Brock
4936.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5023906150,Rebecca Andrews,0000-0001-8954-1652,,,Rebecca Andrews
4937.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5092669339,Jonathan C. Breiter,0000-0001-9671-657X,Key Personnel,Team Wood,Jonathan Breiter
4938.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5102862605,Ru Tian,0000-0002-2201-8928,,,Ru Tian
4939.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5043816912,Christina E. Toomey,0000-0002-5146-3326,Key Personnel,Team Wood,Christina Toomey
4940.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5013212185,Joanne Lachica,0000-0002-2642-3293,Key Personnel,Team Wood,Joanne Lachica
4941.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5050946548,Tammaryn Lashley,0000-0001-7389-0348,Collaborating PI,Team Wood,Tammaryn Lashley
4942.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
4943.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
4944.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
4945.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5038452125,Michele Vendruscolo,0000-0002-3616-1610,Co-PI,Team Wood,Michele Vendruscolo
4946.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
4947.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5050367407,Lucien E. Weiss,0000-0002-0971-7329,Key Personnel,Team Wood,Lucien Weiss
4948.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5056432129,Joseph S. Beckwith,0000-0003-4726-230X,Key Personnel,Team Wood,Joseph Beckwith
4949.0,RASP: Optimal single fluorescent puncta detection in complex cellular backgrounds,Wood,10.1101/2023.12.18.572148,10.1021/acs.jpcb.4c00174,1.0,W4394622590,A5061407972,Steven F. Lee,0000-0003-4492-5139,Co-PI,Team Wood,Steven Lee
4950.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5040895889,Gurvir S. Virdi,0000-0002-8942-0903,,,Gurvir Virdi
4951.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5108206730,Minee L. Choi,,,,Minee Choi
4952.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
4953.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5001792341,Zhi Yao,0000-0002-9490-3870,,,Zhi Yao
4954.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5043990676,Dilan Athauda,0000-0001-8594-2483,,,Dilan Athauda
4955.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5019028054,Stephanie Strohbuecker,0000-0002-9781-6879,Key Personnel,Team Wood,Stephanie Strohbuecker
4956.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5005172607,Raja Sekhar Nirujogi,0000-0002-3177-8566,Key Personnel,Team Alessi,Raja Nirujogi
4957.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5066839058,Anna I. Wernick,0000-0001-9048-9492,Key Personnel,Team Hardy,Anna Wernick
4958.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5003131368,Noelia Pelegrina-Hidalgo,,,,Noelia Pelegrina-Hidalgo
4959.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5063418251,Craig Leighton,0009-0008-1397-1486,,,Craig Leighton
4960.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5047893729,Rebecca S. Saleeb,0000-0002-6587-9867,,,Rebecca Saleeb
4961.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5068651139,Olga Kopach,0000-0002-3921-3674,,,Olga Kopach
4962.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5016671084,Haya Alrashidi,0000-0001-9338-3036,,,Haya Alrashidi
4963.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5065541648,Davide Melandri,0000-0002-3746-308X,,,Davide Melandri
4964.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5054067951,Jimena Perez-Lloret,0000-0002-2666-3764,,,Jimena Perez-Lloret
4965.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5091523616,Plamena R. Angelova,,,,Plamena Angelova
4966.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5057313987,Sergiy Sylantyev,0000-0002-1358-0601,,,Sergiy Sylantyev
4967.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5058744331,Simon Eaton,0000-0003-0892-9204,,,Simon Eaton
4968.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5016596105,Simon Heales,,,,Simon Heales
4969.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5090829486,Dmitri A. Rusakov,0000-0001-9539-9947,,,Dmitri Rusakov
4970.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5054181982,Dario R. Alessi,0000-0002-2140-9185,Lead-PI,Team Alessi,Dario Alessi
4971.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5057119874,Tilo Kunath,0000-0002-8805-7356,,,Tilo Kunath
4972.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5041913324,Mathew H. Horrocks,0000-0001-5495-5492,Collaborating PI,Team Wood,Mathew Horrocks
4973.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5055353781,Andrey Y. Abramov,0000-0002-7646-7235,,,Andrey Abramov
4974.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5076531240,Rickie Patani,0000-0002-3825-7675,,,Rickie Patani
4975.0,Protein aggregation and calcium dysregulation are hallmarks of familial Parkinson’s disease in midbrain dopaminergic neurons,Wood,10.1101/2022.10.28.514238,10.1038/s41531-022-00423-7,1.0,W4309907185,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
4976.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5108206730,Minee L. Choi,,,,Minee Choi
4977.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5046671995,Alexandre Chappard,0000-0002-9522-2575,,,Alexandre Chappard
4978.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5071840021,Bhanu Singh,0000-0003-3309-8772,,,Bhanu Singh
4979.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5033957982,Catherine Maclachlan,0000-0002-3606-6672,,,Catherine Maclachlan
4980.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5101640801,Margarida Rodrigues,0000-0001-6364-7125,,,Margarida Rodrigues
4981.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5069153255,Evgeniya I. Fedotova,0000-0001-6619-4563,,,Evgeniya Fedotova
4982.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5070232549,Alexey V. Berezhnov,0000-0003-0271-6179,,,Alexey Berezhnov
4983.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5056814808,Suman De,0000-0003-1675-0773,,,Suman De
4984.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5037445001,Christopher J. Peddie,0000-0002-8329-5419,,,Christopher Peddie
4985.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5043990676,Dilan Athauda,0000-0001-8594-2483,,,Dilan Athauda
4986.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5040895889,Gurvir S. Virdi,0000-0002-8942-0903,,,Gurvir Virdi
4987.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5100457936,Weijia Zhang,0000-0001-6928-0416,,,Weijia Zhang
4988.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
4989.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5066839058,Anna I. Wernick,0000-0001-9048-9492,Key Personnel,Team Hardy,Anna Wernick
4990.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5052290598,Zeinab Shadman Zanjani,,,,Zeinab Zanjani
4991.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5091523616,Plamena R. Angelova,,,,Plamena Angelova
4992.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5038020678,Noemí Esteras,0000-0002-7938-6131,,,Noemí Esteras
4993.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5082810764,Andrey Y. Vinokurov,0000-0001-8436-1353,,,Andrey Vinokurov
4994.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5033318012,Katie Morris,0000-0002-8944-2264,,,Katie Morris
4995.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5077792072,Kiani Jeacock,0000-0001-9978-7963,,,Kiani Jeacock
4996.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5062158055,Laura Tosatto,0000-0002-5966-8131,,,Laura Tosatto
4997.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5076255180,Daniel Little,0000-0001-8806-3484,,,Daniel Little
4998.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5085511830,Paul Gissen,0000-0002-9712-6122,,,Paul Gissen
4999.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5072718275,David J. Clarke,0000-0002-3741-2952,,,David Clarke
5000.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5057119874,Tilo Kunath,0000-0002-8805-7356,,,Tilo Kunath
5001.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5032614754,Lucy Collinson,0000-0003-0260-613X,,,Lucy Collinson
5002.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5042822683,David Klenerman,0000-0001-7116-6954,,,David Klenerman
5003.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5055353781,Andrey Y. Abramov,0000-0002-7646-7235,,,Andrey Abramov
5004.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5041913324,Mathew H. Horrocks,0000-0001-5495-5492,Collaborating PI,Team Wood,Mathew Horrocks
5005.0,Pathological structural conversion of α-synuclein at the mitochondria induces neuronal toxicity,Wood,10.1101/2022.06.07.494932,10.1038/s41593-022-01140-3,1.0,W4293581901,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5006.0,Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms,Wood,,10.1073/pnas.2313465121,1.0,W4391594219,A5011976831,Alexander Röntgen,0000-0002-0500-4815,Key Personnel,Team Wood,Alexander Röntgen
5007.0,Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms,Wood,,10.1073/pnas.2313465121,1.0,W4391594219,A5006932685,Zenon Toprakcioglu,0000-0003-1964-8432,,,Zenon Toprakcioglu
5008.0,Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms,Wood,,10.1073/pnas.2313465121,1.0,W4391594219,A5033209539,James E. Tomkins,0000-0003-3010-6634,Key Personnel,Team Wood,James Tomkins
5009.0,Modulation of α-synuclein in vitro aggregation kinetics by its alternative splice isoforms,Wood,,10.1073/pnas.2313465121,1.0,W4391594219,A5038452125,Michele Vendruscolo,0000-0002-3616-1610,Co-PI,Team Wood,Michele Vendruscolo
5010.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5005665859,Louise A. Huuki-Myers,0000-0001-5148-3602,,,Louise Huuki-Myers
5011.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5046522772,Abby Spangler,0000-0002-0028-9348,,,Abby Spangler
5012.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5050073727,Nicholas J. Eagles,0000-0002-9808-5254,,,Nicholas Eagles
5013.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5000558908,Kelsey D. Montgomery,0000-0001-8420-0138,,,Kelsey Montgomery
5014.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5066726057,Sang Ho Kwon,0000-0001-5328-0956,,,Sang Kwon
5015.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5012987083,Boyi Guo,0000-0003-2950-2349,,,Boyi Guo
5016.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
5017.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073157888,Heena R. Divecha,0000-0002-1959-0675,,,Heena Divecha
5018.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5064957197,Madhavi Tippani,0000-0002-6465-6418,,,Madhavi Tippani
5019.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5012891700,Chaichontat Sriworarat,0000-0002-1917-3409,,,Chaichontat Sriworarat
5020.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5013771413,Annie B. Nguyen,0000-0003-3842-6923,,,Annie Nguyen
5021.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5019870129,Prashanthi Ravichandran,0000-0002-9364-175X,,,Prashanthi Ravichandran
5022.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5019365383,Matthew N. Tran,0000-0001-9694-7378,,,Matthew Tran
5023.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5068198293,Arta Seyedian,0000-0003-4141-4149,,,Arta Seyedian
5024.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5056413476,Thomas M. Hyde,0000-0002-8746-3037,,,Thomas Hyde
5025.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5020523652,Joel E. Kleinman,0000-0002-4210-6052,,,Joel Kleinman
5026.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5063708781,Alexis Battle,0000-0002-5287-627X,,,Alexis Battle
5027.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5078161242,Stephanie C. Page,0000-0002-1951-7398,,,Stephanie Page
5028.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5029.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
5030.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028505800,Stephanie C. Hicks,0000-0002-7858-0231,,,Stephanie Hicks
5031.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5003322851,Keri Martinowich,0000-0002-5237-0789,,,Keri Martinowich
5032.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5075979341,Leonardo Collado‐Torres,0000-0003-2140-308X,,,Leonardo Collado‐Torres
5033.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5040039946,Kristen R. Maynard,0000-0003-0031-8468,,,Kristen Maynard
5034.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5025600687,Schahram Akbarian,0000-0001-7700-0891,,,Schahram Akbarian
5035.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5078568342,Alexej Abyzov,0000-0001-5405-6729,,,Alexej Abyzov
5036.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5086687499,Nadav Ahituv,0000-0002-7434-8144,,,Nadav Ahituv
5037.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5045102506,Dhivya Arasappan,,,,Dhivya Arasappan
5038.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5067812333,José Juan Almagro Armenteros,0000-0003-0111-1362,,,José Armenteros
5039.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5035042211,Brian J. Beliveau,0000-0003-1314-3118,,,Brian Beliveau
5040.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5054767604,Jaroslav Bendl,0000-0001-9989-2720,,,Jaroslav Bendl
5041.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5022556246,Sabina Berretta,0000-0002-4057-7766,,,Sabina Berretta
5042.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5016188550,Rahul Bharadwaj,0000-0002-7749-8682,,,Rahul Bharadwaj
5043.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5020870665,Arjun Bhattacharya,0000-0003-1196-4385,,,Arjun Bhattacharya
5044.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5032659815,Lucy Bicks,0000-0002-9884-0133,,,Lucy Bicks
5045.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5074392365,Kristen Brennand,0000-0003-0993-5956,,,Kristen Brennand
5046.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5075418930,Davide Capauto,0000-0003-2156-0165,,,Davide Capauto
5047.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5020016338,Frances A. Champagne,0000-0002-3922-084X,,,Frances Champagne
5048.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5102784656,Tanima Chatterjee,0000-0001-8956-6569,,,Tanima Chatterjee
5049.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5008080154,Chris Chatzinakos,0000-0003-0557-9501,,,Chris Chatzinakos
5050.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073357085,Yuhang Chen,0000-0001-9906-4108,,,Yuhang Chen
5051.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5058619001,H. Isaac Chen,0000-0002-7431-6046,,,H. Chen
5052.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5015678181,Yuyan Cheng,0000-0003-4647-4917,,,Yuyan Cheng
5053.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073424048,Lijun Cheng,0000-0001-7606-9563,,,Lijun Cheng
5054.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5029972759,Andrew Chess,0000-0002-4501-8816,,,Andrew Chess
5055.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5070077764,Jo-fan Chien,0000-0002-9319-6182,,,Jo-fan Chien
5056.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5036973507,Zhiyuan Chu,0000-0002-3193-5031,,,Zhiyuan Chu
5057.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5058665008,Declan Clarke,0000-0002-6128-7485,,,Declan Clarke
5058.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5102675271,Ashley Clement,,,,Ashley Clement
5059.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5075979341,Leonardo Collado‐Torres,0000-0003-2140-308X,,,Leonardo Collado‐Torres
5060.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5027561780,Gregory M. Cooper,0000-0001-5509-9923,,,Gregory Cooper
5061.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5040856457,Gregory E. Crawford,0000-0001-6106-2772,,,Gregory Crawford
5062.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5051098845,Rujia Dai,0000-0002-9979-3295,,,Rujia Dai
5063.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5084393367,Nikolaos P. Daskalakis,0000-0003-1660-9112,,,Nikolaos Daskalakis
5064.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5068597405,José Dávila-Velderrain,0000-0003-0271-6267,,,José Dávila-Velderrain
5065.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5062271906,Amy Deep–Soboslay,0000-0002-7762-8942,,,Amy Deep–Soboslay
5066.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5078420356,Chengyu Deng,0000-0003-3595-9935,,,Chengyu Deng
5067.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5092544220,Christopher P. DiPietro,0009-0008-0332-2343,,,Christopher DiPietro
5068.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028086598,Stella Dracheva,0000-0001-5917-8688,,,Stella Dracheva
5069.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5058400785,Shiron Drusinsky,0000-0003-1184-8835,,,Shiron Drusinsky
5070.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5052582390,Ziheng Duan,0000-0003-4696-0042,,,Ziheng Duan
5071.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5061526409,Duc M. Duong,0000-0001-5880-1888,,,Duc Duong
5072.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5000311342,Cagatay Dursun,0000-0002-0897-7671,,,Cagatay Dursun
5073.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5050073727,Nicholas J. Eagles,0000-0002-9808-5254,,,Nicholas Eagles
5074.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5072475529,Jonathan I. Edelstein,,,,Jonathan Edelstein
5075.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024414223,Prashant S. Emani,0000-0002-3091-5231,,,Prashant Emani
5076.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024273553,John F. Fullard,0000-0001-9874-2907,,,John Fullard
5077.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5019374956,Kiki Galani,,,,Kiki Galani
5078.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5027788390,Timur R. Galeev,0000-0002-6241-1011,,,Timur Galeev
5079.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5008274391,Michael J. Gandal,0000-0001-5800-5128,,,Michael Gandal
5080.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5031155218,Sophia C. Gaynor,,,,Sophia Gaynor
5081.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042321575,Mark Gerstein,0000-0002-9746-3719,,,Mark Gerstein
5082.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5018481303,Daniel H. Geschwind,0000-0003-2896-3450,,,Daniel Geschwind
5083.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042895364,Kiran Girdhar,0000-0002-5622-042X,,,Kiran Girdhar
5084.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5051850972,Fernando S. Goes,0000-0001-6262-8264,,,Fernando Goes
5085.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5047325114,William Greenleaf,,,,William Greenleaf
5086.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5079062478,Jennifer Grundman,0000-0003-2266-277X,,,Jennifer Grundman
5087.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5072198607,Hanmin Guo,0000-0001-9022-5307,,,Hanmin Guo
5088.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5060569216,Qiuyu Guo,0000-0001-8549-8335,,,Qiuyu Guo
5089.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5101612909,Chirag Gupta,0000-0002-6121-7065,,,Chirag Gupta
5090.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5002903251,Yoav Hadas,,,,Yoav Hadas
5091.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5066325334,Joachim Hallmayer,0000-0002-8520-4939,,,Joachim Hallmayer
5092.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5046117391,Xikun Han,0000-0002-3823-7308,,,Xikun Han
5093.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5054795331,Vahram Haroutunian,0000-0001-5860-2512,,,Vahram Haroutunian
5094.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5030899935,Natalie Hawken,0000-0002-0473-4373,,,Natalie Hawken
5095.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024105936,Chuan He,0000-0002-6461-7515,,,Chuan He
5096.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5111209904,Ella Henry,,,,Ella Henry
5097.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028505800,Stephanie C. Hicks,0000-0002-7858-0231,,,Stephanie Hicks
5098.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5041500680,Marcus Ho,0000-0002-5819-8342,,,Marcus Ho
5099.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5110083974,Li‐Lun Ho,,,,Li‐Lun Ho
5100.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5046862823,Gabriel E. Hoffman,0000-0002-0957-0224,,,Gabriel Hoffman
5101.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5103839497,Yi‐Ling Huang,,,,Yi‐Ling Huang
5102.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5005665859,Louise A. Huuki-Myers,0000-0001-5148-3602,,,Louise Huuki-Myers
5103.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5027169758,Ahyeon Hwang,0000-0002-4686-3077,,,Ahyeon Hwang
5104.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5056413476,Thomas M. Hyde,0000-0002-8746-3037,,,Thomas Hyde
5105.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5052961967,Artemis Iatrou,0000-0001-9866-5497,,,Artemis Iatrou
5106.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024678571,Fumitaka Inoue,0000-0003-0657-434X,,,Fumitaka Inoue
5107.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5011137240,Aarti Jajoo,,,,Aarti Jajoo
5108.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5046790941,Matthew Jensen,0000-0002-5153-8543,,,Matthew Jensen
5109.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5087406612,Lihua Jiang,0000-0002-2895-2762,,,Lihua Jiang
5110.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5039869995,Peng Jin,0000-0001-6137-6659,,,Peng Jin
5111.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5103200668,Ting Jin,0000-0001-7252-0361,,,Ting Jin
5112.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5001960069,Connor Jops,0000-0003-3813-2407,,,Connor Jops
5113.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5025033341,Alexandre Jourdon,0000-0002-6074-1498,,,Alexandre Jourdon
5114.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5065465113,Riki Kawaguchi,0000-0002-2489-4825,,,Riki Kawaguchi
5115.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5089977648,Manolis Kellis,0000-0001-7113-9630,,,Manolis Kellis
5116.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5020523652,Joel E. Kleinman,0000-0002-4210-6052,,,Joel Kleinman
5117.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5046562318,Steven P. Kleopoulos,0000-0002-9213-9629,,,Steven Kleopoulos
5118.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5057518270,Alexey Kozlenkov,0000-0002-2569-0437,,,Alexey Kozlenkov
5119.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5015724734,Arnold R. Kriegstein,0000-0001-5742-2990,,,Arnold Kriegstein
5120.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5083952534,Anshul Kundaje,0000-0003-3084-2287,,,Anshul Kundaje
5121.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5103895979,Soumya Kundu,,,,Soumya Kundu
5122.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5015163704,Che-Yu Lee,0000-0002-3039-4894,,,Che-Yu Lee
5123.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100422973,Donghoon Lee,0000-0003-0453-6059,,,Donghoon Lee
5124.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5101576584,Junhao Li,0000-0001-6784-3780,,,Junhao Li
5125.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5101705871,Mingfeng Li,0000-0002-7959-6008,,,Mingfeng Li
5126.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028587808,Xiao Lin,,,,Xiao Lin
5127.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100319124,Shuang Liu,0000-0003-3301-6925,,,Shuang Liu
5128.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5101968034,Jason Liu,0000-0001-7197-7319,,,Jason Liu
5129.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5082505621,Jianyin Liu,,,,Jianyin Liu
5130.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100343306,Chunyu Liu,0000-0002-5986-4415,,,Chunyu Liu
5131.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100319124,Shuang Liu,0000-0003-3301-6925,,,Shuang Liu
5132.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5021538432,Shaoke Lou,0000-0002-2626-5897,,,Shaoke Lou
5133.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5062303269,Jacob M. Loupe,0000-0003-1927-9649,,,Jacob Loupe
5134.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100737347,Dan Lu,0000-0001-7811-8250,,,Dan Lu
5135.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5011268118,Shaojie Ma,0000-0002-8782-3047,,,Shaojie Ma
5136.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5041550151,Liang Ma,0000-0001-7034-9011,,,Liang Ma
5137.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5071696583,Michael Margolis,0000-0002-3706-8960,,,Michael Margolis
5138.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5061762745,Jessica Mariani,0000-0003-3657-1748,,,Jessica Mariani
5139.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5003322851,Keri Martinowich,0000-0002-5237-0789,,,Keri Martinowich
5140.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5040039946,Kristen R. Maynard,0000-0003-0031-8468,,,Kristen Maynard
5141.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5047778033,Samantha Mazariegos,0009-0000-1762-6454,,,Samantha Mazariegos
5142.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5053685713,Ran Meng,0000-0003-1271-3975,,,Ran Meng
5143.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5016212527,R Myers,0000-0001-9701-676X,,,R Myers
5144.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5072635493,Courtney Micallef,,,,Courtney Micallef
5145.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5003122447,Tatiana Mikhailova,0000-0003-4169-1322,,,Tatiana Mikhailova
5146.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5004329894,Guo‐li Ming,0000-0002-2517-6075,,,Guo‐li Ming
5147.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5000254294,Shahin Mohammadi,0000-0001-8734-2326,,,Shahin Mohammadi
5148.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5104311626,Emma Monte,,,,Emma Monte
5149.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5043295085,Kelsey S. Montgomery,0000-0002-0126-8944,,,Kelsey Montgomery
5150.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5079819085,Jill E. Moore,0000-0002-3023-0806,,,Jill Moore
5151.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5049940352,Jennifer Moran,0009-0000-1294-2079,,,Jennifer Moran
5152.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5068784328,Eran A. Mukamel,0000-0003-3203-9535,,,Eran Mukamel
5153.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5032456571,Angus C. Nairn,0000-0002-7075-0195,,,Angus Nairn
5154.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5050356892,Charles B. Nemeroff,0000-0001-7867-1160,,,Charles Nemeroff
5155.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5027704938,Pengyu Ni,0000-0001-9878-5480,,,Pengyu Ni
5156.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5075709593,Scott Norton,0000-0002-1366-0628,,,Scott Norton
5157.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024869315,Tomasz J. Nowakowski,0000-0003-2345-4964,,,Tomasz Nowakowski
5158.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5038454932,Larsson Omberg,0000-0002-4719-9120,,,Larsson Omberg
5159.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5078161242,Stephanie C. Page,0000-0002-1951-7398,,,Stephanie Page
5160.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5039117774,Saejeong Park,0000-0002-0926-8076,,,Saejeong Park
5161.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073558047,Ashok Patowary,0000-0001-7507-3907,,,Ashok Patowary
5162.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5001568269,Reenal Pattni,0000-0003-4490-731X,,,Reenal Pattni
5163.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5069088537,Geo Pertea,0000-0002-3210-7182,,,Geo Pertea
5164.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5062246108,Mette A. Peters,0000-0001-7755-611X,,,Mette Peters
5165.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5062121389,Nishigandha Phalke,0000-0003-3980-6450,,,Nishigandha Phalke
5166.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5088479227,Dalila Pinto,0000-0002-8769-0846,,,Dalila Pinto
5167.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5063671038,Milos Pjanic,0000-0001-9746-8838,,,Milos Pjanic
5168.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5058991398,Sirisha Pochareddy,0000-0002-9505-8090,,,Sirisha Pochareddy
5169.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5005062415,Katherine S. Pollard,0000-0002-9870-6196,,,Katherine Pollard
5170.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5060172577,Alex A. Pollen,0000-0003-3263-8634,,,Alex Pollen
5171.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5037976483,Henry Pratt,0000-0001-9413-834X,,,Henry Pratt
5172.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5007489781,Pawel F. Przytycki,0000-0002-3360-6936,,,Pawel Przytycki
5173.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5055844338,Carolin Purmann,,,,Carolin Purmann
5174.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042399779,Zhaohui Qin,0000-0002-1583-146X,,,Zhaohui Qin
5175.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5082141323,Pingping Qu,0000-0003-2487-5402,,,Pingping Qu
5176.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5114014035,Diana Quintero,,,,Diana Quintero
5177.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5050747458,Towfique Raj,0000-0002-9355-5704,,,Towfique Raj
5178.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5077349349,Ananya S. Rajagopalan,0009-0008-2390-4738,,,Ananya Rajagopalan
5179.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5015410051,Sarah Reach,0000-0001-7862-9077,,,Sarah Reach
5180.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5102945404,Thomas Reimonn,0000-0002-5129-7989,,,Thomas Reimonn
5181.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073581575,Kerry J. Ressler,0000-0002-5158-1103,,,Kerry Ressler
5182.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5108523783,D D Ross,,,,D Ross
5183.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5074488210,Panos Roussos,0000-0002-4640-6239,,,Panos Roussos
5184.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5022975867,Joel Rozowsky,0000-0002-3565-0762,,,Joel Rozowsky
5185.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5114167347,Misir Ruth,,,,Misir Ruth
5186.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5083924174,W. Brad Ruzicka,0000-0001-6749-4875,,,W. Ruzicka
5187.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5049906252,Stephan Sanders,0000-0001-9112-5148,,,Stephan Sanders
5188.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5104311625,Juliane M. Schneider,,,,Juliane Schneider
5189.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5034551230,Soraya Scuderi,0000-0001-5126-2009,,,Soraya Scuderi
5190.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5076788078,Robert Sebra,0000-0001-9267-2426,,,Robert Sebra
5191.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5026436089,Nenad Šestan,0000-0003-0966-9619,,,Nenad Šestan
5192.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5022349887,Nicholas T. Seyfried,0000-0002-4507-624X,,,Nicholas Seyfried
5193.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028711885,Zhiping Shao,0009-0006-4889-6637,,,Zhiping Shao
5194.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5094192478,Nicole Shedd,0000-0003-2272-5398,,,Nicole Shedd
5195.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5036796031,Annie W. Shieh,0000-0002-1770-5846,,,Annie Shieh
5196.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5033103731,Joo Heon Shin,0000-0002-5563-8605,,,Joo Shin
5197.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5073444353,Mario Škarica,0000-0002-2478-014X,,,Mario Škarica
5198.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5025952937,Clara Snijders,0000-0001-6794-3722,,,Clara Snijders
5199.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5009183873,Hongjun Song,0000-0002-8720-5310,,,Hongjun Song
5200.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5010207238,Matthew W. State,0000-0003-1624-8302,,,Matthew State
5201.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5075199400,Jason Stein,0009-0008-0545-1181,,,Jason Stein
5202.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5044528045,Marilyn Steyert,0000-0003-4095-4776,,,Marilyn Steyert
5203.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024728856,Sivan Subburaju,0000-0003-3111-9859,,,Sivan Subburaju
5204.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5061921730,Thomas C. Südhof,0000-0003-3361-9275,,,Thomas Südhof
5205.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5024120181,M Snyder,0000-0003-0784-7987,,,M Snyder
5206.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5087325326,Ran Tao,0000-0002-1106-2923,,,Ran Tao
5207.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5053308945,Karen Therrien,0000-0003-3351-7260,,,Karen Therrien
5208.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5042440695,Li‐Huei Tsai,0000-0003-1262-0592,,,Li‐Huei Tsai
5209.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5003270170,Alexander E. Urban,0000-0001-9772-933X,,,Alexander Urban
5210.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5020168218,Flora M. Vaccarino,0000-0003-2167-981X,,,Flora Vaccarino
5211.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5060689942,Harm van Bakel,0000-0002-1376-6916,,,Harm Bakel
5212.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5041737053,Daniel Vo,0000-0003-2057-969X,,,Daniel Vo
5213.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5037342798,Georgios Voloudakis,0000-0002-5729-632X,,,Georgios Voloudakis
5214.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5064346542,Brie Wamsley,0000-0002-4454-9834,,,Brie Wamsley
5215.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100453525,Tao Wang,0000-0002-4355-149X,,,Tao Wang
5216.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5015382049,Sidney H. Wang,0000-0001-8459-1300,,,Sidney Wang
5217.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5053240500,Daifeng Wang,0000-0001-9190-3704,,,Daifeng Wang
5218.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5107249176,Yifan Wang,0009-0003-8649-9681,,,Yifan Wang
5219.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5077980658,Jonathan Warrell,0000-0002-1323-4602,,,Jonathan Warrell
5220.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100377274,Wei Yu,0000-0002-0536-5637,,,Wei Yu
5221.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5014176108,Annika K. Weimer,0000-0001-9944-8769,,,Annika Weimer
5222.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5043264677,Daniel R. Weinberger,0000-0003-2409-2969,,,Daniel Weinberger
5223.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5028880819,Cindy Wen,0000-0001-8747-8231,,,Cindy Wen
5224.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5084369008,Zhiping Weng,0000-0002-3032-7966,,,Zhiping Weng
5225.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5039266926,Sean Whalen,0000-0002-6648-3610,,,Sean Whalen
5226.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5006842195,Kevin P. White,0000-0001-6934-5793,,,Kevin White
5227.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5086857587,A. Jeremy Willsey,0000-0002-9922-3612,,,A. Willsey
5228.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5053251909,Hyejung Won,0000-0003-3651-0566,,,Hyejung Won
5229.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5063160400,Wing H. Wong,,,,Wing Wong
5230.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5089488228,Hao Wu,0000-0002-7866-2544,,,Hao Wu
5231.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5017455998,Feinan Wu,0000-0002-4962-1874,,,Feinan Wu
5232.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5076755077,Stefan Wuchty,0000-0001-8916-6522,,,Stefan Wuchty
5233.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5076478944,Dennis Wylie,0000-0003-0380-3549,,,Dennis Wylie
5234.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5056041012,Siwei Xu,0000-0002-2828-3706,,,Siwei Xu
5235.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5077786982,Chloe X. Yap,0000-0002-1788-2842,,,Chloe Yap
5236.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5030412845,Biao Zeng,0000-0003-4900-2288,,,Biao Zeng
5237.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5101102302,Pan Zhang,0009-0002-7550-6367,,,Pan Zhang
5238.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100439753,Chunling Zhang,0000-0003-2752-1028,,,Chunling Zhang
5239.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100392884,Bin Zhang,0000-0002-9549-5653,,,Bin Zhang
5240.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100345410,Jing Zhang,0000-0002-5970-0509,,,Jing Zhang
5241.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5012628393,Yanqiong Zhang,0000-0002-9358-111X,,,Yanqiong Zhang
5242.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5100841566,Xiao Zhou,,,,Xiao Zhou
5243.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5006765574,Ryan Ziffra,,,,Ryan Ziffra
5244.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5013895619,Zane Zeier,0000-0003-0623-8610,,,Zane Zeier
5245.0,Integrated single cell and unsupervised spatial transcriptomic analysis defines molecular anatomy of the human dorsolateral prefrontal cortex,Wood,10.1101/2023.02.15.528722,10.1126/science.adh1938,1.0,W4398250232,A5084438780,Trisha M. Zintel,0000-0001-7356-0867,,,Trisha Zintel
5246.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5014618738,Ezra Bruggeman,0000-0001-6100-1443,Key Personnel,Team Wood,Ezra Bruggeman
5247.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5030736882,Oumeng Zhang,0000-0001-7318-2130,,,Oumeng Zhang
5248.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5066141243,Lisa-Maria Needham,0000-0002-8139-5862,,,Lisa-Maria Needham
5249.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5017093402,Markus Körbel,0000-0002-8344-8016,,,Markus Körbel
5250.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5072631794,Sam Daly,0000-0002-8559-3161,,,Sam Daly
5251.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5053012169,Matthew R. Cheetham,0000-0001-7412-2332,,,Matthew Cheetham
5252.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5047230610,Ruby Peters,0000-0003-2946-7504,,,Ruby Peters
5253.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5086754519,Tingting Wu,0000-0001-5736-4962,,,Tingting Wu
5254.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5086625921,Andrey S. Klymchenko,0000-0002-2423-830X,,,Andrey Klymchenko
5255.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5064309344,Simon J. Davis,0000-0002-2280-1170,,,Simon Davis
5256.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5020755611,Ewa K. Paluch,0000-0003-4691-2323,,,Ewa Paluch
5257.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5042822683,David Klenerman,0000-0001-7116-6954,,,David Klenerman
5258.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5035949648,Matthew D. Lew,0000-0002-5614-3292,,,Matthew Lew
5259.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5089313370,Kevin O’Holleran,0000-0003-1039-2127,,,Kevin O’Holleran
5260.0,POLCAM: Instant molecular orientation microscopy for the life sciences,Wood,10.1101/2023.02.07.527479,,1.0,W4319593954,A5061407972,Steven F. Lee,0000-0003-4492-5139,Co-PI,Team Wood,Steven Lee
5261.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5076611003,Alicia Gómez-Pascual,0000-0003-2348-9083,,,Alicia Gómez-Pascual
5262.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5105111673,Dow Michael Glikman,0009-0009-5659-6302,,,Dow Glikman
5263.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5104201264,H.-H. Ng,,,,H.-H. Ng
5264.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5033209539,James E. Tomkins,0000-0003-3010-6634,Key Personnel,Team Wood,James Tomkins
5265.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5100366032,Lu Lu,0000-0002-6174-3209,,,Lu Lu
5266.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5074969305,Ying Xu,0000-0003-3563-4233,,,Ying Xu
5267.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5037829890,David G. Ashbrook,0000-0002-7397-8910,,,David Ashbrook
5268.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5073164917,Catherine C. Kaczorowski,0000-0001-5430-0816,,,Catherine Kaczorowski
5269.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5080409608,Gerd Kempermann,0000-0002-5304-4061,,,Gerd Kempermann
5270.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5010396789,John Killmar,,,,John Killmar
5271.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5008443275,Khyobeni Mozhui,0000-0002-6623-4112,,,Khyobeni Mozhui
5272.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5113525546,Oliver Ohlenschläger,,,,Oliver Ohlenschläger
5273.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5053361384,Ruedi Aebersold,0000-0002-9576-3267,,,Ruedi Aebersold
5274.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5044264789,Donald K. Ingram,0000-0001-6509-6910,,,Donald Ingram
5275.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5102861983,Elizabeth G. Williams,0000-0002-1894-7556,,,Elizabeth Williams
5276.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5000103692,Robert W. Williams,0000-0001-8924-4447,,,Robert Williams
5277.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5049587012,Rupert W. Overall,0000-0002-3882-6073,,,Rupert Overall
5278.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5010409175,Mathias Jucker,0000-0001-9045-1072,,,Mathias Jucker
5279.0,Polyglucosan body density in the aged mouse hippocampus is controlled by a novel modifier locus on chromosome 1,Wood,10.1101/2023.11.22.567373,,1.0,W4388892642,A5019701894,Dennis E. M. de Bakker,0000-0002-7373-0093,,,Dennis Bakker
5280.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5023906150,Rebecca Andrews,0000-0001-8954-1652,,,Rebecca Andrews
5281.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5028218464,Bin Fu,0000-0002-8816-2906,Key Personnel,Team Wood,Bin Fu
5282.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5043816912,Christina E. Toomey,0000-0002-5146-3326,Key Personnel,Team Wood,Christina Toomey
5283.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5092669339,Jonathan C. Breiter,0000-0001-9671-657X,Key Personnel,Team Wood,Jonathan Breiter
5284.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5013212185,Joanne Lachica,0000-0002-2642-3293,Key Personnel,Team Wood,Joanne Lachica
5285.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5102862605,Ru Tian,0000-0002-2201-8928,,,Ru Tian
5286.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5056432129,Joseph S. Beckwith,0000-0003-4726-230X,Key Personnel,Team Wood,Joseph Beckwith
5287.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5066141243,Lisa-Maria Needham,0000-0002-8139-5862,,,Lisa-Maria Needham
5288.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5093959417,Gregory J. Chant,0000-0003-0478-7202,,,Gregory Chant
5289.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5046971251,Camille Loiseau,0000-0003-3108-5193,Key Personnel,Team Cragg,Camille Loiseau
5290.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5093959415,Angèle Deconfin,0000-0003-1007-8496,,,Angèle Deconfin
5291.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5093959416,Kenza Baspin,0009-0005-3074-1402,,,Kenza Baspin
5292.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5015406158,Peter J. Magill,0000-0001-7141-7071,Co-PI,Team Cragg,Peter Magill
5293.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5063134863,Zane Jaunmuktane,0000-0001-7738-8881,Co-PI,Team Hardy,Zane Jaunmuktane
5294.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5063134863,Zane Jaunmuktane,0000-0001-7738-8881,Collaborating PI,Team Voet,Zane Jaunmuktane
5295.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5016226904,Oliver Freeman,0000-0003-4009-282X,,,Oliver Freeman
5296.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5067523704,Ben Taylor,0000-0001-6101-3786,,,Ben Taylor
5297.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
5298.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5050946548,Tammaryn Lashley,0000-0001-7389-0348,Collaborating PI,Team Wood,Tammaryn Lashley
5299.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5300.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
5301.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5038452125,Michele Vendruscolo,0000-0002-3616-1610,Co-PI,Team Wood,Michele Vendruscolo
5302.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
5303.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5050367407,Lucien E. Weiss,0000-0002-0971-7329,Key Personnel,Team Wood,Lucien Weiss
5304.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5305.0,Large-scale visualisation of α-synuclein oligomers in Parkinson’s disease brain tissue,Wood,10.1101/2024.02.17.580698,,1.0,W4391947555,A5061407972,Steven F. Lee,0000-0003-4492-5139,Co-PI,Team Wood,Steven Lee
5306.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5008997142,Karishma D’Sa,,,,Karishma D’Sa
5307.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5108206730,Minee L. Choi,,,,Minee Choi
5308.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5045987441,Aaron Z. Wagen,0000-0002-7747-6870,Key Personnel,Team Wood,Aaron Wagen
5309.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5023242444,Núria Setó‐Salvia,0000-0002-3753-0027,,,Núria Setó‐Salvia
5310.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5068651139,Olga Kopach,0000-0002-3921-3674,,,Olga Kopach
5311.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
5312.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5101640801,Margarida Rodrigues,0000-0001-6364-7125,,,Margarida Rodrigues
5313.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5101666243,Patricia López‐García,0000-0002-9594-0497,,,Patricia López‐García
5314.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5013212185,Joanne Lachica,0000-0002-2642-3293,Key Personnel,Team Wood,Joanne Lachica
5315.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5101381851,Jaijeet Singh,,,,Jaijeet Singh
5316.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5064793113,Ali Ghareeb,0000-0002-8552-3139,,,Ali Ghareeb
5317.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5111137707,James Bayne,0000-0002-9728-5393,,,James Bayne
5318.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
5319.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
5320.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5016118485,Zhongbo Chen,0000-0001-6668-7202,,,Zhongbo Chen
5321.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5061828831,Samuel G. Rodriques,0000-0002-2509-0861,,,Samuel Rodriques
5322.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5102982932,Dilan Athauda,0000-0002-2977-0290,,,Dilan Athauda
5323.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
5324.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
5325.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5064487935,Sarah A. Gagliano Taliun,0000-0003-1306-1868,,,Sarah Taliun
5326.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5043816912,Christina E. Toomey,0000-0002-5146-3326,Key Personnel,Team Wood,Christina Toomey
5327.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
5328.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5083857819,George R. Young,0000-0002-1203-588X,,,George Young
5329.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5019028054,Stephanie Strohbuecker,0000-0002-9781-6879,Key Personnel,Team Wood,Stephanie Strohbuecker
5330.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5011838243,Thomas T. Warner,0000-0001-6195-6995,Collaborating PI,Team Voet,Thomas Warner
5331.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5090829486,Dmitri A. Rusakov,0000-0001-9539-9947,,,Dmitri Rusakov
5332.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5076531240,Rickie Patani,0000-0002-3825-7675,,,Rickie Patani
5333.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5051400574,Clare Bryant,0000-0002-2924-0038,,,Clare Bryant
5334.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5042822683,David Klenerman,0000-0001-7116-6954,,,David Klenerman
5335.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5336.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5337.0,Alpha-synuclein aggregates trigger anti-viral immune pathways and RNA editing in human astrocytes,Wood,10.1101/2024.02.26.582055,,1.0,W4392272337,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
5338.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5043990676,Dilan Athauda,0000-0001-8594-2483,,,Dilan Athauda
5339.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
5340.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5087734587,Laura Mahoney‐Sanchez,0000-0002-2377-8267,Key Personnel,Team Wood,Laura Mahoney‐Sanchez
5341.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5040895889,Gurvir S. Virdi,0000-0002-8942-0903,,,Gurvir Virdi
5342.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5102623459,Patricia Lopez-Garcia,0000-0001-6636-5940,Key Personnel,Team Wood,Patricia Lopez-Garcia
5343.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5066839058,Anna I. Wernick,0000-0001-9048-9492,Key Personnel,Team Hardy,Anna Wernick
5344.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5045987441,Aaron Z. Wagen,0000-0002-7747-6870,Key Personnel,Team Wood,Aaron Wagen
5345.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5008997142,Karishma D’Sa,,,,Karishma D’Sa
5346.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5013212185,Joanne Lachica,0000-0002-2642-3293,Key Personnel,Team Wood,Joanne Lachica
5347.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5019028054,Stephanie Strohbuecker,0000-0002-9781-6879,Key Personnel,Team Wood,Stephanie Strohbuecker
5348.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5049771886,Giulia Vecchi,0009-0005-5464-0884,,,Giulia Vecchi
5349.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5063418251,Craig Leighton,0009-0008-1397-1486,,,Craig Leighton
5350.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5047893729,Rebecca S. Saleeb,0000-0002-6587-9867,,,Rebecca Saleeb
5351.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5020879321,Judi O’Shaughnessy,0009-0001-2014-9078,,,Judi O’Shaughnessy
5352.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5043816912,Christina E. Toomey,0000-0002-5146-3326,Key Personnel,Team Wood,Christina Toomey
5353.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5019530991,Nirosen Vijiaratnam,0000-0002-9671-0212,,,Nirosen Vijiaratnam
5354.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5064943801,Christine Girges,0000-0001-5019-6812,,,Christine Girges
5355.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5100669061,Yazhou Li,0000-0002-6048-3660,,,Yazhou Li
5356.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5013330262,Maja Mustapić,0000-0003-0511-2047,,,Maja Mustapić
5357.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5045141651,Khalida Ismail,0000-0001-6084-449X,,,Khalida Ismail
5358.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5084593004,Melanie J. Davies,0000-0002-9987-9371,,,Melanie Davies
5359.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5063213339,Dimitrios Kapogiannis,0000-0003-2181-3118,,,Dimitrios Kapogiannis
5360.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5108206730,Minee L. Choi,,,,Minee Choi
5361.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5362.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
5363.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5041913324,Mathew H. Horrocks,0000-0001-5495-5492,Collaborating PI,Team Wood,Mathew Horrocks
5364.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5056649584,Nigel H. Greig,0000-0002-3032-1468,,,Nigel Greig
5365.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5031389008,Thomas Foltynie,0000-0003-0752-1813,,,Thomas Foltynie
5366.0,GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression,Wood,10.1101/2024.02.28.582460,,1.0,W4392291460,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5367.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5041647947,James R. Evans,0000-0003-2923-281X,Key Personnel,Team Wood,James Evans
5368.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Hardy,Emil Gustavsson
5369.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5072234452,Emil K. Gustavsson,0000-0003-0541-7537,Key Personnel,Team Wood,Emil Gustavsson
5370.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5055233619,Ivan Doykov,0000-0002-4580-6396,,,Ivan Doykov
5371.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5043633854,David Murphy,0000-0002-3771-3800,Key Personnel,Team Wood,David Murphy
5372.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5040895889,Gurvir S. Virdi,0000-0002-8942-0903,,,Gurvir Virdi
5373.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5013212185,Joanne Lachica,0000-0002-2642-3293,Key Personnel,Team Wood,Joanne Lachica
5374.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5011976831,Alexander Röntgen,0000-0002-0500-4815,Key Personnel,Team Wood,Alexander Röntgen
5375.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5055886613,Mhd Hussein Murtada,0000-0003-3402-8864,,,Mhd Murtada
5376.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5103281601,C. Pang,,,,C. Pang
5377.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5064844758,Hannah Macpherson,0000-0002-9535-4025,Key Personnel,Team Wood,Hannah Macpherson
5378.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5066839058,Anna I. Wernick,0000-0001-9048-9492,Key Personnel,Team Hardy,Anna Wernick
5379.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5043816912,Christina E. Toomey,0000-0002-5146-3326,Key Personnel,Team Wood,Christina Toomey
5380.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5102982932,Dilan Athauda,0000-0002-2977-0290,,,Dilan Athauda
5381.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5108206730,Minee L. Choi,,,,Minee Choi
5382.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5020514779,John Hardy,0000-0002-3122-0423,Lead-PI,Team Hardy,John Hardy
5383.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
5384.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5038452125,Michele Vendruscolo,0000-0002-3616-1610,Co-PI,Team Wood,Michele Vendruscolo
5385.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5045744302,Kevin Mills,0000-0003-0763-8288,,,Kevin Mills
5386.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5022560693,Wendy Heywood,0000-0003-2106-8760,,,Wendy Heywood
5387.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5388.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
5389.0,"The diversity of SNCA transcripts in neurons, and its impact on antisense oligonucleotide therapeutics",Wood,10.1101/2024.05.30.596437,,1.0,W4399213038,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5390.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5062533128,Melissa Grant‐Peters,0000-0003-0585-0971,Key Personnel,Team Wood,Melissa Grant‐Peters
5391.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5054705865,Aine Fairbrother-Browne,0000-0002-7196-1410,Key Personnel,Team Wood,Aine Fairbrother-Browne
5392.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5004778160,Amy R. Hicks,0000-0002-3965-5253,Key Personnel,Team Hardy,Amy Hicks
5393.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5012987083,Boyi Guo,0000-0003-2950-2349,,,Boyi Guo
5394.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5040314261,Regina H. Reynolds,0000-0001-6470-7919,,,Regina Reynolds
5395.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5005665859,Louise A. Huuki-Myers,0000-0001-5148-3602,,,Louise Huuki-Myers
5396.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5050073727,Nicholas J. Eagles,0000-0002-9808-5254,,,Nicholas Eagles
5397.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Hardy,Jonathan Brenton
5398.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5017568893,Jonathan Brenton,0000-0002-2381-8484,Key Personnel,Team Wood,Jonathan Brenton
5399.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5033311649,Sonia García-Ruiz,0000-0003-4913-5312,Key Personnel,Team Wood,Sonia García-Ruiz
5400.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5064529704,Nicholas Wood,0000-0002-9500-3348,Lead-PI,Team Wood,Nicholas Wood
5401.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5101470156,Sonia Gandhi,0000-0003-4395-2661,Co-PI,Team Wood,Sonia Gandhi
5402.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5003322851,Keri Martinowich,0000-0002-5237-0789,,,Keri Martinowich
5403.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5040039946,Kristen R. Maynard,0000-0003-0031-8468,,,Kristen Maynard
5404.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5075979341,Leonardo Collado‐Torres,0000-0003-2140-308X,,,Leonardo Collado‐Torres
5405.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Hardy,Mina Ryten
5406.0,Network nature of ligand-receptor interactions underlies disease comorbidity in the brain,Wood,10.1101/2024.06.15.599140,,1.0,W4399716922,A5042439287,Mina Ryten,0000-0001-9520-6957,Co-PI,Team Wood,Mina Ryten
,,Alessi,,,,,A5027580687,,,Key Personnel,Team Alessi,Pawel Lis
,,Alessi,,,,,A5003625877,,,Key Personnel,Team Alessi,Ali Ghoochani
,,Alessi,,,,,A5065188407,,,Key Personnel,Team Alessi,Gloria Shi
,,Alessi,,,,,A5018861529,,,Key Personnel,Team Alessi,Pui Yiu Lam
,,Alessi,,,,,A5030118016,,,Key Personnel,Team Alessi,Sam Scharenberg
,,Alessi,,,,,A5086140564,,,Key Personnel,Team Alessi,Aswini Krishnan
,,Alessi,,,,,A5061529642,,,Key Personnel,Team Alessi,Sreeja Nair
,,Alessi,,,,,A5052997420,,,Key Personnel,Team Alessi,Neringa Pratuseviciute
,,Alessi,,,,,A5003875836,,,Key Personnel,Team Alessi,Aleksandra Levina
,,Alessi,,,,,A5036045846,,,Key Personnel,Team Alessi,Yu-En Lin
,,Alessi,,,,,A5116736684,,,Key Personnel,Team Alessi,Pemba Sherpa
,,Alessi,,,,,,,,Key Personnel,Team Alessi,Mindaugas Viskontas
,,Alessi,,,,,A5100758797,,,Key Personnel,Team Alessi,Zhijun Zhu
,,Alessi,,,,,A5032686050,,,Key Personnel,Team Alessi,Liam Eade
,,Alessi,,,,,,,,Key Personnel,Team Alessi,Matthew Matrongolo
,,Alessi,,,,,,,,Key Personnel,Team Alessi,Matthew Kiely
,,Alessi,,,,,A5115755607,,,Key Personnel,Team Alessi,Chloe Flitton
,,Alessi,,,,,,,,Key Personnel,Team Alessi,Jaijeet Singh
,,Alessi,,,,,,,,Key Personnel,Team Alessi,Aashutosh Tripathi
,,Awatramani,,,,,A5013611528,,,Co-PI,Team Awatramani,Tom Hnasko
,,Awatramani,,,,,A5107962450,,,Key Personnel,Team Awatramani,Divya D. A. Raj
,,Awatramani,,,,,A5029079965,,,Key Personnel,Team Awatramani,Oscar Andrés Moreno Ramos
,,Awatramani,,,,,A5035931221,,,Key Personnel,Team Awatramani,Nicholas Hollon
,,Awatramani,,,,,A5072872393,,,Key Personnel,Team Awatramani,Lotfi Hadjas
,,Awatramani,,,,,A5054493394,,,Key Personnel,Team Awatramani,Shiva Nagappan
,,Awatramani,,,,,A5039421245,,,Key Personnel,Team Awatramani,Elena He
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Maia Datunashvili
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Yuejun Liu
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Andrew Hunter
,,Awatramani,,,,,A5083065650,,,Key Personnel,Team Awatramani,Flavia Aluisi
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Natalia Lopez Gonzales del Rey
,,Awatramani,,,,,A5033809191,,,Key Personnel,Team Awatramani,Jeremy F Atherton
,,Awatramani,,,,,A5050070314,,,Collaborating PI,Team Awatramani,Åsa Wallén-Mackenzie
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Luan Doster
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,James Lyman
,,Awatramani,,,,,A5101843919,,,Key Personnel,Team Awatramani,Lisa Kim
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Sydney Sneed
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Chris Nasios
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Shudi Xu
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Roman Pantazopoulos
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Ana Isabel Silva De Sousa
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Lexe Linderhof
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Alex Garcia
,,Awatramani,,,,,A5064391371,,,Collaborating PI,Team Awatramani,David Gate
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Kaitlyn Quinn
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Danielle Schowalter
,,Awatramani,,,,,A5106960489,,,Key Personnel,Team Awatramani,Beatriz Deo Sorigotto
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Tsogbadrakh Bayasgalan
,,Awatramani,,,,,,,,Key Personnel,Team Awatramani,Lilian Xia
,,Biederer,,,,,A5076555389,,,Lead-PI,Team Biederer,Thomas Biederer
,,Biederer,,,,,A5022502578,,,Co-PI,Team Biederer,Elena Gracheva
,,Biederer,,,,,A5031151569,,,Co-PI,Team Biederer,Michael Higley
,,Biederer,,,,,,,,Project Manager,Team Biederer,Tina Matos
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Marco Mastrotto
,,Biederer,,,,,A5051283321,,,Key Personnel,Team Biederer,Viktor Feketa
,,Biederer,,,,,A5040525760,,,Collaborating PI,Team Biederer,Terrance Kummer
,,Biederer,,,,,A5024352258,,,Key Personnel,Team Biederer,Andrew Sauerbeck
,,Biederer,,,,,A5006321623,,,Collaborating PI,Team Biederer,Ed Boyden
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Bobae An
,,Biederer,,,,,A5012152741,,,Key Personnel,Team Biederer,Jinyoung Kang
,,Biederer,,,,,A5009567403,,,Key Personnel,Team Biederer,Margaret Schroeder
,,Biederer,,,,,A5065105222,,,Key Personnel,Team Biederer,Maria Iuliano
,,Biederer,,,,,A5052823748,,,Key Personnel,Team Biederer,Kondratiuk Ilona
,,Biederer,,,,,A5002698002,,,Key Personnel,Team Biederer,Saroj Sah
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Estela Correa-Chavez
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Paras Patel
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Hao Dong
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Rima Pant
,,Biederer,,,,,A5091794967,,,Key Personnel,Team Biederer,Kate Brynildsen
,,Biederer,,,,,A5010532221,,,Key Personnel,Team Biederer,Eunah Yu
,,Biederer,,,,,A5102987758,,,Key Personnel,Team Biederer,Kieran Murphy
,,Biederer,,,,,A5037229208,,,Key Personnel,Team Biederer,Shubhankar Patankar
,,Biederer,,,,,A5015455736,,,Key Personnel,Team Biederer,Suman Kulkarni
,,Biederer,,,,,A5113152817,,,Key Personnel,Team Biederer,Laura Brasseur
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Lamisa Musarat
,,Biederer,,,,,A5031788033,,,Key Personnel,Team Biederer,Naman Vatsa
,,Biederer,,,,,A5102931151,,,Key Personnel,Team Biederer,Dayana Pérez-Acuña
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Pranav Shedge
,,Biederer,,,,,A5074305003,,,Key Personnel,Team Biederer,Maryann Platt
,,Biederer,,,,,A5040937490,,,Key Personnel,Team Biederer,Christoffer Gretarsson Alexandersen
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Giang Nguyen
,,Biederer,,,,,A5075569080,,,Key Personnel,Team Biederer,Na Wang
,,Biederer,,,,,A5040122670,,,Collaborating PI,Team Biederer,Robert E Kennedy
,,Biederer,,,,,,,,Key Personnel,Team Biederer,Jacob Reiber
,,Calakos,,,,,A5017962710,,,Co-PI,Team Calakos,Cagla Eroglu
,,Calakos,,,,,A5088379859,,,Co-PI,Team Calakos,Sergiu Pasca
,,Calakos,,,,,A5047661140,,,Collaborating PI,Team Calakos,Laurie Sanders
,,Calakos,,,,,A5004078699,,,Collaborating PI,Team Calakos,Simon Gregory
,,Calakos,,,,,A5073515090,,,Key Personnel,Team Calakos,Daichi Shonai
,,Calakos,,,,,A5071939313,,,Key Personnel,Team Calakos,Ankit Choudhury
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Birger Anastasya
,,Calakos,,,,,,,,Key Personnel,Team Calakos,SB Dhanseh
,,Calakos,,,,,A5021652883,,,Key Personnel,Team Calakos,Sejourne Gabrielle
,,Calakos,,,,,A5064817514,,,Key Personnel,Team Calakos,Brose Nicholas
,,Calakos,,,,,A5003837963,,,Key Personnel,Team Calakos,Elazar Nimrod
,,Calakos,,,,,A5090150783,,,Key Personnel,Team Calakos,Baumert Ryan
,,Calakos,,,,,A5064202687,,,Key Personnel,Team Calakos,Wang Shiyi
,,Calakos,,,,,A5025816614,,,Key Personnel,Team Calakos,Lucio Schiapparelli
,,Calakos,,,,,A5072138284,,,Key Personnel,Team Calakos,Haidun Yan
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Raghunathan Kavya
,,Calakos,,,,,A5007813678,,,Key Personnel,Team Calakos,Miura Yuki
,,Calakos,,,,,A5055802646,,,Key Personnel,Team Calakos,Cameron Morris
,,Calakos,,,,,A5101610269,,,Key Personnel,Team Calakos,Il Ji
,,Calakos,,,,,A5075979524,,,Key Personnel,Team Calakos,Leslie Vazquez
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Carlo Vignali
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Sophia Lehrman
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Tara Richbourg
,,Calakos,,,,,A5027563105,,,Key Personnel,Team Calakos,Daniel Quintero
,,Calakos,,,,,A5084890983,,,Key Personnel,Team Calakos,Matt Oliver
,,Calakos,,,,,A5052358706,,,Key Personnel,Team Calakos,Zachary Caffall
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Daisy Perez
,,Calakos,,,,,A5044093065,,,Key Personnel,Team Calakos,Joseph Rittiner
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Yirong Xu
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Jim Roach
,,Calakos,,,,,A5025366779,,,Key Personnel,Team Calakos,Aryana Yousefzadeh
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Russell Ravenel
,,Calakos,,,,,A5033015769,,,Collaborating PI,Team Calakos,Evans Chantell
,,Calakos,,,,,A5105763009,,,Key Personnel,Team Calakos,Kalejaiye Lola
,,Calakos,,,,,,,,Project Manager,Team Calakos,Harini Gangadharan
,,Calakos,,,,,,,,Key Personnel,Team Calakos,Jinhu Kim
,,Chen,,,,,A5080223712,,,Co-PI,Team Chen,Timothy Chan
,,Chen,,,,,A5000768609,,,Collaborating PI,Team Chen,Hussein Tawbi
,,Chen,,,,,A5022297689,,,Key Personnel,Team Chen,Rachit Bakshi
,,Chen,,,,,A5042585597,,,Key Personnel,Team Chen,Chandra Mohan
,,Chen,,,,,A5103230255,,,Key Personnel,Team Chen,Vladimir Makarov
,,Chen,,,,,A5077749574,,,Key Personnel,Team Chen,Eric Macklin
,,Chen,,,,,A5103383699,,,Key Personnel,Team Chen,Leilei Shi
,,Chen,,,,,A5041553722,,,Key Personnel,Team Chen,Navin Varadarajan
,,Chen,,,,,A5044602598,,,Key Personnel,Team Chen,Jian Wang
,,Chen,,,,,,,,Key Personnel,Team Chen,Ning Xia
,,Chen,,,,,,,,Key Personnel,Team Chen,Niyaz Honarvar
,,Chen,,,,,,,,Key Personnel,Team Chen,Chunyu Xu
,,Chen,,,,,A5028161783,,,Collaborating PI,Team Chen,Cassian Yee
,,Chen,,,,,A5029833435,,,Key Personnel,Team Chen,Yongxing Gong
,,Chen,,,,,A5070237973,,,Key Personnel,Team Chen,Grace Crotty
,,Chen,,,,,A5049204983,,,Key Personnel,Team Chen,Shailbala Singh
,,Chen,,,,,A5100654897,,,Key Personnel,Team Chen,Levy Michael
,,Chen,,,,,A5056477702,,,Key Personnel,Team Chen,Jae Ahn
,,Chen,,,,,,,,Key Personnel,Team Chen,Chienwen Su
,,Chen,,,,,A5022172958,,,Project Manager,Team Chen,Jackson Schumacher
,,Chen,,,,,A5025372783,,,Key Personnel,Team Chen,Aline Fassini
,,Chen,,,,,A5031006998,,,Key Personnel,Team Chen,Sarfraz Ahmed
,,Chen,,,,,A5101756802,,,Key Personnel,Team Chen,Yuhang Zhao
,,Chen,,,,,A5084772903,,,Key Personnel,Team Chen,Armin Bayati
,,Chen,,,,,,,,Key Personnel,Team Chen,Hanka Vrban
,,Cragg,,,,,A5004457607,,,Co-PI,Team Cragg,Dinos (Konstantinos) Meletis
,,Cragg,,,,,A5028723665,,,Co-PI,Team Cragg,Richard Wade-Martins
,,Cragg,,,,,A5041944620,,,Project Manager,Team Cragg,Cláudia Mendes
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Lauren Burgeno
,,Cragg,,,,,A5024223034,,,Key Personnel,Team Cragg,Bethan O'Connor
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Lucille Duquenoy
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Jessica Livesey
,,Cragg,,,,,A5023022036,,,Key Personnel,Team Cragg,Kathryn Todd
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Aishwarya Vedula
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Niamh Walker
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Ann O'Brien
,,Cragg,,,,,A5114100400,,,Key Personnel,Team Cragg,Mark Conway
,,Cragg,,,,,A5058373114,,,Key Personnel,Team Cragg,Walifa Waqar
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Alicia Twisselmann
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Guy Yona
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Rasha Elghaba
,,Cragg,,,,,A5103139289,,,Key Personnel,Team Cragg,Teris Tam
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Jennifer Blackmore
,,Cragg,,,,,A5079530972,,,Key Personnel,Team Cragg,Helen Collins
,,Cragg,,,,,A5082797221,,,Key Personnel,Team Cragg,Ricardo Marquez Gomez
,,Cragg,,,,,A5044697919,,,Key Personnel,Team Cragg,Maria Claudia Caiazza
,,Cragg,,,,,A5011590646,,,Key Personnel,Team Cragg,Nora Bengoa-Vergniory
,,Cragg,,,,,A5013827384,,,Key Personnel,Team Cragg,Tara Diviney
,,Cragg,,,,,A5029505686,,,Key Personnel,Team Cragg,Benjamin Vallin
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Oliver Curry
,,Cragg,,,,,A5083740703,,,Key Personnel,Team Cragg,Elliot Mock
,,Cragg,,,,,A5082209540,,,Key Personnel,Team Cragg,Ajantha Abey
,,Cragg,,,,,A5036291205,,,Key Personnel,Team Cragg,Ioannis Mantas
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Marta Graziano
,,Cragg,,,,,A5023314892,,,Key Personnel,Team Cragg,Emil Wärnberg
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Thomas Contesse
,,Cragg,,,,,A5091785996,,,Key Personnel,Team Cragg,Alessandro Contestabile
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Magdalena Krubner
,,Cragg,,,,,A5087924578,,,Key Personnel,Team Cragg,Eleonora Rubino
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Betul Tamer
,,Cragg,,,,,A5016989883,,,Key Personnel,Team Cragg,Anil Joshi
,,Cragg,,,,,,,,Key Personnel,Team Cragg,Hadas Frostig
,,De Camilli,,,,,A5037459294,,,Lead PI,Team De Camilli,Pietro De Camilli
,,De Camilli,,,,,A5040327186,,,Key Personnel,Team De Camilli,Berrak Ugur
,,De Camilli,,,,,A5068282890,,,Key Personnel,Team De Camilli,Agnes Ferguson
,,De Camilli,,,,,A5075174957,,,Key Personnel,Team De Camilli,Alexandros Kotokos
,,De Camilli,,,,,,,,Key Personnel,Team De Camilli,Pablo Muñoz-Llancao
,,De Camilli,,,,,A5019788743,,,Key Personnel,Team De Camilli,Amanda Bentley-DeSousa
,,De Camilli,,,,,A5002387555,,,Key Personnel,Team De Camilli,Anbang Dai
,,De Camilli,,,,,A5047100574,,,Key Personnel,Team De Camilli,Hanieh Falahati
,,De Camilli,,,,,A5062708890,,,Key Personnel,Team De Camilli,Francesca Filippini
,,De Camilli,,,,,,,,Key Personnel,Team De Camilli,Devin Clegg
,,De Camilli,,,,,A5059541590,,,Key Personnel,Team De Camilli,Won Jung
,,De Camilli,,,,,A5030583873,,,Key Personnel,Team De Camilli,Snehashish Ghosh
,,De Camilli,,,,,A5075836743,,,Key Personnel,Team De Camilli,Sofia Delgado
,,De Camilli,,,,,A5045123514,,,Key Personnel,Team De Camilli,Layla Nassar
,,De Camilli,,,,,,,,Key Personnel,Team De Camilli,Chloe Nield
,,De Camilli,,,,,A5013026077,,,Key Personnel,Team De Camilli,Nicole Corbin-Stein
,,De Camilli,,,,,,,,Key Personnel,Team De Camilli,Kriza Sy
,,De Camilli,,,,,A5081607337,,,Key Personnel,Team De Camilli,Hongyan Hao
,,De Camilli,,,,,A5074809585,,,Key Personnel,Team De Camilli,Devin Fuller
,,De Camilli,,,,,A5047711317,,,Key Personnel,Team De Camilli,Bodan Hu
,,De Camilli,,,,,,,,Key Personnel,Team De Camilli,Dazhi Li
,,De Camilli,,,,,A5102748635,,,Key Personnel,Team De Camilli,Jaywon Lee
,,Desjardins,,,,,A5074478086,,,Collaborating PI,Team Desjardins,Jo Anne Stratton
,,Desjardins,,,,,A5024580674,,,Co-PI,Team Desjardins,Louis-Eric Trudeau
,,Desjardins,,,,,A5060556873,,,Project Manager,Team Desjardins,Lilia Rodriguez
,,Desjardins,,,,,A5078393119,,,Co-PI,Team Desjardins,Janelle Drouin-Ouellet
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Camberly Hernandez
,,Desjardins,,,,,A5003969733,,,Key Personnel,Team Desjardins,Marie-Josée Bourque
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Ilyes Nedjar
,,Desjardins,,,,,A5019594246,,,Key Personnel,Team Desjardins,Joel Lanoix
,,Desjardins,,,,,A5080920671,,,Key Personnel,Team Desjardins,Yong Zhong Xu
,,Desjardins,,,,,A5058267162,,,Key Personnel,Team Desjardins,Florence Petit
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Julie Bouquety
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Benoit Barrette
,,Desjardins,,,,,A5058981235,,,Key Personnel,Team Desjardins,Amandine Even
,,Desjardins,,,,,A5089718212,,,Key Personnel,Team Desjardins,Monica Dallmannsauer
,,Desjardins,,,,,A5028297592,,,Key Personnel,Team Desjardins,Camila Tiefensee Ribeiro
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Vanessa Omana
,,Desjardins,,,,,A5082845439,,,Key Personnel,Team Desjardins,Moustafa Nouh
,,Desjardins,,,,,A5002398983,,,Key Personnel,Team Desjardins,Chongyang Li
,,Desjardins,,,,,A5061652250,,,Key Personnel,Team Desjardins,Zaya Mohamad
,,Desjardins,,,,,A5005858229,,,Key Personnel,Team Desjardins,Maria Gentile
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Nour Haroun
,,Desjardins,,,,,,,,Key Personnel,Team Desjardins,Yue Ling
,,Edwards,,,,,A5042504580,,,Co-PI,Team Edwards,Lerner Talia
,,Edwards,,,,,A5029464086,,,Collaborating PI,Team Edwards,Chris Ford
,,Edwards,,,,,A5041830464,,,Key Personnel,Team Edwards,Lorenzo Sansalone
,,Edwards,,,,,A5013543642,,,Key Personnel,Team Edwards,Jessica Perkins
,,Edwards,,,,,A5102877680,,,Key Personnel,Team Edwards,Oluwole Alese
,,Edwards,,,,,A5014280534,,,Key Personnel,Team Edwards,Yuhong Fu
,,Edwards,,,,,A5071415520,,,Key Personnel,Team Edwards,Tony Hsiao
,,Edwards,,,,,A5038735537,,,Key Personnel,Team Edwards,Elizabeth Nielsen
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Louis Van Camp
,,Edwards,,,,,A5011600296,,,Key Personnel,Team Edwards,Nkatha Mwenda
,,Edwards,,,,,A5076562111,,,Key Personnel,Team Edwards,Liao Szu-Chi
,,Edwards,,,,,A5028948696,,,Key Personnel,Team Edwards,Jacob Nadel
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Akio Mori
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Match McGregor
,,Edwards,,,,,A5091329038,,,Key Personnel,Team Edwards,Christiana Kontaxi
,,Edwards,,,,,A5056112365,,,Key Personnel,Team Edwards,Olivia Barnhill
,,Edwards,,,,,A5027927635,,,Key Personnel,Team Edwards,Rodrigo Paz
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Pam Marcott
,,Edwards,,,,,A5030607005,,,Key Personnel,Team Edwards,Anna Lipkin
,,Edwards,,,,,A5060578133,,,Key Personnel,Team Edwards,Bérénice Coutant
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Naeliz Lopez
,,Edwards,,,,,A5022893487,,,Key Personnel,Team Edwards,Joy Adler
,,Edwards,,,,,A5083846976,,,Key Personnel,Team Edwards,Yoshi Sei
,,Edwards,,,,,A5076073841,,,Key Personnel,Team Edwards,ManHua Zhu
,,Edwards,,,,,A5101701899,,,Key Personnel,Team Edwards,Javier Hernandez Lopez
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Amy Burke
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Danielle Wilson
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Heather Schneps
,,Edwards,,,,,A5011273600,,,Key Personnel,Team Edwards,Nikolas Bergum
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Bita Firouzan
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Cao Zirui
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Mahabadian Anahid Ansari
,,Edwards,,,,,,,,Key Personnel,Team Edwards,Rastinejad Daniel
,,Gradinaru,,,,,A5063109286,,,Co-PI,Team Gradinaru,Ashley Seifert
,,Gradinaru,,,,,A5045170248,,,Co-PI,Team Gradinaru,David Van Valen
,,Gradinaru,,,,,A5088379859,,,Collaborating PI,Team Gradinaru,Sergiu Pasca
,,Gradinaru,,,,,A5063286124,,,Project Manager,Team Gradinaru,Catherine Oikonomou
,,Gradinaru,,,,,A5010921137,,,Key Personnel,Team Gradinaru,Gerard Coughlin
,,Gradinaru,,,,,A5071581507,,,Key Personnel,Team Gradinaru,Matheus de Castro Fonseca
,,Gradinaru,,,,,A5013862391,,,Key Personnel,Team Gradinaru,Morgan Schwartz
,,Gradinaru,,,,,A5091919745,,,Key Personnel,Team Gradinaru,Lincoln Ombelets
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Carly Drzewiecki
,,Gradinaru,,,,,A5003826174,,,Key Personnel,Team Gradinaru,Shawn Kamboj
,,Gradinaru,,,,,A5008016466,,,Key Personnel,Team Gradinaru,Renee Donahue
,,Gradinaru,,,,,A5081687976,,,Key Personnel,Team Gradinaru,Alex Chung
,,Gradinaru,,,,,A5029757025,,,Key Personnel,Team Gradinaru,Min Jee Jang
,,Gradinaru,,,,,A5077787922,,,Key Personnel,Team Gradinaru,Sayan Dutta
,,Gradinaru,,,,,A5000866567,,,Key Personnel,Team Gradinaru,Nikki Tjahjono
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Erin Scott
,,Gradinaru,,,,,A5048074423,,,Key Personnel,Team Gradinaru,Jonathan Hoang
,,Gradinaru,,,,,A5071234148,,,Key Personnel,Team Gradinaru,Kyle Puhger
,,Gradinaru,,,,,A5102817325,,,Key Personnel,Team Gradinaru,Yujie Fan
,,Gradinaru,,,,,A5066850713,,,Key Personnel,Team Gradinaru,Leonardo Parra Rivas
,,Gradinaru,,,,,A5029791890,,,Key Personnel,Team Gradinaru,Veronica Cerada
,,Gradinaru,,,,,A5070698221,,,Key Personnel,Team Gradinaru,Patrick Kearney
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Stella Ekaputri
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Joud Mar'i
,,Gradinaru,,,,,A5013441116,,,Key Personnel,Team Gradinaru,Zhe Qu
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Patrick Simpson
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Manxuan Zhou
,,Gradinaru,,,,,A5034670721,,,Key Personnel,Team Gradinaru,Damien Wolfe
,,Gradinaru,,,,,A5026330854,,,Key Personnel,Team Gradinaru,Changfan Lin
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Jitendra Sharma
,,Gradinaru,,,,,,,,Key Personnel,Team Gradinaru,Ebenezer Aryee
,,Gradinaru,,,,,A5017919522,,,Key Personnel,Team Gradinaru,Tim Shay
,,Gradinaru,,,,,A5044635234,,,Key Personnel,Team Gradinaru,Acacia Mayfield
,,Gradinaru,,,,,A5070516493,,,Key Personnel,Team Gradinaru,Tamara Tomanic
,,Hafler,,,,,A5017619994,,,Co-PI,Team Hafler,Rui Chang
,,Hafler,,,,,A5056408708,,,Co-PI,Team Hafler,Ramnik Xavier
,,Hafler,,,,,A5051444924,,,PM,Team Hafler,Nick Buitrago-Pocasangre
,,Hafler,,,,,A5019679682,,,Collaborator,Team Hafler,Jesse Cedarbaum
,,Hafler,,,,,A5026016872,,,Key Personnel,Team Hafler,Daniel Graham
,,Hafler,,,,,A5042099602,,,Collaborator,Team Hafler,Brian Koo
,,Hafler,,,,,A5039563040,,,Collaborator,Team Hafler,David Van Dijk
,,Hafler,,,,,A5041656783,,,personnel,Team Hafler,Vidyadhara DJ
,,Hafler,,,,,A5018895606,,,personnel,Team Hafler,Jialiu Zeng
,,Hafler,,,,,A5020160994,,,Key Personnel,Team Hafler,Shana Leopold
,,Hafler,,,,,A5081452290,,,Key Personnel,Team Hafler,Jacques Deguine
,,Hafler,,,,,A5018808803,,,personnel,Team Hafler,Qiancheng Zhao
,,Hafler,,,,,A5046928645,,,personnel,Team Hafler,Anjelica Martin
,,Hafler,,,,,A5051217231,,,personnel,Team Hafler,Varnica Khetrapal
,,Hafler,,,,,A5009691363,,,personnel,Team Hafler,Mary Alice Allnut
,,Hafler,,,,,A5083282772,,,Collaborator,Team Hafler,Aleks Videnovic
,,Hafler,,,,,A5100363749,,,personnel,Team Hafler,Haowei Wang
,,Hafler,,,,,A5017415918,,,personnel,Team Hafler,Anthony Russo
,,Hafler,,,,,,,,personnel,Team Hafler,Kara Mead
,,Hafler,,,,,,,,personnel,Team Hafler,Salma Elkolaly
,,Hafler,,,,,,,,personnel,Team Hafler,Angela Zhao
,,Hafler,,,,,A5039832064,,,personnel,Team Hafler,Rafiad Islam
,,Hafler,,,,,A5013026077,,,personnel,Team Hafler,Nicole Corbin-Stein
,,Hafler,,,,,A5020259626,,,personnel,Team Hafler,Bajaj Aditya
,,Hafler,,,,,A5019272605,,,personnel,Team Hafler,Rothschild Lily
,,Hafler,,,,,A5077729930,,,personnel,Team Hafler,Chung-Jung Li
,,Hafler,,,,,A5045382878,,,personnel,Team Hafler,Weiyi Tian
,,Hafler,,,,,A5022153955,,,personnel,Team Hafler,Yoshiaki Yasumizu
,,Hafler,,,,,A5071741892,,,personnel,Team Hafler,Leah Harmon
,,Hafler,,,,,A5013109508,,,personnel,Team Hafler,Kong Lingjia
,,Hafler,,,,,,,,Halfer Admin,Team Hafler,Lindsay Young
,,Hafler,,,,,,,,Palm Admin,Team Hafler,Greg Moore
,,Hafler,,,,,,,,Associate Director,Team Hafler,Courtney Grimm
,,Hardy,,,,,A5037609259,,,Co-PI,Team Hardy,Maria Grazia Spillantini
,,Hardy,,,,,A5045734117,,,Key Personnel,Team Hardy,Ana Luisa Gil Martinez
,,Hardy,,,,,A5012240201,,,Key Personnel,Team Hardy,Beatrice Costa
,,Hardy,,,,,A5059141377,,,Key Personnel,Team Hardy,Benjamin O'Callaghan
,,Hardy,,,,,A5097222057,,,Key Personnel,Team Hardy,Capucine De Talhouet
,,Hardy,,,,,,,,Key Personnel,Team Hardy,D'Sa Karishma
,,Hardy,,,,,A5049803575,,,Key Personnel,Team Hardy,Danielle Taylor te Vruchte
,,Hardy,,,,,A5023940227,,,Key Personnel,Team Hardy,David Priestman
,,Hardy,,,,,A5041010859,,,Key Personnel,Team Hardy,Ed Jabbari
,,Hardy,,,,,A5045751785,,,Key Personnel,Team Hardy,Giulio Deangeli
,,Hardy,,,,,A5006285538,,,Key Personnel,Team Hardy,Janine Brandes
,,Hardy,,,,,A5017568893,,,Key Personnel,Team Hardy,Jonathon Brenton
,,Hardy,,,,,A5025988686,,,Key Personnel,Team Hardy,Juan Botia
,,Hardy,,,,,,,,Project Manager,Team Hardy,June Smalley
,,Hardy,,,,,A5013449164,,,Key Personnel,Team Hardy,Kerri Wallom
,,Hardy,,,,,A5016263835,,,Key Personnel,Team Hardy,Methap Bacioglu
,,Hardy,,,,,A5045997682,,,Collaborating PI,Team Hardy,Helene Plun-Favreau
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Kevin (Zhiguang) Zheng
,,Hardy,,,,,A5011514763,,,Key Personnel,Team Hardy,Hannah Duffy
,,Hardy,,,,,A5101409261,,,Key Personnel,Team Hardy,Qiaochu Zhang
,,Hardy,,,,,A5062276033,,,Key Personnel,Team Hardy,Ellie Stafford
,,Hardy,,,,,A5016636144,,,Key Personnel,Team Hardy,Noopur Bhore
,,Hardy,,,,,A5093443267,,,Key Personnel,Team Hardy,Toby Curless
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Iria Trasobares Magdalena
,,Hardy,,,,,A5040350399,,,Key Personnel,Team Hardy,Yau Mun Lim
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Pauline Vessiere
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Charlotte Andrews
,,Hardy,,,,,A5017458937,,,Key Personnel,Team Hardy,Hemanth Nelvagal
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Reuben Bush
,,Hardy,,,,,A5001915719,,,Key Personnel,Team Hardy,Maria Fernandez-Suarez
,,Hardy,,,,,A5011126341,,,Key Personnel,Team Hardy,Darija Šoltić
,,Hardy,,,,,A5021623204,,,Key Personnel,Team Hardy,Katharina Cosker
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Samantha Yu
,,Hardy,,,,,A5080149122,,,Key Personnel,Team Hardy,Lorena Cuenca-Bermejo
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Harry Lau
,,Hardy,,,,,A5017714704,,,Key Personnel,Team Hardy,Caitlin Loh
,,Hardy,,,,,A5082258250,,,Key Personnel,Team Hardy,Daan van Kruining
,,Hardy,,,,,,,,Key Personnel,Team Hardy,Nancy Chiraki
,,Harper,,,,,,,,Key Personnel,Team Harper,Juliana Abramovich
,,Harper,,,,,A5004961303,,,Key Personnel,Team Harper,Ching Chieh (Ian) Chou
,,Harper,,,,,A5108058855,,,Key Personnel,Team Harper,Thanh Thao Do
,,Harper,,,,,A5115866481,,,Key Personnel,Team Harper,Ulrich Dransfeld
,,Harper,,,,,A5061030857,,,Co-PI,Team Harper,Ruben Fernandez-Busnadiego
,,Harper,,,,,A5061982854,,,Key Personnel,Team Harper,Tao Fu
,,Harper,,,,,A5023567689,,,Key Personnel,Team Harper,Ana Galesic
,,Harper,,,,,A5115880484,,,Key Personnel,Team Harper,Maximilian Garhammer
,,Harper,,,,,A5031687007,,,Key Personnel,Team Harper,Miguel Gonzalez
,,Harper,,,,,A5047746208,,,Lead PI,Team Harper,J. Wade Harper
,,Harper,,,,,A5086048712,,,Co-PI,Team Harper,Franz-Ulrich Hartl
,,Harper,,,,,A5047819540,,,Key Personnel,Team Harper,Nazia Hussain
,,Harper,,,,,A5073719209,,,Key Personnel,Team Harper,Gopal Jayaraj
,,Harper,,,,,A5017777250,,,Key Personnel,Team Harper,Leo Kiss
,,Harper,,,,,A5077274718,,,Key Personnel,Team Harper,Tina Lee
,,Harper,,,,,A5100445537,,,Key Personnel,Team Harper,Lisa Li
,,Harper,,,,,A5006940999,,,Key Personnel,Team Harper,Angel Madero
,,Harper,,,,,,,,Key Personnel,Team Harper,Vince Masto
,,Harper,,,,,A5011256990,,,Key Personnel,Team Harper,Arsen Petrovic
,,Harper,,,,,A5069109050,,,Key Personnel,Team Harper,Rajan Jesuraj Prabu
,,Harper,,,,,,,,Key Personnel,Team Harper,Midea Ortiz Rios
,,Harper,,,,,,,,Key Personnel,Team Harper,Kevin Sicking
,,Harper,,,,,,,,Key Personnel,Team Harper,Anna Siegert
,,Harper,,,,,A5004442264,,,Key Personnel,Team Harper,Pinto Sivan
,,Harper,,,,,A5002929255,,,Key Personnel,Team Harper,Cole Sitron
,,Harper,,,,,A5083821008,,,Key Personnel,Team Harper,Airi Tarutani
,,Harper,,,,,A5082805678,,,Key Personnel,Team Harper,Patricia Yuste-Checa
,,Harper,,,,,,,,Key Personnel,Team Harper,Aslan Cook
,,Harper,,,,,A5029306578,,,External Collaborator,Team Harper,Christina Schroeter
,,Harper,,,,,A5047738674,,,Key Personnel,Team Harper,Gisele Andree
,,Harper,,,,,A5060896807,,,Key Personnel,Team Harper,Korbin Kleczko
,,Harper,,,,,,,,Key Personnel,Team Harper,Filiz Civril Stocker
,,Harper,,,,,A5025702868,,,Key Personnel,Team Harper,Ekampreet Singh
,,Harper,,,,,A5100659215,,,Key Personnel ,Team Harper,Wenxin Zhang
,,Hurley,,,,,,,,Acting Project Manager,Team Hurley,Catherine Dea
,,Hurley,,,,,A5065987196,,,Key Personnel,Team Hurley,Justyna Sawa-Makarska
,,Hurley,,,,,A5080220622,,,Key Personnel,Team Hurley,Wai Kit (Leo) Lam
,,Hurley,,,,,A5054466750,,,Key Personnel,Team Hurley,Zeke/Annan Cook
,,Hurley,,,,,A5005021945,,,Key Personnel,Team Hurley,Sierra Palumbos
,,Hurley,,,,,A5011701850,,,Key Personnel,Team Hurley,Chen Minghao
,,Hurley,,,,,A5005119863,,,Key Personnel,Team Hurley,Ainara Claveras
,,Hurley,,,,,A5053773998,,,Key Personnel,Team Hurley,Eric Herrman
,,Hurley,,,,,A5085699682,,,Key Personnel,Team Hurley,Nataraj Neha
,,Hurley,,,,,A5006487637,,,Key Personnel,Team Hurley,Paul Sanjoy
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Srivastava Aayush
,,Hurley,,,,,A5086525063,,,Key Personnel,Team Hurley,Cui Zhicheng (Chen)
,,Hurley,,,,,A5019235461,,,Key Personnel,Team Hurley,Aaron Joiner
,,Hurley,,,,,A5017632428,,,Key Personnel,Team Hurley,Javier Lizarrondo
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Yongjia Duan
,,Hurley,,,,,A5074128852,,,Key Personnel,Team Hurley,Kevin Matthew Rose
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Siwen Liang
,,Hurley,,,,,A5046656497,,,Paid Collaborator,Team Hurley,Samantha Lewis
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Eve Kakudji
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Aniketh Bishnu
,,Hurley,,,,,,,,Key Personnel,Team Hurley,Ye Lu
,,Hurley,,,,,A5005613961,,,Key Personnel,Team Hurley,Juan Zapata Munoz
,,Jakobsson,,,,,A5032075946,,,Co-PI,Team Jakobsson,Molly Gale Hammell
,,Jakobsson,,,,,A5071467664,,,Co-PI,Team Jakobsson,Agnete Kirkeby
,,Jakobsson,,,,,A5057329454,,,Key Personnel,Team Jakobsson,Oliver Tam
,,Jakobsson,,,,,A5064182306,,,Key Personnel,Team Jakobsson,Cole Wunderlich
,,Jakobsson,,,,,A5065606952,,,Key Personnel,Team Jakobsson,Talitha Forcier
,,Jakobsson,,,,,A5067880345,,,Unpaid Collaborator,Team Jakobsson,Jo Jones
,,Jakobsson,,,,,A5067137350,,,Unpaid Collaborator,Team Jakobsson,Annabel Curle
,,Jakobsson,,,,,A5033125199,,,Key Personnel,Team Jakobsson,"Annelies QUAEGEBEUR,"
,,Jakobsson,,,,,A5031544871,,,Key Personnel,Team Jakobsson,Alison Salvador
,,Jakobsson,,,,,A5073678325,,,Key Personnel,Team Jakobsson,Janko Kajtez
,,Jakobsson,,,,,A5054219281,,,Key Personnel,Team Jakobsson,Nina-Lydia Kazakou
,,Jakobsson,,,,,A5048601901,,,Key Personnel,Team Jakobsson,Laura Castilla-Vallmanya
,,Jakobsson,,,,,A5082209159,,,Key Personnel,Team Jakobsson,Josefine Christiansen
,,Jakobsson,,,,,A5027935456,,,Key Personnel,Team Jakobsson,Sara Bermudez
,,Jakobsson,,,,,,,,Key Personnel,Team Jakobsson,Louise Saviø Piilgaard
,,Jakobsson,,,,,A5090157533,,,Key Personnel,Team Jakobsson,Daniel Rainbow
,,Jakobsson,,,,,A5005598568,,,Key Personnel,Team Jakobsson,Angelica Guiloff
,,Jakobsson,,,,,,,,Key Personnel,Team Jakobsson,Sophie Field
,,Jakobsson,,,,,,,,Key Personnel,Team Jakobsson,James Shonhard
,,Jakobsson,,,,,A5104605049,,,Key Personnel,Team Jakobsson,Sasvi Wijesinghe
,,Jakobsson,,,,,A5053350104,,,Key Personnel,Team Jakobsson,Ropafadzo Mzezewa
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Fatih Akkentli
,,Kaplitt,,,,,A5062344898,,,Key Personnel,Team Kaplitt,Kundlik Gadhave
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Deok Jeong
,,Kaplitt,,,,,A5079387074,,,Collaborating PI,Team Kaplitt,Tae-In Kam
,,Kaplitt,,,,,A5030425534,,,Collaborating PI,Team Kaplitt,Hanseok Ko
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Manisha Kumar
,,Kaplitt,,,,,A5006816024,,,Key Personnel,Team Kaplitt,Ramhari Kumbhar
,,Kaplitt,,,,,A5035672227,,,Collaborating PI,Team Kaplitt,Xiaobo Mao
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Jae Jin Song
,,Kaplitt,,,,,A5100387139,,,Key Personnel,Team Kaplitt,Ning Wang
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Cooper Lathrop
,,Kaplitt,,,,,A5051447805,,,Key Personnel,Team Kaplitt,Mihaela Stavarache
,,Kaplitt,,,,,A5051134161,,,Project Manager,Team Kaplitt,Eileen Torres
,,Kaplitt,,,,,A5067702951,,,Key Personnel,Team Kaplitt,Kristine Kolkman
,,Kaplitt,,,,,A5054618323,,,Collaborating PI,Team Kaplitt,Nozomi Nishimura
,,Kaplitt,,,,,A5066785148,,,Collaborating PI,Team Kaplitt,Chris Schaffer
,,Kaplitt,,,,,A5018283116,,,Key Personnel,Team Kaplitt,Laurie Bizimana
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Vivian Chiang
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Chi-Yong Eom
,,Kaplitt,,,,,A5026281113,,,Key Personnel,Team Kaplitt,Wojciech Paslawski
,,Kaplitt,,,,,A5070094844,,,Key Personnel,Team Kaplitt,Michael Lamont
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Andrew Yancura
,,Kaplitt,,,,,,,,Key Personnel,Team Kaplitt,Jacquelyn Haytayan
,,Kirik,,,,,A5016649904,,,Co-PI,Team Kirik,Jennifer Johnston
,,Kirik,,,,,A5019368836,,,Key Personnel,Team Kirik,Stefano Frausin
,,Kirik,,,,,A5078770888,,,Key Personnel,Team Kirik,Cameron Hunt
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Brianna Xuereb
,,Kirik,,,,,A5105976247,,,Key Personnel,Team Kirik,Ryan Davis
,,Kirik,,,,,A5008182071,,,Key Personnel,Team Kirik,Nicolas Dzamko
,,Kirik,,,,,A5014280534,,,Key Personnel,Team Kirik,Yuhong Fu
,,Kirik,,,,,A5037503849,,,Key Personnel,Team Kirik,Louise Cottle
,,Kirik,,,,,A5005197796,,,Project Manager,Team Kirik,Courtney Wright
,,Kirik,,,,,A5016069908,,,Key Personnel,Team Kirik,Tyra Fraser
,,Kirik,,,,,A5020385688,,,Key Personnel,Team Kirik,Serena Viventi
,,Kirik,,,,,A5064840346,,,Key Personnel,Team Kirik,Asheeta Prasad
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Giselle Sagredo
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Jennifer Jin
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Kwan Yu
,,Kirik,,,,,A5109021482,,,Key Personnel,Team Kirik,Peat Cormac
,,Kirik,,,,,A5033917067,,,Key Personnel,Team Kirik,Chedid Jessica
,,Kirik,,,,,A5022683208,,,Key Personnel,Team Kirik,My Andersson
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Sofie Andresen
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Felicia Suteja
,,Kirik,,,,,A5037111235,,,Key Personnel,Team Kirik,Kevin Law
,,Kirik,,,,,A5005077069,,,Key Personnel,Team Kirik,Rebecca Bricker
,,Kirik,,,,,,,,Key Personnel,Team Kirik,Anahid Mahabadian
,,Kirik,,,,,A5055416860,,,Key Personnel,Team Kirik,Qian Gordon
,,Kirik,,,,,A5100356085,,,Key Personnel,Team Kirik,Yang Liu
,,Kordower,,,,,A5056072835,,,Collaborating PI,Team Kordower,Frederic Manfredsson
,,Kordower,,,,,A5016102389,,,Key Personnel,Team Kordower,Alan Landay
,,Kordower,,,,,A5086806840,,,Key Personnel,Team Kordower,Scott Muller
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Jeremy Molina
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Kyle Hauser
,,Kordower,,,,,A5005580223,,,Key Personnel,Team Kordower,Vineet Gupta
,,Kordower,,,,,A5049620072,,,Key Personnel,Team Kordower,Laura Volpicelli-Daley
,,Kordower,,,,,A5013535951,,,Key Personnel,Team Kordower,Jeremy Herskowitz
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Yue Zhang
,,Kordower,,,,,A5069788322,,,Key Personnel,Team Kordower,Jhodi Webster
,,Kordower,,,,,A5005214080,,,Key Personnel,Team Kordower,Lucas Hampton
,,Kordower,,,,,A5022918796,,,Key Personnel,Team Kordower,Bruce Spiegelman
,,Kordower,,,,,A5050274249,,,Key Personnel,Team Kordower,Ameera Shaw
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Sowmya Kamraj
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Mohamed Youssef
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Anirudh Vattikota
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Kelly Glajch
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Josh Randolph
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Xiaobo Li
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Alonso Ledesma
,,Kordower,,,,,,,,Key Personnel,Team Kordower,Yinzhen He
,,Kordower,,,,,,,,Project Manager,Team Kordower,Hayla Ollison
,,Kordower,,,,,A5047680361,,,Key Personnel,Team Kordower,Anna Stoll
,,Lee,,,,,,,,Project Manager,Team Lee,Jane Balster
,,Lee,,,,,A5102345271,,,Key Personnel,Team Lee,Yue Ma
,,Lee,,,,,,,,Key Personnel,Team Lee,Alec Wong
,,Lee,,,,,A5085842744,,,Key Personnel,Team Lee,Indrani Poddar
,,Lee,,,,,,,,Key Personnel,Team Lee,Hector Martinez
,,Lee,,,,,,,,Key Personnel,Team Lee,Mehek Jahan
,,Lee,,,,,,,,Key Personnel,Team Lee,Mehek Jahan
,,Lee,,,,,,,,Key Personnel,Team Lee,Mehek Jahan
,,Lee,,,,,,,,Key Personnel,Team Lee,Mehek Jahan
,,Lee,,,,,,,,Key Personnel,Team Lee,Rachel Tappe
,,Lee,,,,,,,,Key Personnel,Team Lee,Joe Robin
,,Lee,,,,,,,,Key Personnel,Team Lee,Nicole Courtmanche
,,Lee,,,,,,,,Key Personnel,Team Lee,Jordan Rowlands
,,Lee,,,,,,,,Key Personnel,Team Lee,Carmen Perez de Nanclares Fernandez
,,Lee,,,,,A5034385515,,,Co-PI,Team Lee,Mike Henderson
,,Lee,,,,,A5003100221,,,Key Personnel,Team Lee,Aminat Hassan
,,Lee,,,,,A5100386253,,,Key Personnel,Team Lee,Ying Zhang
,,Lee,,,,,,,,Key Personnel,Team Lee,Joshua Carey
,,Lee,,,,,A5043377829,,,Key Personnel,Team Lee,Alex Soto-Avellaneda
,,Lee,,,,,A5044692783,,,Key Personnel,Team Lee,Sam Peters
,,Lee,,,,,A5103234864,,,Key Personnel,Team Lee,Razaul Karim
,,Lee,,,,,,,,Key Personnel,Team Lee,Sam Phillip
,,Lee,,,,,,,,Key Personnel,Team Lee,Ben Van Setters
,,Lee,,,,,A5075186237,,,Key Personnel,Team Lee,Olutayo Olaseinde
,,Lee,,,,,,,,Key Personnel,Team Lee,Noah Lubben
,,Lee,,,,,,,,Key Personnel,Team Lee,Krishna Chennavajula
,,Lee,,,,,,,,Key Personnel,Team Lee,Benjamin Van Setters
,,Liddle,,,,,A5008036209,,,Co-PI,Team Liddle,Malu Tansey
,,Liddle,,,,,,,,Key Personnel,Team Liddle,Ravindra Boddu
,,Liddle,,,,,A5000328118,,,Key Personnel,Team Liddle,Alexandria White
,,Liddle,,,,,A5086578865,,,Key Personnel,Team Liddle,Lisa Blackmer-Raynolds
,,Liddle,,,,,A5001432320,,,Key Personnel,Team Liddle,Ayse Demirkan
,,Liddle,,,,,A5068608837,,,Key Personnel,Team Liddle,Brittney Otero
,,Liddle,,,,,A5070734573,,,Key Personnel,Team Liddle,Alfonso Martin Pena
,,Liddle,,,,,A5009239531,,,Key Personnel,Team Liddle,Christina Caira
,,Liddle,,,,,A5024539060,,,Key Personnel,Team Liddle,Katherine Chavez Velasquez
,,Liddle,,,,,A5050125232,,,Key Personnel,Team Liddle,Ian Williamson
,,Liddle,,,,,A5072679304,,,Project Manager,Team Liddle,Senthil Gounder
,,Liddle,,,,,A5035859489,,,Key Personnel,Team Liddle,Mackenzie Bolen
,,Liddle,,,,,A5035859489,,,Key Personnel,Team Liddle,Mackenzie Bolen
,,Liddle,,,,,A5035859489,,,Key Personnel,Team Liddle,Mackenzie Bolen
,,Liddle,,,,,A5035859489,,,Key Personnel,Team Liddle,Mackenzie Bolen
,,Liddle,,,,,A5015127057,,,Key Personnel,Team Liddle,Ian Krout
,,Liddle,,,,,,,,Key Personnel,Team Liddle,Beilei Lei
,,Liddle,,,,,,,,Key Personnel,Team Liddle,Isabel Fraccaroli
,,Liddle,,,,,A5075093941,,,Key Personnel,Team Liddle,Charles (Chad) Murchison
,,Liddle,,,,,A5007401536,,,Key Personnel,Team Liddle,Adrian Verster
,,Liddle,,,,,A5062013515,,,Key Personnel,Team Liddle,Andrea Merchak
,,Liddle,,,,,,,,Key Personnel,Team Liddle,Vanita Patel
,,Liddle,,,,,A5067523493,,,Key Personnel,Team Liddle,Ibtehaj Naqvi
,,Liddle,,,,,,,,Key Personnel ,Team Liddle,Lyndsey Lipson
,,Liddle,,,,,A5017395247,,,Key Personnel,Team Liddle,Keaton Stagaman
,,MAC,,,,,A5068576885,,,Lead PI,Team MAC,Nicola Segata
,,MAC,,,,,A5052283192,,,Co-PI,Team MAC,Levi Waldron
,,MAC,,,,,A5028950712,,,Project Manager,Team MAC,Federica Pinto
,,MAC,,,,,,,,Key Personnel,Team MAC,Kaelyn Long
,,Mobley,,,,,A5103144746,,,Lead-PI,Team Mobley,Xiang-Dong Fu
,,Mobley,,,,,A5048054072,,,Co-PI,Team Mobley,Steve Dowdy
,,Mobley,,,,,A5086086716,,,Co-PI,Team Mobley,Yuanchao Xue
,,Mobley,,,,,A5029215938,,,Project Manager,Team Mobley,Peter Shaw
,,Mobley,,,,,A5052581222,,,Co-PI,Team Mobley,Allen Wang
,,Mobley,,,,,A5073855965,,,Collaborating PI,Team Mobley,Bing Ren
,,Mobley,,,,,A5101625376,,,Collaborating PI,Team Mobley,Xiaoqun Wang
,,Mobley,,,,,A5045770248,,,Collaborating PI,Team Mobley,Miranda Orr
,,Mobley,,,,,A5033998542,,,Collaborating PI,Team Mobley,Don Cleveland
,,Reck-Peterson,,,,,A5021023250,,,Lead-PI,Team Reck-Peterson,Samara Reck-Peterson
,,Reck-Peterson,,,,,A5006107445,,,Key Personnel,Team Reck-Peterson,Josh Hutchings
,,Reck-Peterson,,,,,A5040750259,,,Collaborating PI,Team Reck-Peterson,Peter Heid
,,Reck-Peterson,,,,,A5070482927,,,Collaborating PI,Team Reck-Peterson,Jasmin Jansen
,,Reck-Peterson,,,,,A5053245720,,,Key Personnel,Team Reck-Peterson,Marta Sanz-Murillo
,,Reck-Peterson,,,,,A5068728058,,,Key Personnel,Team Reck-Peterson,Jaime Alegrio Louro
,,Reck-Peterson,,,,,A5025003947,,,Key Personnel,Team Reck-Peterson,Lindsey Young
,,Reck-Peterson,,,,,,,,Key Personnel,Team Reck-Peterson,Swetha Mahesula
,,Reck-Peterson,,,,,A5111717449,,,Collaborating PI,Team Reck-Peterson,Tom Kraus
,,Reck-Peterson,,,,,A5042417952,,,Key Personnel,Team Reck-Peterson,Sandra Röhm
,,Reck-Peterson,,,,,A5107156285,,,Key Personnel,Team Reck-Peterson,Nicolai Raig
,,Reck-Peterson,,,,,A5092762755,,,Key Personnel,Team Reck-Peterson,Amalia Villagran-Suarez
,,Reck-Peterson,,,,,A5012416487,,,Project Manager,Team Reck-Peterson,Robert Fagiewicz
,,Reck-Peterson,,,,,A5015060333,,,Collaborating PI,Team Reck-Peterson,Marcel Wendel
,,Reck-Peterson,,,,,A5029018046,,,Key Personnel,Team Reck-Peterson,Katy Surridge
,,Reck-Peterson,,,,,A5103007906,,,Key Personnel,Team Reck-Peterson,Erica Xiong
,,Reck-Peterson,,,,,A5072876433,,,Key Personnel,Team Reck-Peterson,Katie Hatch
,,Reck-Peterson,,,,,,,,Key Personnel,Team Reck-Peterson,Niels Pagani
,,Reck-Peterson,,,,,A5084228027,,,Key Personnel,Team Reck-Peterson,Farhaz Shaikh
,,Reck-Peterson,,,,,A5030961057,,,Key Personnel,Team Reck-Peterson,Tanya Bodrug
,,Reck-Peterson,,,,,,,,Key Personnel,Team Reck-Peterson,Alex Flaherty
,,Reck-Peterson,,,,,,,,Key Personnel,Team Reck-Peterson,Nick Lattal
,,Rio,,,,,A5027487536,,,Project Manager,Team Rio,Devin Snyder
,,Rio,,,,,A5000495585,,,Key Personnel,Team Rio,Oriol Busquets Figueras
,,Rio,,,,,,,,Key Personnel,Team Rio,Riana Lo Bu
,,Rio,,,,,,,,Key Personnel,Team Rio,Maria Gonzalez-Calatayud
,,Rio,,,,,,,,Key Personnel,Team Rio,Atul Preetham
,,Rio,,,,,,,,Key Personnel,Team Rio,Maja Haerle
,,Rio,,,,,,,,Key Personnel,Team Rio,Cheng-Yen (Nick) Huang
,,Rio,,,,,,,,Key Personnel,Team Rio,Vivien Simon
,,Rio,,,,,,,,Key Personnel,Team Rio,Jianpu Gao
,,Rio,,,,,,,,Key Personnel,Team Rio,Saskia Altmaier
,,Rio,,,,,,,,Key Personnel,Team Rio,Sarah Paatz
,,Schapira,,,,,A5035849217,,,Co-PI,Team Schapira,Donato Di Monte
,,Schapira,,,,,A5078857122,,,Collaborating PI,Team Schapira,Stanislav Ehrlich
,,Schapira,,,,,A5081742118,,,Collaborating PI,Team Schapira,Hervé Blottiere
,,Schapira,,,,,A5079424364,,,Key Personnel,Team Schapira,Nicolas Pons
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Nathalie Galleron
,,Schapira,,,,,A5050850243,,,Key Personnel,Team Schapira,Ayse Ulusoy
,,Schapira,,,,,A5071630632,,,Key Personnel,Team Schapira,Sinead O'Sullivan
,,Schapira,,,,,A5068582387,,,Key Personnel,Team Schapira,Enza Maria Valente
,,Schapira,,,,,A5022210828,,,Key Personnel,Team Schapira,Antonio Pisani
,,Schapira,,,,,A5100614696,,,Key Personnel,Team Schapira,Maria Jose Perez
,,Schapira,,,,,A5087410187,,,Key Personnel,Team Schapira,Emmanuelle Le Chatelier
,,Schapira,,,,,A5051189127,,,Key Personnel,Team Schapira,Sara Lucas Del Pozo
,,Schapira,,,,,A5052572031,,,Key Personnel,Team Schapira,David (KaiYin) Chau
,,Schapira,,,,,A5035922000,,,Key Personnel,Team Schapira,Pietro La Vitola
,,Schapira,,,,,A5008407091,,,Key Personnel,Team Schapira,Chiao-Yin Lee
,,Schapira,,,,,A5016900497,,,Key Personnel,Team Schapira,Christin Weißleder
,,Schapira,,,,,A5072443513,,,Key Personnel,Team Schapira,Jan-Willem Taanman
,,Schapira,,,,,A5040428714,,,Key Personnel,Team Schapira,Gerardo Ongari
,,Schapira,,,,,A5082132149,,,Key Personnel,Team Schapira,Benoit Quinquis
,,Schapira,,,,,A5011766453,,,Key Personnel,Team Schapira,Chaima Ezzine
,,Schapira,,,,,A5093127061,,,Key Personnel,Team Schapira,Pierfrancesco Mitrotti
,,Schapira,,,,,A5101508838,,,Key Personnel,Team Schapira,Laura Colombo
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Aleesa Nazeer
,,Schapira,,,,,A5073750727,,,Key Personnel,Team Schapira,Heidi Carr
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Rosaria Calabrese
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Revi Shahar Golan
,,Schapira,,,,,A5053300892,,,Key Personnel,Team Schapira,Eva Szegö
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Anushka Takhi
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Rita Stiuso
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Véronique Lejard
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Margot Giat
,,Schapira,,,,,A5090853589,,,Key Personnel,Team Schapira,Florian Plaza-Oñate
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Sébastien Dime
,,Schapira,,,,,A5046759700,,,Key Personnel,Team Schapira,Renata Santos
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Loris Bandirali
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Georgia Pittwood
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Mallia Geiger
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Yani Ren
,,Schapira,,,,,,,,Key Personnel,Team Schapira,Cherif Chahtour
,,Scherzer,,,,,A5030394012,,,Co-PI,Team Scherzer,Su-Chun Zhang
,,Scherzer,,,,,A5050071813,,,Project Manager,Team Scherzer,Beatrice Weykopf
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Yi Zhong
,,Scherzer,,,,,A5085575361,,,Key Personnel,Team Scherzer,Monika Sharma
,,Scherzer,,,,,A5069131024,,,Key Personnel,Team Scherzer,Madison Cline
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Li Feng
,,Scherzer,,,,,A5101798791,,,Key Personnel,Team Scherzer,Kwanho Kim
,,Scherzer,,,,,A5027707195,,,Key Personnel,Team Scherzer,Ewa Grassin
,,Scherzer,,,,,A5100716361,,,Key Personnel,Team Scherzer,Jixiang Zhang
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Ileana Lorenzini
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Anthony Intorcia
,,Scherzer,,,,,A5052272787,,,Key Personnel,Team Scherzer,Syed Hassan Bukhari
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Shun-Yi Zhuo
,,Scherzer,,,,,A5010685595,,,Key Personnel,Team Scherzer,Sidra Aslam
,,Scherzer,,,,,A5101942109,,,Key Personnel,Team Scherzer,Yuxuan Hu
,,Scherzer,,,,,A5020391819,,,Key Personnel,Team Scherzer,Qingru Xu
,,Scherzer,,,,,A5069516796,,,Key Personnel,Team Scherzer,Yiyong Zhao
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Mingming Lu
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Phil Jun Kang
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Matthew Kearny
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Liping Zhao
,,Scherzer,,,,,A5017104287,,,Key Personnel,Team Scherzer,Guilherme H. Gatti da Silva
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Tingwei Liu
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Liping Zhang
,,Scherzer,,,,,A5036660972,,,Key Personnel,Team Scherzer,Ralda Nehme
,,Scherzer,,,,,A5027729610,,,Key Personnel,Team Scherzer,Adina MacMahon Copas
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Maria Olivero-Acosta
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Haru Yamamoto
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Ilinca Mazureac
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Diogo Ferri Marques
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Laura Perna
,,Scherzer,,,,,A5043341509,,,Key Personnel,Team Scherzer,Dunhui Li
,,Scherzer,,,,,A5035436240,,,Key Personnel,Team Scherzer,Zehra F. Calikusu
,,Scherzer,,,,,A5103800420,,,Key Personnel,Team Scherzer,Fang Yuan
,,Scherzer,,,,,A5077465600,,,Key Personnel,Team Scherzer,Sara Rouhiardeshiri
,,Scherzer,,,,,A5064498852,,,Key Personnel,Team Scherzer,Weiqiang (Leo) Liu
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Himanshu Chintalapudi
,,Scherzer,,,,,,,,Key Personnel,Team Scherzer,Deep Patel
,,Schlossmacher,,,,,A5064134027,,,Key Personnel,Team Schlossmacher,Omar Hasan Ali
,,Schlossmacher,,,,,A5077959730,,,Key Personnel,Team Schlossmacher,Michaela Lunn
,,Schlossmacher,,,,,A5045120391,,,Key Personnel,Team Schlossmacher,Benjamin Belfort
,,Schlossmacher,,,,,A5026634089,,,Key Personnel,Team Schlossmacher,Mary Xylaki
,,Schlossmacher,,,,,A5010206691,,,Key Personnel,Team Schlossmacher,Jessica McNeill
,,Schlossmacher,,,,,A5044198912,,,Key Personnel,Team Schlossmacher,Stephanie Simard
,,Schlossmacher,,,,,A5067278835,,,Collaborating PI,Team Schlossmacher,Jacob Reimer
,,Schlossmacher,,,,,A5072384882,,,Key Personnel,Team Schlossmacher,Alex Garza
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Carolin Fabienne Prior
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Alfred Maluach
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Zoe Ortiz
,,Schlossmacher,,,,,A5114471962,,,Key Personnel,Team Schlossmacher,Priya Suman
,,Schlossmacher,,,,,A5047460455,,,Key Personnel,Team Schlossmacher,Thea Würfel
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Chase Groulx
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Emma Green-Berkowitz
,,Schlossmacher,,,,,A5037473598,,,Collaborating PI,Team Schlossmacher,Gianfilippo Coppola
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Devin Brain
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Sukru Aras
,,Schlossmacher,,,,,A5073624190,,,Key Personnel,Team Schlossmacher,Johnathan Jia
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Yi Zhong
,,Schlossmacher,,,,,A5074217299,,,Key Personnel,Team Schlossmacher,Sasidhar Pasupuleti
,,Schlossmacher,,,,,A5010507991,,,Key Personnel,Team Schlossmacher,Avika Chopra
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Karan Thakur
,,Schlossmacher,,,,,,,,Key Personnel,Team Schlossmacher,Raquel Rodriguez Aller
,,Strick,,,,,A5084138592,,,Lead-PI,Team Strick,Peter Strick
,,Strick,,,,,A5041774892,,,Collaborating PI,Team Strick,Afonso Silva
,,Strick,,,,,A5008550747,,,Collaborating PI,Team Strick,Andreas Pfenning
,,Strick,,,,,A5019730324,,,Key Personnel,Team Strick,Adam Lin
,,Strick,,,,,,,,Key Personnel,Team Strick,Mitsutoshi Hanada
,,Strick,,,,,A5054601833,,,Key Personnel,Team Strick,Alexandra Stump
,,Strick,,,,,A5076664123,,,Key Personnel,Team Strick,BaDoi Phan
,,Strick,,,,,,,,Key Personnel,Team Strick,Mara Frum
,,Strick,,,,,,,,Key Personnel,Team Strick,Olivia Brull
,,Strick,,,,,,,,Key Personnel,Team Strick,Ghada Abdelhady
,,Strick,,,,,,,,Key Personnel,Team Strick,Macie Hakim
,,Strick,,,,,,,,Key Personnel,Team Strick,Baylie Leveto
,,Strick,,,,,A5061439029,,,Key Personnel,Team Strick,Megan Fredericks
,,Strick,,,,,A5036931336,,,Key Personnel,Team Strick,Rachel Tittle
,,Strick,,,,,A5019730324,,,Key Personnel,Team Strick,Meng Kuang Lin
,,Strick,,,,,A5039075900,,,Key Personnel,Team Strick,Devin Harsch
,,Strick,,,,,,,,Key Personnel,Team Strick,Shreya Mahajan
,,Strick,,,,,,,,Key Personnel,Team Strick,Mrunal Zambre
,,Strick,,,,,,,,Key Personnel,Team Strick,Rebecca Marflak
,,Strick,,,,,,,,Key Personnel,Team Strick,Cherie Cornmesser
,,Strick,,,,,,,,Key Personnel,Team Strick,Jackie Breter
,,Strick,,,,,,,,Key Personnel,Team Strick,Abby Somich
,,Strick,,,,,,,,Key Personnel,Team Strick,Nili Shah
,,Strick,,,,,,,,Key Personnel,Team Strick,Ny Towler
,,Strick,,,,,,,,Key Personnel,Team Strick,Moya Carrier
,,Studer,,,,,A5068128893,,,Key Personnel,Team Studer,Angelique Di Domenico
,,Studer,,,,,A5065024196,,,Key Personnel,Team Studer,Regine Tipon
,,Studer,,,,,,,,Key Personnel,Team Studer,Marta Skowronska
,,Studer,,,,,A5105878399,,,Key Personnel,Team Studer,Yasmine Nonose
,,Studer,,,,,A5083537031,,,Key Personnel,Team Studer,Sigi Benjamin
,,Studer,,,,,,,,Key Personnel,Team Studer,Niraj Sawarkar
,,Studer,,,,,A5004000538,,,Unpaid Collaborator,Team Studer,Ilya Kruglikov
,,Studer,,,,,A5064033656,,,Unpaid Collaborator,Team Studer,Stefan Semrau
,,Studer,,,,,A5019634581,,,Key Personnel,Team Studer,Kasandra Diaz
,,Studer,,,,,A5040139742,,,Key Personnel,Team Studer,Yunan Luo
,,Studer,,,,,A5067023999,,,Key Personnel,Team Studer,Giacomo Monzio Compagnoni
,,Studer,,,,,A5078575280,,,Key Personnel,Team Studer,Edinson Lucumi Moreno
,,Studer,,,,,A5035296528,,,Key Personnel,Team Studer,Rich Krolewski
,,Studer,,,,,A5009482508,,,Key Personnel,Team Studer,Daniel El Kodsi
,,Studer,,,,,A5007253264,,,Unpaid Collaborator,Team Studer,Malin Parmar
,,Studer,,,,,A5088629796,,,Unpaid Collaborator,Team Studer,Alessandro Fiorenzano
,,Studer,,,,,A5078871380,,,Unpaid Collaborator,Team Studer,Edoardo Sozzi
,,Studer,,,,,A5089146662,,,Unpaid Collaborator,Team Studer,Petter Storm
,,Studer,,,,,,,,Key Personnel,Team Studer,Kavitha Krishna Sudhakar
,,Studer,,,,,A5071777853,,,Key Personnel,Team Studer,Vittoria 
,,Studer,,,,,A5086052373,,,Collaborating PI,Team Studer,Marinka Zitnik
,,Studer,,,,,A5044314299,,,Key Personnel,Team Studer,Valentina Giunchiglia
,,Studer,,,,,A5033357803,,,Key Personnel,Team Studer,Ayush Noori
,,Studer,,,,,A5086724086,,,Co-PI,Team Studer,Gist Croft
,,Studer,,,,,A5057660606,,,Key Personnel,Team Studer,Xiang Lin
,,Studer,,,,,,,,Key Personnel,Team Studer,Yepeng Huang
,,Studer,,,,,A5002031095,,,Key Personnel,Team Studer,Michelle Li
,,Studer,,,,,A5074677291,,,Key Personnel,Team Studer,Ashish Mehta
,,Sulzer,,,,,,,,Key Personnel,Team Sulzer,Yue Zhang
,,Sulzer,,,,,A5056579499,,,Key Personnel,Team Sulzer,Ana Moiseyenko
,,Sulzer,,,,,,,,Key Personnel,Team Sulzer,Vanessa Morales
,,Sulzer,,,,,A5068791795,,,Key Personnel,Team Sulzer,Osama A Al Dalahmah
,,Sulzer,,,,,,,,Key Personnel,Team Sulzer,Manxuan Zhou
,,Sulzer,,,,,,,,Key Personnel,Team Sulzer,Stavros Fanourakis
,,Sulzer,,,,,A5075231025,,,Key Personnel (PI),Team Sulzer,Natividad Stover
,,Sulzer,,,,,A5071581507,,,Key Personnel,Team Sulzer,Matheus Fonseca
,,Sulzer,,,,,,,,Key Personnel,Team Sulzer,Michaelis Tanner
,,Sulzer,,,,,A5026487185,,,Key Personnel,Team Sulzer,Emil Johansson
,,Surmeier,,,,,A5033742239,,,Lead-PI,Team Surmeier,D. James (Jim) Surmeier
,,Surmeier,,,,,A5020694621,,,Co-PI,Team Surmeier,Silvia Arber
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Emily Larsen
,,Surmeier,,,,,A5018267763,,,Key Personnel,Team Surmeier,Qialing Cui
,,Surmeier,,,,,A5055251836,,,Key Personnel,Team Surmeier,Denard Simmons
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Jaime Guzman
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Ema Ilijic
,,Surmeier,,,,,A5026310676,,,Key Personnel,Team Surmeier,Patricia Gonzalez-Rodriquez
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,James Moran
,,Surmeier,,,,,A5006730519,,,Key Personnel,Team Surmeier,Nora Vrieler
,,Surmeier,,,,,A5015020670,,,Key Personnel,Team Surmeier,Akira Fushiki
,,Surmeier,,,,,A5009618249,,,Key Personnel,Team Surmeier,Mafalda Vicente
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Cassandra Nyerges
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Antonio Falasconi
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Harsh Kanodia
,,Surmeier,,,,,A5101465278,,,Key Personnel,Team Surmeier,Lindsay Huang
,,Surmeier,,,,,A5073314031,,,Key Personnel,Team Surmeier,Changwan Chen
,,Surmeier,,,,,A5052180972,,,Key Personnel,Team Surmeier,Arin Pamukcu
,,Surmeier,,,,,A5031664190,,,Key Personnel,Team Surmeier,Fuu Jiun Hwang
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Sasha Ulrich
,,Surmeier,,,,,A5088152896,,,Project Manager,Team Surmeier,Christine Weber-Schmidt
,,Surmeier,,,,,A5020294559,,,Key Personnel,Team Surmeier,Darcy Peterka
,,Surmeier,,,,,A5107996113,,,Key Personnel,Team Surmeier,Ines Vaz
,,Surmeier,,,,,A5069170863,,,Key Personnel,Team Surmeier,Vivek Athalye
,,Surmeier,,,,,A5026584040,,,Key Personnel,Team Surmeier,Tanya Daigle
,,Surmeier,,,,,A5089950659,,,Key Personnel,Team Surmeier,Lili Karashchuk
,,Surmeier,,,,,A5091838554,,,Key Personnel,Team Surmeier,Zirong Gu
,,Surmeier,,,,,A5055317786,,,Key Personnel,Team Surmeier,Joaquim Alves da Silva
,,Surmeier,,,,,A5011486283,,,Key Personnel,Team Surmeier,Lara Scaria
,,Surmeier,,,,,,,,Key Personnel,Team Surmeier,Xinlu Ding
,,Surmeier,,,,,A5039624692,,,Key Personnel,Team Surmeier,Daniel Silverman
,,Vangheluwe,,,,,A5101764645,,,Key Personnel,Team Vangheluwe,Tae-Un Han
,,Vangheluwe,,,,,A5024492574,,,Key Personnel,Team Vangheluwe,Sarah Van Veen
,,Vangheluwe,,,,,A5040886525,,,Key Personnel,Team Vangheluwe,Chris Van den Haute
,,Vangheluwe,,,,,A5070999471,,,Key Personnel,Team Vangheluwe,Joris Van Asselberghs
,,Vangheluwe,,,,,A5049315953,,,Key Personnel,Team Vangheluwe,Annelies Aertgeerts
,,Vangheluwe,,,,,A5015367372,,,Key Personnel,Team Vangheluwe,Wouter Peelaerts
,,Vangheluwe,,,,,A5074178397,,,Key Personnel,Team Vangheluwe,Maria Sanchiz Calvo
,,Vangheluwe,,,,,A5066542048,,,Key Personnel,Team Vangheluwe,Filip Karol Pamula
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Klara Theresa Scholtissek
,,Vangheluwe,,,,,A5007496596,,,Key Personnel,Team Vangheluwe,Louise Louro
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Sasha Frank
,,Vangheluwe,,,,,A5052958046,,,Key Personnel,Team Vangheluwe,Rania Abou El Asrar
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Hanne Dhondt
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Jolien Bejster
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Logan Glasstetter
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Mads Eskesen Christensen
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Charisa Ma
,,Vangheluwe,,,,,A5018057795,,,Key Personnel,Team Vangheluwe,Andrea Perez
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Ana Bright
,,Vangheluwe,,,,,A5017926854,,,Key Personnel,Team Vangheluwe,Samantha Nishimura
,,Vangheluwe,,,,,,,,Key Personnel,Team Vangheluwe,Aisha Sati
,,Vangheluwe,,,,,A5055136980,,,Key Personnel,Team Vangheluwe,Hamid Esmaeili
,,Vangheluwe,,,,,A5032467961,,,Collaborating PI,Team Vangheluwe,Paul Saftig
,,Vangheluwe,,,,,A5076737213,,,Key Personnel,Team Vangheluwe,Marta Montpeyó Garcia-Moreno
,,Vila,,,,,A5062838955,,,Co-PI,Team Vila,Jose Obeso
,,Vila,,,,,A5065389586,,,Co-PI,Team Vila,Matthias Prigge
,,Vila,,,,,A5061710340,,,Project Manager,Team Vila,Javier Hoyo Pérez
,,Vila,,,,,A5013471636,,,"Collaborator, PI",Team Vila,Ernest Arenas
,,Vila,,,,,A5079288330,,,Collaborator,Team Vila,José Luis Lanciego
,,Vila,,,,,A5023479832,,,Collaborator,Team Vila,Jan Tonnesen
,,Vila,,,,,A5047796812,,,Key personnel,Team Vila,Jonathan Evan Draffin
,,Vila,,,,,A5014280534,,,Key personnel,Team Vila,Yuhong Fu
,,Vila,,,,,A5100623853,,,Key personnel,Team Vila,Hongyun Li
,,Vila,,,,,,,,Key personnel,Team Vila,Ping Wu
,,Vila,,,,,,,,Key personnel,Team Vila,Rigamonti Alessandra
,,Vila,,,,,A5051992465,,,Key personnel,Team Vila,Welsh Natalie
,,Vila,,,,,,,,Key personnel,Team Vila,Lee Kawai
,,Vila,,,,,A5106871763,,,Key personnel,Team Vila,Abaurre Carmen
,,Vila,,,,,A5093662147,,,Collaborator,Team Vila,Mario Fernandez
,,Vila,,,,,A5013260183,,,Key personnel,Team Vila,Marta Gonzalez-Sepulveda
,,Vila,,,,,A5090842506,,,Key personnel,Team Vila,Marina Lorente-Picón
,,Vila,,,,,A5062783877,,,Key personnel,Team Vila,Gerard Roch
,,Vila,,,,,A5103098387,,,Key personnel,Team Vila,Thais Cuadros
,,Vila,,,,,A5002959173,,,Key personnel,Team Vila,Joana M. Cladera
,,Vila,,,,,A5074619269,,,Key personnel,Team Vila,Cristian Gonzalez-Cabrera
,,Vila,,,,,A5047198741,,,Key personnel,Team Vila,Inés Trigo
,,Vila,,,,,A5084442661,,,Key personnel,Team Vila,Sebastian Luca D'Addario
,,Vila,,,,,A5029237737,,,Key personnel Lanciego,Team Vila,Alberto J Rico
,,Vila,,,,,,,,Key personnel,Team Vila,Pauline Jakobs
,,Vila,,,,,A5013626188,,,Key personnel Lanciego,Team Vila,Mariangela Massaro
,,Vila,,,,,A5062272188,,,Key personnel,Team Vila,Sandy Gonzalez
,,Vila,,,,,A5010533461,,,PhD student,Team Vila,Anastasia Filimontseva
,,Vila,,,,,A5023850435,,,Collaborator,Team Vila,Jose Angel Pineda-Pardo
,,Vila,,,,,A5049186987,,,Collaborator,Team Vila,Miguel Lopez-Aguirre
,,Vila,,,,,A5029025646,,,Collaborator,Team Vila,Alejandro Reinares-Sebastian
,,Vila,,,,,A5104504312,,,Collaborator,Team Vila,Megan Carrillo- Díaz de Argandoña
,,Vila,,,,,A5106927835,,,Collaborator,Team Vila,Nagore Hernández Pinedo
,,Vila,,,,,A5084740875,,,Collaborator,Team Vila,Noelia Esteban García
,,Vila,,,,,A5040297632,,,Key personnel,Team Vila,Paula Gimenez
,,Vila,,,,,A5025215889,,,Key personnel,Team Vila,Csilla Novák
,,Vila,,,,,A5021944445,,,Key Personnel,Team Vila,Valentina Nesci
,,Vila,,,,,,,,Key personnel,Team Vila,Sandra Gellhaar
,,Vila,,,,,A5075191847,,,Key personnel,Team Vila,Mubasher Mohammed
,,Vila,,,,,,,,Key personnel,Team Vila,Guochang Lyu
,,Vila,,,,,A5027903935,,,Key personnel,Team Vila,Hirofumi Noguchi
,,Vila,,,,,,,,Key personnel,Team Vila,Anahid Ansari Mahabadian
,,Vila,,,,,,,,Key personnel,Team Vila,Sabrina-Ayelén Gatti Quaranta
,,Vila,,,,,,,,Key personnel,Team Vila,Diana Municchi
,,Vila,,,,,,,,Key personnel,Team Vila,Rukhshona Kayumova
,,Vila,,,,,,,,Key personnel,Team Vila,Aleksandra Gritskova
,,Vila,,,,,A5117540536,,,Key personnel Lanciego,Team Vila,Mario M. Ilarduya
,,Voet,,,,,A5051093942,,,Co-PI,Team Voet,Guy Boeckxstaens
,,Voet,,,,,A5044812020,,,Collaborating PI,Team Voet,Pieter Vanden Berghe
,,Voet,,,,,A5037440162,,,Collaborating PI,Team Voet,Fritz J Sedlazeck
,,Voet,,,,,,,,Key Personnel,Team Voet,Anna Diacofotaki
,,Voet,,,,,A5023850944,,,Key Personnel,Team Voet,Qian Yu
,,Voet,,,,,,,,Key Personnel,Team Voet,Paulien Van Minsel
,,Voet,,,,,A5085792549,,,Key Personnel,Team Voet,Kaat Leroy
,,Voet,,,,,A5001979869,,,Key Personnel,Team Voet,Zeliha Zeliha Gözde Turan
,,Voet,,,,,A5099590200,,,Key Personnel,Team Voet,Michal Izydorczyk
,,Voet,,,,,A5033985989,,,Key Personnel,Team Voet,Ceyhun Alar
,,Voet,,,,,A5064977245,,,Key Personnel,Team Voet,Poovathingal Suresh
,,Voet,,,,,A5052410546,,,Key Personnel,Team Voet,Olga Sigalova
,,Voet,,,,,A5029383187,,,Key Personnel,Team Voet,Julie De Man
,,Voet,,,,,A5038440645,,,Project Manager,Team Voet,Sara Salama
,,Voet,,,,,A5113010830,,,Key Personnel,Team Voet,Jarne Geurts
,,Voet,,,,,A5030858914,,,Key Personnel,Team Voet,Markus Bösch
,,Voet,,,,,A5043236998,,,Key Personnel,Team Voet,Georgios Skoufos
,,Voet,,,,,,,,Key Personnel,Team Voet,Antonina Mikorska
,,Voet,,,,,A5114733233,,,Key Personnel,Team Voet,Esther Muñoz Pedrazo
,,Voet,,,,,A5053420565,,,Key Personnel,Team Voet,Carles Calatayud
,,Voet,,,,,,,,Key Personnel,Team Voet,Michaël Moons
,,Voet,,,,,,,,Key Personnel,Team Voet,Emma Moles Garcia
,,Voet,,,,,A5082447220,,,Key Personnel,Team Voet,Natalia Garcia Perez
,,Voet,,,,,A5056164635,,,Key Personnel,Team Voet,Nathalie Stakenborg
,,Voet,,,,,,,,Key Personnel,Team Voet,Elisabetta De Marco
,,Voet,,,,,A5084226167,,,Key Personnel,Team Voet,Maria Francesca Viola
,,Voet,,,,,A5091460068,,,Key Personnel,Team Voet,Elodie Modave
,,Voet,,,,,,,,Key Personnel,Team Voet,Verstraeten Lauren
,,Voet,,,,,,,,Key Personnel,Team Voet,Thompson Ben
,,Voet,,,,,A5107663479,,,Key Personnel,Team Voet,Marte Vandeput
,,Voet,,,,,A5031257628,,,Key Personnel,Team Voet,Maria Krunic
,,Wichmann,,,,,A5073427053,,,Co-PI,Team Wichmann,Hong-Yuan Chu
,,Wichmann,,,,,A5056482545,,,Co-PI,Team Wichmann,Adriana Galvan
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Christina Holbrook
,,Wichmann,,,,,A5023335764,,,Key Personnel,Team Wichmann,Anne-Caroline Martel
,,Wichmann,,,,,A5053818945,,,Collaborating PI,Team Wichmann,Bill Lytton
,,Wichmann,,,,,A5053818945,,,Key Personnel,Team Wichmann,Don Doherty
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Pare Jean-Francois
,,Wichmann,,,,,A5046521896,,,Project Manager,Team Wichmann,Johnson Agniswamy
,,Wichmann,,,,,A5058625347,,,Key Personnel,Team Wichmann,Hiba Douja Chehade
,,Wichmann,,,,,A5101403817,,,Key Personnel,Team Wichmann,Xing Hu
,,Wichmann,,,,,A5042774654,,,Key Personnel,Team Wichmann,Adam Newton
,,Wichmann,,,,,A5092784065,,,Key Personnel,Team Wichmann,Kelly South Pham
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Charlotte Armstrong
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Brian Kim
,,Wichmann,,,,,A5101892405,,,Key Personnel,Team Wichmann,Zihang Wang
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Zakia Sathi
,,Wichmann,,,,,,,,Key Personnel,Team Wichmann,Baijia Xu
,,Wood,,,,,,,,Key Personnel,Team Wood,Karishma D'Sa
,,Wood,,,,,A5045734117,,,Key Personnel,Team Wood,Ana Luisa Gil Martinez
,,Wood,,,,,,,,Project Manager,Team Wood,Saadia Rahman
,,Wood,,,,,A5013212185,,,Key Personnel,Team Wood,Joanna Lachica
,,Wood,,,,,A5062939996,,,Key Personnel,Team Wood,Rahul Arora
,,Wood,,,,,A5009440456,,,Key Personnel,Team Wood,Udit Surya Saha
,,Wood,,,,,,,,Key Personnel,Team Wood,Alicia Gonzalez-Diaz
,,Wood,,,,,A5062533128,,,Key Personnel,Team Wood,Melissa Grant-Peters
,,Wood,,,,,A5087734587,,,Key Personnel,Team Wood,Laura Mahoney Sanchez
,,Wood,,,,,A5102623459,,,Key Personnel,Team Wood,Patricia Lopez Garcia
,,Wood,,,,,A5033311649,,,Key Personnel,Team Wood,Sonia Garcia Ruiz
,,Wood,,,,,,,,Key Personnel,Team Wood,Burleen Chhatwal
,,Wood,,,,,A5056432129,,,Key Personnel,Team Wood,Joe Beckwith
,,Wood,,,,,,,,Key Personnel,Team Wood,Alexis Penverne
,,Wood,,,,,A5011976831,,,Key Personnel,Team Wood,Alexander Roentgen
,,Wood,,,,,,,,Key Personnel,Team Wood,Michaela Brezinova
,,Wood,,,,,A5046726585,,,Key Personnel,Team Wood,Leila Nahidiazar
,,Wood,,,,,A5083038342,,,Key Personnel,Team Wood,Mona Almramhi
,,Wood,,,,,A5030498890,,,Key Personnel,Team Wood,Guillermo Rocamora Parez
,,Wood,,,,,A5102819545,,,Key Personnel,Team Wood,Hannah Clarke
,,Wood,,,,,A5008450447,,,Key Personnel,Team Wood,Rebeka Popovic
,,Wood,,,,,,,,Key Personnel,Team Wood,Joe Robin
,,Wood,,,,,A5082240217,,,Key Personnel,Team Wood,Alexandre Almeida
,,Wood,,,,,,,,Key Personnel,Team Wood,Nika Vinkovic
